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ABSTRACT 
 
Genome-wide Transcriptome Analysis of Laminar Tissue During the Early Stages of 
Experimentally Induced Equine Laminitis. (December 2010) 
Jixin Wang, B.S., Tarim University of Agricultural Reclamation;  
M.S., South China Agricultural University; M.S., Texas A&M University 
Chair of Advisory Committee: Dr. Bhanu P. Chowdhary 
 
Equine laminitis is a debilitating disease that causes extreme sufferring in afflicted 
horses and often results in a lifetime of chronic pain. The exact sequence of 
pathophysiological events culminating in laminitis has not yet been characterized, and 
this is reflected in the lack of any consistently effective therapeutic strategy.  For these 
reasons, we used a newly developed 21,000 element equine-specific whole-genome 
oligoarray to perform transcriptomic analysis on laminar tissue from horses with 
experimentally induced models of laminitis: carbohydrate overload (CHO), 
hyperinsulinaemia (HI), and oligofructose (OF). Samples were collected during the 
developmental (DEV) and Obel grade 1 (OG1) stages of laminitis for the CHO model. 
For the HI model, samples were collected at the Obel grade 2 (OG2) stage. For the OF 
model, samples were collected at the 12 h and 24 h time points. Appropriate control 
samples were obtained for all models.  
This is the first genome-wide transcriptome analysis of laminar tissue using an 
equine 21,000 70-mer long oligoarray approach in CHO, HI and OF induced laminitis. 
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Overall, we identified the differential expression of genes encoding S100 calcium 
binding proteins, extracellular matrix proteins, glycoproteins, transporters, olfactory 
receptors, genes involved in signal transduction, body‟s homeostasis, apoptosis, and 
immune response. Between CHO and OF models of laminitis, there were more shared 
genes. We discovered several common differentially expressed genes (i.e., ADAMTS1, 
CYCS and CXCL14) among all three models that are likely important to the 
pathogenesis of equine laminitis. We also discovered what appear to be central roles of 
apoptosis, inflammatory response, and intracellular ion homeostasis molecular processes 
in CHO and OF models of laminitis. Pathway analysis detected the NOD-like receptor 
signaling pathway, which is involved in recognition of intracellular bacteria in both the 
CHO and OF models of laminitis. Genetic network analysis indicated convergent 
pathway core molecules present in equine acute laminitis: p38 MAPK and NF-κB. Most 
importantly, our results of overexpression of anti-microbial genes (i.e., DEFB4, PI3, and 
CXCL14) suggest the central involvement of these genes in the progression of early 
equine laminitis and will allow refinement of current hypotheses of disease 
pathogenesis. 
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 1 
CHAPTER I 
INTRODUCTION 
 
BACKGROUND 
Laminitis is a devastating disease of the equine digits. The disease affects the 
laminae, which attaches the coffin bone to the inner hoof wall and supports most of the 
horse‟s weight (Pollitt, 2004b). Inflammation and subsequent failure of the laminae to 
remain adhered to the phalanx cause pain and lameness, and with progression of the 
condition this may lead to death. Several factors may trigger laminitis; these range from 
mechanical injury caused by exercise, accident or even the walking/training surface to 
gastrointestinal disturbances, systemic disorders and gut infections. It is due to the latter 
that laminitis is considered to be a systemic disease which affects the horse‟s whole 
body but manifests in a specific region/tissue in the feet (Hood, 1999a). Laminitis occurs 
primarily in adult horses and has been reported in ponies (Harris et al., 2006). While it is 
widely accepted that laminitis does not have a hereditary component and is not restricted 
to a specific breed, it has been reported that some breeds of ponies, particularly the 
Shetland ponies, show higher incidences relative to other equids (McGowan, 2010). 
However, it is noteworthy that the incidences are associated with systemic disorders 
including obesity.  
 
 
____________ 
This dissertation follows the style of Veterinary Immunology and Immunopathology. 
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Approximately 15% of horses are afflicted with laminitis during their lifetime and 
75% of the affected horses develop a chronic condition due to which they must be 
euthanized (Moore et al., 2010). This leads to significant economic losses to the equine 
industry from loss of animals and recurring veterinary care bills. According to the 
American Association of Equine Practitioners (AAEP), laminitis is the second most 
frequent disease affecting horses after colic, and is currently ranked as the most 
important equine disease requiring research (Harris et al., 2006). The United States 
Department of Agriculture (USDA) has also listed laminitis as a priority area for equine 
research funding (www.csrees.usda.gov/funding/afri/pdfs/program_announcement.pdf).  
In fact, according to the Louisiana State University Equine Health Studies 
Program, it is estimated that greater than $13 million was lost annually in the United 
States as a result of diagnosis, treatment, as well as death of horses affected by the 
disease (Eades et al., 2002; Moore et al., 2010). While several reports have been 
published outlining potential causes, methods of prevention and treatment for the 
disease, an understanding of the molecular progression of the disease is sparse. 
Furthermore, the presently available therapeutic approaches for laminitis are limited, and 
their effectiveness is inadequate for complete and/or permanent relief to affected horses. 
The development of effective therapies requires an improved understanding of disease 
progression and underlying molecular mechanisms that lead to laminitis (Silver, 2008).  
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PHASES OF EQUINE LAMINITIS 
  Laminitis has been divided into three phases: the developmental phase (also 
called the prodromal phase indicating the start of laminitis before the clinical sign of foot 
pain occurs), the acute phase and the chronic phase (Pollitt, 2004b). In the 
developmental phase, “laminar separation is triggered” (Pollitt, 2004b). During this 
phase, horses usually have disturbances in body systems such as gastrointestinal, 
cardiovascular, respiratory, musculoskeletal, endocrine or immune system (Engiles, 
2010). The developmental phase may last 8-12 hours when horses have consumed black 
walnut shavings, or 24 to 32 hours when horses have had excess grain intake. Any 
changes that occur to the laminae during this phase indicate the initiation of laminitis. 
Thus, a close scrutiny of pathogenesis during this stage will be particularly important to 
understand the causes of the progression of this disease and determine triggering factors 
that cause laminitis.  
The developmental phase transitions into the acute phase when the first clinical 
sign of laminitis (i.e., foot pain) appears. This phase can last from 34 to 72 hours. 
Factors like obesity, various metabolic syndromes, endotoxemia and endocrinopathic 
problems have been shown to be risk factors for the development of acute laminitis 
(Geor and Harris, 2009; Kronfeld et al., 2006; Parsons et al., 2007; Treiber et al., 2006b). 
If the horse can survive the acute phase, it will recover. However, if progression occurs, 
laminar separation between the coffin bone (distal phalanx) and the hoof wall will 
develop (Fig. 1.1). The chronic phase is relatively slow. It reflects sustained progression 
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of the disease that can cause discomfort to the horse for a long time with clinical signs 
such as continued lameness and hoof wall deformation. 
 
 
 
 
Fig. 1.1. Sagittal section of a foot with chronic laminitis. “The attachment between the 
distal phalanx (DP) and the dorsal hoof wall (DHW) has failed and hoof and bone are 
now widely separated. The dashed yellow line shows the original position of the distal 
phalanx. The solid black line shows that the distal phalanx has rotated (in the direction 
of the curved black arrow) off the normally straight axis of the proximal and middle 
phalanges. The material now between the inner hoof wall and the bone is abnormal and 
consists of epidermal tissue proliferating to form a weak, disorganized mass called the 
lamellar wedge (yellow line). The descent of the unattached distal phalanx into the hoof 
capsule has distorted the growth of the proximal hoof wall tubules and has caused the 
sole to become convex instead of concave (dropped sole). Two dark hemorrhagic zones 
(white arrows) show the sites of greatest pressure and trauma” (Pollitt, 2004b, ©Elsevier 
Inc. Reproduced by permission). 
 
 
CLINICAL SIGNS OF EQUINE LAMINITIS 
Laminitis may develop in both front feet, all four feet or in the foot (front and 
back) opposite to the one with a severe injury or joint infection. It is believed that 
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because horses bear more than 60% of their weight on their front feet, laminitis is more 
likely to occur in the front feet (Papakonstantis et al., 2007), which suggests involvement 
of weight-bearing and other biomechanical forces in the initiation and progression of the 
disease. 
The degree of lameness reflects the severity of laminitis (Obel, 1948). To better 
define the severity of clinical signs exhibited by horses suffering from laminitis, a 
grading system of rating the degree of lameness denoted by Obel grades 1-4 (Obel, 
1948) was established. Horses with Obel grade 1 alternately lift the feet but there is no 
evident lameness at the walk. With Obel grade 2 laminitis, horses walk with a stilted 
gait. Horses with Obel grade 3 resist lifting the foot, and are reluctant to walk. This 
grade of lameness is the clinical measure for the induction of laminitis (Garner et al., 
1975). The most severe grade is Obel grade 4 where affected horses walk only if forced. 
Other clinical signs characteristic of laminitis are warm feet with a temperature of up to 
40°C, bounding digital pulses, and swelling of the coronary band. More severe signs of 
laminitis are the detachment of the distal phalanx from the inner hoof wall and the 
formation of the horizontal rings (Hood, 1999b).     
THE ANATOMY OF NORMAL HOOF LAMINAE AND HISTOLOGICAL 
CHANGES IN LAMINITIS 
In the healthy horse, the distal phalanx is attached to the hoof wall by the epidermal 
and dermal laminae tissue (Black, 2009). The epidermal laminae (primary epidermal 
laminae or PEL) are associated with the hoof wall and dermal laminae (primary dermal 
laminae or PDL) are connected with the distal phalanx. Both of the PEL and PDL have 
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secondary laminae structures to increase the surface area for attachment between the 
distal phalanx and the hoof wall (Pollitt, 2004a). The basement membrane (BM) is the 
interface of the secondary dermal laminae (SDL) and secondary epidermal laminae 
(SEL) (Pollitt and Daradka, 2004). It is composed of the basal cells of the epidermal 
layer of the laminae (Pollitt, 1996). Laminin protein is distributed within BM and is 
essential for the differentiation and attachment of epidermal basal cells (Pollitt, 1994). 
The laminar basal cells are attached to the BM by junctional complexes referred to as 
hemidesmosomes (HDs) (Borradori and Sonnenberg, 1999). HDs are of fundamental 
importance in maintaining the contact between epidermal basal cells and the dermis. 
Common histological changes that occur during laminitis are degradation of the 
BM and detachment of epidermal basal cells of the epidermal laminae from BM (Pollitt 
and Daradka, 1998, 2004). Three laminitis grades based on the histological changes have 
been established (Pollitt, 2004b; Pollitt and Visser, 2010) (Fig. 1.2). In horses with grade 
1 histological laminitis, laminar basal cells change their normal shape and become 
longer. As a result, the BM of the SEL detaches away from the basal cells (Fig. 1.2b). 
The laminar BM disappears between adjacent SELs at grade 2 histological laminitis 
(Fig. 1.2c). Grade 3 histological laminitis is the most severe grade where the SEL 
laminar tips move away from the BM (Fig. 1.2d).  
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Fig. 1.2. Normal laminar histology and three grades of laminitis histopathology in order 
of increasing severity (Pollitt, 2004b, ©Elsevier Inc. Reproduced by permission). 
 
EXPERIMENTAL INDUCTION MODELS OF ACUTE LAMINITIS 
In order to study the initiation and progression of equine laminitis, four 
experimentally induced models have been established: carbohydrate overload (CHO) 
(Garner et al., 1975), black walnut extract (BWE) (Minnick et al., 1987), oligofructose 
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(OF) (van Eps and Pollitt, 2006) and hyperinsulinaemia (HI) (Asplin et al., 2007; de Laat 
et al., 2010).  
Carbohydrate overload (CHO) model 
CHO has become the standard model for induced laminitis studies partially due 
to its similarity in terms of symptoms caused by grain overload, a common cause of 
naturally-occurring acute laminitis. These horses experience pathophysiological 
alterations similar to horses developing naturally-acquired laminitis, such as increased 
heart rate, arterial pressure, packed cell volume, leukocyte count, and hyperproteinemia 
(Fagliari et al., 1998; Garner et al., 1975; Harkema et al., 1978; Moore et al., 1981). It is 
shown that the time between the administration of carbohydrate gruel and the onset of 
lameness varies from 32 to 48 hours (Garner et al., 1975). This largely corroborates the 
observations of Pollitt and coworkers who observed that laminar blood flow increases 
within 12 to 40 h after carbohydrate overload/administration (Pollitt and Davies, 1998). 
Furthermore, a high vascular resistance in the isolated digit has been noted during the 
developmental stage of the CHO model of laminitis (Allen et al., 1990). Usually, after an 
overload of carbohydrate, the BM disintegration is initiated and the attachment between 
BM and the basal cells of the epidermis start to fail/separate (Pollitt, 1996). Furthermore, 
the high content of fructan carbohydrate in diet can also contribute to increased 
production of amine – a bacterial fermentation product - in the large intestine in normal 
ponies, which may enter the circulation and lead to the downstream laminar failure 
(Crawford et al., 2007).  
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Black walnut extract (BWE) model 
The BWE model is regarded as an improved model of laminitis compared to the 
CHO model because of i) reduced time to develop the clinical signs of acute laminitis 
(Eaton et al., 1995), and ii) high induction rate compared to the CHO model (Minnick et 
al., 1987). After BWE administration, clinical evidences such as leukopenia and 
neutropenia develop in horses (Galey et al., 1991). Endotoxins, part of the outer 
membrane of Gram-negative bacteria, have been regarded as potential laminitis trigger 
factor for equine laminitis,  as is evidenced by clinical signs of endotoxemia in horses 
that develop laminitis (Bailey et al., 2004). However, lipopolysaccharide (LPS), a 
biologically active component of endotoxins, was not detected in the plasma of horses 
post BWE administration (Eaton et al., 1995). It is evident that oxidant stress, as 
measured by the marker of oxidant stress 4-Hydroxy-2-nonenal (4-HNE) and caused by 
the production of free radicals, such as reactive oxygen species (ROS), is present in the 
laminae but not in lung, liver, and intestinal tract of BWE model of laminitis, which 
indicated that oxidant stress is a possible contributor to laminitis (Yin et al., 2009). In 
addition to oxidant stress, the pattern of inflammatory events in the lung and liver of 
BWE model of laminitis is similar to that in human sepsis (Stewart et al., 2009). 
However, Stewart and coworkers did observe a low inflammatory response in the horse 
lung and liver compared to that of laminae post BWE administration (Belknap et al., 
2007; Stewart et al., 2009).  
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Oligofructose (OF) model 
Fructan is a form of oligofructose (OF) and is a component of CHO. The 
successful induction of laminitis by OF could link increased fructan consumption at 
pastures to the development of laminitis (van Eps and Pollitt, 2006). Compared to the 
findings that eight of 10 horses with BWE induction (Minnick et al., 1987) and 11 of 12 
horses with CHO induction developed laminitis (Garner et al., 1975), all six horses 
dosed with OF develop laminitis (van Eps and Pollitt, 2006). Therefore, the OF model is 
considered an improvement over CHO and BWE models as far as laminitis induction is 
concerned. The laminar histopathological changes created in the OF model are identical 
to those observed after CHO (van Eps and Pollitt, 2006). Furthermore, the onset time of 
laminitis in the OF model is similar to that induced with starch intake (20-44 h post 
intake; Morgan et al., 2003). A recent study showed that clinical signs of systemic 
inflammations are typically observed in this induction model of laminitis and a change in 
glucose dynamics is observed within 24 to 48 hours of OF administration (Kalck et al., 
2009). An ultrastructural study of laminar tissue following higher OF dosage discovered 
that it leads to greater loss of HDs (French and Pollitt, 2004b).  
Hyperinsulinaemia (HI) model 
Laminitis can also be induced by maintaining prolonged hyperinsulinaemia (HI) 
with euglycaemia (Asplin et al., 2007; de Laat et al., 2010). Consequently, the laminitis 
thus caused is also considered as a model of endocrinopathic laminitis where the 
symptoms are caused due to hormonal influences (Johnson et al., 2004b). Naturally 
occurring HI is a condition of high levels of insulin in the bloodstream and is proposed 
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to be caused by insulin resistance (IR) (Frank, 2009; Johnson et al., 2004b). It is 
noteworthy that IR is the core component of equine metabolic syndrome (EMS) and 
equine Cushing‟s disease (ECD) (Frank, 2009; Johnson et al., 2004a), and is defined as 
failure of tissues to take up glucose via insulin-dependent glucose signaling. Due to IR, 
glucose remains in the blood and the pancreas continues to secret insulin, which causes 
HI (Kronfeld, 2005; Shanik et al., 2008). It has long been recognized that IR predisposes 
horses (e.g., Morgans, Arabians, Norwegian Fjords and Paso Finos) (Frank et al., 2006; 
Johnson, 2002) and ponies (Welsh and Dartmoor) (Geor, 2008; Treiber et al., 2006b) to 
laminitis.  
Euglycaemia is defined as a normal blood glucose level which in the horse body is 
5 mmol/L (Asplin et al., 2007). All ponies (Asplin et al., 2007) and horses (de Laat et al., 
2010) in the HI treatment group developed laminitis. Histological results showed BM 
was disintegrated in laminar tissue in the insulin treated ponies developing clinical 
laminitis (Asplin et al., 2007). Furthermore, laminar lesions in the hoof of ponies studied 
in HI induced laminitis using light and transmission electron microscopy (TEM) showed 
ultrastructural morphology of the laminar tissue affected by HI (Nourian et al., 2009). 
The changes were not similar to the laminar pathology after CHO and OF administration 
(Nourian et al., 2007; Pollitt, 1996). Unlike the CHO and OF laminitis pathology, there 
was no large-scale BM separation in the treated ponies following HI (Nourian et al., 
2009). 
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THEORIES OF PATHOGENESIS 
There are many theories regarding the mechanisms of the development of 
laminitis: vascular (Hood et al., 1993), enzymatic (Pollitt, 1999), traumatic/mechanical 
(Hood, 1999b), inflammatory (Belknap et al., 2007; Loftus et al., 2007), altered glucose 
metabolism (Pass et al., 1998) and cascade failure (Orsini et al., 2009) theory.  
The vascular theory proposes vascular alterations as the initiating factor that 
contributes to structural failure of the laminae (Hood et al., 1993). The presence of a 
warm hoof and bounding digital pulses during acute laminitis suggests a vascular 
component (Moore et al., 2004). Chronic laminitis has many pathological changes 
similar to those caused by ischemia/reperfusion of the digits (Bailey et al., 2004). The 
vascular mechanism that contributes in such cases to laminitis is characterized by 
venoconstriction, which causes decreased laminar perfusion and laminar tissue ischemia. 
Consequently, the epidermal cells in the laminar tissue are damaged that eventually leads 
to laminitis (Hood, 1999b). This corroborates with very early observations that 
decreased central venous pressure (which may be due to venoconstriction) is a feature 
during the developmental stage of CHO model laminitis (Garner et al., 1975).  
The enzymatic theory is based on matrix metalloproteinase (MMP) activation in 
laminar tissue affected by laminitis. MMP enzymes can degrade the BM component of 
extracellular matrix (ECM) (Pollitt, 1996). Laminin, type IV and type VII collagens are 
essential components of the laminar BM. MMP-2 and MMP-9 are thought to degrade 
these proteins and facilitate the detachment between the hoof wall and coffin bone 
(Pollitt and Daradka, 1998). In addition to ECM degradation, MMPs can also interact 
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with cytokines and growth factors (Parks et al., 2004) and their activities are tightly 
regulated by tissue inhibitors of metalloproteinases (TIMPs) (Denhardt et al., 1993). 
However, factors that trigger MMP activation in laminitis are still not known (Moore et 
al., 2004).  
The traumatic/mechanical theory states that laminitis can result from direct trauma 
as well as mechanical overload of the foot instead of systemic diseases. Road founder 
laminitis and laminitis secondary to unilateral weight bearing are examples of trauma-
linked laminitis (Hood, 1999b). Several hypotheses have been purposed as the causes of 
laminar structural failure. One is that direct trauma may initiate inflammatory response, 
which leads to tissue damage (Hood, 1999b). The other hypothesis is that excessive 
mechanical/pressure forces may result in the tearing of laminar interface, which is 
followed by “compartment injury” (Hood, 1999b).  
Although laminar tissue inflammation has long been recognized as a key 
component of laminitis, it is hypothesized that inflammation is a result of primary 
pathological changes such as trauma, rather than being the initial event (Hood, 1999b). 
Nonetheless, recent results suggest that inflammation is indeed likely to be the initiating 
pathological mechanism with MMP accumulation most likely a downstream event 
(Belknap et al., 2007; Loftus et al., 2007). In all stages of laminitis that have been 
investigated after BWE administration, genes encoding proteins associated with 
inflammation (i.e., IL-1β, IL-6, IL-8, ICAM-1 and COX-2) were induced and 
inflammation was considered as central to the development of laminar pathogenesis 
(Loftus et al., 2007).  
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Another hypothesis of laminar failure states that alterations in glucose metabolism 
lead to destruction of laminar tissue. Glucose is important for maintaining the adhesion 
between the basal epidermal cell and the BM (Pass et al., 1998). It has been shown that 
laminar separation occurs when glucose deprivation occurs in vitro (French and Pollitt, 
2004a). However, the inhibition of glucose metabolism leading to hoof laminar 
separation in vivo has yet to be verified.  
 Cascade failure theory is an extension of the systems theory for developing an 
improved understanding of laminitis (Orsini et al., 2009). It is used to unify disparate 
theories of laminitis pathogenesis for precise identification of the potential cause(s) to 
eventually find more effective therapeutic strategies. The cascade failure theory states 
that the failure of a preceding part (e.g., excessive ingestion of grain) can cause the 
failure of subsequent parts (e.g., MMP activation and BM degradation) and the ultimate 
failure in laminitis is the laminar separation. The endpoint failure can be reached by 
mechanisms such as vascular, enzymatic, inflammation or any combination thereof 
(Orsini et al., 2009).  
Among these various theories of laminitis pathogenesis, the inflammation 
mechanism is regarded as a common denominator (Budak et al., 2009; Orsini et al., 
2009) and has recently received more attention by researchers.  
INFLAMMATION AND MMPs 
Inflammation and the role of MMPs are among the important focus areas in equine 
laminitis research (Eades, 2010). It has been indicated that inflammatory processes 
initiated in the beginning due to any stimuli play a key role in the development of 
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laminitis, and may lead to laminar failure (Belknap et al., 2007; Orsini, 2008). Typically 
during any inflammatory process, a number of genes are activated, including TNF-α, IL-
1β, and IFN-γ, which in turn leads to endothelial activation and leukocyte 
(predominantly neutrophils) recruitment. Neutrophils generate reactive oxygen species 
(ROS) and release proteases extracellularly to degrade extracellular matrix resulting in 
tissue damage (Pham, 2008). Examples of important cytokine levels that are increased in 
laminar tissue of horses with laminitis are interleukin-1beta (IL-1β) (Fontaine et al., 
2001), interleukin-6 (IL-6) (Waguespack et al., 2004a),  interleukin-8 (IL-8) (Loftus et 
al., 2007), cyclooxygenase 2 (COX-2), intercellular adhesion molecule 1 (ICAM-1) and 
a cytokine-associated molecule possessing ankyrin-repeats induced by 
lipopolysaccharide (MAIL) (Waguespack et al., 2004b). The induction of cytokines 
recruits and activates leukocytes into the laminar tissue, which contributes to the 
inflammation (Kobayashi et al., 2003).   
In horses, soft tissue damage had been found to be associated with laminitis 
(Johnson et al., 2000) and some of the recent studies suggest that it is caused or mediated 
by MMPs. MMPs are a large family of proteinases that promote degradation of the extra 
cellular matrix or ECM (Ivan Stamenkovic, 2003). Varying activity as compared to 
normal has been detected for three members of the MMP family, MMP-2, MMP-9 and 
MMP-14, in naturally occurring cases (Johnson et al., 1998), the  CHO model (Mungall 
and Pollitt, 1999) and the OF model of laminitis (Kyaw-Tanner et al., 2008). The 
transcriptional activity of MMP-2 increases during the developmental stage (Kyaw-
Tanner and Pollitt, 2004) and the level of tissue inhibitor of metalloproteinase 2 (TIMP-
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2) activity decreases in affected laminar tissue at the onset of laminitis (Kyaw-Tanner et 
al., 2008). Another form of  laminar metalloproteinase, a disintegrin and 
metalloproteinase with thrombospondin motifs (ADAMTS) 4, is found to be activated in 
BWE and CHO induced laminitis (Coyne et al., 2008). This protein plays an important 
role in the ECM protein aggrecan cleavage (Kashiwagi et al., 2004). The activation of 
ADAMTS4 in laminitic horses is possibly necessary for the destruction of the laminar 
tissue through ECM aggrecan degradation, as BM (a thin layer of ECM) degradation is 
an early event during acute laminitis pathogenesis (Pollitt and Daradka, 1998).         
CURRENT TREATMENTS OF EQUINE LAMINITIS  
   As inflammation is a key factor or manifestation in laminitis, the drugs of choice 
to treat this disease have traditionally been anti-inflammatory. Nonsteroidal anti-
inflammatory drugs (NSAIDs) are most often used for this purpose primarily to decrease 
the inflammation and pain within the foot (Baxter and Morrison, 2008; Harman and 
Ward, 2001). Primarily these drugs are COX-2 inhibitors (Waguespack et al., 2004a). 
Flunixin meglumine is another commonly used NSAID in horses for treating 
inflammation although it is not a specific COX-2 inhibitor (Divers, 2003). 
Phenylbutazone and dimethylsufoxide (DMSO) are also some of the other NSAIDs used  
for the treatment of acute form of equine laminitis (Parks, 2003).  
Other medications used to treat laminitis are targeted towards improving laminar 
blood flow. These drugs include acepromazine, isoxsuprine, pentoxifylline, 
nitroglycerin, and ketoprofen (Belknap, 2010; Parks and O'Grady, 2003). Intramuscular 
administration of acepromazine can increase digital blood flow in healthy horses (Leise 
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et al., 2007) and is the widely used vasodilator in the treatment of laminitis; however, 
this drug is not selective in terms of the receptors it antagonizes (Bailey et al., 2004). It 
not only inhibits α-adrenergic receptors, but also inhibits 5-hydroxytryptamine (HT) 
receptors (Bailey et al., 2004). Another vasodilator drug isoxsuprine has been shown to 
reduce lameness with intravenous administration but the reported data are conflicting 
regarding its effect on laminar blood flow (Erkert and Macallister, 2002; Lizarraga et al., 
2004; Rose et al., 1983). Some reported that oral isoxsuprine improved peripheral blood 
flow (Rose et al., 1983) but others demonstrated that it did not increase laminar blood 
flow (Ingle-Fehr and Baxter, 1999). Furthermore, application of nitroglycerin for the 
treatment of laminitis has been shown to improve digital blood flow in CHO-induced 
cases (Eades et al., 2006) but not in healthy horses (Eades et al., 2006; Gilhooly et al., 
2005). Heparin, aspirin, mineral oil and cryotherapy are some of the other therapeutic 
agents (Baxter and Morrison, 2008) used to treat laminitis. Of these, heparin has been 
proven to have anti-inflammatory role in equine laminitis (de la Rebiere et al., 2008). 
Next, aspirin can decrease platelet aggregation in the natural forms of laminitis but the 
benefits of aspirin therapy have not yet been tested in an experimental model of laminitis 
(Parks and O'Grady, 2003; Parks, 2003). It has been shown that platelet activation and 
aggregation occur in the digital blood during the development of acute laminitis (Eades 
et al., 2007; Weiss et al., 1997). Therefore aspirin therapy is assumed to inhibit platelet 
aggregation for laminitis relief. Therapeutic shoeing, mechanical support, and deep 
digital flexor (DDF) tenotomy are the current treatment methods of choice to reduce the 
structural damage for chronic laminitis cases (Moore, 2008; Wylie et al., 2009) because 
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they provide considerable relief to the horse from pain and detachment of the BM. 
Recently it was reported that laminitic horses with different degrees of lameness can 
improve 1 to 2 Obel grades with botulinum toxin type A treatment (Carter and Ben 
Renfroe, 2009). The authors hypothesized that the pull of deep digital flexor tendon 
(DDFT) on the coffin bone contributes to the displacement of distal phalanx from the 
hoof wall (Carter and Ben Renfroe, 2009). Botulinum toxin injection can relax the 
DDFT and reduce the rotation of the distal phalanx.    
Due to the role of MMPs in ECM component degradation in the pathophysiology 
of both human and animal diseases, MMPs have become targets for therapeutic 
treatments/preventatives through the development and use of matrix metalloproteinase 
inhibitors (MMPIs). Synthetic MMPIs, such as batimastat (Tocris Bioscience) and 
marimastat (British Biotech) have been developed as potential treatments for diseases 
such as cancer, osteoarthritis, and rheumatoid arthritis (Lombard et al., 1998). However, 
it is shown that these compounds are either ineffective or have side effects for humans 
(Fingleton, 2008; Ramnath and Creaven, 2004). The main side effect was a 
musculoskeletal syndrome (MSS) that causes joint pain and reduced mobility (Fingleton, 
2008). Presently, doxycycline is the only medication approved for use as an MMPI in 
people with periodontal disease (Fingleton, 2008). Among the synthetic MMPIs, 
batimastat (BB-94) has been tested on horses with laminitis and is shown to prevent 
laminar separation in the explants of laminar hoof in vitro  (Pollitt et al., 1998). 
However, there is no MMPI therapeutic agent currently under trial for the treatment of 
equine laminitis.  
 19 
Many horses are euthanized every year due to the pain and debilitation suffered 
after developing laminitis. The lack of effective treatments for acute laminitis requires 
further investigations to improve our understanding about the underlying 
molecular/genetic mechanisms associated with the causation and progression of the 
disease, which is a prerequisite for the development of novel and effective therapeutic 
approaches.  
Many novel approaches have been applied in human medicine to study 
mechanisms of disease progression and to identify the interplay of genes that regulate 
pathogenic processes associated with the severity of the disease and the 
lesions/symptoms this may cause. During the past decade, these approaches have 
included the use of functional approaches and whole genome tools for transcriptome 
analysis that could provide clues regarding the potential causes of the diseases and 
insights into how various diseases including complex diseases like cancer progress. 
Functional genomics is the science of how genes function and how they are regulated on 
a genome-wide scale. The functions of most genes are mainly regulated by altering their 
transcription levels (Staudt and Brown, 2000) and these changes in transcription levels 
have an impact on the normal physiology/biology, leading to disease. Therefore, gene 
expression profiling based on transcriptional levels is a very useful approach to study the 
states and changes of cellular activity in normal and diseased condition. One of the most 
widely used functional genomics tools is a whole genome DNA microarray (Steinmetz 
and Davis, 2004).   
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MICROARRAY TECHNOLOGY OVERVIEW 
Types 
DNA microarray is a high-throughput technology that enables researchers to study 
gene expression levels of thousands of genes simultaneously at the transcriptional level 
(Brown and Botstein, 1999). In this technology, thousands of expressed gene sequences 
are spotted with high-speed robots to a small surface, such as glass microscope slides 
(Schena et al., 1995). The ability to analyze the transcription profiles on a genome-wide 
scale through these arrays can greatly enhance our understanding of genes and pathways 
involved in disease pathogenesis. The objectives of some microarray experiments are 
“class comparison, class prediction and class discovery” (Simon and Dobbin, 2003). 
Class is defined as the same tissue under different experimental conditions (e.g., disease 
and normal), or different category of disease in terms of stage or time point. Class 
comparison focuses on the identification of differential expression among the classes. 
Class prediction emphasizes the development of a statistical model to predict the results 
of an unknown class based on the expression profile. The objective of class-based 
discovery is to identify undefined classes based on the expression profile. The common 
goal of many microarray experiments is the identification of differentially expressed 
(DE) genes between a diseased and control state as these genes are valuable in studying 
mechanisms of disease progression and eventual pharmaco-genomics based drug 
discovery. Usually a fold change cut-off (>2) and significant p value (e.g., 0.01 or 0.05) 
are used to identify the genes that show statistically significant differential expression 
between conditions (e.g., treatment versus control). The steps of a microarray 
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experiment include experimental design, hybridization, data preprocessing and 
normalization, data analysis to identify DE genes, functional annotation of the latter and 
further analysis to draw biological conclusion (Fig. 1.3). 
 
 
 
 
 
 
 
 
 
 
Fig. 1.3. The workflow of a microarray experiment. 
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During the past decade, three major types of microarray platforms have been 
developed: spotted cDNA, short oligonucleotide, and long oligonucleotide arrays 
(Petersen et al., 2005), of which the cDNA arrays were first. The cDNA arrays are 
prepared by spotting DNA obtained from PCR based amplification of individual cDNA 
generated via tissue specific cloned libraries of expressed genes (Barrett and Kawasaki, 
2003). The oligonucleotide arrays, however, are prepared either by means of ink jet 
technologies or photolithography directly on the slide or also by large scale production 
of small or large oligos and then spotting them robotically on the slides (Hughes et al., 
2001). The cDNA array technique has two important limitations: tedious lab work of 
cDNA preparation and low specificity due to cross-hybridization (Li et al., 2002). In 
cDNA array experiments, certain cDNAs spotted on the slide can hybridize to other 
undesired DNA that share sequence homology and can result in cross-hybridization 
(Chuaqui et al., 2002) leading to background and/or non-specific hybridizations that may 
skew the results. In comparison, oligoarrays are more specific, sensitive and reliable than 
cDNA arrays (Hardiman, 2004; Hughes et al., 2001; Woo et al., 2004). Among the oligo 
based arrays, use of short oligos (on average 25 mers) as hybridization spots are less 
sensitive compared to long oligos because it has less available area for hybridization 
(Hardiman, 2004). Due to this they may not detect low level gene expression. Therefore, 
long oligoarrays (on average 60-70 mers) have become arrays of choice for exploring 
transcriptomes.  
Two approaches have traditionally been used for microarray hybridization 
experiments: single color and dual color. With the single color approach (i.e., 
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Affymetrix Gene Chips), the cDNA of sample is labeled with one fluorophore (such as 
green fluorescent dye cyanine 3 (Cy3) or red fluorescent dye cyanine 5 (Cy5), and 
hybridized to the individual array. Such hybridization experiments will generate absolute 
expression levels because the spot fluorescence intensity reflects the absolute mRNA 
abundance in the single sample. For dual color procedure, however, two cDNA samples 
are each labeled with a different dye (such as Cy3 and Cy5 dyes) and hybridized on a 
single slide to obtain relative expression levels. The Microarray Quality Control 
(MAQC) Consortium tests have indicated that the data obtained from single and dual 
arrays are comparable (Patterson et al., 2006).  
Experimental design 
Efficient experimental design is important for a microarray experiment, as it 
directly affects the downstream data analysis. There are mainly three types of 
experimental design: reference design, balanced block design and loop design (Simon 
and Dobbin, 2003; White and Salamonsen, 2005) (Fig. 1.4).  
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Fig. 1.4. Microarray experimental designs. Letters refer to different treatments and 
subscripts indicate biological replicates. Each arrow represents one microarray, with the 
arrow pointing away from the Cy3 labeled sample and towards the Cy5 labeled sample. 
Double arrows indicate dye-swap pairs. A: Indirect comparison with a common 
reference B: Direct comparison C: Saturated design and D: Time course experiment loop 
design (White and Salamonsen, 2005, Reproduction, 130, 4, ©Society for Reproduction 
and Fertility. Reproduced by permission). 
 
 
In reference design, a common reference sample is prepared (Fig. 1.4A). This 
reference sample is used as an internal comparison standard and is prepared by 
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combining equal amounts (in terms of concentration) of total RNA from different tissues 
to obtain the widest possible representation of the entire transcriptome; alternative, it is a 
pool of RNA from the different samples under study (Kim et al., 2002; Novoradovskaya 
et al., 2004). Genomic DNA has also been used as a universal reference sample in a 
reference design with two color DNA hybridization microarrays (Gadgil et al., 2005). It 
is noteworthy that while most studies use reference samples for comparison with the 
experimental samples, some reports stress that reference sample and reference design is 
inefficient (Churchill, 2002; Kerr and Churchill, 2001b). In reference design, half of the 
hybridization experiments are performed on the reference sample, which is probably of 
no interest.   
Although reference design has some advantages, a balanced block design (direct 
comparison) is preferable because of the gain in efficiency (Dobbin and Simon, 2002). 
For n samples, n hybridizations can be achieved with direct comparisons but reference 
design will require 2n hybridizations. Balanced block design does not need reference 
RNA because it allows direct comparison of case samples on the same microarray with 
balanced dyes. If there are more than two treatments in the experiment, saturated design 
may be applied (White and Salamonsen, 2005). Block design have been embedded in the 
scheme of saturated design (Fig. 1.4C).   
In comparison, loop design is usually used in time course experiments and 
connects the samples in a loop pattern (Fig. 1.4D). It has been proven that loop design is 
preferable for comparisons between sequential time points (Yang and Speed, 2002). 
Compared to reference design, loop design is not effective for cluster analysis because 
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the comparison of two samples far away in the loop involves other samples in between 
as well (Kerr and Churchill, 2001a). Furthermore, loop design is less efficient than block 
design for class comparisons because it requires more sophisticated method of analysis 
(Churchill, 2002).  
Sometimes pooling of RNA samples from several subjects is used in microarray 
experiments when sufficient RNA from individual sample for hybridization can not be 
obtained. Additionally, it is recommended that pooling biological samples is only 
appropriate when less than three arrays are used in each condition (Kendziorski et al., 
2005). Although a pooling strategy can decrease unwanted biological variability while 
reducing the number of microarrays used, it should be avoided when the samples can‟t 
be synchronized (Sasik et al., 2004).  
Replicates  
The use of replicates can help distinguish the truly DE genes from those affected 
by chance alone. This enables researchers to estimate accurately biological variation and 
minimize the systemic variation through average among replicates.   
There are generally two types of replicates in microarray experiments: biological 
and technical (Churchill, 2002). Biological replicates are replicates that taken RNA 
samples under the same condition but from different individuals and they are used to 
address the biological variability (e.g., animal-animal variation). We need to include 
enough biological replicates in order to make inferences about the population. Technical 
replicates are replicates that use the same RNA samples multiple times to reduce 
technical variability between experiments such as RNA isolation, labeling, and 
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hybridization. Two levels of technical replicates have become standard in microarray 
experiments: dye swapping and replication of spotting genes on the array. Biological 
replicates are more important than technical replicates because biological variation is 
greater than technical variation (Sasik et al., 2004). The number of replicates required 
for a microarray experiment depends on the type of experiment. In theory, at least five 
biological replicates are needed for sufficient statistical power, though the best results in 
statistical analysis are obtained using eight to 15 replicates (Pavlidis et al., 2003). In 
practice, a minimum of three biological and at least two technical replicates are needed 
for microarray experimental design (Foster and Huber, 2002; Lee et al., 2000).  
Dye bias 
In dual color microarray experiments, for certain genes, the Cy3/green channel is 
always brighter than Cy5/red channel though the expression is the same. This is called 
dye bias (Dobbin et al., 2005). Furthermore, Cy5 dye is affected by ozone (Branham et 
al., 2007; Fare et al., 2003). There are four different types of dye bias: “(1) dye bias that 
is the same for all genes; (2) dye bias that relies on the spot intensity; (3) gene specific 
dye bias; (4) dye bias that depends on both the sample and the gene” (Dobbin et al., 
2005). Type 1 and 2 dye biases can be eliminated by normalization procedures. Type 3 
dye bias can‟t be suppressed by a locally weighted scatterplot smoothing regression 
(LOWESS) normalization technique (Yang et al., 2002) but can be avoided by statistical 
analysis. It is difficult to eliminate type 4 dye bias but it was shown to have little effect 
on the gene expression difference estimation (Dobbin et al., 2005).  
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For certain genes, the bias is influenced by the dye orientation. This is gene 
specific dye bias (Kerr, 2003; Tseng et al., 2001). In order to minimize labeling error 
caused by the gene specific dye effects, the complete dye swap by reversing the dye 
orientation is an effective way accounting for gene specific dye bias. Dye swap involves 
changing the dyes used for labeling and prevents the sample being labeled by a single 
dye. It is recommended to use dye swap in dual color experiments if possible for gene 
specific dye effect (Martin-Magniette et al., 2005; Yang and Speed, 2002).  
Normalization 
Normalization is an important preprocessing step in microarray data analysis to 
adjust individual hybridization intensities to enable meaningful biological comparisons. 
The statistical tests for differential expression analysis are highly dependent on the 
choice of normalization methods. The assumption underlying microarray analysis is that 
the fluorescence signal intensities represent relative mRNA expression levels. However, 
there are many sources of variation throughout the experiments, such as RNA quality, 
target labeling, dye incorporation, hybridization, image analysis, and scanner 
photomultiplier tube (PMT) settings. These systematic variations can be categorized into 
three: biological, technical and residual variations (Chen et al., 2004).   
Normalization is needed to eliminate systematic variation from microarray data 
and the assumption of normalization is that “the majority of genes on the microarray are 
not differentially expressed” (Benes and Muckenthaler, 2003; Quackenbush, 2002; 
Yang, 2008). Generally there are three normalization techniques: total intensity 
normalization, normalization using regression techniques and normalization using ratio 
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statistics (Quackenbush, 2001). Normalization consists of two steps: within array 
normalization and between array normalization. 
Yang and coworkers suggest using a non-linear LOWESS regression normalization 
algorithm for two channel microarrays as they found that this method accounts for 
intensity and spatial dependent dye bias (Yang et al., 2002). LOWESS normalization is a 
within array normalization method. Loess, a variant of LOWESS, can also be used for 
intensity dependent bias elimination. However loess uses a quadratic polynomial and 
LOWESS uses a linear polynomial (Do and Choi, 2006). Global loess normalization is a 
form of loess normalization and is usually used to address intensity dependent bias 
(Bolstad et al., 2003). This normalization assumes the intensity-based bias is global and 
normalization is applied to the entire data set. Additionally, print-tip LOWESS and 
print-tip loess are used for normalization considering local effects (i.e., print-tip spatial 
effect) (Leung and Cavalieri, 2003). LOWESS and Loess can fit in an MA plot where M 
is the log intensity ratio of the two channels, i.e., M= log2 (Cy5/Cy3) and A is the 
average log intensity values across the two channels, i.e., A= [log2 (Cy5)+log2 (Cy3)]/2. 
MA plot has been widely used as a diagnostic tool for normalization. A common array 
dye-swap (CADS) normalization method has been suggested for two channel 
microarrays and it can remove both dye bias and array effects under general assumptions 
(Dabney and Storey, 2007).   
Alternatively, mixed analysis of variance (ANOVA) models can be applied to 
normalize microarray data and this method can correct for extraneous effects such as dye 
and array effects (Cui and Churchill, 2003; Kerr et al., 2000). Scale normalization is 
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further applied between arrays so that each array has equal median value (Smyth and 
Speed, 2003). For single channel arrays, the quantile method is proposed to use for 
normalization (Bolstad et al., 2003). This method is based on quantiles and creates 
identical distributions of probe intensities for all arrays. Comparative study of the effects 
of different normalizations (i.e., global normalization, LOWESS normalization and 
variance stabilization normalization) on the list of DE genes has shown that there are 
differences among the normalization performances (Chiogna et al., 2009). This study 
also demonstrated that the data preprocessing, such as negative spot value handling in 
the case of high background, has a large effect on the list of DE genes, and the 
combination of two normalizations is effective on the identification of true DE genes 
(Chiogna et al., 2009). Many freely available software tools for microarray 
normalization have been developed, such as the Bioconductor project 
(http://www.bioconductor.org/) in the R statistical computing environment (Gentleman 
et al., 2004). There is, however,  no widely accepted method of microarray data 
normalization and the combination of different normalizations works well with regard to 
the identification of DE genes (Chiogna et al., 2009).    
MICROARRAY APPLICATION IN THE HORSE - AN OVERVIEW  
One of the first microarray experiments in horses used a human cDNA microarray 
in order to understand the gene regulation during the initiation of spermatogenesis (Ing 
et al., 2004). Ninety-three genes were identified as differentially expressed between light 
and dark testicular tissues. In addition, among these DE genes, DYS, DOC1, and GLG1 
were highly expressed in dark testis tissue and ODF2 and PDE3B were more expressed 
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in light testis tissue (Ing et al., 2004). Recently, a human extracellular matrix and 
adhesion molecule cDNA GEarray (SuperArray Biosciences Co., Fredrick, MD) was 
used to show that the MMP13 expression level was up-regulated in the granulation tissue 
of equine digital flexor tendonitis compared to normal tendon in the horse (Nomura et 
al., 2007). The localization and preferential expression of MMP13 in the granulation 
tissue of  tendonitis indicated that MMP13 may play essential role in tendonitis (Nomura 
et al., 2007). Another study used a 22,000 Human Genome U133 Plus 2.0 Gene Chip 
(Affymetrix) to study gene expression profiles during recurrent airway obstruction 
(RAO) and identified 46 DE genes between RAO-affected horses and the controls 
(Ramery et al., 2008). STAT3, MARCKS, PTX3, CYBB, PTPRC and BTG1 have 
potentially functional relevance to RAO among these DE genes (Ramery et al., 2008). It 
was concluded that since the findings were based on a human expression microarray, 
studies using equine specific array are needed to fully verify and understand the 
expression profiles of genes involved in RAO. For example, the human array failed to 
detect some genes known to be implicated in RAO, such as IL-1β and IL-8 (Ramery et 
al., 2008).  
Some equine studies have used mouse microarrays. Mucher and co-workers 
(Mucher et al., 2006) utilized a mouse 15,000 cDNA microarray to investigate the gene 
expression profiles in equine muscle tissues. The results detected 71 DE genes between 
gluteus medius and longissimus lumborum muscle and demonstrated the feasibility of 
using mouse cDNA array to study gene expression profiling of genes involved in equine 
muscles after exercise (Mucher et al., 2006). Another study used the same mouse cDNA 
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microarray to investigate gene expression patterns in blood cells of horses who 
successfully complete competition (S) and those who were disqualified (D) due to 
metabolic disorders. The comparison showed 130 genes were up-regulated and 288 
genes were down-regulated between the successful and disqualified horses, and gene 
ontology analysis showed that more genes were up-regulated in S than in the D group of 
animals (Barrey et al., 2006), indicating long exercise affects significant gene expression 
changes in leukocytes.   
The first horse specific expression microarray (Affymetrix Equine Gene Chip) was 
created using 25-mer oligo probes corresponding to 3,098 equine specific genes (Gu and 
Bertone, 2004). The utility of this array was evaluated by addition of LPS into equine  
synoviocytes and 102 genes had changed their expression and many of them encoding 
inflammatory mediators were up-regulated (Gu and Bertone, 2004). The first study using 
this array investigated the correlation between the histologic and morphologic signatures 
through changes in the gene expression patterns in horses with osteoarthritis. Articular 
cartilage from horses with osteoarthritis in the palmar and dorsal region had different 
gene expression profiles, compared with control cartilage from normal joints. The 
authors concluded that the transcriptomic changes were in accordance with the structural 
features (Ramery et al., 2009; Smith et al., 2006a). Another study using this array 
investigated transcriptional changes of equine fibroblasts transformed by bovine 
papillomavirus-1 (BPV-1). A total of 81 genes in the transformed cell line had 
differential expression compared to the control cell line (Yuan et al., 2008). The results 
suggested that genes involved in cell adhesion and motility increased their expression 
 33 
and some genes involved in the immune response decreased their expression during 
sarcoid development.     
Recently, three equine tissue specific cDNA microarrays have been described. One 
is a 9,367 element equine articular cartilage cDNA microarray (Mienaltowski et al., 
2008) that was used to identify genes with a cartilage-restricted pattern of expression 
(Mienaltowski et al., 2009). The results indicated that different transcriptional profiles 
present in normal articular cartilage and repair tissue and further study of the factors 
which lead to this transcriptional difference may help understand repair process. Another 
tissue specific cDNA microarray was developed and has been applied to study gene 
expression profiles in leukocytes stimulated in vitro with LPS, peptidoglycan or 
lipoteichoic acid (Vandenplas et al., 2005). An equine specific cDNA microarray, 
constructed mostly from equine leukocyte cDNA library, has been used to study 
transcriptional changes during the early stages of equine laminitis (Noschka et al., 2008).  
In 2008, the first species-specific whole-genome expression oligoarrays were created for 
the horse. One of these is a 12,000 element equine 25-mer whole transcript 
oligonucleotide microarray (Affymetrix) that  combines equine ESTs, annotated 
mRNAs, and selected human sequence information (Glaser et al., 2009). This array has 
been validated in cartilage tissue with good performance and will be useful to study 
equine diseases. The other is a 21,000 element 70-mer oligo-based-array that uses the 
available equine EST sequences and the recent horse whole genome sequence data 
(Bright et al., 2009). The latter is currently the most comprehensive expression 
microarray available for the horse (Chowdhary and Raudsepp, 2008). The array has been 
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used in this study and is described in detail (materials and methods section of Chapter 
III, pages 74 to 75). In summary, human cDNA/oligoarray (22,000), mouse cDNA 
(15,000), bovine oligoarray (15,000), equine cDNA array (3,076 and 9,367) and 
oligoarray (3,098) have been used for gene expression study in equine tissues.   
THE USE OF EXPRESSION MICROARRAYS TO STUDY LAMINITIS 
The equine-specific 3,076 gene cDNA microarray has been used to study gene 
expression changes in laminar tissue at different time points after BWE administration 
(Noschka et al., 2008). The results showed that genes associated with inflammation and 
leukocyte activation, including monocyte chemotactic protein 3 (MCP-3), monocyte 
chemoattractant protein 1 (MCP-1), chemokine (C-X-C motif) ligand 10 (CXCL10) and 
ICAM-1 were up-regulated as early as 1.5 h following BWE administration. The results 
suggested that inflammatory response occurs at early developmental stage of BWE 
model of laminitis. While these initial attempts using an expression array are worth 
notating, the array has only 3,076 probes, and thus does not contain many genes that 
could potentially be involved in modulating changes observed during early stages of the 
disease.  
More recently a 15,000 element bovine microarray chip was used to assess gene 
expression patterns in the developmental stage of the OF model of laminitis (Budak et 
al., 2009). The authors found 155 up-regulated genes and none down-regulated in the 
laminitis group compared to the controls. Further, the up-regulated genes were 
predominantly involved in inflammatory response and protein turnover (Budak et al., 
2009). The results concluded that inflammation occurs at the early developmental stage 
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of the OF model of laminitis. The authors recognized several limitations of their use of 
bovine microarray to study equine laminitis. Cross-species hybridization may generate 
false negative results. Furthermore, 15,000 bovine microarray may fail to identify all the 
genes with differential expression in the laminar tissue. While cross-species 
hybridization in microarrays have been used to study equine gene expression, some 
equine genes with low level of sequence homology with bovine, mouse or human 
homologues cannot be detected (Ing et al., 2004; Ramery et al., 2008).  
Thus, it is evident that the two expression arrays used previously have inherent 
limitations that limit our ability to draw meaningful conclusions regarding the potential 
genetic pathways and gene networks associated with the pathogenesis and progression of 
equine laminitis on a genome-wide scale. Although microarray technology is a 
comprehensive and powerful functional genomics tool, it has some limitations in disease 
characterization such as background noise. However, microarray–based genome-wide 
expression study and recently developed next generation sequencing–based technology 
for transcriptome profiling are complementary approaches for gene expression studies 
(Coppée, 2008). Also, microarray is much less costly than RNA sequencing (RNA-Seq) 
which uses deep sequencing technology. Therefore DNA microarray is still a valuable 
platform for studying complex diseases. A comprehensive equine whole-genome 
microarray is needed in order to investigate global gene expression changes in equine 
disease studies.  
We recently developed a comprehensive equine-specific ~21,000 element 
expression microarray at Texas A&M University for functional analysis of the equine 
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genome (Bright et al., 2009). This TAMU oligoarray was constructed using a 2.4 Gb 
whole genome sequence of the horse genome (EquCab2; 
http://www.broad.mit.edu/mammals/horse/), to which the following available 
information was added: RefSeq release 26, UniGene build#3, SwissProt release 12 and 
~43,000 unpublished ESTs, to identify genes and develop oligos specific for genes. The 
array thus developed is thus by far the most representative expression microarray tool for 
examining the equine transcriptome. In this study we utilized the TAMU whole-genome 
oligoarray to investigate global laminar tissue gene expression changes during the early 
stages of three different experimentally induced models of equine laminitis. Because the 
initial stages of laminitis are critical in understanding the progression of the disease, we 
embarked on identifying the genes and their likely interactions that lead to observed 
pathological changes during these stages. Knowing the gene expression changes within 
the laminar tissues during development and progression of laminitis will lead to new 
ways to predict the outcome of disease and design therapies for treatment/prevention.  
THE HYPOTHESES AND OBJECTIVES OF THE DISSERTATION 
Various causes of laminitis lead to altered gene function and regulation in the 
laminar tissue during the developmental and subsequent/advanced stages of the disease. 
These changes reflect the gross and histological changes that are characteristic of various 
stages of the disease. Hence our hypothesis is that: registering gene expression patterns 
in the laminar tissue at various time-points during the progression of the disease and 
comparing them in relation to expression in normal laminar tissue will provide insight 
into the molecular mechanisms associated with the progression of the disease. In this 
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dissertation, our focus is on three different models of laminitis and we target the initial 
stages of the development of the disease, viz., developmental (DEV) and/or the Obel 
grade 1. The three models chosen for this work are CHO, HI and OF. While our long-
term goals are to decipher the molecular mechanisms associated with the initiation and 
progression of laminitis for developing novel and effective approaches to treat the 
disease, our goal in this dissertation research is to understand the molecular processes 
modulating the initial phase of the disease in three different experimental models of 
laminitis that fairly closely mimic the acute form of naturally occurring laminitis (the 
CHO model), endocrinopathic laminitis (the HI model) and pasture associated laminitis 
(the OF model). Broadly, the specific objectives associated with the goal are to: 
(1) identify genes differentially expressed during the early stages (i.e., 
developmental, Obel grade 1, etc.) of experimentally induced equine laminitis in 
relation to normal laminar tissue.  
(2) perform gene ontology enrichment analysis to obtain information about the 
predominant functions of DE genes.  
(3) identify pathways and associated genetic networks of the DE genes to 
understand their role during the pathogenesis of equine laminitis.  
(4) validate the expression of DE genes that play a key role in above described 
pathways and networks by quantitative real time PCR.  
We expect to find differences, as well as common features of the earliest changes in 
the laminar tissue among different models of laminitis during disease progression 
regardless of the triggering factors. The immediate goal and the objectives outlined 
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above are accomplished through three set of experiments each focusing on individual 
experimental model of laminitis, and are presented in this dissertation as Chapters III, IV 
and V as listed below: 
1. Genome-wide transcriptome analysis of laminar tissue during the developmental 
stage and the onset of carbohydrate overload induced equine laminitis 
2. Gene expression profiling in induced laminitic horses by prolonged 
hyperinsulinaemia using an equine whole genome oligoarray 
3. Transcriptome profiling of laminar tissue during the early stages of oligofructose 
induced laminitis in the horse 
RATIONALE AND SIGNIFICANCE OF THE PRESENT STUDIES 
Equine laminitis is a debilitating disease that causes extreme sufferring in afflicted 
horses and often results in a lifetime of chronic pain. The economic impact of this 
disease on the horse industry is also significant as a result of veterinary expenses, cost of 
long-term care, and loss of use of the animal. The exact sequence of pathophysiological 
events culminating in laminitis has not yet been characterized, and this is reflected in the 
lack of any consistently effective therapeutic strategy. The development of more 
effective therapeutic & preventive strategies requires a better understanding of disease 
initiation and progression.  
Two expression arrays have been used for equine laminitis study. One is equine-
specific 3,076 gene cDNA microarray to study gene expression at 1.5, 3 and 12 h of 
BWE model of laminitis. Another study is that bovine 15,000 bovine microarray was 
used to investigate gene expression patterns in the developmental stage (24-32 h) of OF 
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model of laminitis. These two expression arrays used have limitations. For these reasons, 
an equine specific whole-genome microarray is necessary in order to get broad picture 
about the gene expression changes during early stages of equine laminitis.  
Furthermore, CHO, HI and OF models of laminitis represent most common natural 
causes of laminitis. Transcriptomic analysis of early stages of different models of 
laminitis will provide information about gene expression changes resulting from 
different causes. The common differentially expressed genes identified in this study will 
be excellent candidates for future functional study and will be potentially therapeutic 
targets for laminitis treatment.  
The rationale of this project is that if we obtain detailed knowledge about the 
transcriptome expression profiles of laminar tissue of horses at risk for laminitis (i.e., the 
developmental stage) and at onset when horses first exhibit clinical sign of laminitis (i.e., 
Obel grade 1 laminitis stage), a clearer picture of the gene expression changes, metabolic 
pathways, and genetic networks that accompany the development and progression of 
laminitis will be obtained. This will, in turn, lead to new ways to help develop potential 
preventions and therapeutic strategies. This could include the design of antagonist or 
agonist compounds that target the key gene receptor, inhibitor or activator of the target 
enzyme(s), or anti-inflammatory drugs for equine laminitis that could particularly be 
affective during early stages of the disease.  
The proposed research is innovative because no high-density equine 
oligonucleotide microarray has been applied in the study of equine laminitis before. In 
addition, the CHO model of laminitis is more similar to naturally occurring laminitis and 
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thus superior to the BWE model of laminitis used by the studies of Noschka and co-
workers (Noschka et al., 2008). Further, the time points used for OF model of laminitis 
in our study (i.e., 12 h and 24 h time points) is earlier than that of previous study (24-30 
h; Budak et. al., 2009); we may find the very early expression changes in laminar tissue. 
The knowledge obtained from this study will help us to formulate new effective 
strategies to prevent and treat this disease. 
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CHAPTER II 
MATERIALS AND METHODS  
 
LAMINAR SAMPLES ACQUISITION 
CHO samples 
Fifteen clinically normal Quarter horses (10 mares and 5 geldings) between 3 to 12 
years old were used in this study. The Animal Care and Use Committee at the Ohio State 
University approved the experimental protocol. The control samples were obtained 24 h 
following saline injection (CON, n=5). The experimental samples were obtained at two 
stages after CHO (starch) administration at a concentration of 17.6 g/kg of body weight 
via a nasogastric tube according to the method of Garner and coworkers (Garner et al., 
1975): a developmental (DEV) group at the onset of fever (12-22 h, DEV, n=5) and Obel 
grade 1 (OG1) laminitis group at the onset of lameness (20-48 h, OG1, n=5). Physical 
examination including the measurement of rectal temperature and evaluation of 
lameness was performed every two hours. Onset of fever means rectal temperature 
increased two degrees above the starting temperature of individual horse following CHO 
administration. Samples were collected following euthanasia with pentobarbital sodium 
and phenytoin sodium and as described earlier (Belknap et al., 2007; Pollitt, 1996). 
Briefly, the forelimbs were removed by disarticulation of the metacarpophalangeal joint 
from each horse and sagittal sections of the digit were cut with a band saw. Blocks of 
laminar tissue were obtained from the mid-point between the level of the coronary band 
and the ground-bearing surface on the dorsal aspect of the foot by sharp dissection. The 
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samples were immediately frozen in liquid nitrogen and stored at -80°C following 
collection. Frozen laminar tissue samples (kindly provided by Dr. James Belknap, 
Department of Veterinary Clinical Sciences, Ohio State University) were shipped on dry 
ice for use in our laboratory. 
HI samples 
Eight clinically normal Standardbred horses ranging from 3-7 years in age were 
used for this study (7 geldings, 1 filly). The horses were assigned into 4 pairs. Within 
each pair, one was assigned randomly to control (n=4) or experimental groups (n=4). 
The Animal Ethics Committee of the University of Queensland approved the 
experimental protocol. Samples were obtained from horses developed Obel grade 2 
laminitis within 48 h (44-48 h, n=4) after hyperinsulinaemia was induced by constant 
infusion of insulin and from control horses received saline infusion for the same period 
as their paired horse (de Laat et al., 2010). Physical examination including body 
temperature, heart rate and respiration rate was recorded. Samples were collected 
following euthanasia with pentobarbital sodium and as described earlier (de Laat et al., 
2010; Pollitt, 1996). Briefly, all hooves of each horse were disarticulated at the 
metacarpophalangeal joint. The foot was sectioned with a band saw and middle portions 
of the dorsal hoof wall laminae were obtained and snap frozen in liquid nitrogen and 
stored at -80°C. The time between disarticulation and snap freezing was less than 5 min. 
Frozen laminar tissue samples (kindly provided by Dr. Christopher Pollitt, Australian 
Equine Laminitis Research Unit, the University of Queensland and Dr. Hannah 
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Galantino-Homer, Laminitis Institute, University of Pennsylvania) were shipped on dry 
ice for use in our laboratory.  
OF samples 
Eighteen clinically normal Standardbred horses (3 mares, 15 geldings) from 2 to 
12 years of age were used in this study. The Animal Ethics Committee of the University 
of Queensland approved the experimental protocol. The animals were divided into three 
groups: control (CON; n=6) animals given water, experimental animals fed oligofructose 
for 12 h (12 h; n=6) and 24 h (24 h; n=6) at a concentration of 10g/kg of body weight via 
a nasogastric tube according to the method described by van Eps and Pollitt (van Eps 
and Pollitt, 2006). Physical examination including the measurement of rectal 
temperature and evaluation of lameness was performed every two hours. Twelve and 24 
hours post OF administration the horses were anaesthetized with xylazine and ketamine 
and a rubber tourniquet was applied to the fetlock of one fore foot which was then 
disarticulated through the distal metacarpophalangeal joint. The foot was sectioned with 
a band saw and middle portions of the dorsal hoof wall laminae were obtained and snap 
frozen in liquid nitrogen and stored at -80°C. The time between disarticulation and snap 
freezing was always less than 5 min. After this procedure was repeated on the opposite 
fore foot the horse was euthanized by overdosing with pentobarbital sodium. Frozen 
laminar tissue samples (kindly provided by Dr. Christopher Pollitt, Australian Equine 
Laminitis Research Unit, the University of Queensland and Dr. Hannah Galantino-
Homer, Laminitis Institute, University of Pennsylvania) were shipped on dry ice for use 
in our laboratory.  
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MICROARRAY EXPERIMENTAL DESIGN 
CHO experiment 
A two color, balanced design was used for microarray hybridizations. Three 
different comparisons were performed (DEV vs. CON, OG1 vs. CON, and DEV vs. 
OG1) as shown in Figs 2.1-2.3. Five biological replicates were included in each 
comparison. Dye swap was embedded in biological replicates to eliminate dye bias. The 
dyes and samples were balanced throughout 15 hybridizations (five laminar samples 
from controls labeled with Cy5 and five laminar samples from controls labeled with 
Cy3, five laminar samples from horses at the developmental stage labeled with Cy5 and 
five laminar samples from horses at the developmental stage labeled with Cy3, and five 
laminar samples from horses at the Obel grade 1 stage labeled with Cy5 and five laminar 
samples from horses at the Obel grade 1 stage labeled with Cy3). A total of 15 slides (5 
slides per comparison) were used. 
  
CON4
DEV4
DEV3
CON3
DEV1
CON1
DEV5
CON5
CON2
DEV2
 
Fig. 2.1. Experimental design of the comparison of developmental (DEV) vs. control 
(CON). The green color represents Cy3 and the red color represents Cy5. The laminar 
samples labeled with CON1, CON2, CON3, CON4, and CON5 were from control 
horses. The laminar samples labeled with DEV1, DEV2, DEV3, DEV4, and DEV5 were 
from horses at the developmental stage. 
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OG1-4
CON4
CON3
OG1-3
CON1
OG1-1
CON5
OG1-5
OG1-2
CON2
 
 
Fig. 2.2. Experimental design of the comparison of Obel grade 1 (OG1) vs. control 
(CON). The green color represents Cy3 and the red color represents Cy5. The laminar 
samples labeled with CON1, CON2, CON3, CON4, and CON5 were from control 
horses. The laminar samples labeled with OG1-1, OG1-2, OG1-3, OG1-4, and OG1-5 
were from horses at the Obel grade 1 laminitis stage.  
 
 
DEV4
OG1-4
OG1-3
DEV3
OG1-1
DEV1
OG1-5
DEV5
DEV2
OG1-2
 
 
Fig. 2.3. Experimental design of the comparison of developmental (DEV) vs. Obel grade 
1 (OG1). The green color represents Cy3 and the red color represents Cy5. The laminar 
samples labeled with DEV1, DEV2, DEV3, DEV4, and DEV5 were from horses at the 
developmental stage. The laminar samples labeled with OG1-1, OG1-2, OG1-3, OG1-4, 
and OG1-5 were from horses at the Obel grade 1 laminitis stage.  
 
 
 
HI experiment 
A two color, balanced block design was used for microarray hybridizations. The 
hybridizations were carried out based on their matched pairs during HI induction as 
shown in Fig 2.4. Four biological replicates were included in the comparison. Dye swaps 
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were incorporated into the hybridization scheme of the experiment. A total of four 
microarray slides were used. 
 
TH3
CH3
CH2
TH2
TH1
CH1
CH3
TH4
 
Fig. 2.4. Experimental design of the comparison of 48 h time point vs. control. The 
green color represents Cy3 and the red color represents Cy5. The laminar samples 
labeled with CH1, CH2, CH3, and CH4 were from control horses. The laminar samples 
labeled with TH1, TH2, TH3, and TH4 were from HI 48 h induced horses. 
 
 
 
OF experiment 
A two color, balanced design was used for microarray hybridizations. Three 
different comparisons were performed (12 h vs. CON, 24 h vs. CON, and 12 h vs. 24 h) 
as shown in Figs 2.5-2.7. Six biological replicates were included in each comparison. 
Dye swap was embedded in biological replicates to eliminate dye bias. Samples were 
paired to maximize similarity in age, sex and weight. The dyes and samples were 
balanced throughout 18 hybridizations (six laminar samples from controls labeled with 
Cy5 and six laminar samples from controls labeled with Cy3, six laminar samples from 
horses at the 12 h time point with OF induction labeled with Cy5 and six laminar 
samples from horses at the 12 h time point with OF induction labeled with Cy3, and six 
laminar samples from horses at the 24 h time point with OF induction labeled with Cy5 
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and six laminar samples from horses at the 24 h time point with OF induction labeled 
with Cy3). A total of 18 slides (6 slides per comparison) were used. 
 
 
12H-5
CON5
CON4
12H-4
12H-1
CON1
CON6
12H-6
12H-3
CON3
CON2
12H-2
 
 
Fig. 2.5. Experimental design of the comparison of 12 h time point (12H) vs. control 
(CON). The green color represents Cy3 and the red color represents Cy5. The laminar 
samples labeled with CON1, CON2, CON3, CON4, CON5, and CON6 were from 
control horses. The laminar samples labeled with 12H-1, 12H-2, 12H-3, 12H-4, 12H-5, 
and 12H-6 were from horses at the 12 h time point.  
 
 
 
 
CON5
24H-5
24H-4
CON4
CON1
24H-1
24H-6
CON6
CON3
24H-3
24H-2
CON2
 
Fig. 2.6. Experimental design of the comparison of 24 h (24H) time point vs. control 
(CON). The green color represents Cy3 and the red color represents Cy5. The laminar 
samples labeled with CON1, CON2, CON3, CON4, CON5, and CON6 were from 
control horses. The laminar samples labeled with 24H-1, 24H-2, 24H-3, 24H-4, 24H-5, 
and 24H-6 were from horses at the 24 h time point. 
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24H-5
12H-5
12H-4
24H-4
24H-1
12H-1
12H-6
24H-6
24H-3
12H-3
12H-2
24H-2
 
 
Fig. 2.7. Experimental design of the comparison of 12 h (12H) time point vs. 24 h time 
point (24H). The green color represents Cy3 and the red color represents Cy5. The 
laminar samples labeled with 12H-1, 12H-2, 12H-3, 12H-4, 12H-5, and 12H-6 were 
from horses at the 12 h time point. The laminar samples labeled with 24H-1, 24H-2, 
24H-3, 24H-4, 24H-5, and 24H-6 were from horses at the 24 h time point.   
 
RNA ISOLATION  
Total RNA was isolated from frozen laminar samples using Tri reagent (MRC, 
Cincinnati, OH) following RNA cleanup with RNase-free DNase treatment (Qiagen, 
Valencia, CA) according to the manufacturer‟s protocol. Briefly, 80-100 mg of frozen 
laminar tissue sample was disrupted using a mortar and pestle in liquid nitrogen 
followed by homogenization using a needle (18 gauge 1 1/2, PrecisionGlide®) and 
syringe (10 ml NORM-JECT®) (Fisher Scientific, Pittsburgh, PA) in Tri reagent. Then 
RNA was purified by bromochloropropane (BCP) and precipitated with isopropanol. 
After centrifugation, the RNA pellet was washed with 70% ethanol and then with 100% 
ethanol and dissolved in 100 μl RNase-free water. The RNA was cleaned up following 
the Qiagen RNeasy cleanup protocol (RNeasy Mini Kit, Qiagen, Valencia, CA). RNA 
was eluted with 35 μl RNase-free water. RNA concentration was quantified using a 
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spectrophotometer (NanoDrop Technologies, Wilmington, DE) and the quality was 
evaluated using an Agilent 2100 Bioanalyzer and RNA Lab Chip – RNA 6000 Nano 
Assay (Agilent Technologies, Palo Alto, CA).    
MICROARRAY HYBRIDIZATION 
Pre-hybridization treatment of microarray slide 
 The microarray slide rehydration and crosslinking step was done to make sure 
that the probe was spread evenly in the spot and immobilized on the slide. A water bath 
was set at 50°C and a heat block was set at 65°C. The slides were rehydrated by holding 
the slide label side down (spots down) over the steam from the 50°C water bath for 10 
sec and making sure spots don‟t over hydrate and merge. Then the slides were snap dried 
for 5 sec on the heat block with label side up. At the end the slides were brought to room 
temperature (20°C) for 1 min. The process was repeated up to four times. After 
rehydration, the slides were subjected to “crosslinking”. The crosslinking steps were as 
follows: a UV crosslinker was turned on and the energy level was set at 750 MJ/CM
2
. A 
piece of clean Kim Wipe was put inside the UV crosslinker and the START button was 
pressed. The slides were exposed to UV for 2 minutes. The slides were ready for 
hybridization after the exposure was finished.      
CHO experiment 
(1) cDNA synthesis and labeling 
Labeled cDNAs were synthesized from total RNA with the 3DNA Array 350 
Expression Array Detection Kit (Genisphere, Hatfield, PA). This kit was developed 
based on 3DNA dendrimer technology and dendrimer-based detection system has shown 
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ideal signal detection for DNA microarrays (Stears et al., 2000). Three micrograms of 
total RNA was combined with 1 μl of 1pmol/μl oligo-d(T) primer in a final volume of 11 
μl. The mixture was incubated at 80°C for 10 min and cooled on ice for 2 min. Four 
microliters of 5x SuperScript II first strand buffer, 1 μl of dNTP mix, 2 μl of 0.1M 
dithiothreitol and 1 μl of Superase-In RNase inhibitor were added to the RNA sample 
along with 1 μl of SuperScript II reverse transcriptase (200 U/μl) (Invitrogen, Carlsbad, 
CA). The reaction was incubated at 42°C for 2 hours. After that, 3.5 µl of 0.5M 
NaOH/50mM EDTA was added to degrade RNA with a 15 min incubation at 65°C. The 
reaction was neutralized with 5 μl of 1 M Tris-HCl (pH 7.5).  
(2) Microarray cDNA hybridization and wash  
A 580 μl reaction was used for the cDNA hybridization mix. Hybridization 
buffer (2x enhanced) was thawed and resuspended by heating at 70°C for 10 min. Then 
the buffer was vortexed and centrifuged at 4000 rpm for 1 min. The hybridization mix 
was constituted as follows: 28.5 μl of Cy3 cDNA and 28.5 μl of Cy5 cDNA were mixed 
with 2 μl of LNA dT blocker, 201 μl of nuclease-free water, 30 μl of 1x TE buffer and 
290 μl of hybridization buffer (2x enhanced). The hybridization mix (580 μl) was gently 
vortexed, microfuged, and incubated at 75°C for 10 min. The mixture was again 
vortexed, microfuged and applied to the gasket slide of an Agilent microarray 
hybridization chamber. Considerable care was taken to prevent the mixture from 
splashing under the edges of the gasket slide. The microarray slide (array side down) 
was laid on top of the gasket slide and the hybridization chamber was subsequently 
assembled tightly. The hybridization chamber was rotated to make sure the gasket slide 
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was wet and the bubbles moved to the side and were removed. The slides were then 
incubated at 55°C while gently rotating at a speed of 5 rpm in a hybridization oven 
(Agilent Technologies, Santa Clara, CA) for 16 hours. After overnight incubation, the 
hybridization chamber was taken out of the incubator and disassembled. The 
“microarray-gasket slide sandwich” was soaked in a Wheaton jar with pre-warmed 
(42°C) 2x SSC-0.2% SDS wash buffer for 3 min while gently agitating up and down by 
hand. The array slide always remained in the solution. Then a tweezer was used to 
separate the microarray slide from the gasket slide until the gasket slide fell off. The 
slides were transferred to another Wheaton jar with pre-warmed (42°C) 2x SSC-0.2% 
SDS wash buffer and the holder with slides was agitated up and down 10 times and then 
incubated at 42°C for 15 min. Following this, the slides were transferred to a new 
Wheaton jar with 2x SSC wash buffer and the holder with slides was agitated up and 
down for 10 times and incubated at room temperature for 15 min. Following this, the 
slides were transferred to a new Wheaton jar with 0.2x SSC wash buffer and incubated 
and gently rinsed at room temperature for 15 min. The slides (label side up) were dried 
in a 50 ml conical tube with cap off and centrifuged at 1000 rpm for 4 min. Finally, the 
slides were put in a clean slide box and were stored prior to the second hybridization.   
(3) 3DNA hybridization and wash 
3DNA Array 350 capture reagents were thawed in the dark for 20 min at room 
temperature. The capture reagents were then vortexed, microfuged and incubated at 
50°C for 10 min. At the same time, 2x SDS-based hybridization buffer was thawed and 
resuspended by heating at 70°C for 10 min. 3DNA hybridization master mix was 
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prepared by combining 2.5 μl of 3DNA Array 350 capture reagent 1 (Cy3, red cap tube), 
2.5 μl of 3DNA Array 350 capture reagent 2 (Cy5, blue cap tube), 20 μl of nuclease-free 
water, 25 μl of 2x SDS-based hybridization buffer and 0.25 μl of anti-fade reagent. The 
3DNA hybridization mix was incubated at 75-80°C for 10 min, applied to the array 
(label side) and covered with a coverslip in the dark. Care was taken to avoid any 
bubbles under the coverslip. The slide was placed in a 50 ml conical tube with 400 μl of 
nuclease-free water and incubated horizontally at 55°C in a hybridization oven (Agilent 
Technologies, Santa Clara, CA) for 4 hours in the dark. The cap of the tube was closed 
to maintain humidity.  
All washing steps following 3DNA hybridization step were conducted in the 
dark. The 50 ml conical tube with the slide was taken out of the incubator and immersed 
in a Wheaton jar with pre-warmed (42°C) 2x SSC-0.2% SDS wash buffer. The cover 
slip was removed from the array slide by gently agitating the slide up and down without 
touching the bottom of the jar. The array slides were transferred to another Wheaton jar 
with pre-warmed (42°C) 2x SSC-0.2% SDS wash buffer and the holder with slides was 
agitated up and down for 10 times and incubated at 42°C for 15 min. The slides were 
then transferred to a new Wheaton jar with 2x SSC wash buffer and the holder with 
slides was agitated up and down for 10 times and incubated at room temperature for 15 
min. Following this, the slides were transferred to a new Wheaton jar with 0.2x SSC 
wash buffer and incubated and gently rinsed at room temperature for 15 min. The slides 
(label side up) were dried in a 50 ml conical tube with the cap off and centrifuged at 
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1000 rpm for 4 min. Finally, the slides were put in a clean slide box and were stored for 
scanning.  
HI and OF experiments 
(1) cDNA synthesis 
cDNAs were synthesized from total RNA with the 3DNA Array 900MPX 
Expression Array Detection Kit (Genisphere, Hatfield, PA). This kit was also 
developed based on 3DNA dendrimer technology. Compared to 3DNA Array 350 
Expression Array Detection Kit, it requires small amount of starting eukaryotic total 
RNA (0.5-2 μg). One microgram of total RNA was combined with 2 μl of random 
primer, 1 μl of MPX dT primer in a final volume of 11 μl. The mixture was incubated at 
80°C for 10 min and cooled on ice for 2 min. Four microliters of 5x SuperScript II first 
strand buffer, 1 μl of dNTP mix, 2 μl of 0.1M dithiothreitol and 1 μl of Superase-In 
RNase inhibitor were added to the RNA sample along with 1 μl of SuperScript II reverse 
transcriptase (200 U/μl) (Invitrogen, Carlsbad, CA). The reaction was incubated at 42°C 
for 2 hours. After that, 3.5 µl of 0.5M NaOH/50mM EDTA was added to degrade the 
RNA with a 15 min incubation at 65°C. The reaction was neutralized with 5 μl of 1 M 
Tris-HCl (pH 7.5). At the end, 21.5 μl of 1x TE buffer was added to the reaction.   
(2) cDNA purification, tailing and ligation 
The cDNA was purified using the Qiagen MinElute PCR purification kit 
(Qiagen, Valencia, CA) according to the manufacturer‟s protocol. Briefly, 250 μl of 
buffer PB was added to the cDNA sample obtained above, mixed, and then applied to 
the MinElute column for centrifugation at 13,000 rpm for 1 min. The flow through was 
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discarded. Seven hundred microliters of ethanol-containing buffer PE was added to the 
MinElute column and centrifuged at 13,000 rpm for 1 min. The flow through was 
discarded. In order to get rid of the residual ethanol, the MinElute column was placed on 
the same collection tube and centrifuged at 13,000 rpm for additional 2 min. After 
centrifugation, 10 μl of buffer EB was added into the MinElute column placed on a 1.5 
ml nuclease-free tube to elute cDNA. The MinElute column tube was incubated for 2 
min at room temperature and centrifuged at 13,000 rpm for 2 min. Then nuclease-free 
water was added to the purified cDNA isolated in the 1.5 ml nuclease-free tube to a 
volume of 16.5 μl. The cDNA was incubated at 95°C for 10 min in a PCR thermal cycler 
and cooled on ice for 2 min.  
The cDNA was tailed by terminal deoxynucleotidyl transferase (TdT) enzyme in 
a reaction of 25 μl. Purified cDNA was mixed with 2.5 μl of 10x tailing buffer, 4 μl of 
10 mM dTTP, and 2 μl of TdT enzyme. The mixture was incubated at 37°C for 30 min 
and ligated to 3DNA capture sequence. The ligation steps were as follows: The tailed 
DNA was incubated at 95°C for 10 min in a PCR thermal cycler and cooled on ice for 2 
min. Five microliters of 6x ligation mix and 2 μl of T4 DNA ligase were added to the 
tailed DNA and were incubated at room temperature for 30 min. Then, 3.5 µl of 0.5M 
EDTA was added to the ligation reaction and vortexed. Subsequently 14.5 µl of 1xTE 
buffer was added to the reaction to bring the total volume to 50 µl. The 50 µl tagged 
DNA was purified again using the Qiagen MinElute PCR purification kit (Qiagen, 
Valencia, CA) according to the manufacturer‟s protocol. The purified 10 μl of cDNAs 
were combined according to the experimental design of hybridization.        
 55 
(3) Microarray tagged cDNA hybridization and wash  
A 543 μl reaction was used for the tagged cDNA hybridization mix. 
Hybridization buffer (2x enhanced) was thawed and resuspended by heating at 70°C for 
10 min. Then the buffer was vortexed and centrifuged at 4000 rpm for 1 min. The 
hybridization mix was constituted as follows: 10 μl of Cy3-cDNA and 10 μl of Cy5-
cDNA were mixed with 2 μl of LNA dT blocker, 201 μl of nuclease-free water, 30 μl of 
1x TE buffer and 290 μl of hybridization buffer (2x enhanced). The hybridization mix 
(543 μl) was gently vortexed, microfuged, and incubated at 75°C for 10 min. The 
mixture was again vortexed, microfuged and applied to the gasket slide of an Agilent 
microarray hybridization chamber. Considerable care was taken to prevent the mixture 
from splashing under the edges of the gasket slide.  
The microarray slide (array side down) was laid on top of the gasket slide and the 
hybridization chamber was subsequently assembled tightly. The hybridization chamber 
was rotated to make sure the gasket slide was wet and the bubbles moved to the side and 
were removed. The slides were then incubated at 55°C while gently rotating at a speed 
of 5 rpm in a hybridization oven (Agilent Technologies, Santa Clara, CA) for 16 hours. 
After overnight incubation, the hybridization chamber was taken out of the incubator and 
disassembled. The “microarray-gasket slide sandwich” was soaked in a Wheaton jar 
with pre-warmed (42°C) 2x SSC-0.2% SDS wash buffer for 3 min while gently agitating 
up and down by hand. The array slide always remained in the solution. Then a tweezer 
was used to separate the microarray slide from the gasket slide until the gasket slide fell 
off.  
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The slides were transferred to another Wheaton jar with pre-warmed (42°C) 2x 
SSC-0.2% SDS wash buffer and the holder with slides was agitated up and down for 10 
times and then incubated at 42°C for 15 min. Following this, the slides were transferred 
to a new Wheaton jar with 2x SSC wash buffer and the holder with slides was agitated 
up and down for 10 times and incubated at room temperature for 15 min. Following this, 
the slides were transferred to a new Wheaton jar with 0.2x SSC wash buffer and 
incubated and gently rinsed at room temperature for 15 min. The slides (label side up) 
were dried in a 50 ml conical tube with cap off and centrifuged at 1000 rpm for 4 min. 
Finally, the slides were put in a clean slide box and were stored prior to second 
hybridization.   
(4) 3DNA hybridization and wash 
3DNA Array 900MPX capture reagents were thawed in the dark for 20 min at 
room temperature. The capture reagents were then vortexed, microfuged and incubated 
at 50°C for 10 min. At the same time, 2x SDS-based hybridization buffer was thawed 
and resuspended by heating at 70°C for 10 min. 3DNA hybridization master mix was 
prepared by combining 2.5 μl of 3DNA Array 900MPX capture reagent 1 (Cy3, red cap 
tube), 2.5 μl of 3DNA Array 900MPX capture reagent 2 (Cy5, blue cap tube), 20 μl of 
nuclease-free water and 25 μl of 2x SDS-based hybridization buffer. The 3DNA 
hybridization mix was incubated at 75-80°C for 10 min, applied to the array (label side) 
and covered with a coverslip in the dark. Care was taken to avoid any bubbles under the 
coverslip. The slide was placed in a 50 ml conical tube with 400 μl of nuclease-free 
water and incubated horizontally at 55°C in a hybridization oven (Agilent technologies, 
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Santa Clara, CA) for 4 hours in the dark. The cap of the tube was closed to maintain 
humidity.   
All washing steps following 3DNA hybridization step were conducted in the 
dark. The 50 ml conical tube with the slide was taken out of the incubator and immersed 
in a Wheaton jar with the pre-warmed (42°C) 2x SSC-0.2% SDS wash buffer. The cover 
slip was removed from the array slide by gently agitating the slide up and down without 
touching the bottom of the jar. The array slides were transferred to another Wheaton jar 
with pre-warmed (42°C) 2x SSC-0.2% SDS wash buffer and the holder with slides was 
agitated up and down for 10 times and incubated at 42°C for 15 min. The slides were 
then transferred to a new Wheaton jar with 2x SSC wash buffer and the holder with 
slides was agitated up and down for 10 times and incubated at room temperature for 15 
min. Following this, the slides were transferred to a new Wheaton jar with 0.2x SSC 
wash buffer and incubated and gently rinsed at room temperature for 15 min. The slides 
(label side up) were dried in a 50 ml conical tube with the cap off and centrifuged at 
1000 rpm for 4 min. Finally, the slides were put in a clean slide box and were stored for 
scanning.  
MICROARRAY IMAGE PROCESSING  
The slides were scanned with a GenePix Personal 4000B microarray scanner 
(Molecular Devices Corporation, Sunnyvale, CA) at 5 μm resolution and the images 
were saved in 16-bit multi-image Tagged Image Format File (TIFF) format. A preview 
scan was conducted to view the entire slide and select the area on the array that will be 
scanned at high resolution. During the preview scan, the photomultiplier tube (PMT) 
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voltage setting was adjusted so that the ratio of the intensities of both channels (635 nm 
and 532 nm) is around 1. Channel Cy5 is excited by 635 nm red laser light and channel 
Cy3 is excited by 532 nm green laser light. The histogram tab in the GenePix Pro 6.0 
program (Molecular Devices Corporation, Sunnyvale, CA) for GenePix microarray 
scanners can be used as reference for PMT adjustment. The PMT voltage is optimal 
when the lines representing both channels approximately overlap in the histogram tab. 
Once the array was scanned, a GenePix Array List (GAL) file was loaded into the 
GenePix Pro 6.0 program. The GAL file provided position and identity information of 
each spot on the array. Each spot was visually inspected by manual gridding. All 
aberrant (e.g., high background, dust, and scratch) and empty spots were flagged and 
excluded from further analysis. The fluorescence intensities of all spots from each array 
were quantified using GenePix Pro 6.0 program and saved as GenePix Results (GPR) 
file.  
DIFFERENTIAL EXPRESSION DATA ANALYSIS 
CHO experiment 
The subset signal intensity data of GPR file including the median of signal 
intensity and local background of both channels (F635 median, F532 median, B635, and 
B532, F635 median: the foreground median intensity value of all pixels at the red 
channel (635 nm), F532 median: the foreground median intensity value of all pixels at 
the green channel (532 nm), B635: the background intensity value of all pixels at the red 
channel, B532: the background intensity value of all pixels at the green channel) were 
used as input into R statistical computing environment R.10.0 (Ihaka and Gentleman, 
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1996) (http://www.r-project.org/). LOWESS normalization was applied to the signal 
intensity data to eliminate intensity-dependent dye bias (Yang et al., 2002). It is based on 
the fact that the quantified signal intensities are usually related nonlinearly to the 
expression level of the corresponding genes (Ramdas et al., 2001). The efficiency of 
LOWESS normalization was evaluated by checking Cy5 intensity-Cy3 intensity plot for 
data from each array before and after LOWESS normalization. The normalized data was 
then analyzed using a mixed model approach in SAS (SAS 9.1.3) (SAS Institute Inc. 
Cary, NC). The mixed model including treatment (fixed effect), dye (fixed effect), and 
array (random effect) was used to identify significantly differentially expressed genes. 
The SAS estimate function was used to test the statistical significance between 
conditions and the output file with P value and natural logarithms of fold change of each 
gene was obtained.  
HI and OF experiments 
The microarray data were analyzed using the bioconductor 
(http://www.bioconductor.org/) (Gentleman et al., 2004) LIMMA (linear models for 
microarray data) package version 3.4  in the R statistical computing environment R.10.0 
(Ihaka and Gentleman, 1996) (http://www.r-project.org/). LIMMA is a software package 
that uses linear models to assess differential expression (Smyth, 2004). The signal 
intensity file including the median of signal intensity and local background of both 
channels (F635 median, F532 median, B635, and B532) was used as input into LIMMA 
program. The foreground median signal intensity was background corrected for each 
spot. Those spots with negative background corrected intensity in both channels across 
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all replicated slides were filtered. The default print-tip loess normalization was then 
applied to each array as recommended by Smyth and Speed (Smyth and Speed, 2003). 
Scale normalization was performed between arrays if there was evidence of a scale 
difference. The quality of the microarray data was evaluated by examining the MA plot, 
in which log-transformed ratios of fluorescence intensities (M=log2(R/G) were plotted 
against log-transformed multiples of intensities (A=log2(R*G)/2) before and after 
normalization. R represents the background adjusted fluorescence intensity in the red 
channel and G represents the background adjusted fluorescence intensity in the green 
channel. In addition, the boxplot of background intensities of each array was checked to 
assess the microarray quality. After normalization, a linear model was applied to the 
normalized data and a design matrix was specified. The design matrix indicated the 
RNA targets which hybridized into the arrays (including dye swaps). The columns of the 
design matrix represent the parameters to be evaluated (e.g., M values for HI/CON 
comparison) and the rows correspond to the arrays in the experiment. Empirical Bayes 
moderated F statistics was used to assess differential expression. The advantage of the 
empirical Bayes method implemented in LIMMA is that it can borrow information from 
the replicates and make stable inference about each gene (Ritchie et al., 2007; Smyth, 
2004). An output file containing a P value, t-statistic, average log2 expression level, log2-
based fold change of each gene was generated.  
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FUNCTIONAL ANNOTATION ANALYSIS 
Gene ontology analysis 
Gene ontology (GO) was performed to classify the differentially expressed genes 
based on biological process (BP), molecular function (MF), and cellular component 
(CC) (http://www.geneontology.org/). GO analysis can provide information about the 
overrepresented categories among the genes. The list of DE genes (P<0.01 and fold 
change>2) was selected and separated based on the direction of regulation. The Database 
for Annotation, Visualization and Integrated Discovery (DAVID version 6.7) (Dennis et 
al., 2003; Huang et al., 2009) (http://david.abcc.ncifcrf.gov/), based on a Fisher Exact 
statistic methodology, was used to obtain GO terms within up and down-regulated 
genes. The RefSeq protein IDs from human orthologs were used as input and human 
database as background (DAVID default setting). We chose RefSeq protein ID as 
identifier because protein ID is unique. An output file in Functional Annotation Chart of 
DAVID containing GO term, count, percent and P value of each category was generated. 
The column labeled with count means the total number of genes from the input list that 
belong to the corresponding GO term. The column labeled with percent corresponds to 
the number of count divided by the number of input genes. The enrichment P value in 
Functional Annotation Chart is calculated based on EASE score (Hosack et al., 2003). P 
value of 0.05 was used as a cutoff for determining statistical significance as 
recommended by Huang et al. (Huang et al., 2009). GO terms are in a tree structure and 
GO_ALL were used for analysis because the GO terms at this level are more specific.  
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Pathway and network analysis 
 Initial pathway analysis was conducted using GenMAPP version 2.1 (Salomonis 
et al., 2007) (http://www.genmapp.org/) and Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathway databases (Kanehisa et al., 2008) 
(http://www.genome.jp/kegg/). To expand upon these results, we utilized a more robust 
pathway and associated network detection program, Ingenuity Pathways Analysis 
program (Ingenuity Systems, http://www.ingenuity.com/, version 8.7).   
Networks, relevant biofunctions and canonical (i.e., known or established)  
pathways were generated through the use of Ingenuity Pathways Analysis program in 
order to understand the potential pathways and associated networks involved in laminitis 
pathogenesis. A dataset containing gene identifier (RefSeq protein IDs from human 
orthologs), corresponding P value (P<0.01) and fold change (fold change>2) from 
microarray expression analysis were uploaded into the application as input dataset. Each 
gene identifier was mapped to its corresponding gene object in the Ingenuity Knowledge 
Base. These genes, called focus genes, were overlaid onto a global molecular network 
developed from information contained in the Ingenuity Pathway Knowledge Base. 
Networks of these focus genes were then algorithmically generated based on their 
connectivity. Ingenuity will generate several analysis results include one summary file, 
networks, canonical pathways, and function tables. Only top biological functions, 
associated diseases, top canonical pathways and top network based on P value that were 
most significant to the dataset are presented in this study.   
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The functional analysis identified the biological functions and diseases that were 
most significant to the dataset. Genes from the dataset that were associated with 
biological functions and diseases in the Ingenuity Pathway Knowledge Base were 
considered for further analysis. Fisher's exact test was used to calculate a P value 
determining the probability that each biological function and disease assigned to that 
data set is due to chance alone. The functional analysis of a network identified the 
biological functions and diseases that were most significant to the genes in the network. 
The network genes associated with biological functions and diseases in the Ingenuity 
Pathways Knowledge Base were considered for the analysis. Fisher's exact test was used 
to calculate a P value determining the probability that each biological function and 
disease assigned to that network is due to chance alone. 
Canonical pathways analysis identified the pathways from the Ingenuity Pathways 
Analysis library of canonical pathways that were most significant to the dataset. Genes 
from the dataset that were associated with a canonical pathway in the Ingenuity Pathway 
Knowledge Base were considered for analysis. The significance of the association 
between the dataset and the canonical pathway was measured in two ways: first, a ratio 
of the number of genes from the dataset that map to the pathway divided by the total 
number of genes that map to the canonical pathway was obtained. Second, Fisher's exact 
test was used to calculate a P value describing the probability that the association 
between the genes in the dataset and the canonical pathway is explained by chance 
alone. 
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Pathways were constructed using both direct and indirect relationships that 
provided graphical representation of the molecular relationships between genes (Merico 
et al., 2009). In these representations genes or gene products are shown as nodes, and the 
biological relationship between two nodes is presented as a line. All lines are supported 
by at least one reference from the literature. The intensity of the node color indicates the 
degree of up- (red) or down- (green) regulation. Nodes are displayed using various 
shapes that represent the functional class of the gene product. Lines are displayed with 
various labels that describe the nature of the relationship between the nodes. 
QUANTITATIVE REAL TIME PCR 
Although microarray technology is powerful, low-level gene expression is 
difficult to quantify because of low signal intensity which is sensitive to interference 
from factors (e.g., background noise) other than the samples themselves (Provenzano 
and Mocellin, 2007). Quantitative real-time PCR has been used in gene expression 
profiling to overcome the disadvantages encountered in microarray analysis (Dallas et 
al., 2005). To validate the differential expression of microarray results, a subset of DE 
genes (both up and down regulated) were examined by quantitative reverse transcriptase 
PCR (qRT-PCR). Most of DE genes with a small P value and large fold change were 
selected. The fold change of all selected genes is larger than 2. Some DE genes whose 
expression patterns and functional relevance link them to laminitis were also chosen for 
confirmation by qRT-PCR. Many genes that fit the criteria could not be used for real 
time PCR. Primer sets did not produce amplification, formed primer dimers, were not 
specific (as shown by multiple peaks in the melting curve), or had poor efficiency. 
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Primer 3 software (Rozen and Skaletsky, 2000) was used to design gene specific 
primers (http://frodo.wi.mit.edu/primer3/) and the designed primer pairs were checked 
by BLAST program (http://blast.ncbi.nlm.nih.gov/) for specificity. Each of the designed 
amplicons was 100-250 bp in length and each pair of primers were designed to span 
intron and exon boundaries whenever possible. We could not design primers for some 
genes because of an incomplete sequence (can‟t generate gene specific primers) or no 
associated annotation information (e.g., hypothetical protein). 
The cDNA was synthesized using TaqMan® Reverse Transcriptase reagents 
(Applied Biosystems, Carlsbad, CA) according to the manufacturer‟s protocol. In a 10 µl 
reverse transcription reaction, 0.2 µl of RNase inhibitor (20 units/µl), 2 µl of dNTP mix 
(10 mM), 0.25 µl of oligo d(T)16 (50 µM), 0.25 µl of random hexamer (50 µM), 1 µl of 
10x RT buffer, 2.2 µl of MgCl2 (25 mM), 0.25 µl of reverse transcriptase (50 units/µl), 
and 2.85 µl of nuclease-free water were mixed with 1 µl of total RNA (250 ng/µl). The 
reaction was gently vortexed and briefly centrifuged to collect the mixture at the bottom 
of a PCR tube. The reaction was incubated in a thermal cycler under the following 
conditions: 25ºC for 10 min, 48ºC for 30 min and 5 min at 95ºC at the end.  
The synthesized cDNA, horse genomic DNA, and nuclease-free water, were used 
as templates in a PCR reaction. In a 10 µl PCR reaction, the following components were 
added: 1.0 µl of 10x PCR buffer (containing 15 mM MgCl2), 0.1 µl of dNTP mix (20 
mM), 0.6 µl of forward and reverse primer mix (10 µM), 0.25 µl of JumpStart REDTaq 
DNA polymerase, 6.05 µl nuclease-free water with 2 µl of cDNA (25 ng/µl)/genomic 
DNA (25 ng/µl)/nuclease-free water. The cycling conditions for routine PCR 
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amplification were as follows: 1 cycle at 95ºC for 5 min, 30 cycles of 94ºC for 30 sec, 58 
ºC for 30 sec, 72ºC for 30 sec and 10 min at 72ºC at the end. The amplified DNA 
fragment of each gene was run in 2% agarose gel electrophoresis in order to check gene 
specific PCR product.  
Real time PCR amplification was carried out in 96-well plates on a LightCycler 
480 (Roche Diagnostics, Indianapolis, IN). Amplification reactions were performed in 
duplicate from individual laminar cDNA samples from each horse. One hundred 
nanograms of cDNA were used in a total volume of 20 µl with 10 µl 2x LightCycler ® 
480 SYBR Green I master mix (Roche Diagnostics, Indianapolis, IN), 9 µl of water 
(PCR grade) and 1 µl of forward and reverse primers (10 µM). To calculate the PCR 
amplification efficiencies of target and reference genes, a serial dilution of laminar 
cDNA template at different concentrations (200 ng/µl, 100 ng/µl, 50 ng/µl, 25 ng/µl, 
12.5 ng/µl, and 6.25 ng/µl) was made and used as a template for the real time PCR 
amplification reaction. The PCR efficiency was determined from the slope of the line 
along the concentrations as calculated by LightCycler 480 basic software version 1.2 
(Roche Applied Science, Indianapolis, IN). Crossing point (Cp) value is the fluorescence 
signal point where background fluorescence is exceeded and is inversely related to the 
cDNA concentration. The real-time PCR amplification program was 5 min at 95ºC, 
followed by 45 cycles of 10 sec at 95ºC, 5 sec at optimal annealing temperature for each 
specific set of primers and 10 sec at 72ºC. At the end, melting curves of PCR products 
were acquired by increasing the temperature from 65ºC to 95ºC. The primer set was 
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evaluated through the melting curve of the amplification product. The average Cp of the 
two duplicates was used for relative quantification.  
geNorm 
Because of the inherent variation in expression of reference genes (Piehler et al., 
2010; Radonic et al., 2004), qRT-PCR was carried out for several horse reference genes. 
The average expression stability and the optimal number of control genes for 
normalization were calculated using the geNorm computer program version 3.5  
(http://medgen.ugent.be/~jvdesomp/genorm/) (Vandesompele et al., 2002). geNorm is a 
Visual Basic program that evaluates the gene expression stability measure M for the 
reference genes. M is the mean pairwise variation of a reference gene compared with all 
other tested reference genes. For each reference gene, the pairwise variation with all 
other reference genes is calculated as the standard deviation of the logarithmic 2 
transformed expression ratios. Genes with higher M values have greater variation in 
expression. The stepwise exclusion of the gene with the highest M value leads to the 
ranking of the tested genes based on their expression stability. geNorm can also allow 
the determination of the optimal number of reference genes based on the pairwise 
variation V value. In order to determine the optimal number of reference genes, a 
normalization factor (NF) was calculated based on the geometric mean of Cp values of 
the multiple reference genes according to Vandesompele et al. (Vandesompele et al., 
2002). The pairwise variation was determined between two NFs for all samples 
(Vn/n+1=standard deviation of NFn and NFn+1). A large V value means that the additional 
reference gene should be included for NF calculation. A V value of 0.15 was generally 
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used to determine the optimal number of reference genes. The selection of 0.15 cut-off 
value is based on the finding that the inclusion of additional reference gene has less 
effect on the normalization when the pairwise variation between the sequential NFs is 
less than 0.15 (Hellemans et al., 2007).  
In order to get the most stable reference genes for real time PCR data 
normalization, Cp values across all samples obtained from real time PCR need to be 
transformed into relative quantification (Q) data using delta-Cq method. An input file 
containing sample and gene names with Q values was used for geNorm analysis. 
geNorm generated two output figures. First output chart gave information about the most 
stably expressed reference genes in the system. Second output chart gave information 
about how many reference genes needed for optimal normalization.       
qBasePlus 
qRT-PCR data was analyzed by the delta-Cq method (Hellemans et al., 2007). 
This method not only considered the difference of PCR amplification efficiency between 
the gene of interest and the reference gene, but also allowed to use more than one 
reference gene for qRT-PCR data normalization (Hellemans et al., 2007). Therefore it is 
much more accurate and reliable than the comparative Ct method (Livak and 
Schmittgen, 2001) or the Pfaffl method (Pfaffl, 2001). The qBasePlus software version 
1.0 (Biogazelle, Ghent, Belgium) was used to evaluate gene expression difference 
among experimental conditions. The input file containing Cp values, gene name and 
sample information was loaded into qBasePlus program. qBasePlus program converts 
the Cp values into normalized relative quantities (NRQs) based on both the differences 
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in PCR amplification efficiency between target genes and reference genes and multiple 
reference gene factors. It also calculates the calibrated normalized relative quantity 
(CNRQ), which equals the NRQ of the target gene divided by the geometric mean of 
NRQ of the reference genes. The output file of qBasePlus program has CNRQ value of 
each gene across all samples. It also provides the histograms showing the expression 
level and corresponding error bars of each gene across all samples under study. The 
statistical significance of the normalized CNRQ values between two groups was 
determined by nonparametric Mann-Whitney test in SPSS 17.0 statistics software (SPSS 
Inc, Chicago, IL). As gene expression levels often do not follow a normal distribution 
even after normalization (Purdom and Holmes, 2005), Mann-Whitney test is a good 
choice for comparing 2 unpaired groups since this test does not require a normal 
distribution (Motulsky, 2010). A P value less than 0.05 (95% confidence level) was 
considered statistically significant.  
CLUSTER ANALYSIS 
Cluster analysis is an exploratory data analysis approach for gene expression 
experiments. There are four types of clustering: “hierarchical clustering, k-means 
clustering, self organizing maps (SOMs), and principle component analysis (PCA)” 
(Eisen et al., 1998). Methods such as hierarchical clustering can allow us to cluster genes 
and samples respectively based on the expression pattern similarity and generate heat 
maps for visualization (Chipman and Tibshirani, 2006; D'Haeseleer, 2005). 
MultiExperiment viewer and R (MeV/R) program version 4.6 (Chu et al., 2008; Saeed et 
al., 2003) (http://expression.washington.edu/mevr/) was used for hierarchical cluster 
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analysis. The input tab-delimited text file containing gene name and expression values 
was loaded into MeV/R program and an expression image was generated. Then a 
commonly used clustering algorithm hierarchical clustering was performed on the 
expression values with default settings (euclidean distance metric and average linkage 
clustering method) and a heat map was constructed. In the heat map, each column 
corresponds to a sample and each row corresponds to a gene. The green to red color 
scale indicates the level of expression, where red corresponds to higher expression, 
green corresponds to lower expression. In the color scale limits default setting, the low 
end is 0 and midpoint is median value and high end is the value that 80% of the data 
below this value (http://www.tm4.org/documentation/MeV_Manual.pdf).  
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CHAPTER III 
GENOME-WIDE TRANSCRIPTOME ANALYSIS OF LAMINAR TISSUE 
DURING THE DEVELOPMENTAL STAGE AND THE ONSET OF 
CARBOHYDRATE OVERLOAD INDUCED EQUINE LAMINITIS  
 
INTRODUCTION  
Equine laminitis is a painful and debilitating condition that has an enormous 
impact on the economy of the horse industry as well as on quality of life for afflicted 
horses. Acute laminitis often results in the failure of the dermal-epidermal laminae and 
dorsopalmar rotation of the distal phalanx, causing extreme pain and many times leading 
to permanent lameness. The molecular triggers that cause laminitis are still unknown, 
although there are many suspected predisposing factors (Hood, 1999a). Excess grain 
intake, lush pasture, colitis and metritis can all lead to laminitis (Colles and Jeffcott, 
1977). Gastrointestinal disease is the most common problem occurring just prior to the 
onset of acute laminitis (Slater et al., 1995) and it has been suggested that 
“gastrointestinal derived factors are potential triggers for acute equine laminitis” (Elliott 
and Bailey, 2006). Experimentally induced models of laminitis have been established 
through the administration of CHO (Garner et al., 1975), BWE (Minnick et al., 1987), 
OF (van Eps and Pollitt, 2006) and a hyperinsulinemic/euglycemic clamp (Asplin et al., 
2007; de Laat et al., 2010).  
We currently have a limited ability to prevent and treat this devastating disease, 
which reflects a lack of understanding of its pathogenesis. Elucidation of the molecular 
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mechanisms responsible for the development and progression of laminitis may lead to 
improved strategies for early prevention or treatment of this disease. Although an 
equine-specific 3076 element cDNA microarray (Noschka et al., 2008) and a bovine 
15K oligoarray (Budak et al., 2009) have been used to investigate equine laminitis, they 
have inherent limitations that prevent detailed studies aimed at understanding the 
potential genetic pathways and networks associated with the pathogenesis and 
progression of laminitis on a genome-wide scale.  
We recently developed a comprehensive equine-specific ~21,000 element whole 
genome expression microarray for functional analysis of the equine genome (Bright et 
al., 2009). This oligoarray was constructed based on a 2.4 Gb whole genome sequence of 
the horse genome (EquCab2; http://www.broad.mit.edu/mammals/horse/), combined 
with RefSeq release 26, UniGene build#3, SwissProt release 12 and ~43,000 
unpublished ESTs, making it by far the most representative functional analysis tool for 
examining the equine transcriptome. Because the initial stages of laminitis are critical in 
understanding the progression of the disease, we sought to identify differentially 
expressed genes and their likely interactions that could lead to observed pathological 
changes during these stages. To accomplish this aim, we used a 70-mer equine whole-
genome oligoarray to investigate the laminar gene expression profile during the 
developmental stage (defined as the onset of fever) and the onset (Obel grade 1) of 
experimental carbohydrate induced laminitis.  
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MATERIALS AND METHODS 
Experimental design 
Experimental protocols were approved by the Animal Care and Use Committee at 
the Ohio State University.  Fifteen Quarter horses (3-12 years of age) were confirmed to 
be healthy and without any history of metabolic-endocrine disorders. Five horses were 
used for each category (developmental, Obel grade 1 and control). Horses in the 
developmental (DEV) and the Obel grade 1 (OG1) groups were administered 
carbohydrate in the form of corn starch (17.6 g/kg body weight) via nasogastric tube. 
Control group horses (CON) received saline injection. This method is an effective, 
repeatable means by which to induce laminitis (Garner et al., 1975). Laminar samples 
were obtained from the control group at 24 h (CON, n=5), a developmental group at the 
onset of fever (DEV, n=5), or when the onset of lameness was observed (OG1, n=5). 
Laminar tissue was rapidly obtained from the hoof and distal phalanx, snap frozen 
immediately in liquid nitrogen, and stored at -80 °C.   
A two channel, balanced block design was used for genome-wide transcriptional 
analysis. Three different comparisons were carried out (DEV vs. CON, OG1 vs. CON, 
and DEV vs. OG1). Dye swaps were incorporated into the hybridization scheme of the 
experiment to eliminate dye bias. The microarray hybridization experiment conducted in 
this study is shown in Fig. 3.1.   
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Fig. 3.1. Diagram of the CHO model laminitis experimental design. Fifteen 
hybridizations were performed. Arrows represent the hybridization between the laminar 
samples from different groups (n=5). CON: laminar samples from control horses; DEV: 
laminar samples from horses at the developmental stage; OG1: laminar samples from 
horses with Obel grade 1 laminitis.  
 
 
Equine 21K oligonucleotide microarray 
The 70-mer oligoarray was constructed based on a 2.4 Gb EquCab2 of horse 
genome (http://www.broadinstitute.org/mammals/horse), combined with RefSeq release 
26, UniGene build#3, SwissProt release 12 and ~43,000 unpublished ESTs (Bright et al., 
2009). Alignments of transcript and protein sequences to the genomic sequence were 
performed and analyzed in order to group all sequences representing the same gene into 
the same entity. Genes can thus be defined as intervals on the genome and can be given a 
type identified by the nature of sequences that define it (for example, RNA + EST). The 
proportion of transcript sequences represented in the genome assembly serves as an 
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indication of the genome sequence coverage. The genome coverage appears near 
complete (female genome), and supports restricting oligo design to genes present on the 
genome sequence. Genes with RNA, UniGene or EST in their type represent 97.5% of 
all genes (22414 out of 23012) and 13191 of these contain an EST. The other 2.5% of 
genes (598) are documented solely by a protein hit and could represent pseudogenes as 
well as genes. The 70-mer oligo design process resulted in 21351 probes, which were 
synthesized (Invitrogen, Carlsbad, CA) and spotted on amino-silane coated slides 
(Corning Incorporated, Corning, NY).  
RNA isolation and cDNA synthesis 
Total RNA was isolated from 80-100 mg of frozen laminar tissue, which was 
mechanically disrupted in the presence of Tri reagent (MRC, Cincinnati, OH). This was 
followed by RNA cleanup with RNase-free DNase treatment (RNeasy Mini Kit, Qiagen, 
Valencia, CA) of the isolate according to the manufacturer‟s protocol.  RNA was eluted 
with 35 μl RNase-free water. RNA concentration was quantified using a 
spectrophotometer (NanoDrop Technologies, Wilmington, DE) and the quality was 
evaluated with an Agilent 2100 Bioanalyzer and RNA Lab Chip (RNA 6000 Nano 
Assay, Agilent Technologies, Palo Alto, CA). Labeled cDNAs were synthesized from 
total RNA with the 3DNA Array 350 Expression Array Detection Kit (Genisphere, 
Hatfield, PA) using SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA). 
Three micrograms of total RNA was combined with oligo-d(T) primers, incubated at 
80°C for 10 min, and cooled on ice for 2 min. Finally, 0.5M NaOH/50mM EDTA was 
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added to degrade any remaining RNA; this reaction was neutralized with 1 M Tris-HCl 
(pH 7.5).  
Pre-hybridization treatment of microarray slide 
Rehydration and crosslinking of the microarray slide was performed to ensure 
that the probe was spread evenly in the spot and immobilized on the slide.  The slides 
were rehydrated by holding the slide label side down over the steam from a 50°C water 
bath for 10 s. The slides were dried for 5 s at 65°C and then brought to room temperature 
(20°C) for 1 min. This process was repeated up to four times. After rehydration, the 
slides were subjected to UV crosslinking at 750 MJ/cm
2
 for 2 minutes.      
Microarray cDNA hybridization  
A 580 μl reaction was used for the cDNA hybridization mix, which was prepared 
according to the manufacturer‟s instructions (Genisphere, Hatfield, PA).  The mixture 
was applied to the gasket slide of an Agilent microarray hybridization chamber and the 
microarray slide (array side down) was laid on top of the gasket slide. The hybridization 
chamber was assembled and the slides were then incubated at 55°C while rotating at 5 
rpm in a hybridization oven (Agilent Technologies, Santa Clara, CA) for 16 hours.  The 
“microarray-gasket slide sandwich” was then washed once with pre-warmed (42°C) 2x 
SSC-0.2% SDS wash buffer, disassembled, and washed again.  The array slide was then 
washed with 2x SSC and 0.2x SSC wash buffers.  Slides were dried at room 
temperature, centrifuged at 1000 rpm for 4 min, and then stored in a dry box prior to the 
second hybridization.   
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3DNA hybridization and wash 
3DNA hybridization master mix was prepared according to the manufacturer‟s 
instructions (Genisphere, Hatfield, PA), applied to the array, and covered with a 
coverslip in the dark.  The slide was placed in a 50 ml conical tube with 400 μl of 
nuclease-free water and incubated horizontally at 55°C in a hybridization oven (Agilent 
Technologies, Santa Clara, CA) for 4 hours in the dark. All washing steps following 
3DNA hybridization were conducted in the dark. The slide was taken out of the 
incubator and washed with pre-warmed (42°C) 2x SSC-0.2% SDS wash buffer. The 
cover slip was removed and the slide was washed again with 2x SSC-0.2% SDS buffer.  
The slide was then washed with 2x SSC and 0.2x SSC wash buffers. Finally, the slide 
was dried at room temperature, centrifuged at 1000 rpm for 4 min, and stored for 
scanning.  
Microarray image processing and data analysis 
The slides were scanned with a GenePix Personal 4000B microarray scanner 
(Molecular Devices Corporation, Sunnyvale, CA) at a resolution of 5 μm. The 
fluorescence intensities from each array were quantified using GenePix Pro 6.0 
(Molecular Devices Corporation, Sunnyvale, CA). Each spot was inspected by manual 
gridding and empty spots were flagged out. The LOWESS normalization method (Yang 
et al., 2002) was used to normalize the signal intensity of each gene in the R statistical 
computing environment (http://www.r-project.org/). The normalized natural logarithms 
of the intensities were then analyzed using a mixed model in SAS 9.1.3 (SAS Institute 
Inc, Cary, NC). The SAS estimate function was used to test for differential expression. 
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Gene ontology analysis 
Gene ontology (GO) is used to functionally annotate gene products. It has three 
categories: biological process (BP), cellular component (CC) and molecular function 
(MF). The Database for Annotation, Visualization and Integrated Discovery (DAVID 
6.7) (Dennis et al., 2003; Huang et al., 2009) (http://david.abcc.ncifcrf.gov/) was used to 
obtain GO terms, associated diseases, and related KEGG pathways for DE genes for the 
three comparisons: DEV vs. CON, OG1 vs. CON, and DEV vs. OG1. RefSeq protein 
IDs from human orthologs were used as input and Fisher‟s Exact P value of 0.05 was 
used as a cutoff for determining statistical significance. Gene ontology terms of all levels 
were included in the analysis.  
Pathway analysis 
Networks, relevant biofunctions and canonical pathways were generated through 
the use of Ingenuity Pathways Analysis program (Ingenuity Systems, version 8.7) in 
order to understand the potential pathways and associated networks involved in laminitis 
pathogenesis. A data set containing gene identifiers and corresponding expression values 
from the microarray expression analysis was uploaded into the application. Functional 
analysis identified the biological functions and diseases that were most significant to the 
dataset. Fisher's Exact test was used to calculate a P value determining the probability 
that each biological function and disease assigned to that data set (or network) is due to 
chance alone.  
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Quantitative real time PCR    
To further explore microarray results, a subset of DE genes from each comparison 
were examined by quantitative reverse transcription PCR (qRT-PCR).  cDNA was 
synthesized using TaqMan® Reverse Transcriptase reagents (Applied Biosystems, 
Carlsbad, CA) according to the manufacturer‟s protocol.  Real time PCR amplification 
of each gene was carried out in duplicate on a LightCycler ® 480 (Roche Diagnostics, 
Indianapolis, IN) using 2x LightCycler ® 480 SYBR Green I master mix (Roche 
Diagnostics, Indianapolis, IN). To calculate the PCR amplification efficiencies of target 
and reference genes, a serial dilution of laminar cDNA was made (200 ng/µl, 100 ng/µl, 
50 ng/µl, 25 ng/µl, 12.5 ng/µl, and 6.25 ng/µl) and used as a template.  PCR efficiency 
of each gene was determined from the slope of the line along the concentrations as 
calculated by LightCycler ® 480 basic software version 1.2 (Roche Applied Science, 
Indianapolis, IN). Each individual sample was run in duplicate and the average crossing 
point (Cp) value was used for relative quantification.  
Quantitative real time PCR data analysis 
Because of the inherent variation in expression of reference genes (Piehler et al., 
2010; Radonic et al., 2004), qRT-PCR was carried out for seven horse reference genes: 
ACTB, B2M, PPIA, GAPDH, GNB2L1, EEF1A1, and RPLP0. The average expression 
stability and the optimal number of control genes for normalization were calculated 
using the geNorm computer program version 3.5 
(http://medgen.ugent.be/~jvdesomp/genorm/) (Vandesompele et al., 2002). geNorm is a 
Visual Basic program that evaluates the gene expression stability measure M for the 
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reference genes. M is the mean pairwise variation of a reference gene compared with all 
other tested reference genes; genes with higher M values have greater variation in 
expression. The stepwise exclusion of the gene with the highest M value leads to the 
ranking of the tested genes based on their expression stability. The optimal number of 
reference genes was determined based on the pairwise variation V value according to the 
methods of Vandesompele et al. (Vandesompele et al., 2002). A V value of 0.15 was 
selected as a cut-off value (Hellemans et al., 2007).  The two most stable genes were 
used for normalization of qRT-PCR data.  
qRT-PCR data was analyzed by the delta-Cq method (Hellemans et al., 2007) in 
qBasePlus version 1.0 (Biogazelle, Ghent, Belgium). In brief, the qBasePlus program 
converts Cp values into normalized relative quantities (NRQs) based on both the 
differences in PCR amplification efficiency between target genes and reference genes 
and multiple reference gene factors. It also calculates the calibrated normalized relative 
quantity (CNRQ), which is the NRQ of the target gene normalized to the geometric 
mean of the NRQ of the reference genes. The statistical significance of the derived 
CNRQ values between two groups was determined by nonparametric Mann-Whitney test 
in SPSS 17.0 statistics software (SPSS Inc, Chicago, IL). A P value less than 0.05 was 
considered statistically significant. 
Hierarchical cluster analysis 
To identify gene clusters with similar expression pattern among CON, DEV and 
OG1 conditions, hierarchical clustering was performed on the mean values of selected 
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DE genes from qRT-PCR to construct a heat map using MultiExperiment viewer and R 
(MeV/R) program version 4.6 (Chu et al., 2008; Saeed et al., 2003). 
RESULTS 
Differential gene expression profile   
Differential gene expression was determined for the pairwise comparisons among 
the three groups: developmental vs. control (DEV/CON), Obel grade 1 vs. control 
(OG1/CON), and developmental vs. Obel grade 1 (DEV/OG1). There were 68, 149, and 
160 genes differentially expressed (P<0.01, fold change>2) in the DEV/CON, 
OG1/CON and DEV/OG1 comparisons, respectively. Of these, 56, 114, and 135 were 
annotated (Table 3.1). Fold changes ranged from 0.33 to 2.80 (DEV/CON), 0.22 to 38.4 
(OG1/CON), and 0.03 to 5.30 (DEV/OG1). A general predominance of down-regulation 
was seen among differentially expressed (DE) genes in the DEV group, whereas up-
regulated genes were predominant in the OG1 group. The DE genes with the largest fold 
changes are shown in Tables 3.2, 3.3, and 3.4 for each of the three comparisons, 
respectively. Complete lists of DE genes (P<0.01, fold change>2) are shown in Tables 
A.1, A.2, and A.3.  
 
Table 3.1   
Distribution of differentially expressed genes among comparisons. 
 
  Upregulated Downregulated Total 
DEV/CON 11 (19.6%) 45 (80.4%) 56 
OG1/CON 82 (71.9%) 32 (29.1%) 114 
DEV/OG1 30 (22.2%) 105 (77.8%) 135 
    
 Table 3.2 
 Top differentially expressed genes (11 upregulated and 15 downregulated; P < 0.01 and fold change> 2) for the DEV/CON 
comparison.  Unannotated genes are labelled as NULL. Asterisks denote genes selected for confirmation with PCR. 
 
   
Public  
 
Fold 
 
  
Gene 
Name Description Accession P Change PCR 
Upregulated 
     
 
NULL 
 
BM734930 0.0026 3.35 
 
 
CCL2 C-C motif chemokine 2 AJ251189 0.0056 3.00 * 
 
NULL 
 
BI961659 0.0000 2.79 * 
 
MFAP5 Microfibrillar associated protein 5 NULL 0.0071 2.68 
 
 
HOPX Homeodomain-only protein XM_001491312 0.0096 2.45 * 
 
RSPH3 Radial spoke protein homolog 3 XM_001491976 0.0042 2.35 
 
 
CRYAB Alpha crystallin B chain  XM_001501779 0.0031 2.35 * 
 
NULL 
 
CX602928 0.0068 2.31 
 
 
CLEC2L C-type lectin 2L (CD69) XM_001496572 0.0099 2.28 
 
 
USP44 Ubiquitin carboxyl-terminal hydrolase 44  XM_001495993 0.0095 2.07 
 
 
NULL 
 
DN505910 0.0052 2.03 
 
       Downregulated 
     
 
PIGR Polymeric IgG receptor  XM_001492298 0.0001 0.33 
 
 
SNF8 Vacuole protein VPS22  XM_001502240 0.0012 0.34 * 
 
NULL 
 
XM_001498378 0.0028 0.35 
 
 
FLRT3 
Fibronectin leucine rich transmembrane protein 
3 XM_001491950 0.0072 0.37 
 
 
NULL 
 
CX604746 0.0001 0.37 
 
 
SEPP1 Selenoprotein P, plasma, 1 XR_036255 0.0014 0.39 * 
 
ZDHHC6 Zinc finger, DHHC-type containing 6 XM_001498439 0.0050 0.39 
 
 
PTPN6 
Protein tyrosine phosphatase, non-receptor type 
6 XM_001497706 0.0079 0.40 
 
 
TIGD1 Tigger transposable element derived 1 XM_001503915 0.0032 0.40 
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 Table 3.2 continued 
   
Public  
 
Fold 
 
  
Gene 
Name Description Accession P Change PCR 
       Downregulated 
     
 
C11orf59 
 
XM_001499308 0.0080 0.40 
 
 
CA5B Carbonic anhydrase VB XM_001490349 0.0071 0.40 
 
 
CILP2 Cartilage intermediate layer protein 2 XR_036360 0.0007 0.41 
 
 
CDK5RAP2 CDK5 regulatory subunit associated protein 3 XM_001501690 0.0022 0.42 
 
 
C8orf70 
 
XM_001491870 0.0079 0.43 
   PRR15 Proline rich 15 XM_001500279 0.0050 0.43   
 
 
 
 
Table 3.3 
Top differentially expressed genes (15 upregulated and 15 downregulated; P < 0.01 and fold change > 2) for the OG1/CON 
comparison.  Unannotated genes are labelled as NULL. Asterisks denote genes selected for confirmation with PCR. 
 
   
Public  
 
Fold 
 Gene 
Name   Description Accession P Change PCR 
Upregulated 
     
 
S100A8 S100 calcium binding protein A8 XM_001493589 0.0000 38.36 * 
 
S100A12 S100 calcium binding protein A12 CD535886 0.0000 36.47 * 
 
DEFB4 Beta-defensin 4 AY170305 0.0000 31.68 * 
 
NULL 
 
BM734930 0.0000 22.85 
 
 
SOD2 Superoxide dismutase 2, mitochondrial AB001693 0.0000 20.09 
 
 
S100A8 S100 calcium binding protein A8 XM_001494358 0.0000 16.90 
 
 
NULL 
 
CD467650 0.0000 16.27 
 
 
PI3 Peptidase inhibitor 3, skin-derived BM734843 0.0001 15.34 
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Table 3.3 continued 
 
   
Public  
 
Fold 
 Gene 
Name   Description Accession P Change PCR 
                SAA1 Serum amyloid A1 NM_001081853 0.0002 12.03 
 
 
S100A9 S100 calcium binding protein A9 XM_001493530 0.0003 10.42 * 
 
CCL2 Chemokine (C-C motif) ligand 2 AJ251189 0.0000 9.72 
 
 
SERPINB3 Serpin peptidase inhibitor, clade B (ovalbumin), member 3 XM_001491507 0.0001 8.72 
 
 
NULL 
 
CX605648 0.0000 8.11 
 
 
NULL 
 
BI961659 0.0000 7.31 
 
 
ING5 Inhibitor of growth family, member 5 NULL 0.0000 5.97 
 
       Downregulated 
     
 
SELENBP1 Selenium binding protein 1 NULL 0.0004 0.23 
 
 
OR7A10 Olfactory receptor, family 7, subfamily A, member 10 NULL 0.0002 0.25 
 
 
CD69 CD69 molecule XM_001499388 0.0008 0.25 
 
 
CXCL14 Chemokine (C-X-C motif) ligand 14 XM_001502713 0.0022 0.25 
 
 
NULL 
 
CD465749 0.0000 0.25 
 
 
TPPP3 Tubulin polymerization-promoting protein family member 3 CX596053 0.0005 0.26 
 
 
NULL 
 
CX604746 0.0001 0.32 
 
 
NULL 
 
CX603968 0.0026 0.32 
 
 
CD28 CD28 molecule NM_001100179 0.0068 0.34 
 
 
MATN2 Matrilin 2 XM_001490965 0.0006 0.34 
 
 
FIBIN Fin bud initiation factor homolog (zebrafish) AB302195 0.0050 0.36 * 
 
MNAT1 Menage a trois homolog 1, cyclin H assembly factor  XM_001497949 0.0004 0.36 * 
 
ACBD7 Acyl-Coenzyme A binding domain containing 7 XM_001498628 0.0029 0.37 
 
 
FLRT3 Fibronectin leucine rich transmembrane protein 3 XM_001491950 0.0087 0.38 
   SNRPN Small nuclear ribonucleoprotein polypeptide N XM_001492702 0.0099 0.42  * 
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 Table 3.4 
Top differentially expressed genes (15 upregulated and 15 downregulated; P < 0.01 and fold change > 2) for the DEV/OG1 
comparison.  Unannotated genes are labelled as NULL.  Asterisks denote genes selected for confirmation with PCR. 
 
   
Public  
 
Fold 
 
  
Gene 
Name Description Accession P Change PCR 
Upregulated 
     
 
TPPP3 Tubulin polymerization-promoting protein family member 3 CX596053 0.0000 5.31 
 
 
NULL 
 
CX601554 0.0074 4.95 
 
 
CD69 CD69 molecule XM_001499388 0.0000 4.84 
 
 
NDUFA4L2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2 XM_001488582 0.0036 3.77 
 
 
CXCL14 Chemokine (C-X-C motif) ligand 14 XM_001502713 0.0015 3.76 
 
 
HOPX HOP homeobox XM_001491312 0.0004 3.73 * 
 
FAM82C 
 
XM_001501075 0.0047 3.64 
 
 
CALCB Calcitonin-related polypeptide beta AF257470 0.0009 3.59 * 
 
FLJ36070 
 
XM_001489063 0.0020 3.29 
 
 
MFAP5 Microfibrillar associated protein 5 NULL 0.0017 3.25 
 
 
IGFBP7 Insulin-like growth factor binding protein 7 XM_001491171 0.0004 3.19 
 
 
SLC22A12 Solute carrier family 22 (organic anion/urate transporter), member 12 XM_001489840 0.0031 3.18 
 
 
OR7A10 Olfactory receptor, family 7, subfamily A, member 10 NULL 0.0016 3.18 
 
 
PPP2R3B Protein phosphatase 2 (formerly 2A), regulatory subunit B'', beta XM_001488015 0.0004 3.09 
 
 
NULL 
 
CD465749 0.0000 3.09 
 
       Downregulated 
     
 
S100A8 S100 calcium binding protein A8 XM_001493589 0.0000 0.03 
 
 
S100A12 S100 calcium binding protein A12 CD535886 0.0000 0.05 * 
 
S100A8 S100 calcium binding protein A8 XM_001494358 0.0000 0.07 * 
 
S100A9 S100 calcium binding protein A9 XM_001493530 0.0001 0.08 * 
 
SOD2 Superoxide dismutase 2, mitochondrial AB001693 0.0000 0.09 
 
 
DEFB4 Beta-defensin 4 AY170305 0.0001 0.10 * 
 
NULL 
 
CD467650 0.0000 0.12 
 
 
NULL 
 
CX605648 0.0000 0.15 
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Table 3.4 continued 
 
   
Public  
 
Fold 
 
  
Gene 
Name Description Accession P Change PCR 
       Downregulated 
     
 
NULL 
 
BM734930 0.0000 0.15 
 
 
SERPINB3 Serpin peptidase inhibitor, clade B (ovalbumin), member 3 XM_001491507 0.0003 0.15 * 
 
ING5 Inhibitor of growth family, member 5 NULL 0.0000 0.15 
 
 
PI3 Peptidase inhibitor 3, skin-derived BM734843 0.0037 0.19 
 
 
SAA1 Serum amyloid A1 NM_001081853 0.0021 0.16 
 
 
CITED1 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 1 XM_001488044 0.0000 0.17 
   PI3 Peptidase inhibitor 3, skin-derived BM734843 0.0037 0.19   
8
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Only 11 genes were up-regulated in the DEV group as compared with controls 
(Table 3.1). The 7 annotated genes within this list represented a wide range of functions, 
including inflammation/immune response, regulation of transcription, and protein 
folding and ubiquitination. Though the remaining up-regulated genes lack annotation 
data, some share sequence homology with other species to allow a tentative 
identification. The most up-regulated gene, BM734930, is 99% similar to superoxide 
dismutase 2 (Equus caballus SOD2, 63% coverage), a superoxide scavenger.  Likewise, 
BI961659 shares 76% homology with transmembrane protein 49 (Pan troglodytes 
TMEM49/VSP1, 99% coverage), which is associated with intracellular vesicle formation 
during autophagy. Intracellular vesicles and vacuoles have been described in CHO 
model of laminitis (Morgan et al., 2003; Pollitt, 1996; Pollitt and Daradka, 1998). The 44 
down-regulated genes in the DEV/CON comparison (Table A.1) included 4 genes with 
immunoglobulin-like domains, 7 genes encoding proteins with hydrolase function, and 9 
genes for zinc binding proteins.  Among the down-regulated genes with the largest fold 
changes were those expressed by immune effector cells, components of the extracellular 
matrix, a regulator of transcription, and a gene involved in mitochondrial nitrogen 
metabolism. A summary of the differentially expressed genes with the largest fold 
changes is provided in Table 3.2. The names, fold changes, and associated P values of 
fifteen down-regulated genes, as well as all 11 up-regulated genes, are presented in this 
table. 
Many genes that were up-regulated in the OG1 group as compared to the controls 
are involved in the innate immune response; these include 4 S100 calcium binding 
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proteins, 1 acute phase protein, 2 chemokines, and 2 anti-microbial peptides.  Eleven of 
the 15 genes with the largest fold changes were annotated and of these 11, 8 are 
immune-related (Table 3.3).  In addition, SOD2 was overexpressed (two unannotated 
genes, BM734930 and CD467650, share 99 and 78% homology with equine and porcine 
SOD2, respectively), as was the serine protease inhibitor SERPINB3 (Table 3.3) and two 
other SERPINs (Table A.2). Down-regulated genes of the OG1/CON comparison 
included a number of genes associated with cellular proliferation and apoptosis, as well 
as several genes involved in regulation of transcription. Of note, ADAM 
metallopeptidase with thrombospondin type 1 motif, 1 (ADAMTS1), a metalloproteinase 
that is associated with extracellular matrix (ECM) degradation, was up-regulated. 
Matrilin 2 (MATN2), an ECM adaptor protein that is specifically involved in the 
keratinocyte response to wounding, was down-regulated. Up-regulated gene matrix 
metalloproteinase 13 (MMP13) has collagenase activity and can degrade collagen, which 
is a component of basement membrane (BM) of equine hoof laminae.    
As a result of the general trend towards transcriptional down-regulation in the 
developmental stage and the widespread up-regulation in the Obel grade 1 stage, the 
DEV/OG1 comparison exhibited a predominance of down-regulated genes (Table 3.1).  
Genes that were more highly expressed in the DEV group included tubulin 
polymerization-promoting protein family member 3, CD 69 molecule, and 
homeodomain protein HOPX (Table 3.4). Down-regulated genes of this comparison 
consisted primarily of those genes that were dramatically increased in the OG1 group 
(S100 genes, SOD2, DEFB4; Table 3.4), as well as genes encoding 4 zinc finger 
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proteins, 7 solute carriers, and 5 serine protease inhibitors (Table A.3).  Results from this 
comparison thus validate the data generated by the DEV/CON and OG1/CON 
comparisons in addition to highlighting the more subtle changes occurring during the 
transition from the developmental stage to the clinical onset of lameness.   
In addition to genes that were differentially expressed between the two laminitis 
groups, we also found 22 genes that were consistently up- or down-regulated in both the 
DEV and OG1 groups (Table 3.5). Significantly overexpressed genes included 
inflammatory mediators, the antioxidant SOD2, and the vacuole-associated protein 
TMEM49, as well as several unannotated genes.  Eight of the 9 up-regulated genes were 
more highly expressed in the OG1 group than in the DEV group; the remaining gene 
KIAA0391 had a slightly higher expression level in the DEV group. Many of the 
strongly overexpressed genes of the OG1/CON comparison, such as the S100 genes, 
were not differentially expressed in the DEV group, indicating a time-dependence of this 
transcriptional response.  CCL2, however, showed a large fold change in both the DEV 
and OG1 groups (Tables 3.2 and 3.3).  Notably, down-regulated genes included multiple 
DNA binding proteins, a potassium channel, an aldo-keto reductase, and a regulator of 
apoptosis (Table 3.5). The consistent change in expression level suggests that these 22 
genes may be reflective of ongoing processes during the early stages of the progression 
of laminitis.  
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Table 3.5 
 List of differentially expressed genes common to both the DEV and OG1 stages. 
 
Gene Name 
Public 
Accession 
Human 
Protein pDEV DEVfold pOG1 Obelfold 
Up-
regulation       
KIAA0391 XM_001491047 NP_055487.2 0.0181882 2.2809171 0.0395235 2.0322141 
NULL DN505910 NULL 0.0052354 2.0308402 0.0070953 2.1287296 
NULL CX602004 NULL 0.0143219 2.176123 0.0095785 2.2898602 
RSPH3 XM_001491976 NP_114130.3 0.0042391 2.3534586 0.0019278 3.0788139 
PPA1 XM_001502747 NP_066952.1 0.0177216 2.0092664 1.628E-05 4.2789416 
TMEM49 BI961659 NULL 1.498E-05 2.7866203 7.63E-10 7.3082392 
CCL2 AJ251189 NP_002973.1 0.0056063 3.0044443 8.76E-06 9.7152828 
SOD2 BM734930 NULL 0.0026373 3.3508285 4.40E-09 22.847298 
DEFB4 AY170305 NP_004933.1 0.0318583 3.1619832 3.16E-07 31.678786 
       
Down-regulation      
SELENBP1 NULL NP_003935.2 0.0339868 0.4732622 0.0004266 0.230477 
NULL CX604746 NULL 0.0001236 0.3730017 5.79E-05 0.3204686 
NULL CX603968 NULL 0.0220934 0.4816291 0.0026067 0.3230924 
FLRT3 XM_001491950 NP_037413.1 0.0071702 0.372587 0.0087306 0.3831077 
SMARCA1 XM_001500518 NP_003060.2 0.0116903 0.4169139 0.0144975 0.3984922 
BFAR XM_001490098 NP_057645.1 0.0098486 0.4386322 0.0117411 0.4188644 
TMEM38A XM_001499622 NP_076979.1 0.0297946 0.4471773 0.0370885 0.4326369 
EXOSC8 XM_001495546 NP_852480.1 0.0120244 0.4183502 0.0256852 0.4383527 
AKR1C1 XM_001500743 NP_001344.2 0.0240601 0.483199 0.0249889 0.4611078 
C1orf125 XM_001488358 NP_653297.3 0.0229755 0.4616029 0.0452853 0.4802466 
KIAA1377 XM_001498604 NP_065853.2 0.0326062 0.4788407 0.0492041 0.4803119 
ANKRD35 XM_001499402 NP_653299.3 0.0093994 0.4375781 0.0294139 0.4820767 
ZDHHC6 XM_001498439 NP_071939.1 0.0050028 0.3948714 0.0456295 0.5008687 
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Gene ontology  
Overrepresented gene ontologies within up- and down-regulated genes were 
determined using the NIH-DAVID bioinformatics database. The list of DE genes (P< 
0.01, fold change>2) of the DEV/CON comparison did not yield any significantly 
overrepresented gene ontologies, pathways, or diseases, with the exception of the 
biological process GO terms such as response to heat, response to temperature stimulus, 
and negative regulation of cellular process among up-regulated genes and cellular 
component GO term extracellular region part among down-regulated genes.  
 When the number of DE genes was expanded by relaxing the P value cut off to 
0.05 (220 genes: 48 up-regulated and 172 down-regulated), a number of significant 
associations were generated (Table A.4). GO terms associated with biological processes 
shared several common genes, including CCL2, alpha crystallin chains CRYAA and 
CRYAB, and insulin-like growth factor binding proteins IGFBP2 and IGFBP7. The 
biological process categories containing the greatest number of DE genes were response 
to stimulus, response to chemical stimulus, and response to stress. The two 
overrepresented cellular component terms were both extracellular, suggesting a 
transcriptional up-regulation of matrix constituents during the developmental stage of 
laminitis. Interestingly, despite the large number of down-regulated genes in the 
DEV/CON comparison, no GO term was significantly overrepresented. Molecular 
functions were limited to neuronal Cdc2-like kinase binding, hydrolase activity and 
carbon-oxygen lyase activity.  
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Up-regulated genes from the OG1/CON comparison yielded a number of 
overrepresented GO terms (Table A.5). Of the 92 biological processes significantly 
associated with these genes, most were involved in cellular ion regulation, 
inflammation/wounding, or negative regulation of apoptosis. As in the DEV/CON 
comparison of differentially expressed genes, many were found to belong to more than 
one GO term; however, this may be expected given the known interactions between 
intracellular ion concentration, initiation of apoptosis, and control of inflammation (Fox 
et al., 2010; Wessling-Resnick, 2010; Yu et al., 2001).  Cellular component terms all 
pointed to changes in the extracellular matrix and molecular functions were associated 
with peptidase inhibition and binding of G-protein coupled receptors, 
glycosaminoglycans and polysaccharides.  Among down-regulated genes, regulation of 
cell cycle was the only overrepresented biological process, although all molecular 
functions related to fatty acid metabolism. 
Few GO terms were overrepresented among up-regulated genes of the DEV/OG1 
comparison (Table A.6) and included responses to inorganic substance and heat 
(biological processes), involvement of extracellular proteins (cellular component), and 
cytoskeletal protein binding (molecular function).  In contrast, 98 biological processes 
were overrepresented among down-regulated genes. Most of these 98 processes related 
to inflammation/wound healing, regulation of apoptosis, cell motility and migration, and 
intracellular ion homeostasis. Whereas many of the GO terms found in this comparison 
were also found in the DEV/CON and OG1/CON comparisons, the appearance of two 
new terms describing synthesis of interleukin 6 (IL6) and two terms associated with 
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leukocyte trafficking is noteworthy. Most of cellular components in this comparison 
dealt with the extracellular space, while molecular functions were associated with 
peptidase inhibition and protein binding.   
Pathway analysis  
Initial pathway analysis was conducted using the KEGG pathway database 
(Kanehisa et al., 2008) linked through the DAVID database. Two pathways were 
detected for both the OG1/CON and DEV/OG1 comparisons when all genes, both up 
and down-regulated, were included.  These pathways were cytokine-cytokine receptor 
signaling, which is in fact a collection of many unrelated receptor-ligand interactions, 
and the nucleotide binding oligomerization domain (NOD)-like receptor signaling 
pathway, which is involved in recognition of intracellular bacteria.  To expand upon 
these results, we utilized a more robust pathway detection program, Ingenuity Pathways 
Analysis (IPA) version 8.7 (http://www.ingenuity.com/), to establish relationships 
among DE genes (P<0.01 and fold change>2) for the DEV/CON, OG1/CON and 
DEV/OG1 comparisons.  In addition to identifying canonical pathways that include 
differentially expressed genes, Ingenuity also develops regulatory networks that show 
interactions among gene products. Like the gene ontology analysis, it identifies 
overrepresented biofunctions and associated diseases. 
For the DEV/CON comparison, IPA analysis was performed on genes that were 
differentially expressed at P<0.01 with a fold change of 2 or higher. The top biofunctions 
determined by IPA were carbohydrate metabolism, inflammatory response, and 
hematopoiesis (Table 3.6). The associated diseases were nutritional disease, cancer 
 94 
(inflammatory disease), ophthalmic disease, and connective tissue disorders (Table 
3.12). Sixty-three canonical pathways were detected and the top canonical pathways 
determined through the IPA library were liver X receptor/retinoid X receptor 
(LXR/RXR) activation and triggering receptor expressed on myeloid cells (TREM) 1 
signaling. LXR/RXR activation is involved in a variety of cellular functions ranging 
from cholesterol metabolism to inhibition of the inflammatory response. The TREM1 
signaling pathway is stimulated by and negatively regulates TLR4 signal transduction in 
response to ligation of bacterial wall components (Ornatowska et al., 2007; Zheng et al., 
2010). The top network with a score of 33 is shown (Fig. 3.2). The network function was 
gene expression, carbohydrate metabolism, and small molecule biochemistry. This 
network included 35 genes, 15 of which were identified as DE in the differential 
expression analysis of the DEV/CON comparison. Among these 15 genes, RSPH3, 
USP44, CCL2 and CRYAB were up-regulated.   
For the OG1/CON comparison, the top biofunctions were inflammatory response, 
antigen presentation, hematological system development and function (Table 3.6). The 
associated diseases were inflammatory disease, cancer, dermatological diseases and 
conditions, and hematological diseases. The top canonical pathways were IL17 signaling 
and vitamin D receptor/retinoid X receptor (VDR/RXR) activation. The top network 
with a score of 39 exhibited a central importance of p38 MAPK and NF-κB pathway 
molecules (Fig. 3.3). This network included 33 genes, 20 of which were DE. In the 
network, DEFB4, S100A8 and S100A12 showed up-regulation while CD69 showed 
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down-regulation. The top associated network functions were inflammatory response, 
antigen presentation, and cellular movement.  
For the DEV/OG1 comparison, the top biofunctions were cellular movement, 
antigen presentation, hematological system development and function, and immune cell 
trafficking (Table 3.6). The associated diseases were metabolic disease, cancer, 
inflammatory disease, connective tissue disorders (arthritis) and immunological disease. 
Laminitis is also a connective tissue disease (Mobasheri et al., 2004). One hundred and 
twenty-eight canonical pathways were detected among DE genes of the DEV/OG1 
comparison; the top canonical pathways were LXR/RXR activation and IL-17 signaling 
and these pathways are associated with hormone transcriptional activation and immune 
response. The top network with a score of 37 is shown (Fig. 3.4) and its functions were 
cell cycle, DNA replication, recombination, and repair, and nucleic acid metabolism. 
This network included 20 DE genes and displayed the presence of p38 MAPK pathway 
molecule. Furthermore, CALCB was up-regulated and SOD2 was down-regulated within 
the network.  
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Fig. 3.2. Ingenuity network analysis of DEV compared to control. The top network 
identified by IPA with a significant score of 33. Both direct (solid line) and indirect 
(dashed line) interactions among genes (including IL8, CRYAB, and CCL2) were shown 
in the network. This analysis was performed on the DE genes of P<0.01 and FC>2 in the 
DEV/CON comparison. The intensity of the node color are depicted as down-regulated 
(green) or up-regulated (red). Square: cytokine/growth factor; vertical diamond: enzyme; 
horizontal diamond: peptidase; circle: other; parallelogram: transporter; circle-in-circle: 
complex; oval: transmembrane receptor; shaded circle-in-circle: group. 
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Fig. 3.3. Ingenuity network analysis of OG1 compared to control. The top network 
identified by IPA with a significant score of 39. Both direct (solid line) and indirect 
(dashed line) interactions among genes were shown in the network. This network 
showed the central position of p38 MAPK and NF-κB. This analysis was performed on 
the differentially expressed genes of P<0.01 and FC>2 in the OG1/CON comparison. 
The significant biofunctions associated with this network are inflammatory 
disease/connective disorders/skeletal and muscular disorders. The intensity of the node 
color are depicted as down-regulated (green) or up-regulated (red). Square: 
cytokine/growth factor; vertical diamond: enzyme; horizontal diamond: peptidase; 
circle: other; parallelogram: transporter; circle-in-circle: complex; oval: transmembrane 
receptor; shaded circle-in-circle: group.  
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Fig. 3.4. Ingenuity network analysis of DEV compared to OG1. The top network 
identified by IPA with a significant score of 37. Both direct (solid line) and indirect 
(dashed line) interactions among genes were shown in the network. This network 
showed the central position of p38 MAPK. This analysis was performed on the 
differentially expressed genes of P<0.01 and FC>2 in the DEV/OG1 comparison. The 
highest scoring biofunctions associated with this network are inflammatory 
disease/connective disorders/skeletal and muscular disorders. The intensity of the node 
color are depicted as down-regulated (green) or up-regulated (red). Square: 
cytokine/growth factor; vertical diamond: enzyme; horizontal diamond: peptidase; 
circle: other; parallelogram: transporter; circle-in-circle: complex; oval: transmembrane 
receptor; shaded circle-in-circle: group. 
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Table 3.6 
The top biofunctions, associated diseases, canonical pathways, and network functions 
that were most significant to the data set of CHO laminitis experiment. The DE genes at 
the level of P<0.01 and FC>2 were used as input data set for DEV/CON, OG1/CON and 
DEV/OG1 comparison respectively.  
 
 
 
 Biological 
functions 
Associated 
diseases 
Top canonical 
pathways 
Top network 
function 
DEV/CON Carbohydrate 
metabolism, 
inflammatory 
response, and 
hematopoiesis 
Nutritional 
disease, cancer, 
ophthalmic 
disease, and  
connective tissue 
disorders 
 
 
LXR/RXR 
activation and 
TREM1 signaling 
Gene expression, 
carbohydrate 
metabolism, and 
small molecule 
biochemistry 
OG1/CON Inflammatory 
response, 
antigen 
presentation, and 
hematological 
system 
development and 
function 
Inflammatory 
disease, cancer, 
dermatological 
diseases and 
conditions, and  
hematological 
diseases 
IL-17 signaling 
and VDR/RXR 
activation 
 
Inflammatory 
response, antigen 
presentation, and 
cellular movement 
DEV/OG1 Cellular 
movement, antigen 
presentation, 
hematological 
system 
development and 
function, and  
immune cell 
trafficking 
Metabolic disease, 
cancer,  
inflammatory 
disease, 
connective tissue 
disorders 
(arthritis), and  
immunological 
disease 
  
 
 
LXR/RXR 
activation and  
IL-17 signaling 
 
Cell cycle, DNA 
replication, 
recombination, 
and repair, and 
nucleic acid 
metabolism 
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Quantitative real time PCR 
In order to select the best reference gene for normalization of qRT-PCR data, 
expression of seven reference control genes (ACTB, B2M, PPIA, GAPDH, GNB2L1, 
EEF1A1, and RPLP0) was analyzed. The selection of stable reference genes can 
minimize the variation in expression between tissues. Gene expression stability among 
all laminar samples (CON, DEV and OG1) was determined using geNorm software 
version 3.5 (Vandesompele et al., 2002). We found that two reference
  
genes were 
sufficient for normalization as the pairwise variation V for the two genes was less than 
the 0.15 cut-off value recommended by Hellemans et al. (Hellemans et al., 2007). When 
the 7 candidate reference genes were ranked based on their calculated M values, we 
found that EEF1A1 and RPLP0 had less variation in expression among the laminar 
samples compared to the other 5 reference genes.  We thus chose EEF1A1 and RPLP0 
for normalization of qRT-PCR data. 
To confirm the differential expression of microarray results, a total of 30 DE genes 
were selected for qRT-PCR validation. Based on the microarray analysis, we select most 
of the DE genes with a small P value and large fold change. The fold change of all 
selected genes is larger than 2. Three additional genes, each of which was differentially 
expressed in at least one of the three comparisons, were also selected based on their 
likely functional relevance to laminitis. LOXL1 is a member of lysyl oxidase family, 
which plays a role in the oxidation of ECM structural proteins (e.g., collagen and elastin) 
(Lucero and Kagan, 2006). MMP13 is a member of matrix metalloproteinase family, 
which is important in tissue remodeling and ECM degradation (Amalinei et al., 2007). 
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Basement membrane (BM) is a thin layer of ECM and its degradation is believed to be 
involved in the initiation of laminar failure in the pathogenesis of acute laminitis (Pollitt, 
1996). KRT17 is a keratin and keratins are structural component of the hoof wall and  
keratinization is essential for equine hoof integrity (Grosenbaugh and Hood, 1992). qRT-
PCR was performed on 30 genes across all laminar tissues (CON, DEV, and OG1 
stages).   
The primers used for qRT-PCR are listed in Table 3.7. Of the 8 genes analyzed by 
qRT-PCR for the DEV/CON comparison, six (CCL2, CPXM1, CRYAB, FASN, HOPX, 
and TMEM49) had significantly different expression between the two groups (Fig. 3.5). 
Notably, CCL2, CRYAB, HOPX, and TMEM49 were among the 11 up-regulated genes 
identified by microarray analysis. SEPP1 and SNF8, both identified by microarray as 
being down-regulated, were not significantly different from controls. ADAMTS1, 
CCL7, CD14, IL10RB, LOXL1, MATN2, NP, S100A8, S100A9, S100A12 and DEFB4 
were confirmed to be significantly different between OG1 and CON groups (Fig. 3.6). 
Expression levels of the two down-regulated genes, FIBIN and MNAT1, were not 
similar to those found with microarray: FIBIN was not increased, whereas MNAT1 
increased significantly (P<0.05). The direction of expression change of SNRPN gene 
was the same as the microarray result but did not show statistical significance at the level 
of P<0.05.  
Eleven genes were chosen for qRT-PCR analysis from the DEV/OG1 comparison 
(Fig. 3.7). Both up-regulated genes (CALCB and HOPX), as well as all down-regulated 
genes, were confirmed to be significantly different between the two groups. Both GSN 
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and NDEL1 had the same direction of changes in expression as in the microarray 
analysis but the difference shown by real time PCR did not reach statistical significance.  
A heat map was constructed using MeV/R software for the 30 selected DE genes 
based on qRT-PCR results across all conditions (CON, DEV and OG1) (Fig. 3.8). 
Cluster analysis showed a distinct transition in expression pattern among the conditions 
(CON, DEV and OG1). Moreover, the pattern of gene expression in the CON group was 
more similar to that of DEV than OG1, where more genes were up-regulated. Cluster 1 
and cluster 4 had increased expression at the OG1 stage compared to the CON and DEV 
conditions. These genes play essential roles in immunity, inflammation, calcium 
signaling transduction (i.e., S100A8, S100A9 and S100A12) and BM turnover (i.e., 
ADAMTS1 and MMP13). Based on the analysis, five genes in cluster 2 had relatively 
high expression at the DEV stage. These genes have different biological functions but 
are mainly relevant to the maintenance of cell growth. Most of the genes in cluster 3 
were up-regulated at the CON and DEV stage but their expression decreased at the OG1 
stage. Many genes involved in the formation of actin filaments/collagen, such as GSN, 
MATN2, and LOXL1 were in this group.  
 Table 3.7  
Primers of selected genes used for quantitative RT-PCR of CHO laminitis experiment.  
 
Gene 
Symbol Accession 
No. 
Forward Sequence (5’-3’) Reverse Sequence (5’-3’) 
PCR 
Produ
ct Size 
(bp) 
Tm(°C) * 
CCL2 AJ251189 
 
TCCAGTCACCTGCTGCTATAC ATTCTTGGCTTTTGGAGTAGG 235 58 
DEFB4 AY170305 
 
ACTTGCCTTCCTCATTGTCTT AGCAGTTTCTCCGCTTTCTAT 195 58 
SEPP1 
 
XR_036255 
 
AGTGTGGAAACTGCTCTCTCA TTGCTGATTCTCTGAAAGCTG 179 58 
ADAMTS1 AF541975 
 
AGGCTCACAATGAATTTTCG CACAGCCAGCTTTTACACACT 225 58 
CCL7 XM_001501551 TCAATAAGAAGATCCCCATCC TCTTGTCCAGGTAGTTCGTGA 162 58 
IL10RB XM_001498211 
 
TTACCATACCTTGCGAGTCAG CAGGTTCATTCTCAATTTTGG 173 58 
CD14 AF200416 
 
CAGCTCTTTCCAGAGTCCAC AGTTCTCATCGTCCACCTCA 144 60 
MMP13 AF034087 
 
 CTTGAGCTGGACTCGTTGTT  CAGCAGGATTAAGGGGATAGT 131 55 
GSN 
 
U31699 
 
TTACGGAGACTTCTTCACAGG TGTACTTGAGGCCAGACTTGA 248 58 
CALCB AF257470 
 
TCAGCATCTTGGTCCTGTG ATTGGTCTTCCTCTGCACATA 155 58 
MNAT1 XM_001497949 
 
 TGAAGCTGATGGTGAATGTGT  CCTAATCTCAACCTCCTTGTCA 170 58 
TIMP1 CX602739 
 
AGAAGTCAACCAGACCACCTT TCTCCGACCTGTGGAAGTATC 152 58 
1
0
3
 
  
Table 3.7 continued 
  
Gene 
Symbol Accession 
No. 
Forward Sequence (5’-3’) Reverse Sequence (5’-3’) 
PCR 
Produ
ct Size 
(bp) 
Tm(°C) * 
SNF8 XM_001502240 
 
AGCAGGTGTTGAAAGGAAGG 
 
CCACCCACAGGGATGATAC 
 
118 58 
CRYAB XM_001501779 
 
AAGGTGCTGGGAGATGTGATT CTGGGATTCGGTACTTCCTGT 103 58 
S100A8 
 
XM_001493589 
 
ACGGATCTGGAGAATGCTATC 
 
TGATGTCCAACTCTTTGAACC 
 
175 58 
SERPINB3 
 
XM_001491507 
 
CGTGCAGATGATGAAACAAAT 
 
TTCTGTGAGCTTGTCCACTCT 
 
195 58 
NP 
 
XM_001505137 
 
AGCTACAGGAAGGCACTTACG 
 
TTCTCCAGGCTTTCATAATCC 
 
205 58 
MATN2 
 
XM_001490965 
 
CTTTCTGCTGATTCTTGGACA 
 
AATGAACTCCTTGACCTTTGC 
 
217 58 
FIBIN 
 
AB302195 
 
CTTTGTGGTGGTGACGTATTC 
 
CCAATAAGCAAACAGAAGCAA 
 
181 58 
SNRPN 
 
XM_001492702 
 
TTACACCTGAGACGGACTACG 
 
AGGTATTTGCTGTTGCTGAGA 
 
132 58 
LOXL1 
 
CX605389 
 
TGCATGTGAACCCGAAGTA 
 
CTGTCTGTCCACCCTCTCC 
 
145 58 
S100A9 
 
XM_001493485 
 
CGACCTAGAGACCATCATCAA 
 
TGCTTGTCCTCATTAGTGTCC 
 
189 58 
TMEM49 XM_001503742 
 
TTACAGAAGCCATTCCAAGAA 
 
TGGAGTTAATGATGGACAGGA 
 
160 58 
OSMR 
 
XM_001496993 
 
CGTGTCCACAGTCTTGCTTAT 
 
TCGTCCACCCTACTCCTTATC 
 
203 58 
NDEL1 
 
XM_001504824 
 
AGGAAACTGCTTATTGGAAGG 
 
TGCCTCCACTTCATATTTCAG 
 
194 58 
HOPX  XM_001491312 
 
TTCAACAAGGTCAACAAGCA AGGAGAGAAACAGCAGATGGT 219 58 
1
0
4
 
  
Table 3.7 continued 
 
Gene 
Symbol Accession 
No. 
Forward Sequence (5’-3’) Reverse Sequence (5’-3’) 
PCR 
Produ
ct Size 
(bp) 
Tm(°C) * 
KRT17   XM_001496441 
 
TGAAGATCCGAGACTGGTACA ACGAAGCTGGCATTGTCC 127 58 
FASN  XM_001491292 
 
AAGCAGGCACACACTATGGAT AGGTCGAAGAAGAAGGAGAGG 242 55 
S10012 CD535886 TCATCAACATCTTCCACCAGT ACCTTGCACACCAGGACTAC 211 58 
 
CPXM1  XM_001497131 
 
AACCAGGACTTCTCCTTGCAT TCATTCTCGTGAGGGAACTTG 149 55 
EEF1A1
a
 NM_001081781 
 
TGGAAAGAAGCTGGAAGATG CAACCGTCTGTCTCATGTCA 132 58 
RPLP0
a
 BC107717 TTGCATCAGTACCCCATTCT ACCAAATCCCATATCCTCGT 242 58 
ACTB
c
 AF035774  CCAGCACGATGAAGATCAAG GTGGACAATGAGGCCAGAAT 88 58 
GAPDH
c
 AF157626 GATGCCCCAATGTTTGTGA AAGCAGGGATGATGTTCTGG 250 61 
B2M X69083 CGAGACCTCTAACCAGCATC AGACATAGCGGCCAAAGTAG 186 58 
PPIA NM_021130 TGGGGAGAAAGGATTTGGTT CATGGACAAGATGCCAGGAC 178 58 
GNB2L1 CD469980 CAGGGATGAGACCAACTACG ATGCCACACTCAGCACATC 200 58 
 
*The optimal annealing temperature  
 a
EEF1A1 and RPLP0 were used for normalization of quantitative RT-PCR data 
 c 
Information about the primers from (Bogaert et al., 2006) 
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Fig. 3.5. Real time PCR validation of the microarray results of the DEV/CON 
comparison. EEF1A1 and RPLP0 are reference genes used for normalization. Eight DE 
genes from the microarray analysis were selected for real time PCR confirmation. Data 
are presented as mean  SEM. Those genes marked with asterisks are significantly 
different from CON.  
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Fig. 3.6. Real time PCR validation of the microarray results of the OG1/CON 
comparison. EEF1A1 and RPLP0 are reference genes used for normalization. Fourteen 
DE genes from the microarray analysis were selected for real time PCR confirmation. 
Data are presented as mean  SEM. Those genes marked with asterisks are significantly 
different from CON.  
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Fig. 3.7. Real time PCR validation of the microarray results of the DEV/OG1 
comparison. EEF1A1 and RPLP0 are reference genes used for normalization. Eleven DE 
genes from the microarray analysis were selected for real time PCR confirmation. Data 
are presented as mean  SEM. Those genes marked with asterisks are significantly 
between DEV and OG1.  
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Fig. 3.8. Cluster diagram of the mean of calibrated normalized relative quantities 
(CNRQ) values at control, developmental and Obel grade 1 stage as determined by qRT-
PCR. The green to red color scale demonstrates the expression value of mean of CNRQ. 
EEF1A1 and RPLP0 were used as reference genes to calculate normalized ΔCq. 
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DISCUSSION  
Our goal in this study was to identify changes in the gene expression profile 
during the developmental stage and the onset of equine laminitis using an equine whole 
genome oligoarray. Oligoarrays have become a popular technique for exploring the 
transcriptome in domestic animals such as pigs (Zhao et al., 2006), dogs (Higgins et al., 
2003), cattle (Wilson et al., 2005), and chickens (Heidari et al., 2008). We identified 
differential expression of 68 and 149 genes at the DEV and OG1 stages, respectively, as 
well as associated pathways and networks during the initiation and progression of 
laminitis.  
Development of laminitis 
In order to determine genes and regulatory pathways that might be involved in 
the development of laminitis, we performed transcriptional profiling and quantitative 
real time PCR on laminar samples obtained at the onset of fever following carbohydrate 
overload. Rectal temperature begins to increase linearly upon administration of starch, 
with fever generally occurring between 12 and 22 h. At this stage, horses also exhibit an 
elevated heart rate, sweating or nervousness, and signs of gastrointestinal discomfort, but 
show no signs of foot pain associated with laminitis (Garner et al., 1975). In the 
developmental stage, we found few differentially expressed annotated genes (56), and 
the majority of these (80%) were down-regulated when compared to controls (Table 
3.1). This, in conjunction with no significantly overrepresented GO term found for 
down-regulated genes, suggests that the pathophysiological process leading to laminitis 
may first cause non-specific transcriptional suppression of seemingly unrelated genes.  
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This is supported by the down-regulation of 8 genes involved in the regulation of 
transcription. Conversely, only 11 genes were significantly overexpressed at the 
developmental stage, indicating that these genes may be “first responders” and could be 
involved in disease progression.  In particular, the up-regulation of SOD2 points to 
oxidative stress and an excess of reactive oxygen species (ROS), presumably within the 
mitochondria. ROS have been proposed to cause tissue damage in joint diseases and 
SOD enzyme can reduce the ROS production (Afonso et al., 2007). One cause of ROS 
accumulation in the mitochondria is the uncoupling of the respiratory chain, although 
none of the DE genes at the developmental stage encode respiratory chain proteins. 
Another indication of disrupted metabolism is the overexpression of TMEM49, which is 
a component of the membrane of the intracellular vacuoles created during starvation-
induced autophagy (Ropolo et al., 2007). This type of autophagy is initiated when 
cellular energy sources are scarce; the cell begins to catabolize intracellular molecules 
for energy.  Importantly, the formation of intracellular vacuoles is a common feature of 
equine laminitis (Morgan et al., 2003; Pollitt, 1996), although it is not known whether 
TMEM49 localizes to these vacuoles. Differential expression was not seen, however, 
among members of the Atg family of autophagy-associated genes, making interpretation 
of this result difficult.   
Two genes encoding different units of alpha-crystallin, a heat shock protein, were 
up-regulated in the DEV group. Alpha-crystallin are mainly expressed in the lens of the 
eye (Horwitz et al., 1999) and sequesters misfolded proteins that accumulate during 
periods of thermal, oxidative, or metabolic stress (Sun and MacRae, 2005), further 
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suggesting that changes seen during the developmental stage result from a prior cellular 
stressor. Interestingly, the transcription factor HOPX, which is elevated in differentiating 
human keratinocytes (Yang et al., 2010), was up-regulated, possibly as a part of the 
terminal differentiation and apoptosis of keratinocytes as they become part of the 
stratum corneum. Thus, the initiation of laminitis may involve an alteration in the rate of 
programmed cell death in keratinocytes.   
Perhaps the most intriguing DE gene during this stage is CCL2, also known as 
macrophage chemotactic protein 1 (MCP-1). CCL2 is a chemoattractant for 
macrophages but not for neutrophils (Patterson et al., 2002) and may be up-regulated by 
bacterial endotoxin, glucose, trauma, or hypoxia, all of which have been postulated as 
causes of laminitis.  Epithelial cells in other species and anatomical locations have been 
shown to be accessory immune cells and are capable of producing CCL2 when 
stimulated (Barker et al., 1991; Chui and Dorovini-Zis, 2010). We therefore hypothesize 
that CCL2 might represent the beginning of a common unifying pathway that connects 
the various proposed triggers of laminitis (i.e., hypoxia, infection, trauma, 
glucose/insulin) with the ultimate disintegration of the laminae. 
Progression of laminitis 
In contrast to the developmental stage of laminitis, samples taken at the onset of 
clinical symptoms (Obel grade 1 lameness) show a strong transcriptional response and a 
dramatic up-regulation of inflammatory genes.  In addition to SOD2 and CCL2, which 
were seen at the earlier time point, the acute phase protein (APP) serum amyloid A 
(SAA1) was also overexpressed at the OG1 stage. APPs are generally produced by the 
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liver and their abundance may be increased several hundred-fold following acute 
infection (Zhang et al., 2005). Genes encoding several members of the S100 family of 
proteins were also significantly up-regulated (Table 3.3).  S100 proteins, members of the 
damage-associated molecular pattern (DAMP) family of molecules, are important in 
both calcium signaling transduction and in the regulation of inflammation (Foell et al., 
2007a). A recent study has immunolocalized the S100A8/S100A9 complex in the 
laminar tissue of normal and experimentally induced laminitic horses; the complex was 
overexpressed 106 fold at the onset of lameness (Faleiros et al., 2009). The significant 
up-regulation of these genes could amplify the inflammatory response and lead to 
laminar tissue damage. Alternatively, their calcium-binding properties could counteract 
the disruption of cellular ion homeostasis that was suggested by GO analysis (Table 
A.5). The strong induction of S100 proteins in our study and the report of 
overexpression of the S100A8/S100A9 protein complex in a different model of laminitis 
indicate that S100 proteins may play a common role in many forms of laminitis. Perhaps 
more telling than the elevation of the S100 gene expression, however, is the indication of 
a transcriptional response to microbial infection. Beta-defensin 2 (DEFB4) and peptidase 
inhibitor 3 (also called PI3, elafin, or SKALP) are both expressed in keratinocytes and 
have direct anti-microbial properties (Sallenave, 2010; Schneider et al., 2005). Likewise, 
the down-regulation of chemokine CXCL14, particularly in keratinocytes, is taken as 
evidence of bacterial infection (Maerki et al., 2009). It is thought that CXCL14 is up-
regulated immediately following exposure to bacterial components and that, because of 
its potency and potential to cause collateral damage, its expression is quickly suppressed 
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(Maerki et al., 2009; Yang et al., 2003). In this study, the hypothesis of an infection is 
also supported by the overrepresentation members (DEFB4, CCL2, TIMP1, and 
CEBPB) of the IL17 signaling pathway within the group of up-regulated genes.  IL17 is 
produced by T lymphocytes in response to dendritic cell presentation of bacterial 
antigens (Peck and Mellins, 2010). 
The negative regulation of apoptosis was also a common finding in the GO 
analysis of up-regulated genes in the OG1 stage, as was intracellular ion homeostasis.  
Apoptosis often involves a large influx of calcium into the cell, but it is unclear whether 
these two processes are related in this study. Signs of apoptosis have been noted in 
laminar keratinocytes following administration of black walnut extract, another 
experimental model of laminitis (Faleiros et al., 2004). The stimulus for the attempted 
suppression of apoptosis, as well as the reason for the assumed failure of this 
suppression, is unknown. As apoptotic cells inhibit inflammation (Fadok et al., 1998)  
whereas necrotic cells are pro-inflammatory (El Mezayen et al., 2007), one determinant 
of the clinical outcome of acute laminitis may be the relative percentages of these two 
types of cell death, although this remains speculative. 
Transition from developmental to clinical laminitis 
To a certain extent, direct comparison of the early and later stages of laminitis 
recapitulates results found when comparing each stage to the control group. For 
example, GO terms involving inflammation, apoptosis, and ion homeostasis found 
among down-regulated genes of the DEV/OG1 comparison reflect the strong up-
regulation of these genes at the OG1 stage. However, this comparison yielded two new 
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results: the overrepresentation of leukocyte trafficking and IL6 synthesis GO terms. It is 
unclear whether this is due to an up-regulation at the OG1 stage, a down-regulation at 
the DEV stage, or a combination of both. We may postulate that the leukocyte 
chemotaxis terms directly relate to the influx of neutrophils (and presumably other 
inflammatory cell types) into the laminae during this stage. The synthesis of IL6 is 
interesting, however, in light of the conspicuous lack of differential expression of 
“typical” proinflammatory cytokines such as tumor necrosis factor α (TNF ), interleukin 
1 (IL1), and interferon γ (IFN ). The overrepresentation of different peptidase inhibitor 
molecular function terms suggests a strong anti-protease response that could perhaps 
counteract the induction of various matrix metalloproteinases (MMPs) seen in previous 
studies (Kyaw-Tanner et al., 2008; Loftus et al., 2006; Loftus et al., 2009; Riggs et al., 
2007). 
A second type of comparison that may be equally enlightening is the 
identification of differentially expressed genes common to both stages. This search 
found 22 common genes and, while many were not annotated, DEFB4, SOD2, CCL2, 
and TMEM49 were consistently up-regulated, suggesting a central importance of these 
genes (Table 3.5). Likewise, SELENBP1, the apoptosis regulator EXOSC8, and the 
potassium channel TMEM38A were persistently down-regulated. It remains unknown 
whether these genes cause the pathological changes seen in laminitis or are merely a 
physiological reaction to tissue damage that has already occurred. 
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Comparison to previous studies 
Recently, Noschka and colleagues used an equine-specific 3,076 element cDNA 
microarray to investigate changes in laminar gene expression during black walnut extract 
induced laminitis (Noschka et al., 2008). Similar to our study, these authors found up-
regulation of CCL2, CCL7, S100P, SAA, SOD2, beta-defensin 1 (BD1), and SKALP 
(PI3), suggesting a role for these genes in laminitis independent of the mechanism of 
induction. Noschka and colleagues did not identify changes in apoptosis regulators or 
ion channels, perhaps due to the limited number of genes represented in the microarray 
used. For comparison, Budak and colleagues used a 15,000 bovine microarray chip to 
study the oligofructose induction model of laminitis (Budak et al., 2009), which is 
similar to the carbohydrate overload model used in this study. Although the platform 
used by Budak et al. had more complete coverage than the one used by Noschka, only 
three genes (BIRC3, CCL2, and DARC) were differentially expressed both in our study 
and in Budak‟s. The consistent up-regulation of CCL2 among three different models of 
laminitis highlights this molecule‟s likely importance to the pathogenesis of this disease.   
Relevance to current hypotheses 
Currently, the three most popular hypotheses regarding the initiation of laminitis 
implicate vasoconstriction/hypoxia, MMPs, and escape of bacteria from the hindgut into 
the bloodstream (Bailey et al., 2004). Hypoxia typically stimulates expression of 
response factors such as hypoxia-inducible factor (HIF1 ) (Semenza, 1998), vascular 
endothelial growth factor (VEGF) (Shweiki et al., 1992), endothelial nitric oxide 
synthase (eNOS) (Thompson et al., 2000), and heat shock protein 90 (HSP90) (Almgren 
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and Olson, 1999). We saw no evidence of differential expression of these genes and thus 
cannot hypothesize that hypoxia plays a role in this model of laminitis. However, we 
saw evidence of transcriptional up-regulation of MMP13. Therefore, as with the 
vasoconstriction/hypoxia hypothesis, we did not generate new data supporting this 
theory but we cannot rule it out as a possibility. We did, however, find evidence to 
support the hypothesis that bacteria or bacterial components escape from the hindgut and 
cause laminar inflammation. The differential expression of anti-microbial peptides such 
as DEFB4, PI3, and CXCL14 is suggestive of the presence of bacterial antigens, 
although microarray data necessarily need to be confirmed at the protein and functional 
levels. 
CONCLUSION 
We have used a 21,000 equine oligoarray to investigate changes in the 
transcriptional profile of laminar tissue during carbohydrate overload induced laminitis.  
This array is both genome-wide and species-specific, making our dataset the most 
reliable and complete picture of gene expression during laminitis. We discovered what 
appear to be central roles of apoptosis and intracellular ion homeostasis pathways and 
identified a small set of consistently differentially expressed genes that are likely to play 
a role in the development and progression of this disease. Of these, CCL2 is arguably the 
most prominent and could integrate signals from a variety of stimuli (infection, hypoxia, 
elevated glucose) into a common pathway leading to laminar failure. Pathway and 
network analysis revealed biological relationships among DE genes relevant to equine 
laminitis and the presence of p38 MAPK and NF-κB pathway molecules. In addition, the 
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overexpression of several anti-microbial genes supports the hypothesis that bacterial 
components might play a role in the pathogenesis of the carbohydrate overload model of 
laminitis. Transcriptional analysis of other models of laminitis and identification of 
common differentially expressed genes will provide further insight into the cause of this 
devastating disease. 
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CHAPTER IV 
GENE EXPRESSION PROFILING IN INDUCED LAMINITIC HORSES BY 
PROLONGED HYPERINSULINAEMIA (HI) USING AN EQUINE WHOLE 
GENOME OLIGOARRAY 
 
INTRODUCTION  
Equine laminitis is an extremely painful hoof disease that affects the laminar 
tissue. The condition is defined as the separation that occurs between the coffin bone and 
the hoof wall (Pollitt, 2004b). Laminitis has been linked to many factors such as grain 
overload, gastrointestinal tract disease and endotoxemia. Studies have shown that 
metabolic and endocrine abnormalities are risk factors for laminitis in horses and ponies 
(Geor and Frank, 2008; Geor, 2008; Johnson, 2002; Treiber et al., 2006b). 
Experimentally induced models of laminitis have been established through the 
administration of CHO (Garner et al., 1975), BWE (Minnick et al., 1987), OF (van Eps 
and Pollitt, 2006) and prolonged HI with euglycaemia (Asplin et al., 2007; de Laat et al., 
2010).  
HI induced laminitis is considered to be a model of endocrinopathic laminitis. 
Constant infusion of insulin and glucose while maintaining euglycaemia causes laminitis 
in healthy ponies (Asplin et al., 2007) and healthy Standardbred horses (de Laat et al., 
2010). Naturally occurring HI is a condition of high levels of insulin in the bloodstream 
and is proposed to be caused by insulin resistance (IR) (Frank, 2009; Johnson et al., 
2004b). IR is the core component of equine metabolic syndrome (EMS) and equine 
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Cushing‟s disease (ECD) (Frank, 2009; Geor, 2009; Johnson et al., 2004a) and is defined 
as failure of tissues to take up glucose via insulin-dependent glucose transporters. Due to 
IR, glucose remains in the blood and the pancreas continues to secret insulin, which 
causes HI (Kronfeld, 2005; Shanik et al., 2008). Laminar lesions in the hoof were 
demonstrated in HI induced laminitis using light and transmission electron microscopy 
(TEM) (Nourian et al., 2009). There was no global BM separation in affected ponies 
following HI (Nourian et al., 2009). 
EMS is a term used to describe a cluster of conditions, including obesity, IR and 
HI (Johnson, 2002; Johnson et al., 2009). This syndrome is similar to the metabolic 
syndrome in humans, which is primarily associated with cardiovascular disease and type 
2 diabetes mellitus (T2DM) (Caballero, 2004; Miranda et al., 2005). It is a 
neurodegenerative disease (McFarlane, 2007) and has been shown to be associated with 
laminitis (Donaldson et al., 2004). Recent studies have shown a connection between high 
insulin and laminitis with IR in pony breeds (Welsh and Dartmoor) (Kronfeld et al., 
2005; Treiber et al., 2006b). A study using a cohort of ponies demonstrated the 
importance of monitoring insulin concentration and obesity to determine risk of laminitis 
(Carter et al., 2009). Currently, there are several theories regarding the contribution of 
IR/HI to laminitis. One theory states that IR predisposes horses to laminitis by altering 
vascular dynamics and endothelial function (Geor and Frank, 2008; Treiber et al., 
2006a). Another theory states that endocrinopathic laminitis is the result of inflammation 
(McGowan, 2008). Asplin and co-workers suggested that it is not IR but insulin toxicity 
that causes endocrinopathic laminitis (Asplin et al., 2007). Research in the horse has 
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demonstrated that there is an interconnection between IR, altered lipid metabolism, 
inflammation and obesity (Vick et al., 2007). At present, there are two competing 
theories regarding IR in humans: the inflammation theory and the lipid overload theory 
(Taubes, 2009). The lipid overload theory states that IR is associated with the level of 
fatty acids in the bloodstream and that the accumulation of fat promotes IR. On the other 
hand, the inflammatory theory states that the overexpression of inflammatory cytokines 
can induce IR (Taubes, 2009). Human research findings in regard to the relationship 
between obesity, inflammation, and IR may give insight into the association of these 
conditions to laminitis in horses with EMS (de Luca and Olefsky, 2008).  
Because the early stages of laminitis are critical in understanding the progression 
of the disease, we sought to identify differentially expressed genes and their likely 
interactions that may lead to observed pathological changes in the HI model of laminitis. 
Knowing the gene expression changes within the laminar tissue during the development 
and progression of laminitis could lead to new ways to predict disease outcome and 
design therapies for treatment/prevention. The overall objective of this study was to 
determine global gene expression profile and identify differentially expressed genes and 
their likely interactions in laminar tissue 48 h after HI induction using the 70-mer 
equine-specific ~21,000 element whole genome expression microarray (Bright et al., 
2009). 
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MATERIALS AND METHODS 
Experimental design 
Eight clinically normal Standardbred horses (7 geldings, 1 filly) were used for this 
study. The horses were divided into control and experimental groups, with 4 horses in 
each group. The horses were examined and confirmed to be healthy and had no history 
of metabolic-endocrine disorders. Laminitis was induced in the experimental horses 
(labeled TH) using a prolonged euglycemic-hyperinsulinemic clamp (EHC) technique 
(DeFronzo et al., 1979). Each treatment horse was paired with a control horse (labeled 
CH), which had a saline infusion and was then euthanized. The laminar samples were 
rapidly collected from the hoof and distal phalanx, snap frozen in liquid nitrogen, and 
stored at -80°C. The Animal Ethics Committee of the University of Queensland 
approved the experimental protocol.  
A two channel, balanced block design was used to compare HI and control 
samples. Dye swaps were incorporated into the hybridization scheme of the experiment 
to eliminate dye bias. A total of 4 whole genome equine microarray slides were used. 
The microarray hybridization experiment conducted in this study is shown in Fig. 4.1.   
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Fig. 4.1. Diagram of the HI model laminitis experimental design. Four hybridizations 
were performed. The green color represents Cy3 and the red color represents Cy5. The 
laminar samples labeled with CH1, CH2, CH3, and CH4 were from control horses. The 
laminar samples labeled with TH1, TH2, TH3, and TH4 were from HI induced horses. 
Half of the samples from the control group were labeled with Cy3 and the other half 
were labeled with Cy5. Half of the samples from the HI laminitis group were labeled 
with Cy3 and the other half were labeled with Cy5.  
 
 
 
Equine 21K oligonucleotide microarray 
  The 70-mer oligoarray was constructed based on a 2.4 Gb EquCab2 of the horse 
genome, combined with RefSeq release 26, UniGene build#3, SwissProt release 12 and 
~43,000 unpublished ESTs (Bright et al., 2009). Probes were synthesized (Invitrogen, 
Carlsbad, CA) and printed into amino-silane coated slides (Corning Incorporated, 
Corning, NY).  
RNA isolation and cDNA synthesis 
Total RNA was extracted from 80-100 mg of frozen laminar tissue, which was 
disrupted and homogenized in the presence of Tri reagent (MRC, Cincinnati, OH) as 
described in (Chomczynski, 1993). This was followed by RNA cleanup with RNase-free 
DNase treatment (RNeasy Mini Kit, Qiagen, Valencia, CA) of the isolate according to 
CH2 TH1 
CH1 TH2 CH3 TH4 
TH3 CH4 
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the manufacturer‟s protocol. RNA concentration was quantified using a 
spectrophotometer (NanoDrop Technologies, Wilmington, DE) and the quality was 
evaluated with an Agilent 2100 Bioanalyzer and RNA Lab Chip (RNA 6000 Nano 
Assay, Agilent Technologies, Palo Alto, CA). cDNAs were synthesized from total RNA 
with the 3DNA Array 900MPX Expression Array Detection Kit (Genisphere, Hatfield, 
PA) using SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA). One 
microgram of total RNA was combined with random primer and MPX dT primer, 
incubated at 80°C for 10 min, and cooled on ice for 2 min. Finally, 0.5M NaOH/50mM 
EDTA was added to degrade any remaining RNA; this reaction was neutralized with 1 
M Tris-HCl (pH 7.5).  
cDNA purification, tailing and ligation 
The cDNA was purified using the Qiagen MinElute PCR purification kit 
(Qiagen, Valencia, CA) according to the manufacturer‟s protocol. Then nuclease-free 
water was added to the purified cDNA to a volume of 16.5 μl. The cDNA was incubated 
at 95°C for 10 min in a PCR thermal cycler and cooled on ice for 2 min. The cDNA was 
tailed by terminal deoxynucleotidyl transferase (TdT) enzyme and ligated to 3DNA 
capture sequence. The ligated DNA was purified again using the Qiagen MinElute PCR 
purification kit (Qiagen, Valencia, CA) according to the manufacturer‟s protocol.  
Pre-hybridization treatment of microarray slide 
Rehydration and crosslinking of the microarray slide was performed to ensure 
that the probe was spread evenly in the spot and immobilized on the slide.  The slides 
were rehydrated by holding the slide label side down over the steam from a 50°C water 
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bath for 10 s. The slides were dried for 5 s at 65°C and then brought to room temperature 
(20°C) for 1 min. This process was repeated up to four times. After rehydration, the 
slides were subjected to UV crosslinking at 750 MJ/cm
2
 for 2 minutes.      
Microarray cDNA hybridization 
A 543 μl reaction was used for the tagged cDNA hybridization mix, which was 
prepared according to the manufacturer‟s instructions (Genisphere, Hatfield, PA).  The 
mixture was applied to the gasket slide of an Agilent microarray hybridization chamber 
and the microarray slide (array side down) was laid on top of the gasket slide. The 
hybridization chamber was assembled and the slides were then incubated at 55°C while 
rotating at 5 rpm in a hybridization oven (Agilent Technologies, Santa Clara, CA) for 16 
hours.  The “microarray-gasket slide sandwich” was then washed once with pre-warmed 
(42°C) 2x SSC-0.2% SDS wash buffer, disassembled, and washed again.  The array slide 
was then washed with 2x SSC and 0.2x SSC wash buffers.  Slides were dried at room 
temperature, centrifuged at 1000 rpm for 4 min, and then stored in a dry box prior to the 
second hybridization.   
 3DNA hybridization and wash 
3DNA hybridization master mix was prepared according to the manufacturer‟s 
instructions (Genisphere, Hatfield, PA), applied to the array, and covered with a 
coverslip in the dark.  The slide was placed in a 50 ml conical tube with 400 μl of 
nuclease-free water and incubated horizontally at 55°C in a hybridization oven (Agilent 
Technologies, Santa Clara, CA) for 4 hours in the dark. All washing steps following 
3DNA hybridization were conducted in the dark. The slide was taken out of the 
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incubator and washed with pre-warmed (42°C) 2x SSC-0.2% SDS wash buffer. The 
cover slip was removed and the slide was washed again with 2x SSC-0.2% SDS buffer.  
The slide was then washed with 2x SSC and 0.2x SSC wash buffers. Finally, the slide 
was dried at room temperature, centrifuged at 1000 rpm for 4 min, and stored for 
scanning.  
Microarray image processing and data analysis 
The slides were scanned with a GenePix Personal 4000B microarray scanner 
(Molecular Devices Corporation, Sunnyvale, CA) at a resolution of 5 μm. The 
fluorescence intensities from each array were quantified using GenePix Pro 6.0 program 
(Molecular Devices Corporation, Sunnyvale, CA). Each spot was inspected by manual 
gridding and empty spots were flagged out. The median signal intensity and local 
background intensity of each gene were normalized by print-tip loess normalization 
using the bioconductor LIMMA package (Gentleman et al., 2004) in the R statistical 
computing environment (http://www.r-project.org/). Linear models and empirical Bayes 
moderated F statistics (Smyth, 2004) were applied to obtain the P value and log2-based 
fold change for each gene.  
Gene ontology analysis 
The Database for Annotation, Visualization and Integrated Discovery (DAVID 
version 6.7) (Dennis et al., 2003; Huang et al., 2009) (http://david.abcc.ncifcrf.gov/) was 
used to obtain gene ontology (GO) terms of biological process (BP), cellular component 
(CC) and molecular function (MF) for DE genes of the HI/CON comparison. RefSeq 
protein IDs from human orthologs were used as input and Fisher‟s Exact P value of 0.05 
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was used as a cutoff for determining statistical significance. Gene ontology terms of all 
levels were included in the analysis.  
Pathway analysis 
Ingenuity Pathways Analysis program (Ingenuity Systems, version 8.7) was used 
to obtain networks, relevant biofunctions and canonical pathways pertinent to laminitis. 
A data set containing gene identifiers and corresponding expression values from the 
microarray expression analysis was uploaded into the application. Functional analysis 
identified the biological functions and diseases that were most significant to the dataset. 
Fisher's Exact test was used to calculate the P value determining the probability that each 
biological function and disease assigned to that data set (or network) is due to chance 
alone.  
Quantitative real time PCR    
To validate microarray results, the expression of a subset of DE genes from the 
HI/CON comparison were examined by quantitative reverse transcription PCR (qRT-
PCR). cDNA was synthesized from total RNA (250 ng) of each sample (HI and CON) 
using TaqMan® Reverse Transcriptase reagents (Applied Biosystems, Carlsbad, CA) 
according to the manufacturer‟s protocol.  The cDNAs were quantified by qRT-PCR on 
a LightCycler ® 480 thermocycler (Roche Diagnostics, Indianapolis, IN) using 2x 
LightCycler ® 480 SYBR Green I master mix (Roche Diagnostics, Indianapolis, IN). 
Primers for selected genes were designed by Primer 3 program. To calculate the PCR 
amplification efficiencies of target and reference genes, a serial dilution of laminar 
cDNA was made (200 ng/µl, 100 ng/µl, 50 ng/µl, 25 ng/µl, 12.5 ng/µl, and 6.25 ng/µl) 
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and used as a template. PCR efficiency of each gene was determined from the slope of 
the line along the concentrations as calculated by LightCycler ® 480 basic software 
(Roche Applied Science, Indianapolis, IN). Each individual sample was run in duplicate 
and the average crossing point (Cp) value was used for further analysis.  
Quantitative real time PCR data analysis 
In order to select appropriate reference genes for qRT-PCR data normalization, 
qRT-PCR was carried out for eleven equine genes ACTB, B2M, PPIA, GAPDH, 
GNB2L1, EEF1A1, HPRT1, TUBA1, UBB, RPL32 and RPLP0. The average expression 
stability and the optimal number of control genes for normalization were determined  
using the geNorm computer program (http://medgen.ugent.be/~jvdesomp/genorm/) 
(Vandesompele et al., 2002). The two most stable genes from those tested were used for 
normalization of the qRT-PCR data. The data was analyzed by the delta-Cq method 
(Hellemans et al., 2007) in qBasePlus (Biogazelle, Ghent, Belgium). The statistical 
significance of the derived CNRQ values between the two groups was determined by 
nonparametric Mann-Whitney test in SPSS 17.0 statistics software (SPSS Inc, Chicago, 
IL). A P value less than 0.05 was considered statistically significant. 
Hierarchical cluster analysis 
The mean values of selected DE genes from qRT-PCR were used to do 
hierarchical clustering analysis as well as heat map construction using MultiExperiment 
viewer and R (MeV/R) program version 4.6 (Chu et al., 2008; Saeed et al., 2003).   
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RESULTS 
All horses (n=4) in the treatment group developed laminitis (Obel grade 2), whereas 
the control horses (n=4) did not show any signs of clinical laminitis. TH4 was the most 
insulin sensitive horse but all horses treated with insulin were more sensitive than ponies 
and also compared to horses used in previous studies with EHC (Asplin et al., 2007; 
Rijnen and van der Kolk, 2003). Changes in other parameters (e.g., body temperature, 
heart rate and respiration rate) and various clinical outcomes of the horses during the 
study have been described by de Laat et al. (2010).   
Identification of differentially expressed genes in laminar tissue following HI   
Differential gene expression analysis was performed by comparing gene 
expression profiles between laminar tissues from 48 h HI treated and control horses. 
There were 106, 242, and 772 genes differentially expressed (DE) at the cut-off of 
P<0.005, P<0.01 and P< 0.05 respectively (Table 4.1). The fold change range of gene 
expression difference was 38.1 to 0.07 for each cut-off P value. Genes with a P value 
less than 0.01 and fold change larger than 2 were used for subsequent analysis. This 
category contained 242 genes; of which 116 were up-regulated and 126 were down-
regulated (Table 4.1).  
 
Table 4.1  
Distribution of differentially expressed genes at different significance level and fold 
change larger than 2.  
  Upregulated  Downregulated  Total 
P<0.005 57 (53.8%) 49 (46.2%) 106 
P<0.01 116 (47.9%) 126 (52.1%) 242 
P<0.05 342 (44.3%) 430 (55.7%) 772 
  
Table 4.2  
Top differentially expressed genes (14 upregulated and 14 downregulated; P<0.01 and fold change>2) for the HI/CON 
comparison. Unannotated genes are labelled as NULL. Asterisks denote genes selected for confirmation with PCR.  
 
 
Gene Name  Description 
Public 
Accession P 
Fold 
Change PCR 
Upregulated     
CRTAC1 Cartilage acidic protein 1 XM_001501238 0.0008 7.65  
SUGT1 SGT1, suppressor of G2 allele of SKP1 XM_001492933 0.0042 7.58 * 
RILPL2 Rab interacting lysosomal protein-like 2 DN504908 0.0047 7.06  
MORN3 MORN repeat containing 3 XM_001496205 0.0008 6.86  
PTPRQ 
Protein tyrosine phosphatase, receptor 
type,Q XM_001492869 0.0001 6.66  
EIF1AX 
Eukaryotic translation initiation factor 1A, X-
linked XM_001492752 0.0066 6.60 * 
HEMGN Hemogen XM_001504109 0.0008 5.93  
C16orf44 Chromosome 16 open reading frame 44 XM_001502352 0.0021 5.59  
C17orf79 Chromosome 17 open reading frame 79 CX605748 0.0074 5.48  
S100A2 S100 calcium binding protein A2 CX598422 0.0064 5.39 * 
LMOD2 Leiomodin 2 XM_001502348 0.0082 5.18  
TULP3 Tubby like protein 3 XM_001490880 0.0017 5.04 * 
ZNF75A Zinc finger protein 75a XM_001499142 0.0019 4.99  
MAPK14 Mitogen-activated protein kinase 14 XM_001494719 0.0002 4.95 * 
      
Downregulated      
MYBPC2 Myosin binding protein C XM_001494408 0.0017 0.07  
SLC24A2 Solute carrier family 24, member 2 XM_001495010 0.0049 0.14  
TIMM9 
Translocase of inner mitochondrial 
membrane 9 homolog XM_001497047 0.0017 0.15 
 
1
3
0
 
  
Table 4.2 continued 
  
Gene Name  Description 
Public 
Accession P 
Fold 
Change PCR 
Downregulated      
SDF2L1 Stromal cell-derived factor 2-like 1 XM_001493091 0.0057 0.16 * 
RER1 
RER1 retention in endoplasmic reticulum 1 
homolog NULL 0.0065 0.17 * 
RNF32 Ring finger protein 32 XM_001504692 0.0095 0.18  
NULL NULL CX603169 0.0078 0.19  
FANCF Fanconi anemia, complementation group F NULL 0.0079 0.19  
C17orf64 Chromosome 17 open reading frame 64 XM_001501083 0.0026 0.19  
PSMD1 
Proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 1 XM_001498019 0.0027 0.19 * 
C16orf77 Chromosome 16 open reading frame 77 XM_001500794 0.0026 0.20 * 
C16orf46 Chromosome 16 open reading frame 46 XM_001501937 0.0081 0.21  
NULL NULL CX593149 0.0094 0.21  
PACSIN3 
Protein kinase C and casein kinase substrate 
in neurons 3 XM_001490695 0.0017 0.21   
 
 
1
3
1
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A total of 28 DE genes with the largest fold changes (up and down regulated) are 
shown in Table 4.2. Among these 28 genes, the most up-regulated gene CRTAC1 is a 
cartilage-related extracellular matrix protein (Redruello et al., 2010). The degradation of 
extracellular matrix proteins (e.g., collagen and laminin) has been described in acute 
laminitis (Pollitt and Daradka, 1998). SUGT1, HEMGN and MAPK14 are up-regulated 
and are signal transduction regulators and genes maintaining homeostasis. Three genes 
encode adaptor proteins (RILPL2, ZNF75A, and MYBPC2) also changed their 
expression. Additionally, down-regulated gene SLC24A2 is a sodium-calcium 
exchanger (Prinsen et al., 2000).  
The list of all differentially expressed genes (P<0.01 and fold change>2) is shown 
in Table A.7. It is noteworthy that three extracellular matrix proteins encoded by 
KRT15, ADAMTS1 and CRTAC1 were all up-regulated. KRT15 is a member of the 
keratin family and keratins are a structural component of the equine hoof. ADAMTS1 is 
a member of the ADAMTS family and ADAMTSs play an important role in ECM 
components cleavage. The up-regulated gene MAPK14 (also called p38 MAPKα) is a 
member of the mitogen-activated protein kinase (MAPK) subfamily. P38 MAPK is 
associated with neutrophil migration during acute laminitis (Eckert et al., 2008). Among 
other DE genes, PROM2 and STC1 encode glycoproteins and glycoproteins are main 
component of the BM of the lamina. Next, OR7G2, OR5M3, and OR5AK2 are among 
the DE genes that belong to the olfactory receptor family, which is a superfamily of G-
protein coupled receptors (GPCRs). Further, three genes encoding S100 calcium binding 
proteins were differentially expressed, including S100PBP, S100A1 and S100A2. The 
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presence and overexpression of S100A8 and S100A9 have been described in the black 
walnut extract model of laminitis (Faleiros et al., 2009). Metalloproteinase 
carboxypeptidase A6 (CPA6), ADAM-like, decysin 1 (ADAMDEC1) and ADAMTS1 
were all dysregulated. Among these genes, only ADAMTS1 was up-regulated. 
ADAMDEC1 and ADAMTS1 have metalloendopeptidase activity. Both of ADAM and 
ADAMTS family play role in the degradation of ECM components (Cawston and 
Wilson, 2006). CPA6 has carboxypeptidase activity. Carboxypeptidase is a zinc 
metalloenzyme and is important for the keratinization process (Parisi and Vallee, 1969; 
Tomlinson et al., 2004). Keratin is a structural protein of equine hoof and the 
keratinization is essential for the hoof structure integrity (Grosenbaugh and Hood, 1992). 
GO analysis  
Gene ontology analysis was performed within the up and down-regulated DE 
genes (P<0.01 and FC>2) discovered between the 48 h HI and control laminar tissue 
comparison using the NIH-DAVID Bioinformatics Resources version 6.7 software 
(Dennis et al., 2003; Huang et al., 2009). Only enriched GO terms (P<0.05) are shown 
(Table A.8). The biological process categories containing the greatest number of DE 
genes were response to stimulus (31%) and immune response (11%).  
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It is noteworthy that there is only one major histocompatibility complex (MHC) 
gene (HLA-DQA1, MHC class II, DQ alpha 1) in the input gene list, however, DAVID 
algorithm matched it to six different isoforms (the column labeled „Count” is 6 in the 
overrepresented category). DAVID database integrates multiple resources together and 
attempts to remove redundancy and cross linking among resources. However, in each 
original database, many gene accessions could represent the same gene or its different 
isoforms. Thus one MHC gene was counted 6 times. The majority of the GO terms of 
BP category, including immune response (BNIP3, VSIG4, POLM and HLA-DQA1), 
regulation of cell cycle and negative regulation of cell proliferation were found in the 
up-regulated genes (Table A.8). Cellular component terms pointed to changes in cytosol 
and nuclear part. Molecular functions were associated with molecular transducer activity 
and signal transducer activity, suggesting a transcriptional up-regulation of genes 
associated with signal transduction during the OG2 stage of HI associated laminitis. On 
the other hand, genes involved in proteolysis and cellular response to stimulus were 
down-regulated. Two overrepresented cellular components were both intracellular and 
molecular functions related to signal transduction regulation and protein binding.   
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Pathway analysis  
We utilized the GenMAPP version 2.1 (Salomonis et al., 2007), KEGG (Kanehisa 
et al., 2008), and Ingenuity Pathways Analysis (Ingenuity Systems, 
http://www.ingenuity.com/, version 8.7) applications to establish relationships among 
DE genes (P<0.01 with FC>2) and to predict pathways potentially associated with the 
pathogenesis of laminitis. When we mapped the full set of DE genes into the metabolic 
process category in GenMAPP, two up-regulated genes, GAPDH and PGAM1, were 
linked to glycolysis and gluconeogenesis pathway (Fig. 4.2). Another up-regulated gene, 
GALM, was also in the glycolysis and gluconeogenesis pathway but was not mapped by 
GenMAPP program since the MAPP category metabolic process doesn‟t contain this 
gene. Spliceosome pathway was detected using KEGG pathway database linked through 
the DAVID database.  
Network analysis  
Ingenuity analysis was performed on genes that were differentially expressed at 
P<0.01 with a fold change of 2 or higher. The top biofunctions based on P value 
determined by IPA were DNA replication, recombination, repair, cell cycle, organ 
morphology, cardiovascular system development and function (Table 4.3). The 
associated diseases identified through the analysis were cancer (Hu et al., 2010), 
dermatological diseases (Dourmishev and Draganov, 2009) and endocrine system 
disorders (Maser et al., 2006). Essentially, all these conditions have gastrointestinal tract 
involvement (Table 4.3). Many dermatological diseases have been associated with an 
underlying malignancy of gastrointestinal tract (Dourmishev and Draganov, 2009). One 
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hundred and forty-four canonical pathways were detected and the top canonical 
pathways based on P value determined through the IPA library were Parkinson‟s 
signaling and maturity onset diabetes of young (MODY) signaling. Parkinson‟s disease 
is a neurodegenerative disorder that is associated with impairment of insulin signaling 
(Cardoso et al., 2009; Moroo et al., 1994). MODY is a form of diabetes that often occurs 
at young age (Nyunt et al., 2009). The top network with a score of 48 and the second 
network with a score of 37 are shown (Fig. 4.3 A and B). The top network function was 
DNA replication, recombination, repair, cell death, skeletal and muscular system 
development and function. There were 35 genes in the top network, which included 27 
of the genes we identified as DE in the HI/CON comparison. Therefore, additional 8 
genes were found to interact with DE genes through the network. Of the DE genes in the 
network, 17 genes were up-regulated and 10 genes were down-regulated. Furthermore, 
among these 27 genes, SUGT1 had a high degree of up-regulation with a fold change of 
8. Additionally, the network showed the central position of p38 MAPK, MAPK14, and 
NF-κB (not DE) in the pathways, as well as the peripheral role of PSMD1 and HSPA8. 
The second network with a score of 37 had 35 genes, which included 21 genes we 
identified as DE. Another 14 genes had biological relationships with those DE genes 
through the network. Of the DE genes in the network, 13 genes were up-regulated and 8 
genes were down-regulated. The associated network functions were nervous system 
development and function, tissue development and small molecule biochemistry. In the 
network, FOSL1 had a high degree of up-regulation with a fold change of 5.  
  
Fig. 4.2. Glycolysis and gluconeogenesis pathways generated by GenMAPP program.  
The DE genes (P<0.01 and FC>2) of HI/CON comparison were used as input to GenMAPP. The gene database used was 
Hs_std_20070817.gdb. The gene identifier used was the human ortholog protein ID. Those genes linked to MAPPs 
representing the metabolic process (i.e. glycolysis and gluconeogenesis) in GenMAPP are color coded (red: up-regulation, 
green: down-regulation).       
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Table 4.3 
The top biofunctions, associated diseases, canonical pathways, and network functions 
that were most significant to the data set of HI laminitis experiment. The DE genes at the 
level of P<0.01 and FC>2 were used as input data set for HI/CON comparison.  
 
 
 Biological 
functions 
Associated 
diseases 
Top canonical 
pathways 
Top network 
function 
HI/CON DNA replication, 
recombination, and 
repair, cell cycle, 
cardiovascular 
system development 
and function 
 
 
Cancer, 
dermatological 
diseases and 
endocrine system 
disorders 
 
Parkinson‟s signaling, 
maturity onset diabetes of 
young (MODY) signaling 
DNA replication, 
recombination, 
and repair, cell 
death, skeletal 
and muscular 
system 
development and 
function 
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A 
 
 
 
 
Fig. 4.3. Ingenuity network analysis of HI 48 h compared to CON. The top network 
identified by IPA with a significant score of 48 (A) and 37 (B). Both direct (solid line) 
and indirect (dashed line) interactions among genes were shown in the network. This 
analysis was performed on the DE genes of P<0.01 and FC>2. In A, this network 
showed the central position of p38 MAPK and NF-κB. In B, This network showed ERK 
and AP-1 linked to many genes we identified as DE. The intensity of the node color are 
depicted as down-regulated (green) or up-regulated (red). Square: cytokine/growth 
factor; vertical diamond: enzyme; horizontal diamond: peptidase; circle: other; 
parallelogram: transporter; circle-in-circle: complex; oval: transmembrane receptor; 
shaded circle-in-circle: group.  
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Fig. 4.3. continued  
 
 
Quantitative real time PCR 
To select the best reference gene for qRT-PCR data normalization, qRT-PCR was 
carried out for eleven horse reference genes (ACTB, B2M, PPIA, GAPDH, GNB2L1, 
142 
 
 
EEF1A1, HPRT1, TUBA1, UBB, RPL32 and RPLP0). Gene expression stability among 
the laminar samples (HI and CON) was determined according to the geNorm software 
(Vandesompele et al., 2002). We found that GNB2L1 and RPL32 were the most stable 
genes in the HI laminitis.  
To confirm the differential expression results suggested by microarray, 16 genes 
(up-regulated and down-regulated) were selected for qRT-PCR validation. We select 
most of the DE genes based on a small P value and large fold change. The fold change of 
all selected genes was larger than 2. For the HI/CON comparison, there were only 5 
annotated DE genes with a P value less than 0.001 and fold change larger than 2. 
Therefore most of genes were selected from Table 4.2 and have a P value between 0.001 
and 0.01 (shown with an asterisk). Real time PCR was performed on 16 DE genes across 
tissues (CON and HI).  
Three additional genes with P values between 0.01 and 0.05 (CD14, TNFRSF11B, 
and S100PBP) were also chosen based on their probable functional relevance to 
laminitis. CD14 is a lipopolysaccharide (LPS) binding protein that facilitates the 
recognition of pathogen associated molecular patterns (PAMPs) in the innate immune 
response (Akira et al., 2006). It has been shown that the expression of CD14 was 
increased in laminitic horses (Stokes et al., 2010). TNFRSF11B (osteoprotegerin, OPG) 
is a member of the tumor necrosis factor receptor superfamily and is important in bone 
homeostasis (Ueland et al., 2001). Engiles et al. have recently suggested that the digital 
bone microenvironment underlying the laminae may be affected by laminitis (Engiles, 
2010). S100PBP is a member of the S100 protein family, which play a role in the 
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inflammatory response (Foell et al., 2007b). S100A8 and S100A9, members of S100 
protein family, have been recently detected in laminar epidermis and shown to be up-
regulated in BWE model of laminitis (Faleiros et al., 2009).  
The primers used for qRT-PCR are listed in Table 4.4. qRT-PCR results showed 
that 11 genes (C16orf77, CD14, CXCL14, EIF1AX, GAPDH, MAPK14, S100A2, 
S100PBP, TNFRSF11B, TULP3, and ADAMTS1) had significantly different expression 
between HI and CON groups (Fig. 4.4). Of note, ADAMTS1 and TNFRSF11B genes 
had a high fold difference of 22 and 8, respectively, between the experimental and 
control groups in qRT-PCR.  
To visualize the expression patterns of laminar tissue following HI induction, A 
heat map was constructed using MeV/R software for the 16 DE genes based on qRT-
PCR results across the two conditions (CON and HI) (Fig. 4.5). Hierarchical clustering 
classified the genes based on their expression similarity between conditions. Cluster 
analysis showed a distinct expression pattern between the conditions (CON and HI). 
Moreover, the up-regulated group (ADAMTS1, CD14, GAPDH, S100A2, and 
TNFRSF11B) and the down-regulated group (CXCL14, PSMD1, C16orf77, and 
S100A1) were distinctly separated.  
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Fig. 4.4. Real time PCR validation of the microarray results of the HI/CON comparison. 
GNB2L1 and RPL32 are reference genes used for normalization. Sixteen DE genes from 
the microarray analysis were selected for real time PCR confirmation. Data are presented 
as mean  SEM. Those genes marked with asterisks are significantly different from 
CON.   
 
 
 
 
  
Table 4.4  
Primers of genes used for quantitative RT-PCR of HI laminitis experiment.   
 
Gene 
Symbol 
Accession No. Forward Sequence (5’-3’) Reverse Sequence (5’-3’) 
PCR 
Product 
Size 
(bp) 
Tm(°C) * 
ADAMTS1 AF541975 
 
AGGCTCACAATGAATTTTCG CACAGCCAGCTTTTACACACT 225 58 
CXCL14 XM_001502713 ACTGCGAGGAGAAGATGGTTA 
 
CTCGTTCCAGGCGTTGTA 
 
128 58 
S100A1 XM_001494870 AGGGGACAAGTACAAGCTGAG 
 
TCTCGTCTAGCTCCTTCATCA 
 
125 58 
CD14 AF200416 CAGCTCTTTCCAGAGTCCAC AGTTCTCATCGTCCACCTCA 144 60 
S100A2 CX598422 GCGACAAGTTCAAGCTGAGTA 
 
ATAGTGATGAGGGCCAGAAAA 
 
181 58 
TNFRSF11 
B 
XR_036157 CGTCATCTAAAGCACCCTGTA CTGAGCCAATTAGGGGTAAAC 202 58 
GAPDH
c
 AF157626 GATGCCCCAATGTTTGTGA AAGCAGGGATGATGTTCTGG 250 61 
S100PBP XM_001499793 GCCTCTCCAAACTACCTCAAC 
 
CCTTATCAAGCACAGCATCAC 156 58 
MAPK14  XM_001494719 AAGAGGATTACAGCAGCACAA 
 
CGGGATCAAGAGAACAGAAAT 
 
229 58 
TULP3 XM_001490880 CACCATATTCAGAGGCAGAGA TCATCCTTTTCCAAGTGCATA 244 58 
 
 
SUGT1             XM_001492933 
 
CTAGAGGGGCAAGGAGATGT                   
 
CCAACCAATTTATCCCAATTT 
 
107 58 
EIF1AX     XM_001492752 
 
ACGAAATCCAGTTTGATGACA 
 
CAACAGATCACAGCCAAAATC 130 58 
SDF2L1 XM_001493091 CTGCACACGCACCACTTC CATACTGCTCGCCGGTAACT 193 58 1
4
5
 
  
   
Table 4.4 continued 
 
Gene 
Symbol 
Accession No. Forward Sequence (5’-3’) Reverse Sequence (5’-3’) 
PCR 
Product 
Size 
(bp) 
Tm(°C) * 
RER1 XM_001503365 TCTTTGAGGCTTTCAACGTC CTCCTTGCCCTTGTACGTC 155 58 
PSMD1 XM_001498019 
 
CCAGTGAAGACATTGAAGAGC 
 
AATAGCAGGTCTCAGCATGAA 
 
190 58 
C16orf77 XM_001500794 
 
TGGAAGTACCTGGAGGAGGT 
 
CATGACCCGGAAGCAGTT 
 
171 58 
GNB2L1
a
 AY246708 CAGGGATGAGACCAACTACG 
 
ATGCCACACTCAGCACATC 
 
269 58 
RPL32
ac
 CX594263 AGCCATCTACTCGGCGTCA TCCAATGCCTCTGGGTTTC 149 58 
UBB
 c
  AF506969 GCAAGACCATCACCCTGGA 
 
CTAACAGCCACCCCTGAGAC 
 
206 61 
HPRT1
 c
 AY372182 GGCAAAACAATGCAAACCTT 
 
CAAGGGCATATCCTACGACAA 
 
163 61 
TUBA1
c
 AW260995 GCCCTACAACTCCATCCTGA 
 
ATGGCTTCATTGTCCACCA 
 
78 60 
EEF1A1 NM_001081781 
 
TGGAAAGAAGCTGGAAGATG CAACCGTCTGTCTCATGTCA 132 58 
RPLP0 BC107717 TTGCATCAGTACCCCATTCT ACCAAATCCCATATCCTCGT 242 58 
ACTB
c
 AF035774  CCAGCACGATGAAGATCAAG GTGGACAATGAGGCCAGAAT 88 58 
B2M X69083 CGAGACCTCTAACCAGCATC AGACATAGCGGCCAAAGTAG 186 58 
PPIA NM_021130 TGGGGAGAAAGGATTTGGTT CATGGACAAGATGCCAGGAC 178 58 
 
 
* The optimal annealing temperature   
         a 
GNB2L1 and RPL32 were used for normalization during quantitative RT- PCR 
c 
Information about the primers from (Bogaert et al., 2006) 1
4
6
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Fig. 4.5. Cluster diagram of the mean of CNRQ values at HI 48 h time point and control 
as determined by qRT-PCR. The green to red color scale demonstrates expression value 
of mean of CNRQ. GNB2L1 and RPL32 were used as reference genes to calculate 
normalized ΔCq. 
 
 
DISCUSSION  
Whole genome expression oligoarray has served as an extremely useful 
technique for exploring the transcriptome (Hardiman, 2004; Hughes et al., 2001; Woo et 
al., 2004). While previous investigations using microarray technology focused on the OF 
and BWE models of laminitis (Budak et al., 2009; Noschka et al., 2008), our study is the 
first to investigate genome-wide transcriptome profiling in endocrinopathic laminitis at 
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the Obel grade 2 stage of acute laminitis using an equine whole-genome long 
oligonucleotide microarray (Bright et al., 2009).  
Analysis of differentially expressed genes 
Equine whole-genome oligoarray identified differential expression of 242 genes 
(P<0.01 and FC>2) between the experimental and control groups (Table 4.1). Among 
these genes, CXCL14, CD1C, CD33, and SIGLEC10 are involved in inflammation and 
immune response. CXCL14 is a regulator of glucose metabolism and is associated with 
obesity-induced IR in mice (Nara et al., 2007; Tanegashima et al., 2010). CD1C, a 
member of CD1 family, is an antigen presenting molecule and involved in T cell 
recognition of lipid (Moody et al., 2000). SIGLEC10, a member of sialic-acid binding 
immunoglobulin-like lectins (SIGLECS) of the immunoglobulin superfamily, is a ligand 
for vascular adhension protein 1 (VAP-1) and their interaction can mediate leukocyte 
trafficking (Kivi et al., 2009). CD33 is another member of SIGLECS and has been 
shown to modulate leukocyte function (Crocker et al., 2007). The up-regulated 
inflammatory mediators CD33 and SIGLEC10 are potential target genes to develop 
treatments to reduce inflammation associated with endocrinopathic laminitis.  
We also identified the differential expression of other groups of genes, such as 
extracellular matrix proteins KRT15 and keratinocyte protein SPRR1B (Li et al., 2008). 
Keratin is an important component of the epidermis of equine hoof. Furthermore, some 
genes encoding adaptor proteins changed expression following HI induction (Table A.7). 
Adaptor proteins have been demonstrated to play important role in signal transduction 
(Flynn, 2001), hence these proteins are potentially related to the pathogenesis of 
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endocrinopathic laminitis through signal transduction regulation. Three up-regulated 
genes are signal transduction regulators and genes maintaining homeostasis (SUGT1, 
HEMGN, and MAPK14) (Table 4.2). Because HI affects the endocrine system and 
metabolism of the body (i.e., insulin-glucose signal transduction and lipid metabolism) 
(Lovegrove, 2005; Sam, 2000), the up-regulation of these genes in the HI model of 
laminitis may be an attempt to compensate for the endocrine and metabolic effects 
caused by HI. OR7G2, OR5M3, and OR5AK2, members of olfactory receptor family 
were up-regulated. Olfactory receptors are mainly expressed in the nose, but also 
expressed in other tissue types such as the kidney and sperm (Kaupp, 2010; Pluznick et 
al., 2009; Spehr et al., 2003). The expression of olfactory receptors in the foot and their 
possible function in laminitis remain to be investigated.  
Three calcium binding proteins, S100PBP, S100A1, and S100A2, were 
dysregulated in HI relative to control horses in our study. S100 proteins play an 
important role in innate immunity through inflammatory response mediation and 
leukocyte recruitment (Foell et al., 2007b). They also play a role in the maintenance of 
Ca
2+
 homeostasis in the body (Mandinova et al., 1998). These genes may contribute to 
the pathogenesis of the HI model of laminitis by regulating the inflammatory response 
and leukocyte activation. The strong induction of calcium binding proteins in the HI 
model of equine laminitis has not been previously reported.  
In this study, we also identified the differential expression of ADAMDEC1 and 
ADAMTS1 at 48 h time point following HI induction. ADAMDEC1 is associated with 
atherosclerosis (Papaspyridonos et al., 2006) and ADAMTS1 is also up-regulated in the 
150 
 
 
OG1 stage of the CHO model of laminitis (Chapter III). The ADAMs belong to the 
family of metalloproteinases which also includes the adamalysin subfamily ADAMTS 
(Reiss et al., 2006). Both ADAMs and ADAMTSs play an important role in the turnover 
of ECM proteins (e.g., collagen and aggrecan) and their differential expression has been 
implicated in various cancers and arthritis (Tortorella et al., 2009). Another study of the 
comparison of expression between normal and painful tendons further suggests that 
many ADAMTS members might play key role in the pathology of connective tissues  
through the degradation of ECM components (Jones and Riley, 2005). Laminitis is also a 
connective tissue disease and the site of disease occurs at the laminar tissue, which is the 
connective tissue between the hoof wall and coffin bone. Therefore, metalloproteinases 
ADAMTS1 and ADAMDEC1 have potential role in laminitis progression through ECM 
cleavage. Most importantly, ADAMTS1 is a potential target of therapeutic intervention 
for equine laminitis. The inhibition of ADAMTS1 activity could reduce ECM 
components degradation. BM (a thin layer of ECM) degradation is the early pathological 
change during the pathogenesis of equine acute laminitis (Pollitt, 1996). The down-
regulation of CPA6 gene at the OG2 stage may potentially affect the equine hoof 
structure integrity. 
Comparison to previous studies 
Similar to results seen using a 15,000 bovine microarray chip in laminar tissue 
from the OF model of laminitis (Budak et al., 2009), we identified the differential 
expression of FOS and PSMD genes. Compared to the work carried out by an equine-
specific 3,076 element cDNA microarray in laminar tissue of the BWE model laminitis 
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(Noschka et al., 2008), we also identified the differential expression of SERPINF2. 
Additionally, we identified the differential expression of interferon regulatory factor 
IRF4 instead of IRF1, S100 protein S100PBP instead of S100P, and RAS oncogene 
family member RAB3A instead of RAB1A. Differential expression of IRF1, S100P and 
RAB1A were identified in laminar tissue from the BWE model laminitis (Noschka et al., 
2008).  
GO functional enrichment analysis 
GO analysis provides information about the overrepresented categories (i.e., BP, 
MF and CC) among the DE genes. The BP GO terms response to stimulus and immune 
response were significantly enriched among up-regulated genes (Table A.8). During HI 
induced laminitis, these up-regulated genes might counteract the effects of excess insulin 
in an attempt to maintain the body‟s homeostasis. It is noteworthy that one gene 
involved in adaptive immune response HLA-DQA1 was up-regulated. On the other 
hand, genes associated with molecular transducer activity and signal transducer activity 
increased their expression, suggesting a signal transduction regulation following HI 
during the progression of the disease. 
Pathway and network relevance to laminitis 
Pathway analysis identified three DE genes involved in glycolysis and 
gluconeogenesis processes (GALM was not mapped) (Fig. 4.2). Although this is limited 
evidence, differential expression of these genes may disrupt glucose metabolism, which 
could contribute to the pathogenesis of HI laminitis. There is evidence that changes in 
glucose uptake can induce laminar failure in vitro (Pass et al., 1998; Wattle and Pollitt, 
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2004). It has also been shown that abnormal glucose metabolism in horses with ECD 
could cause laminitis (Keen et al., 2004). Interestingly, another study has demonstrated 
the expression of glucose transporter-1 (GLUT-1) and GLUT-4 proteins in equine 
keratinocytes and the expression of GLUT-4 decreased with the progression of laminitis 
(Mobasheri et al., 2004). It remains to be investigated if abnormal glucose metabolism is 
due to the varied expression of GLUT-4 in these studies. Insulin can regulate glucose 
metabolism through the inhibition of gluconeogenesis process (Barthel and Schmoll, 
2003). Although Asplin and co-workers suggested that it is not IR but insulin toxicity 
that causes endocrinopathic laminitis (Asplin et al., 2007), it is also possible that HI 
contributes to laminitis through the disruption of glucose metabolism.  
Pathway analysis of DE genes in the HI/CON comparison showed the central role 
of p38 MAPK and NF-κB pathway molecules and the biological interactions among the 
genes in the networks (Fig. 4.3). The dysregulation of the DE genes in the network may 
affect the activity of other relevant genes. Therefore the biological interactions between 
these genes were disrupted indirectly, which may contribute to the pathogenesis of 
laminitis. Many DE genes are also linked to AP-1. Studies have shown p38 MAPK 
induction in equine neutrophil activation and suggested that p38 MAPK inhibition may 
help decrease the inflammatory response in the affected laminae (Eckert et al., 2008). In 
human medicine, the NF-κB family of transcription factors have been shown to be 
involved in rheumatoid arthritis (RA) (Simmonds and Foxwell, 2008). Interestingly, in 
people with metabolic syndrome and type 2 diabetes, there is an interaction between the 
insulin signaling cascade and obesity-induced inflammation through NF-κB and AP-1 
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(de Luca and Olefsky, 2008). Together, these results indicate the potential molecular 
mechanisms (i.e., p38 MAPK and NF-κB) associated with endocrinopathic laminitis and 
give insight into laminitis cases associated with endocrine dysfunctions.  
Relevance to current theories of hyperinsulinemic laminitis 
 There are several theories regarding the pathogenesis of hyperinsulinemic 
laminitis, including vascular dysfunction (Geor and Frank, 2008), inflammation 
(McGowan, 2008) and insulin toxicity (Asplin et al., 2007). Differential expression 
results of this study showed that some genes involved in inflammation changed their 
expression (e.g., CXCL14 and CD33) during the progression of laminitis. Insulin is not 
only a hormone but also a vasoactive mediator (Johnson et al., 2004b). It can affect the 
blood flow through the modulation of endothelin-1 (ET-1) and nitric oxide (NO) 
production (Muniyappa et al., 2007). ET-1 is a potent vasoconstrictor that may be 
involved in equine laminitis (Katwa et al., 1999). HI has been shown to cause 
endothelial dysfunction in humans (Arcaro et al., 2002) and is associated with the 
impairment of endothelium-dependent vasodilation as well as enhanced production of 
ET-1 (Potenza et al., 2005). ET-1 can induce endothelial dysfunction by reducing NO 
availability in mice (Iglarz and Clozel, 2007). Additionally, it has been suggested that 
endothelial dysfunction is involved in the pathogenesis of diabetic foot disease in 
humans (La Fontaine et al., 2006). Therefore, it is likely that the combination of these 
effects (i.e., vascular dysfunction, inflammation and glucose metabolism changes) 
contributes to the pathogenesis of HI laminitis.  
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CONCLUSION 
Overall, this is the first investigation of genome-wide transcriptome profiling of the 
laminar tissue at 48 h time point after HI induction using an equine-whole genome 
21,000 long oligonucleotide microarray approach. We identified the differential 
expression of several S100 gene family members, signal transduction regulators and 
genes maintaining homeostasis, extracellular matrix proteins, adaptor proteins, 
glycoproteins, and ADAMTS1 and ADAMDEC1 metalloproteinases during the 
progression of HI model laminitis. These genes will be good candidates for further 
functional study in insulin-associated laminitis. Pathway and network analysis revealed 
genes, gene-gene interactions relevant to equine laminitis and the presence of p38 
MAPK and NF-κB pathway molecules. Furthermore, it is possible that HI contributes to 
hyperinsulinemic laminitis through glucose metabolism disruption. These findings will 
be critical in paving the way for predicting and developing improved preventatives and 
treatments for endocrinopathic laminitis in the future. 
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CHAPTER V 
TRANSCRIPTOME PROFILING OF LAMINAR TISSUE DURING THE 
EARLY STAGES OF OLIGOFRUCTOSE INDUCED LAMINITIS IN THE 
HORSE 
 
 INTRODUCTION  
Equine laminitis is a serious disease of the equine foot that is characterized by 
basement membrane (BM) degradation as well as laminar separation at the dermal-
epidermal interface (Pollitt, 2004b). The exact mechanisms by which laminar separation 
occurs need further investigation. However, laminitis has been linked to many factors 
such as grain overload, gastrointestinal (GI) tract disease and endotoxemia. Studies have 
shown that metabolic and endocrine abnormalities are risk factors for the development 
of laminitis in horses and ponies (Geor and Frank, 2008; Geor, 2008; Johnson, 2002; 
Treiber et al., 2006b). In order to study the initiation and progression of equine laminitis, 
four experimentally induced models have been established using the administration of 
CHO (Garner et al., 1975), BWE (Minnick et al., 1987), OF (van Eps and Pollitt, 2006)  
and prolonged HI with euglycaemia (Asplin et al., 2007; de Laat et al., 2010).  
Fructan is a form of oligofructose and OF induced laminitis is a model of pasture 
associated laminitis (van Eps and Pollitt, 2006). It is still unknown which factors trigger 
the onset of OF induced laminitis. Recent work has demonstrated a diverse bacterial 
community in the horse hindgut (Al Jassim and Andrews, 2009). It has been shown that 
changes in the bacterial populations of the GI tract occur during OF induced laminitis 
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(Milinovich et al., 2006). The majority of microbes in the equine hindgut of OF induced 
laminitis are in the genus Streptococcus. Furthermore, microbe S. infantarius ssp. coli 
was overrepresented in the bacterial population before the onset of laminitis (Milinovich 
et al., 2006). Additionally, two novel species of the genus Streptococcus were identified 
in the horse hindgut in the OF induced model of laminitis (Milinovich et al., 2008a). 
Equine hindgut streptococcal species (EHSS) have been proposed as an etiological agent 
and the released cellular components in the GI tract may initiate laminitis (Milinovich et 
al., 2008b).  
Although an equine-specific 3,076 element cDNA microarray (Noschka et al., 
2008), bovine 15,000 oligoarray (Budak et al., 2009) applied in equine laminitis, they 
have inherent limitations that prevent detailed studies aimed at understanding the 
potential genetic pathways and gene networks associated with the pathogenesis and 
progression of equine laminitis on a genome-wide scale. Because early stages of 
laminitis are critical in understanding the initiation of the disease, we sought to identify 
genes and their likely interactions that may lead to observed pathological changes in the 
early time points of the OF model of laminitis. The overall objective of this study was to 
identify transcriptomic profiling and associated pathways in laminar tissue at 12 h and 
24 h time points after OF induction using the 70-mer equine whole-genome oligoarray 
(Bright et al., 2009). 
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MATERIALS AND METHODS 
Experimental design 
Eighteen clinically normal Standardbred horses (2-12 years of age, 15 geldings 
and 3 mares) were used in this study. The horses were examined and confirmed to be 
healthy and without a history of metabolic-endocrine disorders. Six horses were used for 
each category (12 h, 24 h and control). Horses grouped in the „12 h‟ and the „24 h‟ 
stages were administered OF (10 g/kg of body weight) via nasogastric tube. Control 
group horses received water via nasogastric tube. The induction of laminitis using OF 
was carried out according to the method of van Eps and Pollitt (van Eps and Pollitt, 
2006). Laminar samples were obtained from control horses (CON, n=6) at the 24 h time 
point and laminitic horses at 12 h (12 h, n=6) and 24 h (24 h, n=6). The Animal Ethics 
Committee of the University of Queensland approved the experimental protocol. 
A two channel, balanced block design was used for microarray hybridizations. 
Three different comparisons were carried out (12 h vs. control, 24 h vs. control, and 12 h 
vs. 24 h). Dye balance was performed during the experiment to eliminate dye bias. A 
total of 18 slides (6 slides per comparison) were used. The microarray hybridization 
experiment conducted in this study is shown in Fig.5.1.  
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6
 
Fig. 5.1. Diagram of the OF model laminitis experimental design. Eighteen 
hybridizations were performed. Arrows represent the hybridization between the laminar 
samples from different groups. Six animals were included in each group (N=6). CON: 
laminar samples from control horses; 12 H: laminar samples from 12 h OF induced 
horses; 24 H: laminar samples from 24 h OF induced horses.  
 
 
Equine 21K oligonucleotide microarray 
    The 70-mer oligoarray was constructed based on a 2.4 Gb EquCab2 of the horse 
genome, combined with RefSeq release 26, UniGene build#3, SwissProt release 12 and 
~43,000 unpublished ESTs (Bright et al., 2009). Probes were synthesized (Invitrogen, 
Carlsbad, CA) and printed into amino-silane coated slides (Corning Incorporated, 
Corning, NY).  
RNA isolation and cDNA synthesis 
Total RNA was extracted from 80-100 mg of frozen laminar tissue, which was 
disrupted and homogenized in the presence of Tri reagent (MRC, Cincinnati, OH) as 
described in (Chomczynski, 1993). This was followed by RNA cleanup with RNase-free 
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DNase treatment (RNeasy Mini Kit, Qiagen, Valencia, CA) of the isolate according to 
the manufacturer‟s protocol. RNA concentration was quantified using a 
spectrophotometer (NanoDrop Technologies, Wilmington, DE) and the quality was 
evaluated with an Agilent 2100 Bioanalyzer and RNA Lab Chip (RNA 6000 Nano 
Assay, Agilent Technologies, Palo Alto, CA). cDNAs were synthesized from total RNA 
with the 3DNA Array 900MPX Expression Array Detection Kit (Genisphere, Hatfield, 
PA) using SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA). One 
microgram of total RNA was combined with random primer and MPX dT primer, 
incubated at 80°C for 10 min, and cooled on ice for 2 min. Finally, 0.5M NaOH/50mM 
EDTA was added to degrade any remaining RNA; this reaction was neutralized with 1 
M Tris-HCl (pH 7.5).  
cDNA purification, tailing and ligation 
The cDNA was purified using the Qiagen MinElute PCR purification kit 
(Qiagen, Valencia, CA) according to the manufacturer‟s protocol. Then nuclease-free 
water was added to the purified cDNA to a volume of 16.5 μl. The cDNA was incubated 
at 95°C for 10 min in a PCR thermal cycler and cooled on ice for 2 min. The cDNA was 
tailed by terminal deoxynucleotidyl transferase (TdT) enzyme and ligated to 3DNA 
capture sequence. The ligated DNA was purified again using the Qiagen MinElute PCR 
purification kit (Qiagen, Valencia, CA) according to the manufacturer‟s protocol. The 
purified cDNAs were combined according to the experimental design of hybridization.        
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Pre-hybridization treatment of microarray slide 
Rehydration and crosslinking of the microarray slide was performed to ensure 
that the probe was spread evenly in the spot and immobilized on the slide.  The slides 
were rehydrated by holding the slide label side down over the steam from a 50°C water 
bath for 10 s. The slides were dried for 5 s at 65°C and then brought to room temperature 
(20°C) for 1 min. This process was repeated up to four times. After rehydration, the 
slides were subjected to UV crosslinking at 750 MJ/cm
2
 for 2 minutes.      
Microarray cDNA hybridization 
A 543 μl reaction was used for the tagged cDNA hybridization mix, which was 
prepared according to the manufacturer‟s instructions (Genisphere, Hatfield, PA).  The 
mixture was applied to the gasket slide of an Agilent microarray hybridization chamber 
and the microarray slide (array side down) was laid on top of the gasket slide. The 
hybridization chamber was assembled and the slides were then incubated at 55°C while 
rotating at 5 rpm in a hybridization oven (Agilent Technologies, Santa Clara, CA) for 16 
hours.  The “microarray-gasket slide sandwich” was then washed once with pre-warmed 
(42°C) 2x SSC-0.2% SDS wash buffer, disassembled, and washed again.  The array slide 
was then washed with 2x SSC and 0.2x SSC wash buffers.  Slides were dried at room 
temperature, centrifuged at 1000 rpm for 4 min, and then stored in a dry box prior to the 
second hybridization.   
 3DNA hybridization and wash 
3DNA hybridization master mix was prepared according to the manufacturer‟s 
instructions (Genisphere, Hatfield, PA), applied to the array, and covered with a 
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coverslip in the dark.  The slide was placed in a 50 ml conical tube with 400 μl of 
nuclease-free water and incubated horizontally at 55°C in a hybridization oven (Agilent 
Technologies, Santa Clara, CA) for 4 hours in the dark. All washing steps following 
3DNA hybridization were conducted in the dark. The slide was taken out of the 
incubator and washed with pre-warmed (42°C) 2x SSC-0.2% SDS wash buffer. The 
cover slip was removed and the slide was washed again with 2x SSC-0.2% SDS buffer.  
The slide was then washed with 2x SSC and 0.2x SSC wash buffers. Finally, the slide 
was dried at room temperature, centrifuged at 1000 rpm for 4 min, and stored for 
scanning.  
Microarray image processing and data analysis 
The slides were scanned with a GenePix Personal 4000B microarray scanner 
(Molecular Devices Corporation, Sunnyvale, CA) at a resolution of 5 μm. The 
fluorescence intensities from each array were quantified using GenePix Pro 6.0 program 
(Molecular Devices Corporation, Sunnyvale, CA). Each spot was inspected by manual 
gridding and empty spots were flagged out. The median signal intensity and local 
background intensity of each gene were normalized by print-tip loess normalization 
using the bioconductor LIMMA package (Gentleman et al., 2004) in the R statistical 
computing environment (http://www.r-project.org/). Linear models and empirical Bayes 
moderated F statistics (Smyth, 2004) were applied to obtain the P value and log2-based 
fold change of each gene.  
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Gene ontology analysis 
Gene ontology (GO) is used to functionally annotate gene products. It has three 
categories: biological process (BP), cellular component (CC), and molecular function 
(MF). The Database for Annotation, Visualization and Integrated Discovery (DAVID 
version 6.7) (Dennis et al., 2003; Huang et al., 2009) (http://david.abcc.ncifcrf.gov/) was 
used to obtain GO terms and related KEGG pathways for differentially expressed genes 
for the three comparisons: 12 h vs. CON, 24 h vs. CON, and 12 h vs. 24 h. RefSeq 
protein IDs of human orthologs were used as input and Fisher‟s Exact P value of 0.05 
was used as a cutoff for determining statistical significance. Gene ontology terms of all 
levels were included in the analysis.  
Pathway analysis 
Ingenuity Pathways Analysis program (Ingenuity Systems, version 8.7) was used 
to obtain networks, biofunctions and canonical pathways relevant to laminitis. A data set 
containing gene identifiers and corresponding expression values from the microarray 
expression analysis was uploaded into the application. Functional analysis identified the 
biological functions and diseases that were most significant to the dataset. Fisher's Exact 
test was used to calculate the P value determining the probability that each biological 
function and disease assigned to that data set (or network) is due to chance alone.  
Quantitative real time PCR         
To further explore microarray results, a subset of DE genes from each comparison 
were examined by quantitative reverse transcription PCR (qRT-PCR). cDNA was 
synthesized from total RNA (250 ng) of each sample (CON, 12 h, and 24 h) using 
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TaqMan® Reverse Transcriptase reagents (Applied Biosystems, Carlsbad, CA) 
according to the manufacturer‟s protocol. The cDNAs were quantified by qRT-PCR 
using a LightCycler®480 Real-Time PCR System (Roche Diagnostics, Indianapolis, IN) 
with 2x LightCycler®480 SYBR Green I master mix (Roche Diagnostics, Indianapolis, 
IN). To calculate the PCR amplification efficiencies of target and reference genes, a 
serial dilution of laminar cDNA was made (200 ng/µl, 100 ng/µl, 50 ng/µl, 25 ng/µl, 
12.5 ng/µl, and 6.25 ng/µl) and used as a template. PCR efficiency of each gene was 
determined from the slope of the line along the concentrations as calculated by 
LightCycler ® 480 basic software version 1.2 (Roche Applied Science, Indianapolis, 
IN).  Each individual sample was run in duplicate and the average crossing point (Cp) 
value was used for further analysis.  
Quantitative real time PCR data analysis 
In order to select appropriate reference genes for qRT-PCR data normalization, 
qRT-PCR was carried out for ten equine reference genes: ACTB, B2M, PPIA, GAPDH, 
GNB2L1, EEF1A1, HPRT1, TUBA1, UBB and RPL32. The average expression 
stability and the optimal number of control genes for normalization were determined  
using the geNorm computer program (http://medgen.ugent.be/~jvdesomp/genorm/) 
(Vandesompele et al., 2002). The two most stable genes from those tested were used for 
normalization of the qRT-PCR data. The data was analyzed by the delta-Cq method 
(Hellemans et al., 2007) in qBasePlus (Biogazelle, Ghent, Belgium). The statistical 
significance of the derived CNRQ values between two groups was determined by 
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nonparametric Mann-Whitney test in SPSS 17.0 statistics software (SPSS Inc, Chicago, 
IL). A P value less than 0.05 was considered statistically significant. 
Hierarchical cluster analysis 
To get an overview of gene expression pattern of qRT-PCR data among CON, 12 
h and 24 h conditions, hierarchical clustering was performed on the mean values of 
selected DE genes from qRT-PCR to construct a heat map using MultiExperiment 
viewer and R (MeV/R) program version 4.6 (Chu et al., 2008; Saeed et al., 2003).  
RESULTS 
Clinical observations 
No control horses showed clinical evidence of laminitis before euthanasia. While 
there were individual differences, horses in the treatment group didn‟t show clinical 
signs of laminitis at 12 h or 24 h after OF administration. Shortly before euthanasia one 
horse (24 h treatment group) showed lameness. 
Identification of DE genes in laminar tissue following OF   
Differential gene expression was determined by comparing gene expression 
profiles among three different groups (CON, 12 h and 24 h). There were 71, 151, 251 
genes differentially expressed (DE) in each comparison of 12 h/CON, 24 h/CON and 12 
h/24 h at the cut-off of P<0.01 and fold change>2 (Table 5.1). The ranges of fold change 
in differential expression were 5.16 to 0.23, 24.8 to 0.10, and 14.6 to 0.03 in each 
comparison of 12 h/CON, 24 h/CON and 12 h/24 h. A general trend of up-regulation 
was seen among DE genes in the 24 h/CON comparison, whereas down-regulated genes 
were predominant in the 12 h/24 h comparison (Table 5.1). The DE genes with the 
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largest fold changes (up and down regulated) are shown in Table 5.2, 5.3, and 5.4 for 
each of the three comparisons, respectively. Complete lists of DE genes at the p value 
less than 0.01 and fold change larger than 2 are presented in Table A.9, A.10 and A.11.   
 
Table 5.1 
Distribution of differentially expressed genes among comparisons. 
 
  Upregulated  Downregulated   Total 
12 h/CON 33 (46.5%) 38 (53.5%) 71 
24 h/CON 105 (69.5%) 46 (30.5%) 151 
12 h/24 h 92 (36.7%) 159 (63.3%) 251 
 
Among the up-regulated genes with the largest fold changes at the 12 h time 
point compared to control (Table 5.2), XR_035808 shares 97% homology with equine 
leukocyte immunoglobulin-like receptor, subfamily A, member 6. Interesting, 
chemokine CXCL2 (macrophage inflammatory protein 2-alpha) was consistently up-
regulated at 12 h and 24 h compared to controls. CXCL2 is essential chemoattractant for 
neutrophils and neutrophils are primary cell type for host defense against invading 
pathogens at the site of infection. Neutrophil activation has been described in BWE 
model of laminitis (Black et al., 2006). Down-regulated genes included four genes 
(CKM, DHRS2, TAOK3, and RPS6KB2) encoding enzymes. BAX, a member of BCL2 
protein family, plays a role in the regulation of apoptosis (Green and Chipuk, 2008). 
OR7A10, a member of olfactory receptor family, also belonged to the group of down-
regulated genes and is involved in odorant signal transduction.  
  
Table 5.2 
Top differentially expressed genes (15 upregulated and 15 downregulated; P<0.01 and fold change>2) for the 12 h/CON 
comparison. Unannotated genes are labelled as NULL. Asterisks denote genes selected for confirmation with PCR.  
 
Gene Name  Description 
Public 
Accession P 
Fold 
Change PCR 
Upregulated      
IFI30 interferon, gamma-inducible protein 30 XM_001500556 0.0059 4.66 * 
GLMN glomulin XM_001492771 0.0034 4.37 * 
PSIP1 PC4 and SFRS1 interacting protein 1 DQ873682 0.0081 3.96  
MITD1 
microtubule interacting and transport, domain 
containing 1 XM_001490447 0.0013 3.73 * 
BAIAP3 BAI1-associated protein 3 XM_001497570 0.0041 3.61  
NULL NULL XR_035808 0.0023 3.45  
NULL NULL CX601068 0.0007 3.38  
NULL NULL CX596707 0.0023 3.32  
CXCL2 chemokine (C-X-C motif) ligand 2 AF053497 0.0023 3.21 * 
PARP6 poly (ADP-ribose) polymerase family, member 6 XM_001494491 0.0041 3.19  
CBARA1 calcium binding atopy-related autoantigen 1 XM_001503797 0.0025 3.10  
CCDC67 coiled-coil domain containing 67 XM_001491708 0.0030 2.89  
NULL NULL CX593986 0.0073 2.88  
EZH2 enhancer of zeste homolog 2 XM_001504629 0.0081 2.65  
ZNF30 zinc finger protein 30 XM_001493964 0.0042 2.63  
      
Downregulated      
NULL NULL DN510842 0.0010 0.23  
CKM creatine kinase, muscle XM_001502522 0.0011 0.25  
LOC284890  XM_001489526 0.0081 0.25  1
6
6
 
  
 
Table 5.2 continued 
Gene Name  Description 
Public 
Accession P 
Fold 
Change PCR 
      
Downregulated      
PTGFR prostaglandin F receptor (FP) DQ385610 0.0083 0.26 * 
COMMD2 COMM domain containing 2 DN509689 0.0086 0.26 * 
OR7A10 olfactory receptor, family 7, subfamily A, member 10 XM_001492035 0.0028 0.26  
ZNF451 zinc finger protein 451 XM_001499700 0.0093 0.27  
DHRS2 dehydrogenase/reductase member 2 XM_001489482 0.0017 0.27  
LOC26010 viral DNA polymerase-transactivated protein 6 XM_001502795 0.0032 0.29  
NULL NULL CX604266 0.0005 0.30  
TAOK3 TAO kinase 3 XM_001490545 0.0021 0.30  
LGALS4 lectin, galactoside-binding, soluble, 4 XM_001497350 0.0062 0.34  
RPS6KB2 ribosomal protein S6 kinase, 70kDa, polypeptide 2 XM_001497573 0.0029 0.34  
MAGED2 melanoma antigen family D, 2 XM_001496158 0.0037 0.36  
BAX BCL2-associated X protein NULL 0.0011 0.36  
1
6
7
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Many genes that were up-regulated at the 24 h time point as compared to controls 
are involved in the immune response; these include acute phase protein SAA1, 
interleukin IL12A, anti-microbial peptides DEFB4 and PI3, calcium binding protein 
S100A8 and S100A9, and antioxidant enzyme SOD2. The differentially expressed genes 
with the largest fold changes at the 24 h time point compared to control are shown in 
Table 5.3. The up-regulated gene, CD467650, is 71% similar to superoxide dismutase 2 
(Canis familiaris SOD2, 81% coverage), which is associated with oxidative stress. 
Oxidative stress has been described in affected laminar tissue of BWE model of laminitis 
(Yin et al., 2009). Likewise, BI961659 shares 76% homology with transmembrane 
protein 49 (Pan troglodytes, TMEM49, 99% coverage), which is associated with the 
formation of intracellular vacuoles in autophagy (Ropolo et al., 2007). The presence of 
intracellular vacuoles has been detected in the laminar epidermis of CHO model of 
laminitis (Morgan et al., 2003). Chemokine CCL2 was also up-regulated at 24 h. The 
down-regulated genes with the largest fold changes included 2 genes encoding 
cytoskeletal matrix proteins, 2 genes for enzymes, and a solute carrier transporter 
protein. Of note, ADAMTS1, a metalloproteinase that involved in the degradation of 
extracellular matrix (ECM) components, was up-regulated at 24 h compared to control 
(Table A.10).  
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Table 5.4 shows a total of 30 DE genes with the largest fold changes at the 12 h 
time point compared to 24 h time point. CD467650, has 78% homology with superoxide 
dismutase 2 (Sus scrofa, SOD2, 56% coverage), increased its expression at 24 h time 
point. Among these genes, S100A8, S100A9, S100A12, SOD2, PI3, DEFB4, and SAA1 
dramatically increased their expression at 24 h time point. MMP26, a member of MMP 
family was up-regulated (Table A.11) and MMP26 has been shown the role in ECM 
cleavage in human (Lee et al., 2006). BM (a thin layer of ECM) degradation has been 
described as early pathological change in equine laminitis (Pollitt, 1996). The up-
regulated genes with the largest fold changes included 3 genes associated with body 
homeostasis and 2 genes encoding transcription factors. FREM1, an ECM related protein 
that is involved in epidermal differentiation, was also up-regulated. Of note, OR5M9, 
OR5AR1, OR7A5, OR56B1, and OR2J3, members of olfactory receptor superfamily of 
GPCRs, had differential expression during the transition from the 12 h time point to 24 h 
time point.    
 
  
Table 5.3 
 Top differentially expressed genes (15 upregulated and 15 downregulated; P<0.01 and fold change>2) for the 24 h/CON 
comparison. Unannotated genes are labelled as NULL. Asterisks denote genes selected for confirmation with PCR.  
 
Gene Name  Description 
Public 
Accession P 
Fold 
Change PCR 
Upregulated     
S100A8 S100 calcium binding protein A8 XM_001493589 0.0000 24.76 * 
SOD2 Superoxide dismutase 2 AB001693 0.0000 11.28  
DEFB4 Defensin, beta 4 AY170305 0.0000 10.57 * 
EREG Epiregulin XM_001490281 0.0001 6.91 * 
SAA1 Serum amyloid A1 NM_001081853 0.0018 6.77  
NULL NULL CD467650 0.0002 4.79  
FTH1 Ferritin, heavy polypeptide 1 XM_001489262 0.0048 4.77  
NULL NULL XM_001498707 0.0002 4.47  
S100A9 S100 calcium binding protein A9 XM_001493530 0.0047 4.46 * 
IL12A Interleukin 12A  Y11130 0.0032 4.45  
NULL NULL CD535521 0.0012 4.38  
NULL NULL BI961659 0.0001 4.31  
HINT2 Histidine triad nucleotide binding protein 2 NULL 0.0073 4.04  
GLUL Glutamate-ammonia ligase XM_001489235 0.0005 4.02  
KIAA1524 KIAA1524 XM_001503233 0.0037 3.99  
      
Downregulated      
NDUFB3 NADH dehydrogenase 1 beta subcomplex, 3 XM_001503625 0.0009 0.10 * 
NULL NULL CX592434 0.0038 0.19  
PSMA4 Proteasome subunit, alpha type, 4 XM_001489071 0.0062 0.20 * 
NKX3-1 NK3 homeobox 1 XM_001491242 0.0066 0.24  
SLC5A6 Solute carrier family 5, member 6 XM_001502487 0.0020 0.25  1
7
0
 
  
Table 5.3 continued 
 
Gene Name  Description 
Public 
Accession P 
Fold 
Change PCR 
      
Downregulated      
LOC650780 CD466835 0.0081 0.26  
NEB Nebulin NULL 0.0018 0.27  
ANKRD26 Ankyrin repeat domain 26 CX601264 0.0015 0.31  
EIF2AK4 
Eukaryotic translation initiation factor 2 alpha 
kinase 4 XM_001501267 0.0042 0.32  
TNNT1 Troponin T type 1 NULL 0.0048 0.32  
NRBF2 Nuclear receptor binding factor 2 XM_001502366 0.0041 0.32  
NPHP4 Nephronophthisis 4 XM_001497162 0.0009 0.33  
ISCU Iron-sulfur cluster scaffold homolog  NULL 0.0057 0.34  
NULL NULL CX601609 0.0069 0.36  
GMPS Guanine monphosphate synthetase XM_001488228 0.0070 0.36   
 
1
7
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Table 5.4  
Top differentially expressed genes (15 upregulated and 15 downregulated; P<0.01 and fold change>2) for the 12 h/24 h 
comparison. Unannotated genes are labelled as NULL. Asterisks denote genes selected for confirmation with PCR.  
 
Gene Name  Description 
Public 
Accession P 
Fold    
Change PCR 
Upregulated      
NULL NULL DN508706 0.0001 14.59  
C3orf26 Chromosome 3 open reading frame 26 XM_001502207 0.0037 5.76  
ARHGAP11A Rho GTPase activating protein 11A XM_001503656 0.0092 4.32 * 
LGALS4 Lectin, galactoside-binding, soluble, 4 XM_001497350 0.0005 4.18  
HMGN3 
High mobility group nucleosomal binding domain 
3 XM_001499096 0.0020 4.12  
BBS7 Bardet-Biedl syndrome 7 XM_001503097 0.0005 4.04  
COCH Coagulation factor C homolog, cochlin XM_001489788 0.0046 3.95  
RNF113A Ring finger protein 113A XM_001491814 0.0031 3.83  
NULL NULL CX603542 0.0001 3.79  
STAT4 Signal transducer and activator of transcription 4 XM_001502206 0.0019 3.74  
C17orf70 Chromosome 17 open reading frame 70 XM_001489884 0.0028 3.60  
FREM1 FRAS1 related extracellular matrix 1 XM_001493917 0.0050 3.40  
SPAG17 Sperm associated antigen 17 XM_001500885 0.0068 3.23  
P2RY13 Purinergic receptor P2Y,G-protein coupled,13 XM_001489171 0.0041 3.22  
NULL NULL DN506907 0.0052 3.13  
      
Downregulated      
S100A12 S100 calcium binding protein A12 CD535886 0.0003 0.03 * 
S100A8 S100 calcium binding protein A8 XM_001494358 0.0000 0.04 * 
S100A8 S100 calcium binding protein A8 XM_001493589 0.0001 0.06  
NULL NULL CD467650 0.0000 0.06  
1
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Table 5.4 continued 
 
Gene Name  Description 
Public 
Accession P 
Fold    
Change PCR 
Downregulated      
SOD2 Superoxide dismutase 2 AB001693 0.0000 0.07 * 
S100A9 S100 calcium binding protein A9 XM_001493530 0.0045 0.12 * 
PI3 Peptidase inhibitor 3 BM734843 0.0007 0.12  
DEFB4 Defensin, beta 4 AY170305 0.0001 0.12  
SAA1 Serum amyloid A1 NM_001081853 0.0004 0.16  
OR5M9 
Olfactory receptor, family 5, subfamily M, 
member 9 XM_001488291 0.0009 0.19  
THBS1 Thrombospondin 1 XM_001503599 0.0008 0.19  
SLA Src-like-adaptor XM_001498789 0.0066 0.20  
ORMDL1 ORM1-like 1  XM_001501956 0.0018 0.20  
HSPA8 Heat shock 70kDa protein 8 NULL 0.0069 0.21  
MORC3 MORC family CW-type zinc finger 3 XM_001493319 0.0073 0.21   
1
7
3
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GO analysis  
Gene ontology was performed for each comparison using NIH-DAVID software 
version 6.7. Overrepresented GO terms of BP, CC and MF within up and down-
regulated genes (P value less than 0.01 and fold change larger than 2) were determined. 
Only enriched (P<0.05) GO terms are presented.  
There were no significant GO terms of CC and MF categories found when using 
the DE genes of P<0.01 and FC>2 as input data for the 12 h/CON comparison. The GO 
term immune system process was found in the up-regulated genes in the 12 h/CON 
comparison (Table A.12). On the other hand, GO terms, including hemopoiesis, 
hemopoietic or lymphoid organ development, immune system development, immune 
system process, and leukocyte differentiation were found in the down-regulated genes at 
the 12 h time point.  
Up-regulated genes from the 24 h/CON comparison yielded a number of 
overrepresented GO terms (Table A.13). Of the 29 biological processes significantly 
associated with these genes, most genes were involved in defense response, 
inflammation/wounding or regulation of cell proliferation/adhesion/death. The BP 
category containing the greatest number of DE genes was response to stress. The two 
overrepresented cellular component terms were mitochondrial intermembrane space and 
organelle envelope lumen.  
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Among down-regulated genes, cellular amino acid metabolic process and cellular 
response to starvation were the only overrepresented biological processes. Interestingly, 
most of cellular components dealt with the intracellular part, while all molecular 
functions were related to transferase activity.    
Most GO terms were overrepresented in down-regulated genes of the 12 h/24 h 
comparison (Table A.14). Of the 127 biological processes significantly overrepresented 
among these genes, many were associated with response to stress/stimulus, 
inflammation/wounding or chemotaxis. In contrast, 7 biological processes were 
overrepresented among up-regulated genes. Most were involved in sensory perception 
and system process. Cell component was limited to plasma membrane and molecular 
function related to olfactory receptor activity. Although many of the GO terms found in 
this comparison were also found in the 24 h/CON comparison, the appearance of eleven 
new terms associated with cellular ion homeostasis and two new terms describing 
synthesis of interleukin 1 (IL1) is noteworthy. Cellular components dealt with both of 
intracellular and extracellular and the molecular function containing most of DE genes 
was protein binding.  
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Pathway analysis  
Pathway analysis was conducted using the KEGG pathway database (Kanehisa et 
al., 2008) (http://www.genome.jp/kegg/) linked through the NIH-DAVID database. 
Totally two pathways were detected for both the 24 h/CON and 12 h/24 h comparisons 
when the full set of DE genes (P<0.01 with FC>2) were included. These pathways were 
Huntington‟s disease (24 h/CON) and nucleotide binding oligomerization domain 
(NOD)-like receptor (NLR) signaling pathway (12 h/24 h). NLR can recognize 
intracellular pathogens and play essential role in the innate immunity (Shaw et al., 
2010). To expand on these results, we utilized the Ingenuity Pathways Analysis (IPA; 
Ingenuity Systems, http://www.ingenuity.com/, version 8.7) application to establish 
relationships between the full set of DE genes (P<0.01 with FC>2) for 12 h/CON, 24 
h/CON and 12 h/24 h comparisons and predict potential pathways associated with  
laminitis pathogenesis.  
The top biofunctions determined by IPA were cellular growth and proliferation, 
nervous system development and function, and inflammatory response for the 12 h/CON 
comparison (Table 5.5). The associated diseases identified through the analysis were 
cancer, dermatological diseases and reproductive diseases. The top canonical pathways 
were urea cycle, metabolism of amino groups and primary immunodeficiency signaling. 
The top network with a score of 23 is shown (Fig. 5.2). The network function was 
embryonic development, inflammatory response, cell to cell signaling and interaction. 
This network included 35 genes, 14 of which were identified as DE in the 12 h/CON 
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comparison. Five DE genes were up-regulated (IGLL1, ZBP1, MED7, CXCL2, and 
SLC27A2).  
 
 
 
 
Fig. 5.2. Ingenuity network analysis of 12 h time point compared to control. The top 
network identified by IPA with a significant score of 23. Both direct (solid line) and 
indirect (dashed line) interactions among genes (including CXCL2, BAX, and IGLL1) 
were shown in the network. This analysis was performed on the DE genes of P<0.01 and 
FC>2 in the 12 h/CON comparison. The intensity of the node color are depicted as 
down-regulated (green) or up-regulated (red). Square: cytokine/growth factor; vertical 
diamond: enzyme; horizontal diamond: peptidase; circle: other; parallelogram: 
transporter; circle-in-circle: complex; oval: transmembrane receptor; shaded circle-in-
circle:group.
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Additionally, NF-κB, CXCL2 and BAX were in the central positions of network. 
The dysregulation of DE genes potentially affected the activity of other genes and 
associated pathways (e.g., core molecule NF-κB in NF-κB pathway) during the 
pathogenesis of laminitis due to the biological interactions among the genes in the 
network.   
For the 24 h/CON comparison, the top biofunctions were inflammatory response, 
cell death, and free radical scavenging (Table 5.5). The associated diseases were 
connective tissue disorders, immunological disease, inflammatory disease, skeletal and 
muscular disorders. Laminitis is also a connective tissue disease. The top canonical 
pathways were VDR/RXR activation (Sanchez-Martinez et al., 2006), glucocorticoid 
receptor signaling (Smoak and Cidlowski, 2004) and TNF-like weak inducer of 
apoptosis (TWEAK) signaling (Kumar et al., 2009). VDR/RXR signaling is the 
heterodimer formed between vitamin D receptor (VDR) and retinoid receptor (RXR) can 
regulate gene expression (Sanchez-Martinez et al., 2006). These pathways are associated 
with gene expression regulation at the transcriptional level. The top network with a score 
of 34 is shown (Fig. 5.3). The network function was inflammatory response, free radical 
scavenging and lipid metabolism. This network included 34 genes, of which 19 were 
identified as DE in the 24 h/CON comparison. Therefore an additional 15 genes were 
related to DE genes through biological interactions. The network also showed a central 
role of non DE genes p38 MAPK, PI3K, ERK, Akt, and NF-κB and the peripheral role 
of DE genes PI3 and FAIM. In the network, both S100A8 and SOD2 had higher 
expression level with fold changes of 24.76 and 11.28, respectively. Also all 19 DE 
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genes (except NKX3-1) in the network were up-regulated and they were connected 
directly or indirectly based on their biological relationships.  
The top biofunctions associated with DE genes of the 12 h/24 h comparison were 
inflammatory response, protein degradation, antigen presentation, cell to cell signaling 
and interaction, and hematological system development and function (Table 5.5). The 
associated diseases were dermatological disease, hematological disease, cancer, and 
connective tissue disease. The top canonical pathways that were most significant to the 
dataset were calcium signaling (Marambaud et al., 2009), role of nuclear factor of 
activated T cells (NFAT) in cardiac hypertrophy (Molkentin, 2004), IL-17 signaling 
(Henness et al., 2006) and aldosterone signaling in epithelial cells (Stockand, 2002). 
Essentially, these pathways are associated with MAPK signaling transduction, 
suggesting the likely involvement of MAPK signaling pathway in the early stage of OF 
model of laminitis. The top network with a score of 33 is shown (Fig. 5.4). The 
associated network functions were tissue development, cancer, dermatological diseases 
and conditions. This network included 23 DE genes and all of them linked to non DE 
gene p38 MAPK through direct and indirect interactions. Among these DE genes, 
SYNE2, HDAC9, and SLC12A6 were up-regulated and were in peripheral positions in 
the network.  
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Fig. 5.3. Ingenuity network analysis of 24 h time point compared to control. The top 
network identified by IPA with a significant score of 34. Both direct (solid line) and 
indirect (dashed line) interactions among genes were shown in the network. This 
analysis was performed on the DE genes of P<0.01 and FC>2 in the 24 h/CON 
comparison. This network showed the central position of p38 MAPK and NF-κB. The 
intensity of the node color are depicted as down-regulated (green) or up-regulated (red). 
Square: cytokine/growth factor; vertical diamond: enzyme; horizontal diamond: 
peptidase; circle: other; parallelogram: transporter; circle-in-circle: complex; oval: 
transmembrane receptor; shaded circle-in-circle: group.  
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Fig. 5.4. Ingenuity network analysis of 12 h time point compared to 24 h time point. The 
top network identified by IPA with a significant score of 33. Both direct (solid line) and 
indirect (dashed line) interactions among genes were shown in the network. This 
network showed the central position of p38 MAPK. This analysis was performed on the 
DE genes of P<0.01 and FC>2 in the 12 h/24 h comparison. The highest scoring 
biofunctions associated with this network are inflammatory disease/connective 
disorders/skeletal and muscular disorders. The intensity of the node color are depicted as 
down-regulated (green) or up-regulated (red). Square: cytokine/growth factor; vertical 
diamond: enzyme; horizontal diamond: peptidase; circle: other; parallelogram: 
transporter; circle-in-circle: complex; oval: transmembrane receptor; shaded circle-in-
circle: group.  
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Table 5.5  
The top biofunctions, associated diseases, canonical pathways, and network functions 
that were most significant to the data set of OF laminitis experiment. The DE genes at 
the level of P<0.01 and FC>2 were used as input data set for 12 h/CON, 24 h/CON and 
12 h/24 h comparison respectively.  
 
 
 Biological 
functions 
Associated 
diseases 
Top canonical 
pathways 
Top network 
function 
12 h/CON Cellular growth and 
proliferation, 
nervous system 
development and 
function, and 
Inflammatory 
response 
Cancer, 
dermatological 
diseases, and 
reproductive system 
diseases 
Urea cycle and 
metabolism of 
amino groups, 
primary 
immunodeficiency 
signaling 
Embryonic 
development, 
inflammatory 
response, and cell 
to cell signaling 
and interaction 
24 h/CON Inflammatory 
response, cell death, 
free radical 
scavenging 
Connective tissue 
disorders (such as  
rheumatoid 
arthritis), 
immunological 
disease, 
inflammatory 
disease and skeletal 
and muscular 
disorders (collagen-
induced arthritis) 
VDR/RXR 
activation, 
glucocorticoid 
receptor signaling, 
and TWEAK 
signaling 
Inflammatory 
response, free 
radical 
scavenging, and 
lipid metabolism 
12 h/24 h Inflammatory 
response, protein 
degradation, antigen 
presentation, cell to 
cell signaling and 
interaction, and 
hematological 
system development 
and function 
Dermatological 
disease, 
hematological 
disease, cancer and  
connective tissue 
disease 
Calcium signaling, 
role of NFAT in 
cardiac 
hypertrophy, IL-17 
signaling and 
aldosterone 
signaling in 
epithelial cells 
Tissue 
development, 
cancer, 
dermatological 
diseases and 
conditions 
 
Quantitative real time PCR 
To select the best reference gene for qRT-PCR data normalization, qRT-PCR was 
performed for ten reference control genes, including ACTB, B2M, PPIA, GAPDH, 
GNB2L1, EEF1A1, HPRT1, TUBA1, UBB and RPLP32. The gene expression stability 
among the laminar samples (CON, 12 h and 24 h) of OF model laminitis was determined 
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according to the geNorm software (Vandesompele et al., 2002). The 2 reference genes 
that received best score (EEF1A1 and UBB) from those tested were used for qRT-PCR 
data normalization.  
To validate the differential expression of microarray results, a total of 28 DE genes 
(up-regulated and down-regulated) were selected for qRT-PCR confirmation. Based on 
the microarray analysis, we selected most of the DE genes based on a small P value and 
large fold change. The fold change of all selected genes was larger than 2. Four 
additional genes with P values between 0.01 and 0.05 were also chosen based on their 
likely functional relevance to laminitis. ADAMTSL2 is a member of ADAMTS-like 
protein subfamily and plays a key role in transforming growth factor beta (TGF-β) 
signaling (Le Goff et al., 2008). TGF-β can regulate the expression of integrin ligands 
(Margadant and Sonnenberg, 2010). Integrins are ligands of ECM proteins (e.g., laminin, 
fibronectin and collagen) (Friedl and Brocker, 2000). ECM is the component of equine 
hoof laminar tissue. BM (a thin layer of ECM) degradation is an early event of 
pathological changes in the pathogenesis of equine laminitis (Pollitt, 1994). S100A2 and 
S100A4 are members of S100 protein family, which are involved in the inflammatory 
response (Foell et al., 2009). The presence and overexpression of other S100 protein 
members (i.e., S100A8 and S100A9) have been described in the BWE model of 
laminitis (Faleiros et al., 2009). TMEM38A is an important molecule for calcium 
signaling. Calcium signaling has been demonstrated to mediate intracellular adhesion in 
connective tissue (Ko et al., 2001). Laminitis is a disease of the connective tissue 
laminae of the hoof.  
  
184 
The primers used for qRT-PCR are listed in Table 5.6. Of the 10 genes analyzed by 
qRT-PCR for the 12 h/CON comparison, CXCL2, IFI30 and TMEM38A had 
statistically different expression between the two groups (Fig. 5.5). Among the 
inconsistencies, GLMN, COMMD2, PTGFR, ARPC5L and ADAMTSL1 had the same 
direction of expression change as in the microarray but the difference shown by real time 
PCR did not reach statistical significance. For genes MITD1 and CD19, the direction of 
change in expression was different from the microarray analysis and did not show 
statistical significance at the level of P<0.05. ADAMTS1, DEFB4, S100A8, S100A9, 
PI3, TMEM49, PSMA4 and EREG were significantly different between 24 h and CON 
groups and were consistent with microarray results (Fig. 5.6). OF the 11 genes tested by 
qRT-PCR for the 12 h/24 h comparison, eight (CCL2, CXCL14, S100A8, S100A9, 
S100A12, SERPINB3, TLR4, and SOD2) were significantly different between the two 
groups (Fig. 5.7). SOD2, S100A12, and SERPINB3 had fold changes of 17.74, 17.87, 
and 17.58, respectively. S100A4 had the same direction of change in expression as in the 
microarray analysis for the 12 h/24 h comparison but was not significantly increased at 
12 h time point.  
Cluster analysis was performed for the 28 differentially expressed genes based on 
their mean values among (CON, 12 h and 24 h) groups and a heat map was constructed 
(Fig. 5.8). The result showed a distinct expression pattern among the conditions (CON, 
12 h and 24 h). Moreover, the pattern of gene expression in CON was closer to the 12 h 
time point than that of the 24 h time point. Most of the genes were up-regulated at the 24 
h time point compared to either the CON or the 12 h time point.  
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Fig. 5.5. Real time PCR validation of the microarray results of the 12 h/CON 
comparison. EEF1A1 and UBB are reference genes used for normalization. Ten DE 
genes from the microarray analysis were selected for real time PCR confirmation. Data 
are presented as mean  SEM. Those genes marked with asterisks are significantly 
different from CON.  
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Fig. 5.6. Real time PCR validation of the microarray results of the 24 h/CON 
comparison. EEF1A1 and UBB are reference genes used for normalization. Nine DE 
genes from the microarray analysis were selected for real time PCR confirmation. Data 
are presented as mean  SEM. Those genes marked with asterisks are significantly 
different from CON. 
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Fig. 5.7. Real time PCR validation of the microarray results of the 12 h/24 h comparison. 
EEF1A1 and UBB are reference genes used for normalization. Eleven DE genes from 
the microarray analysis were selected for real time PCR confirmation. Data are presented 
as mean  SEM. Those genes marked with asterisks are significantly different between 
12 h and 24 h.  
  
Table 5.6  
Primers of genes used for quantitative RT-PCR of OF laminitis experiment.   
 
Gene 
Symbol Accession 
No. 
Forward Sequence (5’-3’) Reverse Sequence (5’-3’) 
PCR 
Produ
ct Size 
(bp) 
Tm(°C) * 
CCL2 AJ251189 TCCAGTCACCTGCTGCTATAC ATTCTTGGCTTTTGGAGTAGG 235 58 
DEFB4 AY170305 ACTTGCCTTCCTCATTGTCTT AGCAGTTTCTCCGCTTTCTAT 195 58 
ADAMTS1 AF541975 AGGCTCACAATGAATTTTCG CACAGCCAGCTTTTACACACT 225 58 
S100A8 
 
XM_001493589 
 
ACGGATCTGGAGAATGCTATC 
 
TGATGTCCAACTCTTTGAACC 
 
175 58 
SERPINB3 XM_001491507 CGTGCAGATGATGAAACAAAT 
 
TTCTGTGAGCTTGTCCACTCT 
 
195 58 
S100A9 
 
XM_001493485 
 
CGACCTAGAGACCATCATCAA 
 
TGCTTGTCCTCATTAGTGTCC 
               
189 58 
TMEM49 XM_001503742 
 
TTACAGAAGCCATTCCAAGAA 
 
TGGAGTTAATGATGGACAGGA 
 
160 58 
S100A12 CD535886 TCATCAACATCTTCCACCAGT ACCTTGCACACCAGGACTAC 211 58 
 
CXCL14 XM_001502713 ACTGCGAGGAGAAGATGGTTA 
 
CTCGTTCCAGGCGTTGTA 
 
128 58 
S100A2 CX598422 GCGACAAGTTCAAGCTGAGTA 
 
ATAGTGATGAGGGCCAGAAAA 
 
181 58 
TLR4 AY005808 GGCCAGTGATTTTCCAGTATT AGGGTGGTCAGGTTAGTCATC 195 58 
 
TMEM38A XM_001499622 TGGTACTTGGTTTTCTTCTGC GACTCTCACCACCTCCTTCAT 102 58 
 
SOD2 AB001693 ACTTTGGTTCCTTCGACAAAT CAGGGGAATAAGACCTGTTGT 167 58 
S100A4 CX604383 GGATGTGATGGTATCCACCTT GCAGGACAGGAAGACACAGTA 217 58 
NDUFB3 XM_001503625 
 
GGAAGATAGAAGGGACACCAT TCCTACAGCTACCACAAATGC 185 58 1
8
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Table 5.6 continued 
Gene 
Symbol Accession 
No. 
Forward Sequence (5’-3’) Reverse Sequence (5’-3’) 
PCR 
Produ
ct Size 
(bp) 
Tm(°C) * 
PI3 BM734843 CTTCTTGATCCTGGTGGTGTT ACTGAATCTTGCCCTTTGACT 162 58 
ADAMTSL2 XM_001497636 
 
ACACCCACCTTGGTTACTCTC TGCCGTTGAAGAAGTAGTAGC 132 58 
CD19 CX592103 AGACTCCTTCTCCAACGGTAA CCACCTCTTCATCCTCATTCT 157 58 
CXCL2 AF053497 AACCGAAGTCATAGCCACTCT CCTTTTCTCCAGGTTAGTTGG 125 58 
ARPC5L XM_001502042 CTATGCCTTTGTCCACGAGTA AAACAAGCTCTCCCTCTACCA 161 58 
GLMN XM_001492771 CATAGATGAAGGGCACGTAGA ATTCCATAAAAGGCATCGAAC 121 58 
MITD1 XM_001490447 AAGGCAGTAGGAGAGAACAGC TAATCAAGTCCCCTTCCAATC 163 58 
IFI30 XM_001500556 CAGCTCCTGTACCTCGTCTG CTGGACTTCATGGAATGTGTC 222 58 
COMMD2 DN509689 AGACCTTCCCAGTTACCACAG TTGTTTTCATCTCCTCCAGTG 210 58 
 
PTGFR DQ385610 TGCCATCACAGGAATTACACT AGCGTTGTTTCACAGGTCTC 201 58 
EREG XM_001490281 ACATGAATGGCTACTGTTTGC 
 
AGTATATGGAACCGGCGACTA 
 
204 58 
PSMA4 XM_001489071 TGAAGTCAGCACTTGCTCTTG 
 
CTCACGCTCAGCTTTAGCTTC 
 
194 58 
ARHGAP11 XM_001503656 CAGGTTGCTTCTCTCCTAAAA 
 
TCGACCAACATTTTCACATCT 
 
134 58 
EEF1A1
a
 NM_001081781 
 
TGGAAAGAAGCTGGAAGATG CAACCGTCTGTCTCATGTCA 132 58 
UBB
a
 AF506969 GCAAGACCATCACCCTGGA CTAACAGCCACCCCTGAGAC 206 61 
HPRT1
 c
 AY372182 GGCAAAACAATGCAAACCTT 
 
CAAGGGCATATCCTACGACAA 
 
163 61 
TUBA1
c
 AW260995 GCCCTACAACTCCATCCTGA ATGGCTTCATTGTCCACCA 78 60 
1
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Table 5.6 continued 
Gene 
Symbol Accession 
No. 
Forward Sequence (5’-3’) Reverse Sequence (5’-3’) 
PCR 
Produ
ct Size 
(bp) 
Tm(°C) * 
RPLP0 BC107717 TTGCATCAGTACCCCATTCT ACCAAATCCCATATCCTCGT 242 58 
ACTB
c
 AF035774  CCAGCACGATGAAGATCAAG GTGGACAATGAGGCCAGAAT 88 58 
B2M X69083 CGAGACCTCTAACCAGCATC AGACATAGCGGCCAAAGTAG 186 58 
PPIA 
 
NM_021130 TGGGGAGAAAGGATTTGGTT CATGGACAAGATGCCAGGAC 178 58 
GNB2L1 AY246708 CAGGGATGAGACCAACTACG 
 
ATGCCACACTCAGCACATC 
 
    269 58 
RPL32
c
 CX594263 AGCCATCTACTCGGCGTCA TCCAATGCCTCTGGGTTTC     149 58 
GAPDH
c
 
 
AF157626       GATGCCCCAATGTTTGTGA AAGCAGGGATGATGTTCTGG 
 
250 61 
 
 
* The optimal annealing temperature  
 a EEF1A1 and UBB were used for normalization during quantitative RT- PCR 
        c 
Information about the primers from (Bogaert et al., 2006) 
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Fig. 5.8. Cluster diagram of the mean of CNRQ values at control, 12 h and 24 h time 
point as determined by qRT-PCR. The green to red color scale demonstrates the 
expression value of mean of CNRQ. EEF1A1 and UBB were used as reference genes to 
calculate normalized ΔCq. 
 
 
 
 
192 
 
 
DISCUSSION 
This is the first study to investigate the genome wide transcriptome profiling 
during the early time points of OF induced equine laminitis using an equine whole 
genome long oligonucleotide microarray. Equine whole genome oligoarray identified 
differential expression of 71 and 151 genes at 12 h and 24 h time points (Table 5.1) as 
well as associated pathways and networks accompanying the initiation of laminitis. 
Initiation of laminitis 
 In order to determine genes and relevant pathways that might be associated with 
the initiation of laminitis, we performed transcriptomic profiling on laminar tissue 
samples collected at 12 h and 24 h time points following oligofructose administration. 
Most of horses used (3 mares, 15 geldings) are geldings in this study. On the other hand, 
most of horses used in CHO model laminitis (Chapter III) are mares (10 mares, 5 
geldings). There was no stallion used in the study. Alford and coworkers found age, sex, 
and breed were risk factors for acute laminitis (Alford et al., 2001). This same study 
found mares (not stallions) had greater risk for acute laminitis when compared with 
geldings. In addition, the Thoroughbred (TB) is at decreased risk of laminitis compared 
to other breeds (Alford et al., 2001). In contrast, other epidemiological studies have 
reported that there was no significant association between age, breed, sex or weight and 
the development of acute laminitis (Polzer and Slater, 1997; Slater et al., 1995). At 24 h, 
horses exhibit an increased rectal temperature and heart rate. Horses at 12 h and 24 h 
time points show no clinical sign of lameness except one horse developed Obel grade 2 
lame at 24 h.  
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We identified differential expression of genes involved in signal transduction, 
immune response, genes encoding transcription factors and enzymes (Table 5.2, 5.3 and 
5.4). At 12 h time point, few differentially expressed genes were identified when 
compared to controls (Table 5.1). Overrepresented GO term of immune system process 
found from both of up and down-regulated genes (Table A.12), suggesting that the 
immune response that contributing to/affected by laminitis likely occur at least at 12 h 
before any clinical evidence of laminitis. Among the DE genes, BAX was down-
regulated (Table 5.2). BAX has been shown to enhance apoptosis (Green and Chipuk, 
2008). Therefore apoptosis may be associated with early histological changes of 
laminitis.  
Perhaps the most intriguing DE gene during this stage is CXCL2, also known as 
macrophage inflammatory protein 2 (MIP-2). This chemokine was consistently 
overexpressed at 12 h and 24 h. CXCL2 is a crucial chemoattractant for neutrophils 
(polymorphonuclear leukocytes)  and has been shown to be up-regulated by bacterial 
LPS in enterocytes (De Plaen et al., 2006). Neutrophils provide the first line of host 
defense against invading microbial pathogens through phagocytosis process (Kobayashi 
et al., 2003). In addition to neutralize pathogens through the release of ROS and 
proteases at the site of infection/inflammation, neutrophils cause host tissue destruction 
(Brown et al., 2006). It has been indicated that the control of neutrophil apoptosis 
following phagocytosis is essential to minimize the tissue damage (Haslett, 1999; 
Kobayashi et al., 2003; Weiss, 1989). The presence and activation of neutrophil has been 
reported in the developmental stage and the onset of different model of laminitis (Black 
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et al., 2006). It remains unknown whether the up-regulation of CXCL2 is the potential 
cause or a result of neutrophil activation in this study. However, together with the fact 
that the up-regulation of CXCL2 occurs (i.e., 12 h time point) before the horses exhibit 
clinical sign of laminitis (i.e., foot pain), we therefore hypothesize that CXCL2 may play 
initialing role in neutrophil accumulation in the OF induced laminitis. Of course the role 
of neutrophil in laminitis pathology needs further investigation.  
Development of laminitis 
In contrast to 12 h time point, samples taken at the 24 h time point show a strong 
transcriptomic response and a dramatic up-regulation of inflammatory genes. This is also 
supported by GO analysis and most of significantly enriched GO terms of 24 h/CON 
comparison are associated with inflammation and immune response (Table A.13). Among 
the DE genes with largest fold changes at the 24 h time point, SAA1, EREG, DEFB4, 
SOD2 and S100A8 were highly up-regulated genes with large fold changes in expression 
(Table 5.3). SAA1 has been shown to induce cytokine production and inhibit neutrophil 
apoptosis in inflammation (Christenson et al., 2008). EREG, a member of epidermal 
growth factor family, plays a regulatory role in human keratinocyte growth (Hashimoto, 
2000). Keratinocytes are the main cell type in the hoof epidermis and their growth is 
essential for the hoof‟s structural integrity. DEFB4 is an antimicrobial peptide and plays 
antimicrobial role in innate immunity (Ganz, 2003). It has recently been suggested that 
S100A8 may have an anti-oxidant function (Perera et al., 2010)  and regulate oxidative 
modification (Lim et al., 2009). SOD2 is an antioxidant enzyme and is also up-regulated at 
the developmental stage of CHO model laminitis (Chapter III). It remains unknown that 
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whether S100A8 and SOD2 may contribute to the early pathological change of laminitis or 
are merely a physiological reaction to underlying tissue damage that has already occurred 
at cellular level. It is noteworthy that five members of the olfactory receptor superfamily 
showed differential expression during the transition from the 12 h time point to 24 h time 
point (Table A.11). Olfactory receptors are mainly expressed in the nose but have been 
shown to be expressed in other tissue types such as the kidney and sperm (Kaupp, 2010; 
Pluznick et al., 2009; Spehr et al., 2003). Further study is needed to investigate their 
possible function in laminitis.  
Metalloproteinase ADAMTS1 was overexpressed at the 24 h time point (Table 5.6) 
and had no differential expression at the 12 h time point. Based on our findings, 
ADAMTS1 has been up-regulated in three different models of laminitis investigated 
(Chapter III and IV). ADAMTSs have been shown to play an essential role in ECM 
components (e.g., collagen) degradation (Apte, 2009) and their differential expression 
has been found in cancer and arthritis (Tortorella et al., 2009). Therefore ADAMTS1 
may be essential for equine laminitis pathogenesis.  
Genes encoding calcium binding proteins S100A8, S100A9, and S100A12 were 
up-regulated at 24 h time point relative to control horses, and S100A4, S100A8, 
S100A9, and S100A12 were up-regulated at 24 h time point relative to 12 h time point. 
This gene family has been shown to play an essential role in the inflammatory response 
during arthritis (Perera et al., 2010), leukocyte recruitment during inflammation (Roth et 
al., 2003) and calcium homeostasis (Heizmann et al., 2002). S100 proteins may also play 
a regulatory role in oxidative stress (Lim et al., 2009). Oxidative stress had been shown 
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to be essential for laminar tissue damage in laminitic horses (Yin et al., 2009). 
Therefore, their regulatory role in oxidative stress could control the production of 
hydrogen peroxide and superoxide anion as indicated by GO analysis (Table 5.9). 
S100A4 is correlated with the progression of rheumatoid arthritis (RA) (Oslejskova et 
al., 2009). S100A8 and S100A9 have been shown to play a role in cartilage destruction 
in osteoarthritis (OA) (Zreiqat et al., 2010). RA is both a joint (Diarra et al., 2007) and 
connective tissue disease (Bateman et al., 2009; Vincenti and Brinckerhoff, 2001). 
Laminitis is a connective tissue disease (Mobasheri et al., 2004). The differential 
expression of the S100 family of genes could promote inflammation and regulate 
oxidative stress in the laminae through leukocyte activation and migration, which may 
lead to laminar tissue damage. Furthermore, the strong induction of S100 family of 
proteins in CHO (Chapter III), HI (Chapter IV) and OF models of laminitis indicated 
that the overexpression of S100 proteins is likely a common scenario of laminitis 
pathogenesis.  
Interestingly, an indication of a transcriptional response to microbial infection was 
observed. The protein encoded by SAA1 is an acute phase protein and opsonizes Gram-
negative bacteria (Shah et al., 2006). CXCL2 is a critical chemokine for neutrophils and 
neutrophils are the first line of defense against bacterial infection. Beta-defensin 2 
(DEFB4) and peptidase inhibitor 3 (PI3) are both expressed in keratinocytes and have 
direct anti-microbial properties (Sallenave, 2010; Schneider et al., 2005). Likewise, the 
down-regulation of chemokine CXCL14, particularly in keratinocytes, is taken as 
evidence of bacterial infection (Maerki et al., 2009). The identification of metabolic 
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pathway of NOD-like receptor signaling, which is involved in recognition of 
intracellular bacteria and detection of bacterial components in the cytosol (Franchi et al., 
2006; Kanneganti et al., 2007), also indicated a bacterial infection. The hypothesis of an 
infection is also supported by the overrepresented GO terms of response to external 
stimulus, defense response and leukocyte chemotaxis within the group of up-regulated 
genes.   
Transition from 12 h to 24 h of developmental laminitis 
Direct comparison of the 12 h and 24 h time points of laminitis generates some 
results found when comparing each stage to the control group.  For example, GO terms 
involving inflammatory response, regulation of apoptosis, and response to external 
stimulus found among down-regulated genes of the 12 h/24 h comparison reflect the 
strong up-regulation of these genes at the 24 h stage compared to controls. However, this 
comparison yielded two new results: the overrepresentation of cellular ion homeostasis 
and synthesis of IL1 GO terms. It is unclear whether this is due to an up-regulation at the 
24 h stage, a down-regulation at the 12 h stage, or a combination of both. Ion 
homeostasis has been linked to inflammatory response and infection (Wessling-Resnick, 
2010). IL1 is a “typical” cytokine in inflammatory response and can be produced by 
macrophages, neutrophils, and epithelial cells (e.g., keratinocytes).       
The common DE inflammatory mediators between the 24/CON comparison and 
12 h/24 h comparison included SAA1, S100A8, SOD2, and DEFB4 (Table 5.3 and 5.4). 
These genes are potential targets for anti-inflammatory treatment through the design of 
antagonists to counteract their inflammatory effect. A recent review has indicated that a 
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critical point of inflammation control is at the transcriptional level (Medzhitov and 
Horng, 2009). Those transcription factors, transcriptional activator/repressor, and 
chromatin remodeling involved in the toll like receptor (TLR) induced inflammatory 
response were inflammation control points (Medzhitov and Horng, 2009).  
Comparison to previous studies 
Similar to results seen using an equine-specific 3,076 element cDNA microarray in 
laminar tissue of the black walnut extract model of laminitis (Noschka et al., 2008), we 
identified the up-regulation of CCL2 and SAA1 at the 24 h time point, suggesting the 
role of these genes in laminitis pathogenesis regardless of the mechanism of induction. 
We also identified the up-regulation of DEFB4, IL16, CXCL4, CXCL2, TLR4, CD19, 
COX17, and ADAMTS1 as well as several S100 family members. Differential 
expression of these genes was not detected (except S100P) at any time point of BWE 
model laminitis (Noschka et al., 2008). Compared to the work carried out by 15 K 
bovine microarray chip in the OF model laminitis (Budak et al., 2009), we identified the 
up-regulation of CCL2. However, we didn‟t find many common differentially expressed 
genes. This may be due to the different time points we used. In Budak‟s study, the 
authors euthanatized the OF horses after 24-30 h (Budak et al., 2009). In our study, we 
collected tissue at 12 h and 24 h. Therefore the laminar tissue samples we collected may 
be at different phase of laminitis pathogenesis, which could cause differences in gene 
expression.  
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Pathway and network study of laminitis 
Pathway and network analysis of DE genes in the 12 h/CON, 24 h/CON and 12 
h/24 h comparisons indicated that many DE genes were linked to p38 MAPK and NF-κB 
pathway molecules at  both the 12 h and 24 h time points (Fig. 5.2, 5.3, and 5.4). Similar 
results were found in the CHO and HI models of laminitis, as shown in previous 
chapters of the dissertation. Inhibition of the NF-κB and the MAPK signaling pathways 
has been investigated in OA and RA (Murphy and Nagase, 2008; Sweeney and Firestein, 
2007). Laminitis is also a connective tissue disease as RA and hence they may share 
common features of pathogenesis (e.g., pathway) (Zhernakova et al., 2009). The 
inhibition of p38 MAPK and NF-κB can suppress cytokine production (Matsumori et al., 
2004; Smith et al., 2006b). It is likely that the design of NF- κB and p38 MAPK 
inhibitors can alleviate the laminar tissue destruction at the site of inflammation by 
reducing cytokine production. The analysis of top biofunctions and associated diseases 
also demonstrated that laminitis has many similarities with other connective tissue 
diseases such as RA. 
Relevance to current hypotheses 
Currently, the three most popular hypotheses regarding the initiation of laminitis 
implicate vasoconstriction/hypoxia, MMPs, and escape of bacteria from the hindgut into 
the bloodstream (Bailey et al., 2004). We saw no evidence of differential expression of 
these genes and thus cannot hypothesize that hypoxia/MMP play a role in this model of 
laminitis. However, we found evidence support the hypothesis that bacteria or bacterial 
components escape from the hindgut and cause laminar inflammation. It has been shown 
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that changes in microbial populations of equine GI tract occur in the OF model of 
laminitis (Milinovich et al., 2006). The differential expression of anti-microbial peptides 
such as DEFB4, PI3, and CXCL14 and critical chemokine CXCL2 for neutrophil 
accumulation at the site of infection is suggestive of the presence of bacterial antigens, 
although microarray data necessarily need to be confirmed at the protein and functional 
levels. 
Our qRT-PCR validation experiments showed that most of the qRT-PCR results 
were consistent with those generated using the microarray (Fig. 5.4, 5.5 and 5.6) except 
the 12 h/CON comparison. It is possible due to the experimental condition that the subtle 
difference in gene expression of laminar tissue occurs between 12 h time point and 
control. Microarray has an inherent limitation to detect small changes between 
conditions because of the “noise” from different variations during experiments (Yao et 
al., 2004). Together with qRT-PCR validation of CHO and HI microarray experiments, 
for those genes that did not correlate with microarray analysis, most of them did not 
reach statistical significance by qRT-PCR. Microarray is hybridization-based technology 
and it tends to produce false positives (Pawitan et al., 2005). On the other hand, qRT-
PCR is much more sensitive and specific than microarray (Sinicropi et al., 2007). Large 
variation between biological replicates was seen in qRT-PCR, which caused higher P 
value. It is also possible the non-specific primers used (e.g., located at different cDNA) 
although we have checked the specificity of primer sets with BLAST search. Another 
possibility of inconsistency is that qRT-PCR primer sets did not target the same 
transcript as the microarray probe (Dallas et al., 2005).  
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CONCLUSION 
In conclusion, this is the first investigation of genome-wide transcriptome profiling 
of the laminar tissue at two early time points (i.e., 12 h and 24 h) following OF 
administration using an equine whole genome microarray. The genes with differential 
expression we identified are more comprehensive compared to the two expression arrays 
used previously in laminitis. We identified the differential expression of genes encoding 
enzymes, olfactory receptors, extracellular matrix proteins, and genes involved in signal 
transduction, homeostasis, apoptosis and immune response in the initiation of equine 
laminitis. We also identified the differential expression of S100 family members and 
metalloproteinase ADAMTS1. These genes will be good candidates for further 
functional investigation in laminitis. We performed pathway and network analysis on the 
DE genes of each comparison and elucidated the gene-gene interactions relevant to 
equine laminitis and the pertinent p38 MAPK and NF-κB pathway molecules. In 
addition, the overexpression of several anti-microbial genes and chemoattractant CXCL2 
for neutrophils supports the hypothesis that bacterial components might play a role in the 
pathogenesis of the OF model of laminitis. These discoveries may contribute to better 
understanding of the molecular mechanism underlying the initiation of laminitis. Our 
results provide better understanding of equine laminitis pathogenesis and these findings 
will be critical in paving the way for developing improved preventatives and treatments 
for equine laminitis in the future. 
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SUMMARY AND FUTURE DIRECTIONS  
 
SUMMARY 
 
This is the first genome-wide transcriptome analysis of laminar tissue during the 
early stages of CHO, HI and OF induced equine laminitis using an equine 21,000 70-mer 
long oligoarray approach. The work described in this dissertation substantially improved 
current knowledge regarding molecular underpinnings of the pathogenesis of equine 
laminitis and helped identify DE genes, potential pathways, and genetic networks 
associated with the initiation and progression of the disease. The findings in this study 
gave us a better comparative understanding of the genes associated with the interplay 
that occurs during early stages of the progression of the disease compared to the two 
previous arrays used (Budak et al., 2009; Noschka et al., 2008) in laminitis. 
Additionally, we verified earlier results describing gene expression analysis in laminar 
tissue that have been focused on selected genes considered central in disease 
progression.  
The identified DE genes will be good candidates for further functional study in 
equine laminitis. Furthermore, we identified the presence of NOD-like receptor signaling 
metabolic pathway, which is involved in recognition of intracellular bacteria in both of 
CHO and OF models of laminitis. The most important finding of this study is the 
implication of laminitis initiation: the overexpression of anti-microbial genes supports 
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the hypothesis that bacterial components might play a role in the pathogenesis of the 
CHO and OF models of laminitis. 
We investigated three models of laminitis: carbohydrate overload, a common 
cause of naturally occurring laminitis, oligofructose, a specific type of nonstructural 
carbohydrate, representation of pasture-associated laminitis, and hyperinsulinemic 
laminitis, usually associated with endocrine dysfunctions. The comparative study of 
gene expression during the early stages of CHO, HI and OF models of laminitis showed 
common features as well as differences among all three models.  
Common changes of gene expression patterns among three models 
Although the laminar tissue samples obtained from different time points of early 
stages of acute laminitis,  common functional categories of DE genes were found among 
these models, which include genes involved in signal transduction, immune response, 
enzymes, enzyme inhibitors, transcription factors, extracellular matrix proteins, and 
S100 calcium binding proteins. Between CHO and OF models of laminitis, there were 
more shared genes.  
The strong induction of inflammatory mediators such as SOD2, SAA1, DEFB4, 
SERPINB3, SERPINB11, PI3, CCL2, CXCL2, S100A8, S100A9, and S100A12, 
vacuole-associated transmembrane protein TMEM49, epidermal growth factor EREG, 
the up-regulation of BIRC3, CEBPB, CYCS, and SEC11C and the down-regulation of 
the potassium channel TMEM38A were observed between CHO and OF models of 
laminitis.  
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The consistent up-regulation of ADAMTS1, apoptosis-associated molecule 
cytochrome c (CYCS), and down-regulation of CXCL14 among CHO, HI and OF 
models of laminitis highlight these molecules‟ likely importance to the pathogenesis of 
equine laminitis. Another unexpected result from this study was the differential 
expression of olfactory receptors. Olfactory receptors were mainly expressed in the nose 
and play essential role in sensory perception. Their possible function in equine laminitis 
needs further investigation.  
Differential expression also showed the likely involvement of S100 calcium 
binding proteins in the progression of equine laminitis. S100P, S100A8, S100A9 and 
S100A12, were up-regulated at OG1 stage relative to control horses in the CHO model 
of laminitis. S100PBP, S100A1, and S100A2 were dysregulated at OG2 stage relative to 
control horses in the HI model of laminitis. S100A8, S100A9, and S100A12 were up-
regulated at 24 h time point relative to control horses in the OF model of laminitis. 
S100A2, S100A4, S100A8, S100A9, and S100A12 (S100A4 was down-regulated) were 
up-regulated at the 24 h time point relative to the 12 h time point in the OF model of 
laminitis. The up-regulation of S100 proteins in laminitis and their known function in 
other diseases suggest that they may promote inflammation, regulate ion homeostasis 
and control oxidative stress, which could lead to laminar tissue destruction during the 
pathogenesis of equine laminitis. To the best of our knowledge, the strong induction of 
S100 calcium binding proteins in CHO, HI and OF models of equine laminitis has not 
been previously reported.  
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Furthermore, we discovered convergent pathway core molecules potentially 
associated with equine laminitis: p38 MAPK and NF-κB in the CHO, HI and OF models 
of laminitis. Pathway and genetic network analysis revealed DE genes and the likely 
gene-gene biological interactions relevant to the pathogenesis of equine laminitis. It also 
allowed us to link primary gastrointestinal disease or other systemic diseases (e.g., 
rheumatoid arthritis) to laminitis. This is a key advancement of current limited 
knowledge of molecular mechanisms of laminitis. The inhibition of these cell signaling 
molecules can be evaluated for laminitis therapy in the future.  
Different features of gene expression patterns among three models 
On the other hand, there were different features of expression patterns among 
these models of laminitis. Most DE genes were different among these three models. The 
number of DE genes associated with immune response in HI model is smaller than that 
of either CHO or OF model at the same statistical confidence level. This may be due to 
the fact that the laminar tissue samples we collected at different time points (i.e., OG2 
stage in HI model). Another interesting feature is that the associated top canonical 
pathways and diseases were different among these three models even though CHO and 
OF models shared some common associated diseases (e.g., connective tissue disease).  
One prominent difference is the differential expression of CCL2 and CXCL2 
between CHO and OF models of laminitis. Chemokine CCL2 was consistently 
overexpressed at DEV (12-18 h) and OG1 stages (20-48 h) of CHO model of laminitis. 
It showed no differential expression at 12 h time point and up-regulated at 24 h time 
point (P value 0.03 and fold change 2.90) of OF model of laminitis. For CXCL2 gene, it 
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was consistently up-regulated at 12 and 24 h time point of OF model of laminitis. 
However it did not show differential expression at DEV and OG1 stages of CHO model 
of laminitis. The different model and time point/stage may be the possible reasons for 
the expression difference. The time for laminar tissue samples collected at DEV stage 
(onset of fever) of CHO model ranged from 12 to 18 h. It is suggested that the up-
regulation of CXCL2 may occur at very early developmental stage (i.e., 12 h time point) 
and possibly initiate neutrophil accumulation and followed by the up-regulation of 
CCL2.  
The most stable reference genes were different in expression among three models 
in qRT-PCR. Only one reference gene such as GAPDH or ACTB was used in most 
published real time PCR studies in horse and human medicine. Because the expression 
level of reference genes has been demonstrated to vary among different conditions 
(Suzuki et al., 2000), the selection of reliable reference genes is essential for the accurate 
interpretation of qRT-PCR data. We not only consider the difference of PCR 
amplification efficiency between gene of interest and reference gene but use more than 
one reference gene for qRT-PCR data normalization as well. The data suggested that 
EEF1A1 and RPLP0 can be used in the CHO model laminitis, GNB2L1 and RPL32 may 
be used in the HI model laminitis, and EEF1A1 and UBB are good reference genes for 
the OF model of laminitis expression studies.  
Overall, the studies described advanced our current understanding of the equine 
laminitis pathogenesis. The common gene expression changes of early stages of CHO, 
HI and OF models of laminitis data will be potentially useful to design antagonist or 
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agonist that targets the key gene receptor, inhibitor, activator of the target enzyme, or 
anti-inflammatory therapies for use in the developmental stage of laminitis. 
FUTURE DIRECTIONS  
One direction for future laminitis study is to study this disease at protein level. The 
validation and functional significance of the identified DE genes in this study may be 
evaluated using proteomic techniques (e.g., western blotting). Proteomic approaches 
have been proposed to predict the onset of laminitis and help elucidate the molecular 
causes of laminitis (Mankowski and Graham, 2008).  
The primary laminar basal epithelial cell (LBEC) culture within BM or cell line 
needs to be established and the study of functional aspects of the DE genes identified 
through this study at cellular level will be essential. The better understanding of the 
mechanism of laminar failure is impossible without the knowledge of events occurring at 
cellular level. Recently a primary culture of keratinocyte has been established for horses 
and will be a valuable tool to study the ECM components in laminitis (Visser and Pollitt, 
2010). Another attempt to isolate epidermal cells from equine hoof is underway 
(Galantino-Homer et al., 2010).  
Another direction for future study is to identify the trigger that initiates laminitis. 
Several DE genes common to both of CHO and OF models of laminitis have 
antimicrobial property and therefore support the bacterial components trigger theory. 
Laminitis has been associated with CHO overload (i.e., excess lush pasture or excess 
grain). The natural place to look for the trigger is the GI tract. GI disease is the most 
common disease associated with laminitis (Cohen and Woods, 1999; Slater et al., 1995). 
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This is supported by several studies that have suggested that the origin of the trigger for 
laminitis is in the hindgut (Bailey et al., 2004; Milinovich et al., 2010). Understanding 
the events that occur in the gastrointestinal tract (i.e., hindgut) during laminitis 
pathogenesis may help us to identify the trigger that causes laminitis. The elucidation of 
the equine gut microbiome in the future will eventually contribute to the better 
understanding of the pathogenesis of laminitis.    
Furthermore, the identification of many inflammatory mediators and p38 
MAPK/NF-κB pathway molecules in this study will enable the design of gene specific 
anti-inflammatory drugs (e.g., anticytokine therapy) as well as p38 MAPK/NF-κB 
inhibitors (Dinarello, 2010). The in vitro assays of testing (e.g., with an antibody, or 
siRNA) and evaluation of these targets as well as clinical trial will be essential. This 
therapeutics has been investigated in connective tissue diseases such as rheumatoid 
arthritis (RA). For example, p38 MAPK inhibitor has been investigated in RA (Chopra 
et al., 2010). The application of therapeutic strategy for RA treatment through NF-κB 
inhibition (Criswell, 2010) has been proposed.    
The availability of the draft sequence of horse genome generates a single nucleotide 
polymorphism (SNP) map as well as enables the development of an equine whole 
genome SNP chip (Swinburne, 2009; Wade et al., 2009). This tool will be valuable for 
genome wide association study (GWAS) in laminitis to investigate disease susceptibility. 
Recent studies using the Illumina equine 50K SNP chip has led to the identification of a 
haplotype associated with lordosis (Cook et al., 2009), and a causative mutation in 
Lavender Foal Syndrome (LFS) (Brooks et al., 2010) in horses. 
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Overall, the outcome and significance of the findings expanded the current 
knowledge about equine laminitis and can lead to new ways to help develop potential 
preventions and therapeutic strategies. As the mission “ To Conquer Laminitis by 2020”, 
postulated by Equine Laminitis Research Community (Orsini and Moore, 2010), the 
unified information from diverse components of laminitis such as gene expression, 
association study, histological, pathological, endocrinological, and immunological 
aspects will help elucidate the disease pathogenesis and provide a more effective 
treatment strategy.  
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APPENDIX 
 
Table A.1 List of all differentially expressed genes (P<0.01 and fold change>2) for the 
DEV/CON comparison. Fold change indicates expression level larger than 2 is up-
regulation and expression level less than 0.5 is down-regulation.  
 
Gene Name 
Public 
Accession Human Protein P Value Fold Change 
PIGR XM_001492298 NP_002635.2 5.947E-05 0.3348796 
SNF8 XM_001502240 NP_009172.2 0.0012115 0.3395826 
NULL XM_001498378 NULL 0.0028365 0.3504448 
NULL NULL NULL 0.0004497 0.359265 
FLRT3 XM_001491950 NP_037413.1 0.0071702 0.372587 
NULL CX604746 NULL 0.0001236 0.3730017 
SEPP1 XR_036255 NP_001087195.1 0.001416 0.3907 
ZDHHC6 XM_001498439 NP_071939.1 0.0050028 0.3948714 
NULL NULL NULL 0.0053603 0.3958571 
PTPN6 XM_001497706 NP_002822.2 0.0078528 0.3958807 
TIGD1 XM_001503915 NP_663748.1 0.0032456 0.4011188 
C11orf59 XM_001499308 NP_060377.1 0.0080243 0.4040881 
CA5B XM_001490349 NP_009151.1 0.0070788 0.404286 
CILP2 XR_036360 NP_694953.2 0.0006521 0.4063774 
NULL NULL NULL 0.0040508 0.4197584 
CDK5RAP2 XM_001501690 NP_060719.4 0.0022011 0.4202178 
NULL NULL NULL 0.0084249 0.4269597 
C8orf70 XM_001491870 NP_057094.1 0.0078665 0.4277105 
PRR15 XM_001500279 NP_787083.1 0.0050108 0.4321916 
NULL NULL NULL 0.0025279 0.4323748 
NCAPG XR_036336 NP_071741.2 0.0041005 0.4331997 
NULL CD535422 NULL 0.0005955 0.4369529 
CRABP1 NULL NP_004369.1 0.0011655 0.437203 
ANKRD35 XM_001499402 NP_653299.3 0.0093994 0.4375781 
BFAR XM_001490098 NP_057645.1 0.0098486 0.4386322 
ATP6V1B1 XM_001489315 NP_001683.2 0.0063162 0.439582 
NULL NULL NULL 0.0024622 0.4434318 
HERPUD2 XM_001501128 NP_071768.2 0.0089616 0.4436919 
ARL6IP4 XM_001497593 NP_057722.2 0.0085555 0.4502788 
NULL DN507028 NULL 0.0024213 0.4529776 
IGLL1 XM_001492772 NP_064455.1 0.0026492 0.4540942 
ZNF709 XM_001496191 NP_689814.1 0.0087303 0.4553173 
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OR7A5 XM_001499777 NP_059976.1 0.00625 0.4557727 
RNF138 XM_001496619 NP_057355.2 0.0052927 0.4587432 
OR52B4 XM_001496850 NP_001005161.2 0.0095427 0.4590887 
DNAL4 XM_001501707 NP_005731.1 0.0055489 0.4611828 
NULL NULL NULL 0.0093934 0.461473 
NULL NULL NULL 0.0078178 0.4633147 
NULL CD468881 NULL 0.003374 0.465527 
CD1A XM_001489596 NP_001754.2 0.0056835 0.4690903 
CPXM1 XM_001497131 NP_062555.1 0.0044105 0.4693193 
ERCC2 XM_001500474 NP_000391.1 0.0065647 0.4697824 
ITGAX XM_001495577 NP_000878.2 0.0044879 0.4709893 
APOC4 XM_001502367 NP_001637.1 0.0025516 0.473609 
NULL NULL NULL 0.0022607 0.4790313 
FASN XM_001491292 NP_004095.4 0.0099156 0.4825165 
SCHIP1 CX601415 NP_055390.1 0.0062503 0.4870996 
KIAA1430 XM_001491109 NP_065878.1 0.0077734 0.4875496 
MAF NULL NP_001026974.1 0.0042664 0.4927487 
LMO4 XM_001495584 NP_006760.1 0.0081393 0.4928831 
ADAM20 NULL NP_003805.3 0.0026238 0.4941237 
RPUSD3 XM_001491328 NP_775930.1 0.0039738 0.4960581 
LIPE XM_001499337 NP_005348.2 0.0085767 0.4982896 
NULL DN505910 NULL 0.0052354 2.0308402 
NULL NULL NULL 0.0005355 2.0335743 
USP44 XM_001495993 NP_001035862.1 0.0095144 2.0710755 
NULL NULL NULL 0.0060986 2.1888989 
NULL NULL NULL 0.0027135 2.2296383 
CLEC2L XM_001496572 XP_499478.3 0.0098924 2.2764744 
NULL CX602928 NULL 0.0067592 2.3067414 
CRYAB XM_001501779 NP_001876.1 0.0030662 2.3516061 
RSPH3 XM_001491976 NP_114130.3 0.0042391 2.3534586 
NULL NULL NULL 0.0013585 2.3849153 
HOPX XM_001491312 NP_631957.1 0.009606 2.4503332 
MFAP5 NULL NP_003471.1 0.0071275 2.6792705 
NULL BI961659 NULL 1.498E-05 2.7866203 
CCL2 AJ251189 NP_002973.1 0.0056063 3.0044443 
NULL BM734930 NULL 0.0026373 3.3508285 
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Table A.2 List of all differentially expressed genes (P<0.01 and fold change>2) for the 
OG1/CON comparison. Fold change indicates expression level larger than 2 is up-
regulation and expression level less than 0.5 is down-regulation.  
 
 
Gene Name 
Public 
Accession Human Protein P Value Fold Change 
NULL NULL NULL 1.28E-06 0.2243435 
SELENBP1 NULL NP_003935.2 0.0004266 0.230477 
OR7A10 NULL NP_001005190.1 0.0002225 0.2455636 
CD69 XM_001499388 NP_001772.1 0.0007847 0.2475105 
CXCL14 XM_001502713 NP_004878.2 0.0021719 0.2476481 
NULL CD465749 NULL 3.38E-07 0.2489918 
NULL NULL NULL 0.0015373 0.2517936 
TPPP3 CX596053 NP_057048.2 0.0004892 0.2601816 
NULL CX604746 NULL 5.79E-05 0.3204686 
NULL CX603968 NULL 0.0026067 0.3230924 
NULL NULL NULL 0.0017855 0.3352171 
CD28 NM_001100179 NP_006130.1 0.0067911 0.3363899 
MATN2 XM_001490965 NP_002371.3 0.0005736 0.3430338 
FIBIN AB302195 NP_976249.1 0.0049942 0.3565335 
MNAT1 XM_001497949 NP_002422.1 0.0003989 0.3616633 
ACBD7 XM_001498628 NP_001034933.1 0.0029252 0.3654203 
NULL NULL NULL 0.001703 0.3706927 
NULL NULL NULL 0.0005058 0.3741379 
NULL NULL NULL 0.0094844 0.3771931 
FLRT3 XM_001491950 NP_037413.1 0.0087306 0.3831077 
NULL NULL NULL 0.0004609 0.3832289 
NULL NULL NULL 0.000323 0.4031742 
NULL NULL NULL 0.0023111 0.4090921 
NULL NULL NULL 0.0030918 0.4141212 
SNRPN XM_001492702 NP_073718.1 0.0099055 0.416691 
NULL CX599404 NULL 0.0004803 0.4307558 
NULL NULL NULL 0.0011537 0.4317607 
NULL NULL NULL 0.0052625 0.4339479 
BEX2 XM_001503044 NP_116010.1 0.0002856 0.4339661 
NULL XM_001489844 NULL 0.0084422 0.4405005 
HMGB2 XM_001498819 NP_002120.1 0.0031908 0.4420842 
NULL BM734727 NULL 0.0017935 0.4429278 
NULL NULL NULL 0.001481 0.4458845 
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IGFBP6 NULL NP_002169.1 0.0002723 0.4479038 
FOXN2 XM_001498254 NP_002149.2 0.005868 0.448417 
HADHB XR_036425 NP_000174.1 0.006971 0.4501272 
SFRS5 XM_001500464 NP_001034554.1 0.0026026 0.4504911 
P4HA3 XM_001495901 NP_878907.1 0.0007058 0.4510091 
FLJ32810 XM_001498479 XP_001127623.1 0.0078741 0.4512612 
PARP15 BI960814 NP_689828.1 0.0073446 0.4572764 
NULL CX601687 NULL 0.0069093 0.4577299 
CLCN6 XM_001491741 NP_001277.1 0.0043323 0.4613162 
NULL NULL NULL 0.009559 0.4646382 
AMACR XM_001500251 NP_055139.4 0.008385 0.4704083 
NULL NULL NULL 0.0057003 0.471815 
NULL NULL NULL 0.0052032 0.4731391 
NULL CX601418 NULL 0.0067509 0.4879627 
NULL NULL NULL 0.0020198 0.4921633 
HDAC3 XM_001503978 NP_003874.2 0.0098546 0.4945629 
NULL CX604949 NULL 0.0054996 0.4947603 
DARC XM_001490641 NP_002027.2 0.0032638 1.99601 
CYCS XM_001498822 NP_061820.1 0.0029425 2.0557252 
FOLR2 XM_001499257 NP_000794.2 0.0063268 2.0609106 
ODC1 XM_001502323 NP_002530.1 0.0041776 2.0729218 
SEC11C XM_001489285 NP_150596.1 0.0019041 2.105893 
LOC390110 XM_001489817 NP_001027025.2 0.0058495 2.1211488 
EREG XM_001490281 NP_001423.1 0.007791 2.1255396 
NULL DN505910 NULL 0.0070953 2.1287296 
TSPAN10 XM_001489838 NP_114151.3 0.0075185 2.1297393 
NULL NULL NULL 0.0022141 2.1489989 
NULL NULL NULL 8.419E-05 2.1599908 
LCTL XM_001497027 NP_997221.2 0.0075704 2.1607625 
YTHDF2 XM_001500333 NP_057342.2 0.0085737 2.2031424 
KRT33A XM_001497042 NP_004129.2 0.0050126 2.2216277 
ARRDC3 XM_001504616 NP_065852.1 0.0059223 2.2223945 
NULL NULL NULL 0.0035004 2.2302144 
NULL XR_036017 NULL 0.0047643 2.2576145 
C3orf43 XM_001501186 NP_001071125.1 0.0079749 2.2646277 
NULL CX602004 NULL 0.0095785 2.2898602 
NULL NULL NULL 0.0001092 2.2916307 
DUSP1 XM_001499555 NP_004408.1 0.0046203 2.3105742 
SPI1 XM_001491380 NP_003111.2 0.0073011 2.3109014 
USP48 XM_001504296 NP_115612.4 0.0073837 2.3224186 
254 
 
 
FGR XM_001504019 NP_001036212.1 0.0005024 2.3310042 
TOP1 XM_001500194 NP_003277.1 0.0069103 2.3448075 
ALKBH6 XM_001492599 NP_116267.3 0.0010388 2.3519466 
CD14 AF200416 NP_000582.1 0.00062 2.3583871 
NULL NULL NULL 0.0061586 2.3739544 
NULL NULL NULL 0.0033003 2.4071213 
BACE2 DN509102 NP_036237.2 0.0046631 2.4221088 
NULL DN509649 NULL 0.0010582 2.4457472 
NULL NULL NULL 0.0007546 2.4623677 
BCL6 XM_001499813 NP_001697.2 0.002523 2.4815853 
NULL NULL NULL 0.0009478 2.4840235 
BIRC3 XM_001499875 NP_001156.1 0.0032213 2.5252948 
IL10RB XM_001498211 NP_000619.3 0.0006236 2.5356816 
MCHR1 XM_001502221 NP_005288.3 0.0023582 2.5547138 
TMEM49 XM_001503742 NP_112200.2 0.0014963 2.5553442 
VASP NULL NP_003361.1 0.0094729 2.577176 
NULL CX605555 NULL 0.0014384 2.5904008 
UTS2R XM_001490444 NP_061822.1 0.0072268 2.5994938 
NULL NULL NULL 0.0070955 2.6028953 
RNF144B XM_001494349 NP_877434.2 0.0003606 2.633142 
SLC30A1 XM_001489279 NP_067017.2 0.0047388 2.6424103 
ATP5B NULL NP_001677.2 0.001352 2.6531306 
IFIT1L XM_001498801 NP_001010987.1 0.0018264 2.6566017 
LYZL6 XM_001494897 NP_065159.1 0.0008346 2.7076256 
NULL NULL NULL 0.0004822 2.7748101 
TIMP1 CX602739 NP_003245.1 0.0035118 2.8742931 
OR7G2 XM_001500467 NP_001005193.1 0.0024333 3.0249114 
RSPH3 XM_001491976 NP_114130.3 0.0019278 3.0788139 
C13orf33 XM_001495031 NP_116238.2 0.0050774 3.1231197 
SLC1A1 XM_001492215 NP_004161.4 0.0008968 3.1266973 
NULL CD470175 NULL 3.208E-05 3.2130747 
NULL CD472171 NULL 3.451E-05 3.2354271 
SRGN XM_001503648 NP_002718.2 0.0009494 3.2437712 
LOC554251 XM_001491993 NP_001019851.1 0.0005633 3.2822625 
ACAT2 XM_001491705 NP_005882.2 0.0001489 3.3253795 
NULL NULL NULL 0.0039998 3.3416776 
HTRA4 XM_001491574 NP_710159.1 0.0029486 3.3526877 
RTEL1 XM_001492913 NP_057518.1 3.315E-05 3.4729818 
CFB XM_001492552 NP_001701.2 0.0003293 3.5048192 
NULL CX602140 NULL 0.0015575 3.6025274 
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EGR1 XM_001502553 NP_001955.1 0.0003762 3.6345378 
HSPA5 CX604607 NP_005338.1 0.0016049 3.6835669 
ADAMTS1 AF541975 NP_008919.3 6.16E-06 3.6920106 
NULL NULL NULL 0.0002092 3.7164806 
CEBPB CX605423 NP_005185.2 3.39E-06 3.8388041 
NULL XM_001498707 NULL 0.0004245 3.8916559 
NULL NULL NULL 0.0012631 3.9363377 
ZNF452 XM_001504878 NP_443155.1 0.0001085 3.9371162 
NULL NULL NULL 0.0012994 4.0195753 
LYZ XM_001494130 NP_000230.1 8.123E-05 4.0478677 
PPA1 XM_001502747 NP_066952.1 1.628E-05 4.2789416 
SEMA3C XM_001489227 NP_006370.1 1.628E-05 4.3360604 
S100P BM734933 NP_005971.1 9.64E-06 4.4704722 
CCL7 XM_001501551 NP_006264.2 7.51E-06 4.5401825 
CITED1 XM_001488044 NP_004134.1 1.02E-05 4.7508868 
TK1 XM_001491081 NP_003249.2 6.653E-05 5.3486915 
NP XM_001505137 NP_000261.2 0.0014357 5.4863287 
ING5 NULL XP_946119.1 7.90E-06 5.969279 
NULL NULL NULL 1.64E-07 6.5516629 
NULL BI961659 NULL 7.63E-10 7.3082392 
NULL CX605648 NULL 1.286E-05 8.11198 
SERPINB3 XM_001491507 NP_008850.1 7.806E-05 8.7247251 
NULL NULL NULL 9.63E-07 9.2995608 
CCL2 AJ251189 NP_002973.1 8.76E-06 9.7152828 
S100A9 XM_001493530 NP_002956.1 0.0003288 10.4183 
SAA1 NM_001081853 NP_000322.2 0.0002056 12.032089 
NULL NULL NULL 1.88E-05 12.166194 
PI3 BM734843 NP_002629.1 5.141E-05 15.338701 
NULL CD467650 NULL 2.66E-06 16.265843 
S100A8 XM_001494358 NP_002955.2 7.27E-06 16.895748 
SOD2 AB001693 NP_000627.2 3.45E-09 20.087348 
NULL BM734930 NULL 4.40E-09 22.847298 
DEFB4 AY170305 NP_004933.1 3.16E-07 31.678786 
S100A12 CD535886 NP_005612.1 2.97E-07 36.467473 
S100A8 XM_001493589 NP_002955.2 1.92E-06 38.355221 
NULL NULL NULL 4.17E-07 44.814777 
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Table A.3 List of all differentially expressed genes (P<0.01 and fold change>2) for the 
DEV/OG1 comparison. Fold change indicates expression level larger than 2 is up-
regulation and expression level less than 0.5 is down-regulation.  
 
 
Gene Name 
Public 
Accession Human Protein P Value Fold Change 
S100A8 XM_001493589 NP_002955.2 9.57E-07 0.0288268 
S100A12 CD535886 NP_005612.1 4.38E-06 0.0478126 
NULL NULL NULL 2.756E-05 0.056055 
S100A8 XM_001494358 NP_002955.2 7.54E-06 0.0737037 
S100A9 XM_001493530 NP_002956.1 7.066E-05 0.0826332 
SOD2 AB001693 NP_000627.2 2.39E-07 0.0921965 
DEFB4 AY170305 NP_004933.1 0.0001131 0.0998139 
NULL CD467650 NULL 3.451E-05 0.1157475 
NULL CX605648 NULL 1.465E-05 0.1454532 
NULL BM734930 NULL 1.613E-05 0.1466619 
SERPINB3 XM_001491507 NP_008850.1 0.0003378 0.1482778 
ING5 NULL XP_946119.1 3.43E-06 0.1510994 
NULL NULL NULL 0.00032 0.1578443 
SAA1 NM_001081853 NP_000322.2 0.002144 0.1603395 
CITED1 XM_001488044 NP_004134.1 1.87E-06 0.1745981 
PI3 BM734843 NP_002629.1 0.0037051 0.1888568 
NULL NULL NULL 2.825E-05 0.1957813 
TK1 XM_001491081 NP_003249.2 2.478E-05 0.2119661 
NULL NULL NULL 7.23E-06 0.2137199 
NP XM_001505137 NP_000261.2 0.0017391 0.2150607 
ZNF452 XM_001504878 NP_443155.1 1.99E-05 0.2328493 
S100P BM734933 NP_005971.1 1.038E-05 0.2550218 
CCL7 XM_001501551 NP_006264.2 3.205E-05 0.2559178 
SLC30A1 XM_001489279 NP_067017.2 0.0001117 0.2637864 
MCHR1 XM_001502221 NP_005288.3 2.319E-05 0.2646922 
LYZ XM_001494130 NP_000230.1 0.0003195 0.2887071 
CFB XM_001492552 NP_001701.2 0.0001614 0.2915984 
SEMA3C XM_001489227 NP_006370.1 0.0001526 0.2919968 
CEBPB CX605423 NP_005185.2 4.64E-06 0.2952954 
EGR1 XM_001502553 NP_001955.1 0.0003338 0.2977721 
NULL CX602140 NULL 0.0017299 0.3069089 
CCL2 AJ251189 NP_002973.1 0.0034131 0.3092493 
NULL CX605555 NULL 0.0001424 0.3360394 
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SLC1A1 XM_001492215 NP_004161.4 0.0014339 0.3381174 
USP48 XM_001504296 NP_115612.4 0.0003982 0.3387717 
LYZL6 XM_001494897 NP_065159.1 0.0002152 0.3492745 
SERPINB11 XM_001491598 NP_536723.2 0.009936 0.3503465 
C13orf33 XM_001495031 NP_116238.2 0.0059983 0.3562235 
NULL NULL NULL 1.48E-06 0.3584886 
MYO1B XM_001502243 NP_036355.2 0.0015173 0.3610238 
OSMR XM_001496993 NP_003990.1 0.0031108 0.3620245 
TMEM49 XM_001503742 NP_112200.2 0.0003079 0.3639768 
NULL NULL NULL 0.0003028 0.3640168 
KLHDC1 XM_001496298 NP_751943.1 0.0016552 0.3667146 
OR7G2 XM_001500467 NP_001005193.1 0.0055619 0.3690666 
ADAMTS1 AF541975 NP_008919.3 0.0002115 0.3695796 
NULL NULL NULL 0.000398 0.3710287 
CLIC5 XM_001502577 NP_058625.2 0.0048234 0.3729854 
RPUSD3 XM_001491328 NP_775930.1 0.0001867 0.3809596 
LILRB4 CD467691 NP_001074907.1 2.143E-05 0.3812759 
NULL BI961659 NULL 3.397E-05 0.3812984 
FCN1 XM_001498857 NP_001994.2 0.0027354 0.384454 
NULL NULL NULL 0.0002537 0.3884835 
FOLR2 XM_001499257 NP_000794.2 0.0003366 0.3961459 
WDR46 XR_036191 NP_005443.2 0.0003122 0.39841 
DC2 XM_001502983 NP_067050.1 0.0065113 0.4026614 
EREG XM_001490281 NP_001423.1 0.0009776 0.4027592 
NULL NULL NULL 0.0076446 0.4061879 
SCN3A XM_001493704 NP_008853.3 0.0064515 0.4068865 
NULL CX605497 NULL 0.0036885 0.4070287 
TUBGCP2 NULL NP_006650.1 0.0026574 0.407333 
ACAT2 XM_001491705 NP_005882.2 0.0029132 0.4106937 
CD14 AF200416 NP_000582.1 0.0005103 0.4170751 
TIMP1 CX602739 NP_003245.1 0.008357 0.4188957 
ZFAND5 XM_001488383 NP_001095891.1 0.0016253 0.4212034 
PDE4B XM_001500306 NP_001032417.1 0.0074854 0.4212567 
TOP1 XM_001500194 NP_003277.1 0.0063576 0.4222173 
PDGFRB XM_001501493 NP_002600.1 0.0080532 0.4222192 
CHRNA1 XM_001499557 NP_000070.1 0.0026541 0.4262115 
NULL CX604543 NULL 0.0039756 0.4268117 
SLC36A4 XM_001491833 NP_689526.2 0.0082755 0.427013 
YTHDF2 XM_001500333 NP_057342.2 0.0029081 0.4284453 
ARHGEF6 XM_001489854 NP_004831.1 0.0026054 0.4299731 
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CDK5RAP2 XM_001501690 NP_060719.4 0.0028398 0.4313085 
LAMP3 XM_001496283 NP_055213.2 0.0025171 0.4329997 
OR2AG1 XM_001499969 NP_001004489.1 0.0061342 0.4389212 
NULL DN504949 NULL 0.0077082 0.4400972 
BCL6 XM_001499813 NP_001697.2 0.005757 0.4412427 
SLC30A9 XM_001494445 NP_006336.3 0.0001669 0.4425522 
BIRC3 XM_001499875 NP_001156.1 0.005193 0.4438224 
C3orf43 XM_001501186 NP_001071125.1 0.008508 0.444991 
SPI1 XM_001491380 NP_003111.2 0.0055936 0.4483773 
RTEL1 XM_001492913 NP_057518.1 0.0015744 0.4495376 
BCS1L XM_001492073 NP_001073335.1 0.0030146 0.4546236 
ATP5B NULL NP_001677.2 0.0042165 0.4570922 
DNAJA1 XM_001499089 NP_001530.1 0.0014345 0.457459 
TRA16 XM_001503457 NP_795361.1 0.0021945 0.4578523 
NULL DN506948 NULL 0.0043932 0.4586279 
NULL NULL NULL 0.002963 0.4602054 
RRS1 XM_001494813 NP_055984.1 0.0099761 0.4647966 
LOX NULL NP_002308.2 0.003095 0.4657464 
NULL CX602993 NULL 0.0011721 0.4670793 
NAGK XM_001489139 NP_060037.2 0.0081676 0.4697813 
AP3M2 XM_001489349 NP_006794.1 0.0047091 0.4733129 
ARL4D XM_001491841 NP_001652.2 0.0021579 0.4733809 
PPFIA1 NULL NP_003617.1 0.004967 0.4767974 
NULL NULL NULL 0.0035033 0.4773099 
TTK XM_001499324 NP_003309.2 0.0056815 0.4791926 
SLC36A3 XM_001501339 NP_861439.2 0.009041 0.4793468 
NULL NULL NULL 0.007711 0.4796046 
AP3S1 XR_036452 NP_001275.1 0.0088783 0.4810254 
HIGD1A CX601442 NP_001093138.1 0.000829 0.4814442 
NULL DN506142 NULL 0.0004433 0.4824114 
NULL NULL NULL 0.0011598 0.4825585 
TAS2R39 XM_001495492 NP_795362.2 0.0093784 0.4830005 
SELS XM_001490893 NP_060915.2 0.0051201 0.4831007 
CKAP4 CX602638 NP_006816.2 0.0036315 0.484203 
SERPINB8 XM_001492201 NP_002631.3 0.0022524 0.4859701 
CCDC67 XM_001491708 NP_857596.2 0.0059073 0.4885446 
PTMA NULL NP_002814.3 0.0045857 0.4941418 
FLJ35773 XM_001503222 NP_689812.2 0.0053729 0.4944675 
ODZ2 XM_001503295 XP_950879.2 0.0010627 0.4958106 
EIF3J NULL NP_003749.2 0.0082104 0.4963824 
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CCDC50 XM_001498671 NP_848018.1 0.0082523 0.4977543 
IL1B XM_001495729 NP_000567.1 0.001322 0.4984435 
NULL CD470175 NULL 0.0027558 0.5009265 
TM6SF1 XM_001497976 NP_075379.1 0.000401 0.5011357 
SERPINH1 XM_001494685 NP_001226.2 0.0012734 0.5015004 
JMJD1C XR_036457 NP_116165.1 0.0025169 2.0141667 
NULL NULL NULL 0.0077744 2.0860558 
OR8B12 XM_001502045 NP_001005195.1 0.0007377 2.1098599 
NULL CX599404 NULL 0.0015285 2.1116958 
NULL CX605637 NULL 0.0097283 2.1189819 
NULL NULL NULL 0.0042387 2.1365711 
NULL NULL NULL 0.0005084 2.1655942 
NULL NULL NULL 0.0052575 2.1707062 
NULL NULL NULL 0.0068335 2.1760527 
NULL CX603435 NULL 0.0018159 2.2078648 
NULL NULL NULL 0.008459 2.210933 
HSPB8 XM_001490413 NP_055180.1 0.0002012 2.4258193 
NULL NULL NULL 0.0097527 2.4467649 
NULL CX605682 NULL 0.0077231 2.4548339 
39693 XM_001503016 NP_004395.1 0.0021521 2.4734803 
IGFBP6 NULL NP_002169.1 2.508E-05 2.4836402 
MNAT1 XM_001497949 NP_002422.1 0.0003253 2.5929511 
GSN U31699 NP_000168.1 0.0002085 2.6573509 
NULL NULL NULL 0.0030061 2.6591971 
NULL NULL NULL 0.0003494 2.6708748 
ENPP3 XM_001503291 NP_005012.2 0.0076128 2.7223846 
39539 XM_001493843 NP_002961.1 0.0039058 2.7354169 
NDEL1 XM_001504824 NP_001020750.1 0.0015702 2.7608585 
NULL NULL NULL 0.0090299 2.7908398 
CAT CX593238 NP_001743.1 0.0023817 2.9414448 
CRYAB XM_001501779 NP_001876.1 0.000237 3.0568817 
NULL CD465749 NULL 2.93E-06 3.0858067 
PPP2R3B XM_001488015 NP_037371.2 0.0003873 3.0916075 
OR7A10 NULL NP_001005190.1 0.0015833 3.1780203 
SLC22A12 XM_001489840 NP_653186.2 0.0031423 3.1816108 
IGFBP7 XM_001491171 NP_001544.1 0.0004492 3.1864308 
MFAP5 NULL NP_003471.1 0.001718 3.2520741 
FLJ36070 XM_001489063 NP_872380.1 0.0019684 3.2882248 
NULL NULL NULL 2.509E-05 3.4534275 
CALCB AF257470 NP_000719.1 0.0008718 3.5857351 
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FAM82C XM_001501075 NP_060615.1 0.0047303 3.6421132 
HOPX XM_001491312 NP_631957.1 0.000353 3.7320819 
CXCL14 XM_001502713 NP_004878.2 0.0015326 3.7552859 
NDUFA4L2 XM_001488582 NP_064527.1 0.0036162 3.7680783 
CD69 XM_001499388 NP_001772.1 3.61E-05 4.8445118 
NULL CX601554 NULL 0.0073619 4.9493333 
TPPP3 CX596053 NP_057048.2 1.407E-05 5.3052718 
 
 
 
 
  
 
Table A.4 Overrepresented gene ontology terms identified among differentially expressed genes (P<0.05 and fold change>2) 
of the DEV/CON comparison. BP: biological process; CC: cellular component; MF: molecular function  
    Term Count % P 
Upregulated 
Genes     
BP GO:0009408~response to heat 4 14.81481 5.48E-05 
 GO:0009266~response to temperature stimulus 4 14.81481 1.77E-04 
 GO:0009725~response to hormone stimulus 5 18.51852 0.001278 
 GO:0009628~response to abiotic stimulus 5 18.51852 0.001291 
 GO:0009719~response to endogenous stimulus 5 18.51852 0.001838 
 GO:0048545~response to steroid hormone stimulus 4 14.81481 0.002044 
 GO:0040011~locomotion 5 18.51852 0.002307 
 GO:0033273~response to vitamin 3 11.11111 0.003498 
 GO:0051384~response to glucocorticoid stimulus 3 11.11111 0.00485 
 GO:0042221~response to chemical stimulus 7 25.92593 0.005319 
 GO:0031960~response to corticosteroid stimulus 3 11.11111 0.005733 
 GO:0040008~regulation of growth 4 14.81481 0.01016 
 GO:0051704~multi-organism process 5 18.51852 0.011657 
 GO:0032870~cellular response to hormone stimulus 3 11.11111 0.013567 
 GO:0010033~response to organic substance 5 18.51852 0.014157 
 GO:0007584~response to nutrient 3 11.11111 0.014954 
 GO:0006935~chemotaxis 3 11.11111 0.01924 
 GO:0042330~taxis 3 11.11111 0.01924 
 GO:0006950~response to stress 7 25.92593 0.019661 
 GO:0051716~cellular response to stimulus 5 18.51852 0.021767 
 GO:0007610~behavior 4 14.81481 0.023768 
 GO:0009617~response to bacterium 3 11.11111 0.027299 
 GO:0050896~response to stimulus 10 37.03704 0.027319 
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GO:0001558~regulation of cell growth 3 11.11111 0.027561 
 GO:0031667~response to nutrient levels 3 11.11111 0.028355 
 GO:0032387~negative regulation of intracellular transport 2 7.407407 0.029218 
 GO:0006916~anti-apoptosis 3 11.11111 0.03079 
 GO:0009605~response to external stimulus 5 18.51852 0.031001 
 GO:0009991~response to extracellular stimulus 3 11.11111 0.03474 
 GO:0032526~response to retinoic acid 2 7.407407 0.043523 
 GO:0007017~microtubule-based process 3 11.11111 0.044783 
      
CC GO:0005576~extracellular region 8 29.62963 0.015489 
 GO:0044421~extracellular region part 5 18.51852 0.040395 
      
MF GO:0005212~structural constituent of eye lens 2 7.407407 0.020027 
 GO:0005520~insulin-like growth factor binding 2 7.407407 0.02932 
      
Downregulated Genes    
BP none     
      
CC GO:0005737~cytoplasm 60 50 0.013882 
      
MF GO:0042808~neuronal Cdc2-like kinase binding 2 1.666667 0.0189 
 GO:0016836~hydro-lyase activity 3 2.5 0.031665 
  GO:0016835~carbon-oxygen lyase activity 3 2.5 0.047539 
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Table A.5 Overrepresented gene ontology terms identified among differentially expressed genes (P<0.01 and fold change>2) 
of the OG1/CON comparison. BP: biological process; CC: cellular component; MF: molecular function  
    
    Term Count % P 
Upregulated Genes     
BP GO:0006954~inflammatory response 13 19.11765 4.08E-09 
 GO:0009605~response to external stimulus 19 27.94118 6.89E-09 
 GO:0006952~defense response 16 23.52941 1.01E-08 
 GO:0009611~response to wounding 15 22.05882 1.27E-08 
 GO:0002376~immune system process 18 26.47059 1.69E-07 
 GO:0006950~response to stress 22 32.35294 7.70E-07 
 GO:0050896~response to stimulus 32 47.05882 9.67E-07 
 GO:0007610~behavior 12 17.64706 1.87E-06 
 GO:0042221~response to chemical stimulus 18 26.47059 5.51E-06 
 GO:0055080~cation homeostasis 9 13.23529 1.57E-05 
 GO:0006935~chemotaxis 7 10.29412 3.92E-05 
 GO:0042330~taxis 7 10.29412 3.92E-05 
 GO:0055066~di-, tri-valent inorganic cation homeostasis 8 11.76471 4.18E-05 
 GO:0040011~locomotion 10 14.70588 4.50E-05 
 GO:0030003~cellular cation homeostasis 8 11.76471 6.15E-05 
 GO:0001817~regulation of cytokine production 7 10.29412 7.80E-05 
 GO:0007626~locomotory behavior 8 11.76471 9.89E-05 
 GO:0006873~cellular ion homeostasis 9 13.23529 1.05E-04 
 GO:0009617~response to bacterium 7 10.29412 1.11E-04 
 GO:0055082~cellular chemical homeostasis 9 13.23529 1.18E-04 
 GO:0009607~response to biotic stimulus 9 13.23529 1.26E-04 
 GO:0048519~negative regulation of biological process 19 27.94118 1.39E-04 
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GO:0042592~homeostatic process 12 17.64706 1.48E-04 
 GO:0050801~ion homeostasis 9 13.23529 1.95E-04 
 
GO:0051239~regulation of multicellular organismal 
process 13 19.11765 2.51E-04 
 
GO:0030005~cellular di-, tri-valent inorganic cation 
homeostasis 7 10.29412 2.69E-04 
 GO:0048247~lymphocyte chemotaxis 3 4.411765 3.21E-04 
 GO:0006955~immune response 11 16.17647 3.37E-04 
 GO:0030595~leukocyte chemotaxis 4 5.882353 4.18E-04 
 GO:0065008~regulation of biological quality 16 23.52941 4.45E-04 
 GO:0019725~cellular homeostasis 9 13.23529 4.69E-04 
 GO:0060326~cell chemotaxis 4 5.882353 4.88E-04 
 GO:0048246~macrophage chemotaxis 3 4.411765 5.47E-04 
 GO:0016477~cell migration 7 10.29412 7.57E-04 
 GO:0006874~cellular calcium ion homeostasis 6 8.823529 7.75E-04 
 GO:0048878~chemical homeostasis 9 13.23529 8.70E-04 
 GO:0055074~calcium ion homeostasis 6 8.823529 8.75E-04 
 GO:0051707~response to other organism 7 10.29412 9.79E-04 
 GO:0042742~defense response to bacterium 5 7.352941 0.001004 
 GO:0006875~cellular metal ion homeostasis 6 8.823529 0.001055 
 GO:0055065~metal ion homeostasis 6 8.823529 0.001288 
 GO:0048870~cell motility 7 10.29412 0.001312 
 GO:0051674~localization of cell 7 10.29412 0.001312 
 GO:0006916~anti-apoptosis 6 8.823529 0.001316 
 GO:0050900~leukocyte migration 4 5.882353 0.001487 
 GO:0048523~negative regulation of cellular process 16 23.52941 0.001594 
 GO:0042493~response to drug 6 8.823529 0.001623 
 GO:0048518~positive regulation of biological process 18 26.47059 0.001693 
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GO:0030593~neutrophil chemotaxis 3 4.411765 0.002271 
 GO:0006928~cell motion 8 11.76471 0.002604 
 GO:0043066~negative regulation of apoptosis 7 10.29412 0.002692 
 
GO:0051240~positive regulation of multicellular 
organismal process 6 8.823529 0.00276 
 
GO:0043069~negative regulation of programmed cell 
death 7 10.29412 0.002886 
 GO:0060548~negative regulation of cell death 7 10.29412 0.002926 
 GO:0051716~cellular response to stimulus 10 14.70588 0.00466 
 
GO:0051605~protein maturation by peptide bond 
cleavage 4 5.882353 0.004796 
 GO:0051704~multi-organism process 9 13.23529 0.005149 
 GO:0001819~positive regulation of cytokine production 4 5.882353 0.005444 
 GO:0008284~positive regulation of cell proliferation 7 10.29412 0.005778 
 GO:0050707~regulation of cytokine secretion 3 4.411765 0.006262 
 GO:0002526~acute inflammatory response 4 5.882353 0.006893 
 GO:0008219~cell death 9 13.23529 0.007093 
 GO:0016265~death 9 13.23529 0.007385 
 GO:0031667~response to nutrient levels 5 7.352941 0.007676 
 GO:0048145~regulation of fibroblast proliferation 3 4.411765 0.008457 
 
GO:0007204~elevation of cytosolic calcium ion 
concentration 4 5.882353 0.00946 
 GO:0016485~protein processing 4 5.882353 0.009935 
 GO:0048583~regulation of response to stimulus 7 10.29412 0.009983 
 GO:0012501~programmed cell death 8 11.76471 0.010124 
 GO:0006953~acute-phase response 3 4.411765 0.010948 
 GO:0009991~response to extracellular stimulus 5 7.352941 0.011203 
 GO:0048522~positive regulation of cellular process 15 22.05882 0.011402 
 GO:0051480~cytosolic calcium ion homeostasis 4 5.882353 0.011442 
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GO:0042127~regulation of cell proliferation 9 13.23529 0.011908 
 GO:0051604~protein maturation 4 5.882353 0.012517 
 GO:0042981~regulation of apoptosis 9 13.23529 0.013422 
 GO:0043067~regulation of programmed cell death 9 13.23529 0.014182 
 GO:0010941~regulation of cell death 9 13.23529 0.014475 
 GO:0048513~organ development 14 20.58824 0.016602 
 GO:0030155~regulation of cell adhesion 4 5.882353 0.01705 
 GO:0031347~regulation of defense response 4 5.882353 0.019088 
 GO:0050708~regulation of protein secretion 3 4.411765 0.022171 
 GO:0080134~regulation of response to stress 5 7.352941 0.023179 
 GO:0006915~apoptosis 7 10.29412 0.03133 
 GO:0050727~regulation of inflammatory response 3 4.411765 0.036538 
 GO:0006959~humoral immune response 3 4.411765 0.039204 
 GO:0048468~cell development 7 10.29412 0.041457 
 GO:0051046~regulation of secretion 4 5.882353 0.046027 
 GO:0014823~response to activity 2 2.941176 0.046598 
 GO:0048821~erythrocyte development 2 2.941176 0.046598 
 GO:0006259~DNA metabolic process 6 8.823529 0.049662 
 GO:0050793~regulation of developmental process 7 10.29412 0.049843 
      
CC GO:0005576~extracellular region 19 27.94118 1.88E-04 
 GO:0044421~extracellular region part 11 16.17647 0.002261 
 GO:0005615~extracellular space 8 11.76471 0.011893 
      
MF GO:0001664~G-protein-coupled receptor binding 4 5.882353 0.008416 
 GO:0005515~protein binding 41 60.29412 0.008732 
 GO:0005539~glycosaminoglycan binding 4 5.882353 0.015733 
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GO:0004866~endopeptidase inhibitor activity 4 5.882353 0.017264 
 GO:0030414~peptidase inhibitor activity 4 5.882353 0.019883 
 GO:0030247~polysaccharide binding 4 5.882353 0.020225 
 GO:0001871~pattern binding 4 5.882353 0.020225 
 GO:0003796~lysozyme activity 2 2.941176 0.037021 
 
GO:0004553~hydrolase activity, hydrolyzing O-glycosyl 
compounds 3 4.411765 0.048811 
      
Downregulated Genes    
BP GO:0051726~regulation of cell cycle 4 17.3913 0.006806 
      
CC GO:0043231~intracellular membrane-bounded organelle 16 69.56522 0.021424 
 GO:0043227~membrane-bounded organelle 16 69.56522 0.021626 
      
MF GO:0031406~carboxylic acid binding 3 13.04348 0.015252 
 GO:0000062~acyl-CoA binding 2 8.695652 0.020934 
  GO:0005504~fatty acid binding 2 8.695652 0.04904 
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Table A.6 Overrepresented gene ontology terms identified among differentially expressed genes (P<0.01 and fold change>2) 
of the DEV/OG1 comparison.  BP: biological process; CC: cellular component; MF: molecular function  
 
    Term Count % P 
Upregulated Genes     
BP GO:0009408~response to heat 3 12 0.003093 
 GO:0010035~response to inorganic substance 4 16 0.00331 
 GO:0009266~response to temperature stimulus 3 12 0.006671 
 GO:0048523~negative regulation of cellular process 8 32 0.008024 
 GO:0042221~response to chemical stimulus 7 28 0.009092 
 GO:0048519~negative regulation of biological process 8 32 0.012852 
 GO:0040008~regulation of growth 4 16 0.013459 
 GO:0009628~response to abiotic stimulus 4 16 0.016496 
 GO:0050896~response to stimulus 11 44 0.019487 
 GO:0000226~microtubule cytoskeleton organization 3 12 0.01987 
 GO:0007010~cytoskeleton organization 4 16 0.025747 
 GO:0065007~biological regulation 17 68 0.025906 
 GO:0001558~regulation of cell growth 3 12 0.033248 
 GO:0006461~protein complex assembly 4 16 0.037502 
 GO:0070271~protein complex biogenesis 4 16 0.037502 
 GO:0050789~regulation of biological process 16 64 0.041775 
 GO:0006996~organelle organization 6 24 0.042058 
      
CC GO:0005819~spindle 3 12 0.017358 
 GO:0015630~microtubule cytoskeleton 4 16 0.038667 
 GO:0044421~extracellular region part 5 20 0.040395 
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MF GO:0015631~tubulin binding 3 12 0.00998 
 GO:0005520~insulin-like growth factor binding 2 8 0.037316 
 GO:0008092~cytoskeletal protein binding 4 16 0.039597 
 GO:0005515~protein binding 18 72 0.040335 
      
Downregulated Genes    
BP GO:0042221~response to chemical stimulus 24 26.37363 7.83E-08 
 GO:0009611~response to wounding 16 17.58242 8.04E-08 
 GO:0006954~inflammatory response 13 14.28571 1.11E-07 
 GO:0050896~response to stimulus 40 43.95604 2.30E-07 
 GO:0040011~locomotion 14 15.38462 3.22E-07 
 GO:0002376~immune system process 20 21.97802 5.97E-07 
 GO:0009605~response to external stimulus 19 20.87912 7.77E-07 
 GO:0060326~cell chemotaxis 6 6.593407 1.73E-06 
 GO:0006935~chemotaxis 9 9.89011 1.83E-06 
 GO:0042330~taxis 9 9.89011 1.83E-06 
 GO:0006952~defense response 15 16.48352 3.10E-06 
 GO:0051674~localization of cell 11 12.08791 4.29E-06 
 GO:0048870~cell motility 11 12.08791 4.29E-06 
 GO:0007610~behavior 13 14.28571 5.31E-06 
 GO:0006950~response to stress 24 26.37363 9.65E-06 
 GO:0007626~locomotory behavior 10 10.98901 1.26E-05 
 GO:0016477~cell migration 10 10.98901 1.33E-05 
 GO:0042592~homeostatic process 15 16.48352 2.99E-05 
 GO:0009607~response to biotic stimulus 11 12.08791 3.01E-05 
 GO:0030595~leukocyte chemotaxis 5 5.494505 4.03E-05 
 GO:0001817~regulation of cytokine production 8 8.791209 4.43E-05 
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GO:0030593~neutrophil chemotaxis 4 4.395604 1.07E-04 
 GO:0055080~cation homeostasis 9 9.89011 1.22E-04 
 GO:0006873~cellular ion homeostasis 10 10.98901 1.41E-04 
 GO:0019725~cellular homeostasis 11 12.08791 1.51E-04 
 GO:0055082~cellular chemical homeostasis 10 10.98901 1.59E-04 
 GO:0006928~cell motion 11 12.08791 1.76E-04 
 GO:0050900~leukocyte migration 5 5.494505 2.23E-04 
 GO:0006955~immune response 13 14.28571 2.28E-04 
 GO:0055066~di-, tri-valent inorganic cation homeostasis 8 8.791209 2.51E-04 
 GO:0050801~ion homeostasis 10 10.98901 2.75E-04 
 GO:0030003~cellular cation homeostasis 8 8.791209 3.62E-04 
 GO:0009617~response to bacterium 7 7.692308 5.18E-04 
 GO:0048247~lymphocyte chemotaxis 3 3.296703 5.60E-04 
 GO:0006916~anti-apoptosis 7 7.692308 7.29E-04 
 GO:0032675~regulation of interleukin-6 production 4 4.395604 8.72E-04 
 GO:0042493~response to drug 7 7.692308 9.33E-04 
 GO:0048246~macrophage chemotaxis 3 3.296703 9.53E-04 
 GO:0051239~regulation of multicellular organismal process 14 15.38462 0.001062 
 GO:0051716~cellular response to stimulus 13 14.28571 0.00107 
 GO:0006953~acute-phase response 4 4.395604 0.001189 
 GO:0030005~cellular di-, tri-valent inorganic cation homeostasis 7 7.692308 0.001206 
 GO:0010033~response to organic substance 12 13.18681 0.001261 
 GO:0001819~positive regulation of cytokine production 5 5.494505 0.001265 
 GO:0048878~chemical homeostasis 10 10.98901 0.001375 
 GO:0008284~positive regulation of cell proliferation 9 9.89011 0.00142 
 GO:0002526~acute inflammatory response 5 5.494505 0.001733 
 GO:0001944~vasculature development 7 7.692308 0.00201 
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GO:0045408~regulation of interleukin-6 biosynthetic process 3 3.296703 0.002369 
 GO:0051789~response to protein stimulus 5 5.494505 0.00239 
 GO:0043066~negative regulation of apoptosis 8 8.791209 0.002504 
 GO:0043069~negative regulation of programmed cell death 8 8.791209 0.002708 
 GO:0006874~cellular calcium ion homeostasis 6 6.593407 0.002712 
 GO:0060548~negative regulation of cell death 8 8.791209 0.00275 
 GO:0055074~calcium ion homeostasis 6 6.593407 0.003046 
 GO:0080134~regulation of response to stress 7 7.692308 0.003111 
 GO:0065008~regulation of biological quality 17 18.68132 0.003418 
 GO:0006875~cellular metal ion homeostasis 6 6.593407 0.00364 
 GO:0051179~localization 27 29.67033 0.003937 
 GO:0051707~response to other organism 7 7.692308 0.004108 
 GO:0055065~metal ion homeostasis 6 6.593407 0.004404 
 GO:0030155~regulation of cell adhesion 5 5.494505 0.005782 
 GO:0006986~response to unfolded protein 4 4.395604 0.006124 
 GO:0031347~regulation of defense response 5 5.494505 0.006716 
 GO:0050727~regulation of inflammatory response 4 4.395604 0.007393 
 GO:0048518~positive regulation of biological process 20 21.97802 0.00743 
 GO:0048513~organ development 18 19.78022 0.007506 
 GO:0042127~regulation of cell proliferation 11 12.08791 0.007736 
 GO:0051704~multi-organism process 10 10.98901 0.008999 
 GO:0051240~positive regulation of multicellular organismal process 6 6.593407 0.009066 
 GO:0001568~blood vessel development 6 6.593407 0.009218 
 GO:0048583~regulation of response to stimulus 8 8.791209 0.010833 
 GO:0048519~negative regulation of biological process 18 19.78022 0.011237 
 GO:0001701~in utero embryonic development 5 5.494505 0.013659 
 GO:0048585~negative regulation of response to stimulus 4 4.395604 0.015555 
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GO:0042060~wound healing 5 5.494505 0.01792 
 GO:0007204~elevation of cytosolic calcium ion concentration 4 4.395604 0.020007 
 GO:0042742~defense response to bacterium 4 4.395604 0.020973 
 GO:0010564~regulation of cell cycle process 4 4.395604 0.021965 
 GO:0048523~negative regulation of cellular process 16 17.58242 0.023803 
 GO:0051480~cytosolic calcium ion homeostasis 4 4.395604 0.024024 
 GO:0048514~blood vessel morphogenesis 5 5.494505 0.024772 
 GO:0048522~positive regulation of cellular process 17 18.68132 0.027909 
 
GO:0007169~transmembrane receptor protein tyrosine kinase signaling 
pathway 5 5.494505 0.029972 
 GO:0045410~positive regulation of interleukin-6 biosynthetic process 2 2.197802 0.03105 
 GO:0007167~enzyme linked receptor protein signaling pathway 6 6.593407 0.033556 
 GO:0050671~positive regulation of lymphocyte proliferation 3 3.296703 0.033671 
 GO:0032946~positive regulation of mononuclear cell proliferation 3 3.296703 0.034801 
 GO:0007088~regulation of mitosis 3 3.296703 0.034801 
 GO:0070665~positive regulation of leukocyte proliferation 3 3.296703 0.034801 
 GO:0051783~regulation of nuclear division 3 3.296703 0.034801 
 GO:0002684~positive regulation of immune system process 5 5.494505 0.036246 
 GO:0045785~positive regulation of cell adhesion 3 3.296703 0.039469 
 GO:0022414~reproductive process 9 9.89011 0.045467 
 GO:0007346~regulation of mitotic cell cycle 4 4.395604 0.045581 
 GO:0048745~smooth muscle tissue development 2 2.197802 0.046216 
 GO:0000003~reproduction 9 9.89011 0.046941 
 GO:0051222~positive regulation of protein transport 3 3.296703 0.048168 
      
CC GO:0044421~extracellular region part 14 15.38462 0.001339 
 GO:0005615~extracellular space 11 12.08791 0.002927 
 GO:0005576~extracellular region 21 23.07692 0.002965 
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GO:0034358~plasma lipoprotein particle 3 3.296703 0.014314 
 GO:0032994~protein-lipid complex 3 3.296703 0.014314 
      
MF GO:0004866~endopeptidase inhibitor activity 6 6.593407 6.69E-04 
 GO:0030414~peptidase inhibitor activity 6 6.593407 8.52E-04 
 GO:0004867~serine-type endopeptidase inhibitor activity 5 5.494505 0.001008 
 GO:0005515~protein binding 51 56.04396 0.007611 
 GO:0004857~enzyme inhibitor activity 6 6.593407 0.009736 
 GO:0005102~receptor binding 11 12.08791 0.009742 
 GO:0001664~G-protein-coupled receptor binding 4 4.395604 0.016446 
 GO:0005539~glycosaminoglycan binding 4 4.395604 0.030077 
 GO:0001871~pattern binding 4 4.395604 0.03826 
 GO:0030247~polysaccharide binding 4 4.395604 0.03826 
  GO:0003796~lysozyme activity 2 2.197802 0.047188 
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Table A.7 List of all differentially expressed genes (P<0.01 and fold change>2) for the 
HI/CON comparison. Fold change indicates expression level larger than 2 is up-
regulation and expression level less than 0.5 is down-regulation.  
 
Gene Name 
Public 
Accession Human Protein P Value Fold Change 
MYBPC2 XM_001494408 NP_004524.3 0.0017275 0.0699979 
NULL NULL NULL 0.0003498 0.1054814 
SLC24A2 XM_001495010 NP_065077.1 0.004872 0.1442599 
NULL NULL NULL 0.0013554 0.1473677 
TIMM9 XM_001497047 NP_036592.1 0.0016536 0.1505449 
NULL NULL NULL 0.0011128 0.1511689 
NULL NULL NULL 0.0054514 0.1542023 
SDF2L1 XM_001493091 NP_071327.2 0.0056883 0.1580587 
RER1 NULL NP_008964.3 0.0064773 0.1701455 
RNF32 XM_001504692 NP_112198.1 0.0095354 0.1785734 
NULL CX603169 NULL 0.0078371 0.1887082 
FANCF NULL NP_073562.1 0.0079414 0.1900315 
C17orf64 XM_001501083 NP_859058.1 0.0025644 0.1916201 
PSMD1 XM_001498019 NP_002798.2 0.0026899 0.1937769 
C16orf77 XM_001500794 NP_689669.1 0.0026411 0.2000197 
C16orf46 XM_001501937 NP_689550.2 0.0081165 0.2059071 
NULL CX593149 NULL 0.0093932 0.207234 
PACSIN3 XM_001490695 NP_057307.2 0.0016852 0.2102296 
CYP2S1 XM_001498467 NP_085125.1 0.0036436 0.2138021 
NULL NULL NULL 0.0045124 0.2146746 
NULL NULL NULL 0.0018411 0.2161441 
ATXN7L1 XM_001491802 NP_065776.1 0.0071196 0.2180239 
PIGS XM_001504143 NP_149975.1 0.0054443 0.2185866 
EGLN2 XM_001499481 NP_444274.1 0.0094036 0.2222128 
MRPL18 XM_001500639 NP_054880.2 0.005535 0.2298689 
PDE4B XM_001500306 NP_001032417.1 0.0066108 0.2408653 
PRKRA XM_001497357 NP_003681.1 0.0039884 0.2409602 
WDR34 XM_001499860 NP_443076.2 0.0074615 0.2486677 
NULL NULL NULL 0.0017686 0.2571222 
NULL NULL NULL 0.0005789 0.2643645 
REEP3 XM_001502396 NP_001001330.1 0.0031271 0.2655691 
EID1 DN506034 NP_055150.1 0.0014789 0.2659805 
NULL XR_036460 NULL 0.0099968 0.266661 
LASP1 XM_001498270 NP_006139.1 0.0071777 0.26801 
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NULL NULL NULL 0.0044389 0.2787338 
NULL NULL NULL 0.0013782 0.2822127 
NULL CX595121 NULL 0.0063358 0.2849044 
NULL NULL NULL 0.0040474 0.2903837 
WDR16 XM_001504842 NP_659491.4 0.0042109 0.2920273 
CIB1 XM_001502860 NP_006375.2 0.0039233 0.2922247 
CXCL14 XM_001502713 NP_004878.2 0.0049898 0.2933628 
NULL NULL NULL 0.0015356 0.2975359 
TCF12 XM_001500594 NP_996919.1 0.0054357 0.2999355 
MGMT XM_001488425 NP_002403.1 0.0022102 0.3012046 
CKMT2 NULL NP_001093206.1 0.0087914 0.3032878 
NULL CX603184 NULL 0.0065575 0.3035236 
C16orf5 XM_001502354 NP_037531.2 0.002641 0.3041797 
NULL NULL NULL 0.0007023 0.3046916 
DDB2 XM_001490725 NP_000098.1 0.0014547 0.308985 
DENND4A XM_001497645 NP_005839.2 0.0061562 0.3125341 
DAPP1 DN504745 NP_055210.2 0.0011481 0.318897 
KLHL13 XM_001488075 NP_277030.2 0.0056754 0.3198587 
SH3BP1 XM_001499540 NP_061830.3 0.0056837 0.3205051 
CAST XM_001503694 NP_001035907.1 0.0033652 0.3205195 
DLX3 XM_001499545 NP_005211.1 0.0057972 0.3214089 
RAD23B XM_001492372 NP_002865.1 0.0011974 0.3216039 
GFRA2 XM_001489919 NP_001486.4 0.0026619 0.3234562 
SH3BGRL XM_001490406 NP_003013.1 0.0062632 0.3265332 
SCHIP1 CX601415 NP_055390.1 0.0062951 0.3288063 
NULL NULL NULL 0.0065943 0.3306403 
39701 XM_001492722 NP_653311.1 0.0068402 0.3344442 
ATP13A4 XM_001498805 NP_115655.2 0.0079657 0.3356457 
AVPI1 XM_001501347 NP_068378.1 0.009536 0.3357656 
NULL NULL NULL 0.0081486 0.3363076 
NULL NULL NULL 0.0058221 0.3368466 
C10orf141 XM_001503213 NP_001034851.1 0.0086793 0.3395423 
FAH XM_001487834 NP_000128.1 0.0023979 0.3403649 
NULL NULL NULL 0.0076579 0.3405396 
NULL NULL NULL 0.0063836 0.347444 
NXN XM_001502168 NP_071908.2 0.0085644 0.3478976 
CD1C XM_001490135 NP_001756.2 0.0016166 0.3487102 
HEPH XM_001504864 NP_620074.1 0.0098591 0.3490278 
NULL XM_001492880 NULL 0.0044021 0.3505891 
NULL NULL NULL 0.0022677 0.3528399 
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NULL NULL NULL 0.0085905 0.3577692 
COL4A3BP XM_001504676 NP_005704.1 0.0045915 0.3623331 
NDRG2 XM_001505150 NP_963833.1 0.0059321 0.3638133 
NULL NULL NULL 0.0014601 0.3651931 
TFPI XM_001498692 NP_006278.1 0.0091937 0.3657985 
ANAPC11 DN504808 NP_001002249.1 0.0092178 0.3672803 
ADAMDEC1 XM_001491607 NP_055294.1 0.0086452 0.3685127 
ANKRD34B XM_001504644 NP_001004441.1 0.0029363 0.369124 
NULL NULL NULL 0.0035139 0.379051 
SETDB2 XM_001489997 NP_114121.1 0.0032434 0.3810122 
NULL NULL NULL 0.0017887 0.3849447 
NULL NULL NULL 0.0035138 0.3854789 
NULL NULL NULL 0.0064604 0.3866686 
ABHD12 XM_001490613 NP_001035937.1 0.0093963 0.3904888 
COL11A1 CX601563 NP_542196.2 0.0073889 0.3923163 
NULL CX600577 NULL 0.0090658 0.394568 
PROM2 NULL NP_653308.1 0.0023866 0.3973588 
MBIP XM_001491919 NP_057670.1 0.0058828 0.3993639 
NULL CX603925 NULL 0.0043601 0.4018999 
FXYD5 XM_001491379 NP_054883.3 0.0098531 0.4019916 
CPA6 XM_001494527 NP_065094.2 0.0066739 0.4020393 
LPCAT2 XM_001490683 NP_060309.2 0.0073665 0.4074338 
CFP XM_001492656 NP_002612.1 0.0076536 0.4130272 
NULL XM_001504970 NULL 0.0061778 0.4167525 
GRB7 XM_001501037 NP_001025173.1 0.0027385 0.4175093 
NR2E1 XM_001502023 NP_003260.1 0.0091141 0.4221142 
HES2 XM_001496558 NP_061962.2 0.0097561 0.4225404 
LPIN1 XM_001502170 NP_663731.1 0.0082695 0.4303699 
ALS2CR8 XM_001497530 NP_001098056.1 0.0045846 0.4304722 
CRLS1 XM_001496092 NP_061968.1 0.003587 0.432384 
RPE XM_001488217 NP_954699.1 0.0096834 0.4347594 
RPL17 XM_001493896 NP_000976.1 0.0080591 0.4399097 
MIER2 XM_001497040 NP_060020.1 0.0080167 0.4414595 
SEC11C NULL NP_150596.1 0.0070691 0.4417672 
GLUL NULL NP_001028228.1 0.0053041 0.4426383 
C13orf30 XM_001492527 NP_872314.1 0.0079363 0.4460854 
KLHL20 XM_001493014 NP_055273.2 0.005155 0.4567624 
EIF3F CD468288 NP_003745.1 0.0057162 0.4573036 
ASB17 XM_001497338 NP_543144.1 0.0098928 0.4708352 
NULL NULL NULL 0.0084293 0.4715522 
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S100A1 XM_001494870 NP_006262.1 0.0082842 0.4727981 
RCBTB2 XM_001489540 NP_001259.1 0.0058783 0.4741265 
SC65 CX601224 NP_006446.1 0.0096569 0.4756731 
PLCE1 XM_001502375 NP_057425.3 0.0059059 0.4761308 
FABP2 AY536518 NP_000125.1 0.006261 0.476338 
POU2AF1 XM_001501588 NP_006226.1 0.009337 0.477636 
SELENBP1 NULL NP_003935.2 0.0065238 0.4835818 
LILRA5 AB120409 NP_067073.1 0.0065398 0.4844157 
39517 XM_001495682 NP_001094345.1 0.008643 0.4858746 
NULL BM781161 NULL 0.0073275 0.4878836 
LOC92345 XM_001498445 NP_612395.1 0.007841 0.4957594 
NULL DN508773 NULL 0.0085115 0.4965929 
NULL CX604543 NULL 0.0072708 2.0317136 
GALM XM_001500603 NP_620156.1 0.0071312 2.0410974 
ZNF283 XM_001500016 NP_862828.1 0.0081688 2.0537128 
RPS3A XM_001490864 NP_000997.1 0.0093609 2.0562014 
NULL NULL NULL 0.0067949 2.0970089 
NULL NULL NULL 0.0088036 2.1053077 
RLBP1L1 XM_001496222 NP_775790.1 0.0068557 2.1151309 
SYF2 XM_001501117 NP_056299.1 0.0069305 2.1293155 
NULL NULL NULL 0.0054865 2.1419173 
RGS18 XR_035866 NP_570138.1 0.0082082 2.1520262 
NULL NULL NULL 0.0058114 2.1797717 
H3F3A XM_001489242 NP_002098.1 0.0046879 2.1893185 
SFXN3 XM_001500003 NP_112233.2 0.0096333 2.2047023 
CYCS XM_001498822 NP_061820.1 0.0063539 2.209556 
NULL NULL NULL 0.0058887 2.2145204 
RNF135 XM_001501660 NP_115698.3 0.0079646 2.2329259 
CACYBP XM_001493405 NP_055227.1 0.0043275 2.2517425 
OR1L6 XM_001500963 NP_001004453.1 0.0065601 2.2640971 
SULT1C4 XM_001504131 NP_006579.2 0.0071682 2.3009472 
SIGLEC10 XM_001496570 NP_149121.2 0.0039808 2.3181673 
NULL NULL NULL 0.006242 2.3424452 
AOF1 XM_001496578 NP_694587.3 0.007793 2.3720352 
NPHP4 XM_001497162 NP_055917.1 0.0062397 2.4110565 
TRPM3 XM_001488577 NP_001007472.2 0.0033413 2.41156 
NULL NULL NULL 0.0026967 2.4204938 
GAPDH XM_001488655 NP_002037.2 0.0094886 2.4477494 
SF3B14 XM_001499114 NP_057131.1 0.0029253 2.4581919 
NULL NULL NULL 0.0029608 2.4804581 
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NULL NULL NULL 0.0044353 2.5240682 
NULL BI961659 NULL 0.0053127 2.5607697 
NULL NULL NULL 0.0046999 2.5902993 
NULL NULL NULL 0.001759 2.6107841 
OR5AK2 XM_001496889 NP_001005323.1 0.0030854 2.6149144 
HSPA8 AF411802 NP_006588.1 0.0029975 2.6182568 
SFN XM_001504058 NP_006133.1 0.0035723 2.623244 
C21orf56 XM_001488132 NP_115637.3 0.0092659 2.662824 
SILV XM_001504795 NP_008859.1 0.0093626 2.7194637 
NULL NULL NULL 0.0014602 2.7591903 
STC1 XM_001493195 NP_003146.1 0.0029398 2.782161 
OR7G2 XM_001500467 NP_001005193.1 0.0022386 2.8307113 
NULL XM_001489334 NULL 0.0014855 2.8696375 
NULL NULL NULL 0.0093799 2.885379 
DNAJC8 XM_001503994 NP_055095.2 0.007485 2.890405 
GAPDH XR_036506 NP_002037.2 0.004779 2.9062039 
PGAM1 XM_001500395 NP_002620.1 0.0039137 2.9154883 
RAD17 XM_001504700 NP_579917.1 0.0073087 2.9186752 
NPAS1 XM_001500899 NP_002508.2 0.0084239 2.9451486 
BMF XM_001503570 NP_001003940.1 0.0084744 2.9649022 
OR5M3 XM_001496132 NP_001004742.1 0.0038709 2.9693139 
APOA1 XM_001502469 NP_000030.1 0.0070588 2.9704195 
HLA-DQA1 XM_001492558 NP_002113.2 0.0089639 2.9733437 
GPR97 XM_001494146 NP_740746.3 0.0037309 2.9777741 
NULL CX602448 NULL 0.006728 2.9791469 
NULL CX601472 NULL 0.0018201 2.9905411 
LRRC37B XM_001494937 NP_443120.2 0.0089115 3.0183093 
NULL NULL NULL 0.0032496 3.0774836 
ACPL2 XM_001494614 NP_001032249.1 0.0034547 3.1550837 
VSIG4 XM_001496244 NP_009199.1 0.0074554 3.1763793 
GAPDH XM_001502360 NP_002037.2 0.0096203 3.1938999 
NULL CD465724 NULL 0.0070584 3.3209467 
TTN NULL NP_596869.3 0.0086814 3.339381 
NULL DN504249 NULL 0.007513 3.3861793 
EPHA7 XM_001503790 NP_004431.1 0.0061345 3.3869069 
NULL CX603926 NULL 0.0065164 3.3872744 
ZBTB11 XR_036400 NP_055230.1 0.0059493 3.4305652 
SNRPB XM_001497470 NP_003082.1 0.0042357 3.4408721 
C1orf54 XM_001491679 NP_078855.1 0.0046856 3.449926 
KLHL3 XM_001504326 NP_059111.1 0.0034031 3.4500373 
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OR2L2 XM_001496326 NP_001004686.1 0.0053988 3.4634571 
RANGAP1 XM_001500278 NP_002874.1 0.0050138 3.4810165 
VN1R4 XM_001495521 NP_776256.2 0.0042569 3.4827935 
BNIP3 NULL NP_004043.2 0.0072418 3.4921979 
NULL NULL NULL 0.008618 3.5450256 
NULL NULL NULL 0.0038346 3.6094531 
SDC3 XM_001500186 XP_945760.2 0.0084942 3.6372938 
KRT15 XM_001491980 NP_002266.2 0.0016547 3.6386009 
CD33 XM_001496657 NP_001763.3 0.0033165 3.6905345 
HSPA8 NULL NP_006588.1 0.0066182 3.7094358 
NPM1 XM_001503118 NP_002511.1 0.005857 3.7129388 
POLM XM_001495659 NP_037416.1 0.007816 3.7419811 
SARDH XM_001498978 NP_009032.2 0.0054667 3.8531574 
NULL NULL NULL 0.0033287 3.9062824 
RNF138 XM_001496619 NP_057355.2 0.0020209 3.9528493 
ADAMTS1 AF541975 NP_008919.3 0.002452 4.024977 
NULL NULL NULL 0.0038395 4.1332205 
PHLDB1 XM_001500987 NP_055972.1 0.0025142 4.1600044 
PEO1 XM_001499940 NP_068602.2 0.0032827 4.2657155 
SPRR1B XM_001494012 NP_003116.2 0.0040974 4.357908 
RANBP6 XM_001493360 NP_036548.1 0.0049244 4.3649003 
NULL NULL NULL 0.00289 4.4563701 
HDC XM_001499648 NP_002103.2 0.0025542 4.4688984 
NRIP2 XM_001490793 NP_113662.1 0.0025741 4.5564965 
LRRTM3 XM_001503559 NP_821079.3 0.0045826 4.6536439 
TLE6 XM_001492284 NP_079036.1 0.0017777 4.7758165 
ZNF264 XM_001492087 NP_003408.1 0.0095766 4.7787081 
DNAJB1 NULL NP_006136.1 0.0093279 4.8424844 
SNW1 XM_001492123 NP_036377.1 0.0030075 4.8844098 
FOSL1 XM_001494797 NP_005429.1 0.0090406 4.9200385 
MAPK14 XM_001494719 NP_620581.1 0.0002011 4.95007 
ZNF75A XM_001499142 NP_694573.1 0.0019125 4.9926437 
TULP3 XM_001490880 NP_003315.2 0.0017377 5.0402268 
NULL NULL NULL 0.0032701 5.0787827 
NULL NULL NULL 0.0083796 5.1162394 
LMOD2 XM_001502348 NP_997046.1 0.0081939 5.1764298 
NULL NULL NULL 0.0079539 5.2579312 
S100A2 CX598422 NP_005969.1 0.0064023 5.3878673 
C17orf79 CX605748 NP_060875.1 0.0073615 5.4793567 
C16orf44 XM_001502352 NP_079007.2 0.0020625 5.5934822 
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HEMGN XM_001504109 NP_060907.2 0.0008385 5.9338524 
EIF1AX XM_001492752 NP_001403.1 0.0065925 6.5976465 
PTPRQ XM_001492869 XP_945428.2 5.77E-05 6.6616652 
MORN3 XM_001496205 NP_776254.2 0.0007549 6.8635457 
RILPL2 DN504908 NP_659495.1 0.0047256 7.061033 
SUGT1 XM_001492933 NP_006695.1 0.0042123 7.5801031 
CRTAC1 XM_001501238 NP_060528.3 0.0008 7.6519913 
NULL NULL NULL 7.77E-05 38.105349 
 
  
Table A.8 Overrepresented gene ontology terms identified among differentially expressed genes (P<0.01 and fold change>2) 
of the HI/CON comparison.  BP: biological process; CC: cellular component; MF: molecular function  
 
 
    Term Count % P 
Upregulated 
Genes     
BP GO:0002504~antigen processing and presentation of peptide or polysaccharide antigen via MHC class II 6 7.0588235 6.37E-07 
 GO:0019882~antigen processing and presentation 6 7.0588235 6.39E-05 
 GO:0006955~immune response 9 10.588235 0.023821 
 GO:0051726~regulation of cell cycle 6 7.0588235 0.0268143 
 GO:0008285~negative regulation of cell proliferation 6 7.0588235 0.0369433 
 GO:0050896~response to stimulus 26 30.588235 0.0380858 
 GO:0000377~RNA splicing, via transesterification reactions with bulged adenosine as nucleophile 4 4.7058824 0.0432814 
 GO:0000375~RNA splicing, via transesterification reactions 4 4.7058824 0.0432814 
 GO:0000398~nuclear mRNA splicing, via spliceosome 4 4.7058824 0.0432814 
 GO:0051085~chaperone mediated protein folding requiring cofactor 2 2.3529412 0.0498665 
      
CC GO:0042613~MHC class II protein complex 6 7.0588235 2.36E-07 
 GO:0042611~MHC protein complex 6 7.0588235 7.51E-06 
 GO:0005829~cytosol 13 15.294118 0.0232556 
 GO:0044428~nuclear part 15 17.647059 0.0483506 
      
MF GO:0032395~MHC class II receptor activity 6 7.0588235 3.98E-08 
 GO:0060089~molecular transducer activity 21 24.705882 0.0128493 
 GO:0004871~signal transducer activity 21 24.705882 0.0128493 
 GO:0004872~receptor activity 18 21.176471 0.0143354 
 GO:0004888~transmembrane receptor activity 14 16.470588 0.0187251 
      2
8
1
 
  
Downregulated Genes    
BP GO:0006508~proteolysis 12 13.483146 0.0172403 
 GO:0051716~cellular response to stimulus 10 11.235955 0.0230598 
 GO:0033554~cellular response to stress 8 8.988764 0.024984 
 GO:0043632~modification-dependent macromolecule catabolic process 8 8.988764 0.0267112 
 GO:0019941~modification-dependent protein catabolic process 8 8.988764 0.0267112 
 GO:0042176~regulation of protein catabolic process 3 3.3707865 0.0288718 
 GO:0051603~proteolysis involved in cellular protein catabolic process 8 8.988764 0.0328885 
 GO:0044257~cellular protein catabolic process 8 8.988764 0.0336583 
 GO:0051247~positive regulation of protein metabolic process 5 5.6179775 0.0354814 
 GO:0030163~protein catabolic process 8 8.988764 0.0388161 
 GO:0006974~response to DNA damage stimulus 6 6.741573 0.0415765 
      
CC GO:0044424~intracellular part 61 68.539326 0.0083676 
 GO:0005622~intracellular 61 68.539326 0.0242054 
 GO:0005829~cytosol 12 13.483146 0.0465824 
      
MF GO:0030674~protein binding, bridging 4 4.494382 0.009764 
 GO:0005070~SH3/SH2 adaptor activity 3 3.3707865 0.0221178 
 GO:0060090~molecular adaptor activity 3 3.3707865 0.0394082 
  GO:0030234~enzyme regulator activity 9 10.11236 0.04201 
 
 
 
 
 
 
2
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Table A.9 List of all differentially expressed genes (P<0.01 and fold change>2) for the 
12 h/CON comparison. Fold change indicates expression level larger than 2 is up-
regulation and expression level less than 0.5 is down-regulation.  
 
Gene Name 
Public 
Accession Human Protein P Value Fold Change 
NULL DN510842 NULL 0.0010388 0.2285384 
NULL NULL NULL 0.0067226 0.2302249 
NULL NULL NULL 0.007491 0.2430798 
CKM XM_001502522 NP_001815.2 0.0011477 0.2496086 
LOC284890 XM_001489526 XP_208261.5 0.0080739 0.2521315 
PTGFR DQ385610 NP_000950.1 0.0082772 0.2551626 
COMMD2 DN509689 NP_057178.2 0.0086175 0.2600997 
OR7A10 XM_001492035 NP_001005190.1 0.0028144 0.2636787 
NULL NULL NULL 0.0091277 0.2672035 
ZNF451 XM_001499700 NP_001026794.1 0.0093143 0.2697189 
DHRS2 XM_001489482 NP_005785.1 0.0016674 0.2697426 
LOC26010 XM_001502795 NP_001093893.1 0.0032249 0.2907372 
NULL NULL NULL 0.0059763 0.2977389 
NULL CX604266 NULL 0.0005164 0.2977975 
TAOK3 XM_001490545 NP_057365.3 0.0021094 0.2981413 
LGALS4 XM_001497350 NP_006140.1 0.0061987 0.3355403 
RPS6KB2 XM_001497573 NP_003943.2 0.0028872 0.3372703 
NULL NULL NULL 0.0082611 0.3478251 
MAGED2 XM_001496158 NP_803182.1 0.0036666 0.3606807 
BAX NULL NP_620119.1 0.0010662 0.3648417 
AP1S1 XM_001492538 NP_001274.1 0.004469 0.373292 
OR5M3 XM_001496132 NP_001004742.1 0.0070959 0.3799617 
NULL CD464177 NULL 0.0077033 0.3919731 
RGS1 CD471812 NP_002913.3 0.0085076 0.4033988 
39509 XM_001487921 NP_001005415.1 0.0087391 0.4061091 
EBI2 XM_001491948 NP_004942.1 0.0069198 0.4141028 
39701 XM_001492722 NP_653311.1 0.0053352 0.4143381 
NULL NULL NULL 0.0069208 0.4160444 
PPP1R16B XM_001502590 NP_056383.1 0.0069937 0.4193189 
ARPC5L XM_001502042 NP_112240.1 0.0010492 0.4216098 
SPHKAP XM_001494233 NP_085126.1 0.002936 0.4224087 
TTC25 XM_001496697 NP_113609.1 0.0083073 0.4581841 
BTBD11 NULL NP_001017523.1 0.0098254 0.4589088 
284 
 
 
MYO1E CD470665 NP_004989.2 0.0012028 0.469526 
ZNF75A XM_001499142 NP_694573.1 0.0074739 0.4821721 
NULL NULL NULL 0.0026163 0.4840725 
FAM83B XM_001503204 NP_001010872.1 0.0033558 0.4920167 
LY96 AY398685 NP_056179.1 0.0095719 0.4975637 
SLC25A36 XM_001494830 NP_001098117.1 0.0077008 2.00178 
IGLL1 XM_001492822 NP_064455.1 0.0064467 2.0102886 
SLC27A2 XM_001502007 NP_003636.1 0.0054066 2.1125642 
PHF21B XM_001488104 NP_612424.1 0.0027205 2.158315 
SMS XM_001493443 NP_004586.2 0.0073773 2.1605126 
SFRS17A XM_001499533 NP_005079.2 0.0095884 2.1943928 
CD19 CX592103 NP_001761.3 0.0090144 2.2204638 
ZBP1 XM_001489797 NP_110403.1 0.005605 2.2305589 
NULL NULL NULL 0.0029069 2.2419775 
UGT2B4 XM_001501836 NP_066962.2 0.0003995 2.2691945 
IARS XM_001491121 NP_002152.2 0.0090226 2.4354471 
MED7 DN510032 NP_001094286.1 0.0089484 2.4395096 
OGFR CX594651 NP_031372.2 0.0071332 2.4645238 
HDHD2 XM_001498811 NP_115500.1 0.0084142 2.4785925 
RC3H2 XM_001502327 NP_001094058.1 0.0043159 2.6217118 
ZNF30 XM_001493964 NP_919306.2 0.0042361 2.6287018 
EZH2 XM_001504629 NP_004447.2 0.0081039 2.6480484 
NULL NULL NULL 0.0058402 2.653315 
NULL CX593986 NULL 0.0073218 2.8820654 
CCDC67 XM_001491708 NP_857596.2 0.0030146 2.8918394 
CBARA1 XM_001503797 NP_006068.2 0.0024634 3.1009249 
PARP6 XM_001494491 NP_064599.2 0.004096 3.1867118 
CXCL2 AF053497 NP_002080.1 0.0023269 3.2086441 
NULL CX596707 NULL 0.0022732 3.316525 
NULL CX601068 NULL 0.0006656 3.3824369 
NULL XR_035808 NULL 0.0023138 3.4532776 
BAIAP3 XM_001497570 NP_003924.2 0.0041313 3.6134225 
MITD1 XM_001490447 NP_620153.1 0.0013292 3.7270823 
NULL NULL NULL 0.0021472 3.9077373 
PSIP1 DQ873682 NP_150091.2 0.0081126 3.9570482 
GLMN XM_001492771 NP_444504.1 0.0034141 4.3715151 
IFI30 XM_001500556 NP_006323.2 0.0058657 4.6637277 
NULL NULL NULL 0.0048743 5.1623082 
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Table A.10 List of all differentially expressed genes (P<0.01 and fold change>2) for the 
24 h/CON comparison. Fold change indicates expression level larger than 2 is up-
regulation and expression level less than 0.5 is down-regulation.  
 
 
Gene Name 
Public 
Accession Human Protein P Value Fold Change 
NDUFB3 XM_001503625 NP_002482.1 0.0008969 0.0955369 
NULL CX592434 NULL 0.0038225 0.1903698 
PSMA4 XM_001489071 NP_001096137.1 0.0062061 0.1979544 
NKX3-1 XM_001491242 NP_006158.2 0.0065995 0.2380197 
NULL NULL NULL 0.0017236 0.2401955 
SLC5A6 XM_001502487 NP_066918.1 0.0020126 0.254905 
LOC650780 CD466835 XP_944952.1 0.0080678 0.2568331 
NEB NULL NP_004534.2 0.0017782 0.2730702 
ANKRD26 CX601264 NP_055730.2 0.0015177 0.3134063 
NULL NULL NULL 0.0006725 0.3156989 
EIF2AK4 XM_001501267 NP_001013725.2 0.0042304 0.3168934 
TNNT1 NULL NP_003274.2 0.0047804 0.3203982 
NRBF2 XM_001502366 NP_110386.2 0.0040922 0.3216879 
NPHP4 XM_001497162 NP_055917.1 0.0008924 0.3311557 
ISCU NULL NP_998760.1 0.005719 0.3365259 
NULL CX601609 NULL 0.0069302 0.3551368 
GMPS XM_001488228 NP_003866.1 0.0070444 0.3603534 
C9orf32 CD464166 NP_054783.2 0.0062808 0.3615934 
CADPS XM_001490163 NP_003707.2 0.0072232 0.3617686 
NULL NULL NULL 0.0062248 0.3669122 
NULL NULL NULL 0.005749 0.3713646 
NULL NULL NULL 0.0040174 0.3810504 
SAC3D1 NULL NP_037431.3 0.0091259 0.3927282 
PLA2G12A XM_001502916 NP_110448.2 0.0049632 0.4025784 
NSUN3 XM_001502968 NP_071355.1 0.0091709 0.4054896 
NULL NULL NULL 0.0081703 0.4073516 
C14orf140 XM_001491724 NP_078919.2 0.0099415 0.4102526 
NULL NULL NULL 0.0087261 0.4302952 
NULL DN509452 NULL 0.0058838 0.4332689 
STX8 XM_001503237 NP_004844.1 0.0042372 0.4365832 
FAM71F1 XM_001501602 NP_115988.1 0.0053475 0.4379389 
SLC25A15 XM_001499022 NP_055067.1 0.0054855 0.4407576 
HFE XM_001505039 NP_000401.1 0.0096566 0.4470755 
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LOC90113 XM_001497176 XP_291077.4 0.0033299 0.456717 
NULL NULL NULL 0.0091437 0.4589917 
LTBP1 XM_001500182 NP_996826.1 0.0038256 0.4673029 
MBNL3 XM_001488749 NP_060858.2 0.0012634 0.4701863 
NULL NULL NULL 0.008789 0.4712081 
HOXB6 XM_001502088 NP_061825.2 0.0083336 0.4737989 
RG9MTD2 XM_001498449 NP_689505.1 0.0085612 0.4802059 
FABP9 XM_001489404 NP_001073995.1 0.0015799 0.4866081 
CFP XM_001492656 NP_002612.1 0.004921 0.4869356 
FAM22G XM_001492443 NP_001038942.1 0.0066396 0.4896364 
ANKRD6 XM_001500748 NP_055757.2 0.0046097 0.4958728 
C20orf19 XM_001492895 NP_060944.3 0.0057122 0.4961214 
NULL NULL NULL 0.0039953 0.4962043 
R3HCC1 XM_001491126 XP_114618.5 0.006939 2.0134575 
NULL NULL NULL 0.0032318 2.0135209 
C17orf85 XM_001504729 NP_061023.1 0.006464 2.0137738 
LOC124512 XM_001491460 NP_001073979.2 0.0086618 2.0508085 
DUSP1 XM_001499555 NP_004408.1 0.0016309 2.0559998 
NULL NULL NULL 0.0061312 2.0680121 
OR5M9 XM_001489238 NP_001004743.1 0.008824 2.0812068 
POLR2B XR_035933 NP_000929.1 0.0030154 2.1001999 
CRISPLD2 XM_001499908 NP_113664.1 0.0092155 2.1038223 
NULL NULL NULL 0.0074283 2.1076708 
LOC283999 XM_001491026 XP_211287.4 0.0040496 2.1131741 
NULL NULL NULL 0.0012577 2.1298418 
SERPINB11 XM_001491598 NP_536723.2 0.004239 2.1331906 
OR51G2 XM_001498239 NP_001005238.1 0.0047411 2.1755089 
CHSY1 XM_001490809 NP_055733.2 0.0056188 2.1952397 
ADAMTS1 AF541975 NP_008919.3 0.003679 2.2139889 
NULL NULL NULL 0.0095705 2.2491883 
GLRA2 XM_001489464 NP_002054.1 0.0024703 2.2839264 
C1orf159 XM_001496587 NP_060361.2 0.0069137 2.2970038 
LOC285588 XM_001499636 XP_209668.3 0.0013293 2.3281263 
NULL CX604081 NULL 0.0094071 2.3713775 
SAA1 XM_001504959 NP_000322.2 0.0012686 2.3855719 
TSSK4 XM_001489964 NP_777604.2 0.0007108 2.393651 
NULL NULL NULL 0.0080698 2.3944199 
TMEM49 XM_001503742 NP_112200.2 0.0048984 2.4131855 
SAA1 BM780679 NP_000322.2 0.0019341 2.4186575 
SAA1 XM_001504960 NP_000322.2 0.0025128 2.4286297 
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CD300LF XM_001497307 NP_620587.2 0.0094142 2.4372623 
CAPS XM_001495900 NP_004049.1 0.0092483 2.4578076 
QSOX1 XM_001488615 NP_002817.2 0.0024708 2.4984072 
NULL CX592382 NULL 0.0004705 2.4999978 
ZFHX3 XM_001500141 NP_008816.3 0.0014035 2.5056612 
SH3GL3 NULL NP_003018.2 0.0088225 2.5246567 
SEC11C XM_001489285 NP_150596.1 0.0037914 2.5356077 
PTMA XM_001501542 NP_002814.3 0.0010587 2.543564 
BMF XM_001503570 NP_001003940.1 0.0081287 2.5437235 
NULL BM414570 NULL 0.0080186 2.5584218 
NULL NULL NULL 0.006327 2.6014969 
SLC2A9 NULL NP_001001290.1 0.0032032 2.60651 
NULL CD466589 NULL 0.0071998 2.6128365 
BIRC3 XM_001499875 NP_001156.1 0.0034269 2.6294381 
SF3B14 XM_001503183 NP_057131.1 0.0056972 2.6374823 
CEBPB CX605423 NP_005185.2 0.0042483 2.6632929 
NULL CX604543 NULL 0.0016985 2.6685059 
NULL NULL NULL 0.0035459 2.6711891 
NULL DN509256 NULL 0.0038003 2.6730442 
NULL NULL NULL 0.0068815 2.6737607 
C8orf53 XM_001496257 NP_115710.1 0.0065647 2.7108601 
FAIM XM_001495529 NP_001028203.1 0.0059779 2.7327459 
ZNF182 XM_001501391 NP_001007089.1 0.0031242 2.751908 
NULL NULL NULL 0.0076667 2.7568769 
TIMM23 XM_001500113 NP_006318.1 0.0063184 2.7615193 
GLUL NULL NP_001028228.1 0.0044547 2.7686658 
TTC14 XM_001495771 NP_597719.1 0.0052194 2.7950877 
NSMCE1 XM_001497008 NP_659547.2 0.0090951 2.8033414 
RPL26 XR_036170 NP_000978.1 0.0018374 2.8379658 
CYCS XM_001500631 NP_061820.1 0.0073342 2.8626494 
NULL NULL NULL 0.0045502 2.895858 
TSC22D2 XM_001490871 NP_055594.1 0.0063014 2.9273247 
POU5F1 XM_001490108 NP_002692.2 0.0088791 2.9318778 
NULL CX605490 NULL 0.0073967 2.9436673 
MYO1E CD470665 NP_004989.2 0.0086722 2.9699868 
PI15 XM_001491205 NP_056970.1 0.0018505 3.0655083 
TPH1 XM_001504954 NP_004170.1 0.002155 3.1246394 
NULL NULL NULL 0.0034389 3.1249823 
CTRC XM_001489099 NP_009203.2 0.006641 3.1568459 
FAM132A XM_001496492 NP_001014980.1 0.0051963 3.1839855 
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NULL NULL NULL 0.0032521 3.1943672 
NULL BI961214 NULL 0.0008256 3.2503006 
CD163 XM_001492693 NP_004235.3 0.0014443 3.2662141 
MRPS23 XM_001500440 NP_057154.2 0.0029156 3.2826537 
NULL NULL NULL 0.002071 3.2952712 
DYNC1I2 XM_001498670 NP_001369.1 0.0007614 3.3686275 
NULL NULL NULL 0.0084661 3.4226228 
NULL NULL NULL 0.0025578 3.4708038 
MED29 XM_001497555 NP_060062.1 0.0018667 3.5051673 
NULL NULL NULL 0.0003051 3.5255789 
NULL NULL NULL 0.0021702 3.5453521 
ZNF567 XM_001492950 NP_689816.2 0.0027419 3.5917722 
ARHGAP20 XM_001487839 NP_065860.2 0.0014472 3.7015039 
NULL NULL NULL 0.0007026 3.7349927 
CYBA XM_001488006 NP_000092.2 3.94E-05 3.7631849 
FKBP5 XM_001499198 NP_004108.1 0.0069106 3.8287248 
LOC728937 DN510217 NP_001087200.2 0.0084396 3.8293137 
PDK1 XM_001495093 NP_002601.1 0.0017783 3.8780423 
HIST2H2AA4 CX603409 NP_001035807.1 0.0027317 3.879084 
ATP6V1G3 XM_001494440 NP_573569.1 0.0080896 3.8896743 
PI3 BM734843 NP_002629.1 0.0002748 3.8978023 
KIAA1524 XM_001503233 NP_065941.1 0.0037366 3.9916696 
GLUL XM_001489235 NP_001028228.1 0.0005385 4.0227095 
HINT2 NULL NP_115982.1 0.0073188 4.0383714 
NULL BI961659 NULL 0.0001246 4.307964 
NULL CD535521 NULL 0.0011927 4.3849263 
IL12A Y11130 NP_000873.2 0.0032432 4.4546355 
S100A9 XM_001493530 NP_002956.1 0.0047402 4.4561501 
NULL XM_001498707 NULL 0.0001833 4.4721561 
FTH1 XM_001489262 NP_002023.2 0.0047984 4.7716089 
NULL CD467650 NULL 0.0001854 4.7858347 
SAA1 NM_001081853 NP_000322.2 0.0018345 6.7685543 
NULL NULL NULL 4.69E-06 6.8999429 
EREG XM_001490281 NP_001423.1 0.0001479 6.9077909 
DEFB4 AY170305 NP_004933.1 1.57E-05 10.571007 
SOD2 AB001693 NP_000627.2 1.07E-06 11.283848 
S100A8 XM_001494358 NP_002955.2 0.0001049 13.808318 
S100A8 XM_001493589 NP_002955.2 1.25E-05 24.756712 
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Table A.11 List of all differentially expressed genes (P<0.01 and fold change>2) for the 
12 h/24 h comparison. Fold change indicates expression level larger than 2 is up-
regulation and expression level less than 0.5 is down-regulation.  
 
Gene Name 
Public 
Accession Human Protein P Value Fold Change 
S100A12 CD535886 NP_005612.1 0.0002941 0.0312015 
S100A8 XM_001494358 NP_002955.2 4.22E-07 0.0416582 
S100A8 XM_001493589 NP_002955.2 5.81E-05 0.0576884 
NULL CD467650 NULL 1.99E-05 0.0583316 
SOD2 AB001693 NP_000627.2 4.74E-06 0.0694325 
S100A9 XM_001493530 NP_002956.1 0.0045247 0.1154095 
PI3 BM734843 NP_002629.1 0.0006503 0.121293 
DEFB4 AY170305 NP_004933.1 9.27E-05 0.1222276 
SAA1 NM_001081853 NP_000322.2 0.0003899 0.1614716 
NULL NULL NULL 0.0047673 0.1681315 
NULL NULL NULL 0.0047756 0.1682847 
NULL NULL NULL 0.0004048 0.1776457 
OR5M9 XM_001488291 NP_001004743.1 0.0009264 0.188936 
THBS1 XM_001503599 NP_003237.2 0.0007574 0.1940095 
NULL NULL NULL 1.87E-05 0.1945179 
SLA XM_001498789 NP_001039022.1 0.0065622 0.1976541 
ORMDL1 XM_001501956 NP_057551.1 0.0018282 0.2019237 
HSPA8 NULL NP_006588.1 0.0069204 0.2051958 
NULL NULL NULL 0.0003183 0.2065697 
MORC3 XM_001493319 NP_056173.1 0.007338 0.208536 
LYZL6 XM_001494897 NP_065159.1 0.0014104 0.2086065 
ARPC5 CX604507 NP_005708.1 0.0063349 0.2089287 
ANKRD10 XM_001496718 NP_060134.2 0.006467 0.2186919 
NULL XM_001498707 NULL 0.0052303 0.2228975 
LOC283999 XM_001491026 XP_211287.4 0.0086698 0.2252925 
NULL NULL NULL 0.0008158 0.2266554 
RLBP1L1 XM_001496222 NP_775790.1 0.0003398 0.2286446 
NULL BM735339 NULL 0.0022796 0.2324314 
NULL NULL NULL 0.0026077 0.235477 
CNPY2 NULL NP_055070.1 0.0008219 0.2357222 
RPUSD3 XM_001491328 NP_775930.1 0.00173 0.2366615 
NULL BI961659 NULL 0.0004196 0.2381768 
ADAMTS1 AF541975 NP_008919.3 0.0013168 0.2406131 
NULL CX605648 NULL 0.0006864 0.2411547 
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PRDM11 XM_001490144 NP_064614.2 0.0088167 0.2417397 
LOC730593 XM_001490568 XP_001126460.1 0.0081285 0.2430951 
NULL CX602359 NULL 0.0040223 0.2434114 
COL9A1 CX605273 NP_001842.3 0.0082564 0.2468013 
EREG XM_001490281 NP_001423.1 0.0041863 0.2533209 
PSENEN XM_001492730 NP_758844.1 0.0031487 0.2537129 
LINS1 XM_001490353 NP_001035706.1 0.0021945 0.2575248 
THOP1 XM_001493535 NP_003240.1 0.0037074 0.2584734 
GSTO2 XM_001499366 NP_899062.1 0.0040847 0.2584903 
H2AFY2 XM_001503710 NP_061119.1 0.0058558 0.2597315 
TAGLN XM_001502596 NP_001001522.1 0.0014263 0.2604284 
GCA XM_001494347 NP_036330.1 0.0050796 0.2632455 
HSPA5 CX604607 NP_005338.1 8.78E-05 0.2644439 
PI15 XM_001491205 NP_056970.1 0.000651 0.2699115 
FGFBP1 XM_001498741 NP_005121.1 0.0079345 0.2708487 
SERPINB3 XM_001491507 NP_008850.1 0.0042591 0.2710106 
HNRPAB XM_001499029 NP_004490.2 0.0021627 0.2770756 
ITPR2 XM_001502700 NP_002214.2 0.0026107 0.2823533 
OR8B3 XM_001501898 NP_001005467.1 0.0052964 0.2841699 
OGG1 XM_001494881 NP_002533.1 0.0031311 0.2844899 
CALU CX605787 NP_001210.1 0.0015659 0.2859299 
GLUL NULL NP_001028228.1 0.0007799 0.2868079 
RGS1 CD471812 NP_002913.3 0.0058246 0.2886835 
EIF3I XM_001503817 NP_003748.1 0.002652 0.2921869 
DDX47 XM_001501444 NP_057439.2 0.0052828 0.2928334 
NULL CX601417 NULL 0.006105 0.2932302 
NULL NULL NULL 0.0028286 0.2967394 
GADD45B XM_001493821 NP_056490.2 0.0082575 0.2968482 
MYH3 XM_001504848 NP_002461.2 0.0038229 0.2983001 
PTPN4 XM_001492520 NP_002821.1 0.0037175 0.2996852 
NCBP2 XM_001501008 NP_031388.2 0.0043083 0.3009056 
NULL NULL NULL 0.0043599 0.3020566 
SAA1 XM_001504960 NP_000322.2 0.0001831 0.3021274 
JAK2 XM_001492663 NP_004963.1 0.0058692 0.3024495 
USP36 XM_001491130 NP_079366.3 0.0030133 0.3047215 
PARP6 XM_001494491 NP_064599.2 0.00776 0.3050135 
NULL NULL NULL 0.0078661 0.3055134 
ADM XM_001500996 NP_001115.1 0.0014336 0.3091763 
NULL NULL NULL 0.0019154 0.3137025 
NULL XM_001503131 NULL 0.0050829 0.3147854 
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NULL NULL NULL 0.0030706 0.3152047 
NULL CD536247 NULL 0.0083626 0.315834 
LRRC4C XM_001488162 NP_065980.1 0.0067154 0.3159477 
USP20 NULL NP_001103773.1 0.0069376 0.3176783 
MRPL48 XM_001498632 NP_057139.1 0.0031766 0.3182676 
KRT222P XM_001500146 NP_689562.1 0.005494 0.3208563 
KIAA1949 XM_001491396 NP_597728.1 0.0049425 0.3209562 
PPP3CC XM_001490720 NP_005596.2 0.005101 0.3219688 
HPSE XM_001493282 NP_001092010.1 0.0051608 0.326519 
IGLL1 DQ125416 NP_064455.1 0.0085744 0.3285533 
HSP90B1 XM_001497922 NP_003290.1 0.0011107 0.3295273 
BCL3 XM_001500256 NP_005169.1 0.0020051 0.3307912 
TCF25 XM_001488412 NP_055787.1 0.0066937 0.3322528 
SLC1A3 XM_001499617 NP_004163.2 0.0048886 0.3377181 
NULL NULL NULL 0.0050383 0.3394779 
PPP1R3B XM_001494371 NP_078883.2 0.006617 0.3410787 
PREP DN505238 NP_002717.3 0.0077696 0.3421426 
DHCR24 XM_001488247 NP_055577.1 0.0048868 0.3440417 
NULL NULL NULL 0.0083784 0.3456873 
RABL4 XM_001499264 NP_006851.1 0.0082317 0.3490061 
NULL NULL NULL 0.0062878 0.3494084 
EPN3 XM_001502825 NP_060427.2 0.0097246 0.3495553 
THAP4 XM_001497749 NP_057047.3 0.0047282 0.3499826 
HMGN4 XM_001505090 NP_006344.1 0.0077932 0.3518574 
PGK1 XM_001502668 NP_000282.1 0.0076215 0.3525187 
PDIA3 XM_001502988 NP_005304.3 0.0056393 0.3526035 
GPSM2 XM_001493568 NP_037428.2 0.0090316 0.3541887 
NULL CX598740 NULL 0.0003692 0.3554258 
CCL2 AJ251189 NP_002973.1 0.0022299 0.3596737 
NULL NULL NULL 0.009343 0.3630632 
MYO5B XM_001499160 XP_944193.1 0.0054423 0.3688 
NULL NULL NULL 0.000351 0.3703969 
NULL NULL NULL 0.0026589 0.3736836 
GLUL XM_001489235 NP_001028228.1 0.0040854 0.3747821 
ERO1L CX601828 NP_055399.1 0.0090849 0.3760276 
BIRC3 XM_001499875 NP_001156.1 0.0010892 0.3781491 
CRISPLD2 XM_001499908 NP_113664.1 0.0030128 0.3807604 
C11orf30 XM_001494053 NP_064578.2 0.003394 0.3838901 
TOP1 XM_001500194 NP_003277.1 0.0033418 0.3843697 
NULL NULL NULL 0.0029642 0.3853809 
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GNG8 XM_001503002 NP_150283.1 0.0022282 0.3941202 
AARS XM_001501012 NP_001596.2 0.0096603 0.3962516 
MID1IP1 CX604299 NP_001092261.1 0.0014773 0.3967994 
SAA1 XM_001504959 NP_000322.2 0.0018947 0.404232 
OR7G2 XM_001500467 NP_001005193.1 0.0085642 0.406257 
RNF144B XM_001494349 NP_877434.2 0.0015145 0.406621 
DCUN1D3 XM_001495107 NP_775746.1 0.0035036 0.4089635 
DDX58 XM_001497845 NP_055129.2 0.0093733 0.4110164 
MEF2A CD464185 NP_005578.1 0.0022392 0.4128078 
HSPA8 AF411802 NP_006588.1 0.0018211 0.4128337 
HDAC4 XM_001497151 NP_006028.2 0.0068071 0.4145777 
CCT6A XM_001499414 NP_001753.1 0.0013151 0.4242592 
PTMA XM_001501542 NP_002814.3 0.0015005 0.4259638 
GOLIM4 XM_001494089 NP_055313.1 0.0087559 0.4268391 
GFAP XM_001488816 NP_002046.1 0.0094357 0.4271732 
LOC338809 XM_001495196 NP_001032760.1 0.0006908 0.4284314 
TGIF2LX XM_001501915 NP_620410.3 0.00406 0.4311837 
ANKS4B XM_001494691 NP_665872.2 0.0086163 0.4324151 
YTHDF2 XM_001500333 NP_057342.2 0.0092936 0.4339689 
SP140 XM_001494747 NP_009168.3 0.0088735 0.4372654 
TLR4 AY005808 NP_612564.1 0.0066541 0.4388419 
MUC16 XM_001494817 NP_078966.2 0.0050593 0.4389319 
CCKBR XM_001504583 NP_795344.1 0.0060558 0.4451907 
ALMS1 XM_001491738 NP_055935.4 0.0064886 0.4452616 
CCDC94 XM_001496436 NP_060544.2 0.0076663 0.4454342 
C17orf56 XM_001489994 NP_653280.1 0.0046786 0.4496341 
NULL NULL NULL 0.001173 0.4566383 
CREBL1 XM_001493153 NP_004372.3 0.0076692 0.4657573 
RPS14 NULL NP_001020242.1 0.0098846 0.4664648 
GAPDH XR_036361 NP_002037.2 0.0032546 0.4668949 
TPM1 NULL NP_001018005.1 0.0013657 0.4679278 
LOC285556 XM_001496866 XP_373030.3 0.0030353 0.4707343 
TSSK4 XM_001489964 NP_777604.2 0.0030359 0.4719277 
CAMK1G XM_001490285 NP_065172.1 0.0060354 0.4732164 
NULL NULL NULL 0.0098905 0.4732378 
CLP1 XM_001497108 NP_006822.1 0.0059328 0.4759919 
NULL BI961150 NULL 0.0048967 0.476628 
CYCS XM_001498822 NP_061820.1 0.0062856 0.4811904 
NULL XR_036342 NULL 0.0088768 0.4822694 
SEC61B CX592223 NP_006799.1 0.0027511 0.4860176 
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SART1 NULL NP_005137.1 0.00761 0.4907682 
LHX6 XM_001501453 NP_055183.2 0.0042436 0.4943996 
LDHA XM_001504963 NP_005557.1 0.0035451 0.4974905 
XPOT NULL NP_009166.2 0.0066458 0.4979606 
LCN2 XM_001501148 NP_005555.2 0.0079727 0.499899 
NULL DN511229 NULL 0.008524 2.0078493 
NULL CX594466 NULL 0.0030845 2.017792 
TRIM39 XM_001492176 NP_742013.1 0.0045124 2.0245279 
COX10 XM_001503366 NP_001294.2 0.0046542 2.0440492 
NULL NULL NULL 0.0038567 2.0543571 
CD33 XM_001496603 NP_001763.3 0.0073252 2.07117 
MCTS1 XR_036369 NP_054779.1 0.0078768 2.0724382 
UNC5D XM_001494091 NP_543148.1 0.0097519 2.0726267 
OR5AR1 XM_001496569 NP_001004730.1 0.0046509 2.098321 
MAGEB1 XM_001488253 NP_796379.1 0.0061232 2.1043499 
ATP13A5 XM_001498779 NP_940907.2 0.002564 2.1065364 
NULL CX605497 NULL 0.0082547 2.1359314 
NAPSA XM_001490835 NP_004842.1 0.0091232 2.1466249 
SUMO2 XM_001494020 NP_008868.3 0.0011291 2.1500866 
MMP26 XM_001497732 NP_068573.2 0.0016409 2.1620324 
NULL NULL NULL 0.0079301 2.1666932 
LRRC49 XM_001495228 NP_060161.2 0.008344 2.1975564 
C21orf58 XM_001489518 NP_478060.2 0.0066052 2.2163037 
NULL NULL NULL 0.0071162 2.2233239 
OR7A5 XM_001501205 NP_059976.1 0.0016227 2.2410455 
NULL NULL NULL 0.0085577 2.262762 
HDAC9 XM_001496688 NP_848512.1 0.0065964 2.2714248 
GJB6 XM_001488823 NP_001103691.1 0.0040544 2.2841907 
CEL XM_001498274 NP_001798.2 0.0019936 2.2961466 
TMPRSS11A XM_001497444 NP_872412.2 0.0047899 2.3261182 
GDF2 XM_001500654 NP_057288.1 0.0097597 2.333065 
NULL NULL NULL 0.007887 2.3348297 
BTN2A1 XM_001492502 NP_008980.1 0.0034012 2.3395265 
SNAI2 XM_001488056 NP_003059.1 0.0009749 2.3772354 
NULL NULL NULL 0.0024313 2.3961272 
ANKRD6 XM_001500748 NP_055757.2 0.0057303 2.3985989 
PCDHGA5 XM_001504024 NP_114443.1 0.0080952 2.409591 
NULL NULL NULL 0.0020882 2.4255549 
FKTN XM_001493424 NP_001073270.1 0.0045699 2.4375705 
MYOT NULL NP_006781.1 0.0015216 2.4438922 
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CXCL14 XM_001502713 NP_004878.2 0.0077398 2.4455754 
NULL NULL NULL 0.0006983 2.4562982 
NULL NULL NULL 0.0049686 2.4977797 
NULL NULL NULL 0.002443 2.5023968 
NULL DN504122 NULL 0.0025977 2.5045382 
RGS12 XM_001488851 NP_937872.1 0.0098584 2.5186997 
OR56B1 XM_001504509 NP_001005180.1 0.0006266 2.5223909 
SLC26A4 XM_001491415 NP_000432.1 0.0086054 2.5276036 
NULL NULL NULL 0.0048109 2.5296504 
NULL NULL NULL 0.0090193 2.6072912 
OR2J3 XM_001492129 NP_001005216.1 0.0030346 2.6244782 
OR52R1 XM_001497504 NP_001005177.2 0.007486 2.6292634 
CCL11 AJ251188 NP_002977.1 0.0048805 2.6344786 
SYNE2 XR_036037 NP_878918.2 0.0093788 2.6528621 
SEC14L5 XM_001499664 NP_055507.1 0.0086505 2.6589973 
NULL XM_001494906 NULL 0.0053783 2.6917979 
FAM149A XM_001490364 NP_001006656.1 0.0025988 2.702849 
NULL DN510842 NULL 0.008927 2.7204253 
AP2B1 XM_001503924 NP_001025177.1 0.0037447 2.7363777 
SLC4A1 AB242565 NP_000333.1 0.0099905 2.7877988 
KLHL31 XM_001499245 NP_001003760.2 0.0070629 2.8259552 
NULL NULL NULL 0.0040293 2.8466627 
UTP14A XM_001491734 NP_006640.2 0.0067981 2.9413664 
NULL XR_035845 NULL 0.0017984 2.951134 
TBC1D25 XM_001493681 NP_002527.1 0.0021183 2.9660242 
NULL NULL NULL 0.0022093 2.972469 
C7orf57 XM_001496533 NP_001093629.1 0.0029925 2.9983715 
SLC12A6 NULL NP_005126.1 0.0071002 3.0132056 
CD1A XM_001489552 NP_001754.2 0.0054223 3.0639925 
TULP3 XM_001490880 NP_003315.2 0.005595 3.0661984 
NULL NULL NULL 0.0047843 3.0882741 
FXYD5 XM_001491379 NP_054883.3 0.0071221 3.1121611 
NULL NULL NULL 0.0047815 3.1148616 
NULL XM_001495803 NULL 0.0058398 3.1148905 
NULL DN506907 NULL 0.0051779 3.1250039 
P2RY13 XM_001489171 NP_076403.2 0.0041307 3.218154 
NULL NULL NULL 0.004146 3.2214684 
SPAG17 XM_001500885 NP_996879.1 0.0067862 3.230009 
NULL NULL NULL 0.0090001 3.3905441 
FREM1 XM_001493917 NP_659403.4 0.0050171 3.3969602 
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C17orf70 XM_001489884 NP_001103230.1 0.0027942 3.6009639 
STAT4 XM_001502206 NP_003142.1 0.0019232 3.738519 
NULL CX603542 NULL 7.16E-05 3.7857016 
NULL NULL NULL 0.0023883 3.8035913 
RNF113A XM_001491814 NP_008909.1 0.0031309 3.8284761 
COCH XM_001489788 NP_004077.1 0.0045814 3.9493985 
NULL NULL NULL 0.0036349 4.0227201 
BBS7 XM_001503097 NP_789794.1 0.0004973 4.0381013 
HMGN3 XM_001499096 NP_004233.1 0.0020182 4.1234867 
LGALS4 XM_001497350 NP_006140.1 0.0005165 4.1756397 
ARHGAP11A XM_001503656 NP_055598.1 0.0091897 4.3236811 
NULL NULL NULL 0.0012487 4.3324721 
NULL NULL NULL 0.005792 5.3811581 
C3orf26 XM_001502207 NP_115735.1 0.0036829 5.7588642 
NULL NULL NULL 0.0002427 9.5614929 
NULL NULL NULL 0.0072642 11.197911 
NULL DN508706 NULL 0.0001121 14.586985 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table A.12 Overrepresented gene ontology terms identified among differentially expressed genes (P<0.01 and fold change>2) 
of the 12 h/CON comparison.  BP: biological process; CC: cellular component; MF: molecular function  
 
    Term Count % P 
Upregulated Genes     
BP GO:0002376~immune system process 5 20 0.041001 
      
CC none     
      
      
MF none     
      
Downregulated Genes     
BP GO:0030097~hemopoiesis 4 14.28571 0.003668 
 
GO:0048534~hemopoietic or lymphoid organ 
development 4 14.28571 0.004811 
 GO:0002520~immune system development 4 14.28571 0.005681 
 GO:0002376~immune system process 6 21.42857 0.008822 
 GO:0002521~leukocyte differentiation 3 10.71429 0.013181 
 GO:0048569~post-embryonic organ development 2 7.142857 0.014712 
 GO:0007165~signal transduction 9 32.14286 0.023998 
 
GO:0007166~cell surface receptor linked signal 
transduction 7 25 0.030381 
 GO:0045321~leukocyte activation 3 10.71429 0.041325 
      
CC none     
      
MF none         
2
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Table A.13 Overrepresented gene ontology terms identified among differentially expressed genes (P<0.01 and fold change>2) 
of the 24 h/CON comparison.  BP: biological process; CC: cellular component; MF: molecular function  
 
    Term Count % P 
Upregulated Genes     
BP GO:0006953~acute-phase response 4 5.970149 4.73E-04 
 GO:0006952~defense response 10 14.92537 4.90E-04 
 GO:0009605~response to external stimulus 12 17.91045 5.77E-04 
 GO:0009611~response to wounding 9 13.43284 8.50E-04 
 GO:0002376~immune system process 12 17.91045 0.001195 
 GO:0006954~inflammatory response 7 10.44776 0.001449 
 GO:0042330~taxis 5 7.462687 0.003237 
 GO:0006935~chemotaxis 5 7.462687 0.003237 
 GO:0007626~locomotory behavior 6 8.955224 0.003867 
 GO:0001819~positive regulation of cytokine production 4 5.970149 0.004916 
 GO:0001817~regulation of cytokine production 5 7.462687 0.005019 
 GO:0002526~acute inflammatory response 4 5.970149 0.00623 
 GO:0030595~leukocyte chemotaxis 3 4.477612 0.008781 
 GO:0006950~response to stress 14 20.89552 0.009571 
 GO:0060326~cell chemotaxis 3 4.477612 0.009722 
 GO:0008285~negative regulation of cell proliferation 6 8.955224 0.012068 
 GO:0031347~regulation of defense response 4 5.970149 0.017331 
 GO:0050900~leukocyte migration 3 4.477612 0.020044 
 GO:0045785~positive regulation of cell adhesion 3 4.477612 0.022068 
 GO:0040011~locomotion 6 8.955224 0.024078 
 GO:0048247~lymphocyte chemotaxis 2 2.985075 0.026478 
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 GO:0050665~hydrogen peroxide biosynthetic process 2 2.985075 0.026478 
 GO:0042981~regulation of apoptosis 8 11.9403 0.032605 
 GO:0007610~behavior 6 8.955224 0.033032 
 GO:0048246~macrophage chemotaxis 2 2.985075 0.033916 
 GO:0043067~regulation of programmed cell death 8 11.9403 0.034147 
 GO:0010941~regulation of cell death 8 11.9403 0.034737 
 GO:0006955~immune response 7 10.44776 0.047176 
 GO:0042554~superoxide anion generation 2 2.985075 0.048625 
      
CC GO:0005758~mitochondrial intermembrane space 3 4.477612 0.007857 
 GO:0031970~organelle envelope lumen 3 4.477612 0.010586 
 GO:0005739~mitochondrion 10 14.92537 0.017982 
 GO:0005576~extracellular region 14 20.89552 0.03039 
 GO:0032991~macromolecular complex 19 28.35821 0.033603 
 GO:0005744~mitochondrial inner membrane presequence translocase complex 2 2.985075 0.043624 
      
MF GO:0022884~macromolecule transmembrane transporter activity 2 2.985075 0.046219 
 
GO:0015450~P-P-bond-hydrolysis-driven protein transmembrane transporter 
activity 2 2.985075 0.046219 
      
Downregulated Genes     
BP GO:0006520~cellular amino acid metabolic process 3 9.677419 0.043891 
 GO:0009267~cellular response to starvation 2 6.451613 0.046574 
      
CC GO:0044444~cytoplasmic part 17 54.83871 6.18E-05 
 GO:0005737~cytoplasm 18 58.06452 0.002863 
 GO:0043226~organelle 20 64.51613 0.002998 
 GO:0043229~intracellular organelle 19 61.29032 0.011782 
     29
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 GO:0005865~striated muscle thin filament 2 6.451613 0.020554 
 GO:0044424~intracellular part 20 64.51613 0.035828 
 GO:0005813~centrosome 3 9.677419 0.037901 
 GO:0044430~cytoskeletal part 5 16.12903 0.039349 
 GO:0005815~microtubule organizing center 3 9.677419 0.047229 
      
MF GO:0008168~methyltransferase activity 3 9.677419 0.027161 
  GO:0016741~transferase activity, transferring one-carbon groups 3 9.677419 0.028054 
 
 
 
Table A.14 Overrepresented gene ontology terms identified among differentially expressed genes (P<0.01 and fold change>2) 
of the 12 h/24 h comparison. BP: biological process; CC: cellular component; MF: molecular function  
 
    Term Count % P 
Upregulated Genes     
BP GO:0007600~sensory perception 9 16.07143 0.002744 
 GO:0003008~system process 12 21.42857 0.004431 
 GO:0050890~cognition 9 16.07143 0.005538 
 GO:0050877~neurological system process 9 16.07143 0.027768 
 GO:0007605~sensory perception of sound 3 5.357143 0.035163 
 GO:0050954~sensory perception of mechanical stimulus 3 5.357143 0.039222 
 GO:0007608~sensory perception of smell 5 8.928571 0.041482 
      
CC GO:0005886~plasma membrane 20 35.71429 0.006195 
      
MF GO:0004984~olfactory receptor activity 5 8.928571 0.044169 
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Downregulated Genes     
BP GO:0006950~response to stress 31 25.83333 6.47E-07 
 
GO:0051240~positive regulation of multicellular organismal 
process 12 10 9.79E-07 
 GO:0009607~response to biotic stimulus 14 11.66667 2.42E-06 
 GO:0001819~positive regulation of cytokine production 8 6.666667 2.92E-06 
 GO:0042221~response to chemical stimulus 25 20.83333 5.01E-06 
 GO:0050896~response to stimulus 45 37.5 1.10E-05 
 GO:0009611~response to wounding 15 12.5 1.67E-05 
 GO:0051716~cellular response to stimulus 18 15 4.44E-05 
 GO:0009605~response to external stimulus 19 15.83333 5.04E-05 
 GO:0042981~regulation of apoptosis 17 14.16667 1.24E-04 
 GO:0043067~regulation of programmed cell death 17 14.16667 1.39E-04 
 GO:0010941~regulation of cell death 17 14.16667 1.45E-04 
 GO:0048519~negative regulation of biological process 27 22.5 1.95E-04 
 GO:0001817~regulation of cytokine production 8 6.666667 2.63E-04 
 GO:0006952~defense response 14 11.66667 3.20E-04 
 GO:0048523~negative regulation of cellular process 24 20 8.24E-04 
 GO:0008285~negative regulation of cell proliferation 10 8.333333 9.00E-04 
 GO:0051707~response to other organism 9 7.5 9.16E-04 
 GO:0048247~lymphocyte chemotaxis 3 2.5 9.79E-04 
 GO:0012501~programmed cell death 13 10.83333 0.00105 
 GO:0002376~immune system process 17 14.16667 0.001343 
 GO:0055066~di-, tri-valent inorganic cation homeostasis 8 6.666667 0.001368 
 GO:0048246~macrophage chemotaxis 3 2.5 0.001664 
 GO:0006874~cellular calcium ion homeostasis 7 5.833333 0.001717 
 GO:0006954~inflammatory response 9 7.5 0.001891 
 GO:0055074~calcium ion homeostasis 7 5.833333 0.001968 
     3
0
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GO:0030595~leukocyte chemotaxis 4 3.333333 0.002125 
 GO:0009617~ response to bacterium 7 5.833333 0.002246 
 GO:0001666~response to hypoxia 6 5 0.002399 
 GO:0006875~cellular metal ion homeostasis 7 5.833333 0.002426 
 GO:0060326~cell chemotaxis 4 3.333333 0.002474 
 GO:0065009~regulation of molecular function 16 13.33333 0.002699 
 GO:0070482~response to oxygen levels 6 5 0.00299 
 GO:0006915~apoptosis 12 10 0.003001 
 GO:0055065~metal ion homeostasis 7 5.833333 0.003032 
 GO:0006916~anti-apoptosis 7 5.833333 0.003106 
 GO:0031347~regulation of defense response 6 5 0.003177 
 GO:0043066~negative regulation of apoptosis 9 7.5 0.003204 
 GO:0043069~negative regulation of programmed cell death 9 7.5 0.003488 
 GO:0060548~negative regulation of cell death 9 7.5 0.003548 
 GO:0055080~cation homeostasis 8 6.666667 0.003749 
 GO:0008219~cell death 13 10.83333 0.004057 
 GO:0034504~protein localization in nucleus 5 4.166667 0.004134 
 GO:0016265~death 13 10.83333 0.004287 
 GO:0006913~nucleocytoplasmic transport 6 5 0.004602 
 GO:0051169~nuclear transport 6 5 0.004856 
 GO:0030005~cellular di-, tri-valent inorganic cation homeostasis 7 5.833333 0.004986 
 GO:0006935~chemotaxis 6 5 0.00512 
 GO:0042330~taxis 6 5 0.00512 
 GO:0051239~regulation of multicellular organismal process 15 12.5 0.005153 
 GO:0033554~cellular response to stress 11 9.166667 0.005861 
 GO:0032732~positive regulation of interleukin-1 production 3 2.5 0.006062 
 GO:0006091~generation of precursor metabolites and energy 8 6.666667 0.006103 
     
3
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GO: 0030593~neutrophil chemotaxis 
GO:0007204~elevation of cytosolic calcium ion concentration 
3 
5 
2.5 
4.166667 
0.00679 
0.007195 
 GO:0050900~leukocyte migration 4 3.333333 0.00724 
 GO:0044093~positive regulation of molecular function 11 9.166667 0.007423 
 GO:0048513~organ development 22 18.33333 0.007446 
 GO:0051704~multi-organism process 12 10 0.007501 
 GO:0042742~defense response to bacterium 5 4.166667 0.00766 
 GO:0045785~positive regulation of cell adhesion 4 3.333333 0.008341 
 GO:0051091~positive regulation of transcription factor activity 4 3.333333 0.008341 
 GO:0030003~cellular cation homeostasis 7 5.833333 0.008495 
 GO:0051480~cytosolic calcium ion homeostasis 5 4.166667 0.009172 
 GO:0051235~maintenance of location 4 3.333333 0.009956 
 GO:0051101~regulation of DNA binding 5 4.166667 0.009996 
 GO:0032652~regulation of interleukin-1 production 3 2.5 0.010977 
 GO:0010332~response to gamma radiation 3 2.5 0.010977 
 GO:0010033~response to organic substance 12 10 0.011238 
 GO:0065008~regulation of biological quality 19 15.83333 0.011738 
 GO:0007626~locomotory behavior 7 5.833333 0.012046 
 GO:0080134~regulation of response to stress 7 5.833333 0.012046 
 GO:0043388~positive regulation of DNA binding 4 3.333333 0.012696 
 GO:0006986~response to unfolded protein 4 3.333333 0.013191 
 GO:0046677~response to antibiotic 3 2.5 0.013912 
 GO:0009628~response to abiotic stimulus 8 6.666667 0.014095 
 GO:0042592~homeostatic process 12 10 0.014877 
 GO:0030155~regulation of cell adhesion 5 4.166667 0.0152 
 GO:0006873~cellular ion homeostasis 8 6.666667 0.015281 
     
3
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GO:0019725~cellular homeostasis 9 7.5 0.015687 
 GO:0050727~regulation of inflammatory response 4 3.333333 0.015828 
 GO:0007610~behavior 9 7.5 0.016244 
 GO:0055082~cellular chemical homeostasis 8 6.666667 0.016537 
 GO:0051099~positive regulation of binding 4 3.333333 0.016959 
 GO:0006928~cell motion 9 7.5 0.017402 
 GO:0033365~protein localization in organelle 5 4.166667 0.018759 
 GO:0009266~response to temperature stimulus 4 3.333333 0.019983 
 GO:0042127~regulation of cell proliferation 12 10 0.020352 
 GO:0051098~regulation of binding 5 4.166667 0.021858 
 GO:0006606~protein import into nucleus 4 3.333333 0.02193 
 GO:0000060~protein import into nucleus, translocation 3 2.5 0.02317 
 GO:0034976~response to endoplasmic reticulum stress 3 2.5 0.02317 
 GO:0051170~nuclear import 4 3.333333 0.023284 
 GO:0050801~ion homeostasis 8 6.666667 0.023656 
 GO:0006984~ER-nuclear signaling pathway 3 2.5 0.024464 
 GO:0048145~regulation of fibroblast proliferation 3 2.5 0.024464 
 GO:0043523~regulation of neuron apoptosis 4 3.333333 0.024682 
 GO:0032101~regulation of response to external stimulus 5 4.166667 0.024749 
 GO:0048878~chemical homeostasis 9 7.5 0.02589 
 GO:0048731~system development 25 20.83333 0.026994 
 GO:0006979~response to oxidative stress 5 4.166667 0.027327 
 GO:0042327~positive regulation of phosphorylation 4 3.333333 0.029928 
 GO:0043065~positive regulation of apoptosis 8 6.666667 0.029978 
 GO:0040011~locomotion 8 6.666667 0.030305 
 GO:0043068~positive regulation of programmed cell death 8 6.666667 0.030966 
 GO:0007275~multicellular organismal development 29 24.16667 0.031193 
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GO:0010942~positive regulation of cell death 8 6.666667 0.031637 
 
GO:0010562~positive regulation of phosphorus metabolic 
process 4 3.333333 0.032342 
 GO:0045937~positive regulation of phosphate metabolic process 4 3.333333 0.032342 
 GO:0050790~regulation of catalytic activity 12 10 0.032381 
 GO:0032507~maintenance of protein location in cell 3 2.5 0.032825 
 GO:0006457~protein folding 5 4.166667 0.034761 
 GO:0051090~regulation of transcription factor activity 4 3.333333 0.034855 
 GO:0048518~positive regulation of biological process 22 18.33333 0.037669 
 GO:0051789~response to protein stimulus 4 3.333333 0.038359 
 GO:0046907~intracellular transport 10 8.333333 0.038678 
 GO:0010225~response to UV-C 2 1.666667 0.040946 
 GO:0050867~positive regulation of cell activation 4 3.333333 0.042036 
 GO:0006096~glycolysis 3 2.5 0.042135 
 GO:0016477~cell migration 6 5 0.043113 
 GO:0042108~positive regulation of cytokine biosynthetic process 3 2.5 0.043772 
 GO:0051651~maintenance of location in cell 3 2.5 0.043772 
 GO:0045185~maintenance of protein location 3 2.5 0.043772 
 GO:0007243~protein kinase cascade 7 5.833333 0.043879 
 GO:0051223~regulation of protein transport 4 3.333333 0.044906 
 GO:0022900~electron transport chain 4 3.333333 0.044906 
 GO:0048522~positive regulation of cellular process 20 16.66667 0.049407 
      
CC GO:0005737~cytoplasm 70 58.33333 2.19E-05 
 GO:0044432~endoplasmic reticulum part 9 7.5 0.001979 
 GO:0044424~intracellular part 84 70 0.002372 
 GO:0042470~melanosome 5 4.166667 0.00275 
 GO:0048770~pigment granule 5 4.166667 0.00275 
     3
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GO:0044444~cytoplasmic part 46 38.33333 0.004665 
 GO:0043233~organelle lumen 22 18.33333 0.006581 
 GO:0031974~membrane-enclosed lumen 22 18.33333 0.008192 
 GO:0005789~endoplasmic reticulum membrane 7 5.833333 0.008442 
 GO:0005622~intracellular 84 70 0.009877 
 GO:0070013~intracellular organelle lumen 21 17.5 0.010619 
 GO:0042175~nuclear envelope-endoplasmic reticulum network 7 5.833333 0.010847 
 GO:0005788~endoplasmic reticulum lumen 4 3.333333 0.015503 
 GO:0044446~intracellular organelle part 39 32.5 0.015922 
 GO:0044422~organelle part 39 32.5 0.017551 
 GO:0005576~extracellular region 22 18.33333 0.019132 
 GO:0044421~extracellular region part 13 10.83333 0.022679 
 GO:0031410~cytoplasmic vesicle 10 8.333333 0.02465 
 GO:0005829~cytosol 16 13.33333 0.02597 
 GO:0016023~cytoplasmic membrane-bounded vesicle 9 7.5 0.027658 
 GO:0032991~macromolecular complex 30 25 0.029611 
 GO:0031982~vesicle 10 8.333333 0.031262 
 GO:0031988~membrane-bounded vesicle 9 7.5 0.032597 
 GO:0048471~perinuclear region of cytoplasm 6 5 0.040617 
 GO:0005783~endoplasmic reticulum 12 10 0.048897 
      
MF GO:0008201~heparin binding 5 4.166667 0.004804 
 GO:0005515~protein binding 67 55.83333 0.008985 
 GO:0005539~glycosaminoglycan binding 5 4.166667 0.013854 
 GO:0030247~polysaccharide binding 5 4.166667 0.018999 
 GO:0001871~pattern binding 5 4.166667 0.018999 
 GO:0030554~adenyl nucleotide binding 18 15 0.02872 
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GO:0001883~purine nucleoside binding 18 15 0.032598 
 GO:0001882~nucleoside binding 18 15 0.034501 
  GO:0051082~unfolded protein binding 4 3.333333 0.040575 
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